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Abstract
In the light of the current patient-centred approach to healthcare delivery, this research investi-
gated the effectiveness and safety of paediatric complementary and alternative medicines (CAMs)
from the users’ perspective in order to generate suitable data to inform healthcare policy and
planning. The research was in three parts: a systematic review (SR), a database analysis and a
survey.
The SR of papers published on the topic from 2000 to July 2011 identified 46 eligible studies
conducted predominantly in the USA (14; 30%); with only 5 UK studies (11%), of which 2 were
Scottish. Generally, their findings indicated a high report of positive health outcomes by CAM
users, and a low report of adverse outcomes. Critical appraisal, however, highlighted the low
methodological quality of most studies; with an overall quality rating of 45%, and only 9 studies
(20%) possessing up to 8 of 12 quality indices. A tendency towards selective outcome reporting
bias was also observed.
The database research explored the suspected adverse reactions (ADRs) associated with paedi-
atric use of natural health products (NHPs) as reported on the Yellow Card Scheme (YCS) from
its inception until July 2012. The YCS data was mined to estimate the frequency and seriousness
of the ADRs reported. NHPs were found to have contributed <1% of ADR reports within the pe-
riod, with paediatric subjects contributing 8.6% of NHP reports (192 reports). These profiled 332
specific ADRs, 30% of which were described as serious. Female subjects contributed marginally
more ADRs than males (51.5%). Rash and other skin and subcutaneous disorders were the most
common ADRs. Herb-drug combination products were found to generate the most ADRs, with
the senna-piperazine combination being the most frequently reported (89 ADRs). The product
most associated with fatalities was soybean oil (5 reports). Generally, however, NHP-related
ADRs reported for paediatric subjects in the YCS were found to be relatively few, and of low
severity (6%) and fatality (2%); with over 75% resolution, and mostly within 3 days (68%).
The survey component of the research was a bi-modal analytic cross-sectional survey of parents
in Aberdeen, and aimed to determine the nature and demography of the use and user-reported
outcomes of CAM among children in Aberdeen. Consenting parents recruited from the general
population were invited to complete online or paper versions of a validated questionnaire. 212
parents of 391 children completed the survey, of which 143 reported CAM use in their chil-
dren (67.5%). Participants were mainly mothers (73.6%); Caucasian (84.4%); aged 30-44 years
(59.7%); and educated beyond secondary level (85.3%). 213 children had ever used CAM, 64.3%
of which had always used CAM; while 21.1% had only used CAM within the last 12 months, and
14.6% had used it only previously. 53.1% of child CAM users were female. Parental self CAM use
was found to be the strongest predictor of paediatric CAM use. 102 of the 123 parents that rated
their children’s CAM use (82.9%) perceived them as helpful; 76 of which said they helped “a lot”.
Finding personal CAM use helpful was the only factor found to significantly predict perceived
effectiveness for paediatric CAM use. 9 parents reported adverse outcomes, mainly allergic skin
reactions.
In all, this research featured the first SR of user-perceived effectiveness and safety outcomes of
paediatric CAMs; the first analysis of NHP-associated ADR reports on the YCS; and the first
population-based Scottish study of paediatric CAM use. A triangulation of the results from
these three strands validated the key finding that CAM is used widely among children, with high
perceived effectiveness and safety outcomes. The implications of this finding for healthcare policy
and planning were highlighted.
Keywords: Complementary and alternative medicine; perceived effectiveness; safety; children;
parents; outcomes; Yellow Card Scheme; pharmacovigilance; systematic review; natural health
products; Aberdeen; Scotland
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Foreword
This thesis embodies the research I carried out over my four and half years of study at the Robert
Gordon University, Aberdeen. Within that period, I explored the positive and negative experi-
ences associated with the use of complementary and alternative medicines (CAMs) in children in
Aberdeen.
Upon my graduation as a pharmacist from the University of Nigeria, Nsukka, Nigeria, I was re-
tained by my home faculty of Pharmaceutical Sciences for the mandatory one-year pre-registration
internship training as a graduate pharmacist. After my full registration with the Pharmacists’
Council of Nigeria, I worked as a hospital pharmacist for a year; and thereafter spent two more
years in community pharmacy practice. I then decided to return to my first love, the academia;
and was employed as graduate assistant in the Department of Pharmacology & Toxicology of my
alma mater. After completing a Master of Pharmacy programme in Pharmacology, I joined the
teaching faculty as a Lecturer II, with the job description of undergraduate teaching and research.
Over the years, I rose up the ranks, attaining the post of Senior Lecturer and Acting Head of
Department in 2008, a post I held up until 2010 when I came to the UK for doctoral studies.
My interest in complementary and alternative medicines stemmmed from my years of research
into the folkloric claims of various herbs used in traditional medicine in Nigeria. I commenced
such research during my MPharm project, in which I investigated the hypotensive claims of petals
of Hibiscus sabdariffa using laboratory animals. Encouraged by the findings of that study, I went
on to investigate other related ethnomedicinal claims of the plant, as well as the pharmacological
consequences of its use alone and in combination with various conventional anti-hypertensive
drugs. I also explored its use in various physiological and pathological conditions. While the
preliminary experiments yielded results that supported many of the ethnomedicinal claims, the
studies on possible drug-herb interaction as well as its effects on physiological and pathological
states produced conflicting results, highlighting the risk potential of its long-term use. These
findings worried me in the light of the popular use of the herb in the community.
My first impressions of the high use of herbal medicines were to associate such with the combina-
tion of inadequate health care services and lack of health information by the public. A search of
the literature, however, informed me better, as it revealed the global nature of high use of herbal
medicines –even in economically advanced countries. I also noted with alarm their reported
high use in children; which birthed in me the desire to investigate the outcomes of such herbal
x
medicinal product use in paediatric populations. As a pharmacist, I was particularly interested
in patient safety; hence my emphasis on pharmacovigilance. Further internet search led me to
reach out to my first principal supervisor; and ultimately resulted in my acceptance for doctoral
training. Further discussions with him helped broaden my research outlook to focusing not only
on paediatric herbal medicinal product use, but also on the use of complementary and alternative
medicinal products generally in that demographic.
The last four years of doctoral research training have given me insight into the psycho-social and
legal issues surrounding not only the use of CAMs, but also paediatric research in general. I have
also come to appreciate the immense challenges and benefits of health services research generally.
I look forward to honing the skills I have now acquired through the practice that makes perfect;
so that one day I can effectively help others achieve what I have been enabled to achieve over the
last few years.
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Chapter 1
General Introduction
1.1 Complementary and Alternative Medicine (CAM)
This doctoral research is on the effectiveness and safety outcomes associated with the use of
complementary and alternative medicines (CAM) in children. This introductory chapter seeks
to provide a contextual definition of each of the key concepts associated with the research. This
first section introduces CAM therapies in general, as well as outlines the key aspects relevant to
the research.
1.1.1 CAM: Definition and classification
There is no commonly agreed definition for CAM among the several proposed in literature [1, 2].
While it can broadly be described as non-conventional medicine that is used either along with
(complementary) or in preference (alternative) to conventional medicine [3], the specifics of what
it embodies vary depending on the perspective from which it is viewed. For instance, the World
Health Organisation (WHO) regards CAM somewhat as a new improved version of traditional
medicine (TM), in that it originated from it and shares many of its features; differing only in
the context within which it is used. Thus, while it defines TM as ‘the sum total of knowledge,
skills and practices based on the theories, beliefs and experiences indigenous to different cultures,
whether explicable or not, used in the maintenance of health as well as in prevention, diagnosis,
improvement or treatment of physical and mental illnesses’ [4], it defines CAM in the same
document as ‘a broad set of health care practices that are not part of a country’s own tradition
and are not integrated into the dominant health care system’. The WHO therefore sees TM and
CAM as different sides of the same coin, preferring to use the acronym TM/CAM [5] or T&CM
[6] to either separate term. The Cochrane Collaboration, however, while adopting an essentially
similar theoretical definition for CAM as the WHO, qualified it with a caveat. It defined CAM
1
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as “a broad domain of healing resources that encompasses all health systems, modalities, and
practices and their accompanying theories and beliefs, other than those intrinsic to the politically
dominant health system of a particular society or culture in a given historical period”; but then
added: “CAM includes all such practices and ideas self-defined by their users as preventing or
treating illness or promoting health and well-being” [7, 8]. This definition was also adopted by the
Institute of Medicine in 2005 with a slight amendment in the caveat, replacing “...as preventing
or treating illness or promoting health and well-being” with “...as associated with positive health
outcomes” [9, 10]; and is the definition most widely accepted by CAM researchers.
Due to the broad and ambiguous nature of these theoretical definitions, there was the need for
operational definitions and classification schemes that utilise explicit and transparent criteria to
clarify the scope of CAM [1, 2]. In line with this, the WHO categorized T&CM broadly into
medication-based (or product-based) therapies -if they involve use of herbal medicines, animal
parts and/or minerals; or non-medication-based (or practitioner-based) therapies—if carried out
primarily through the agency of a specific therapist or practitioner, usually without the use of
natural products, as in the case of acupuncture, manual therapies and spiritual therapies [5].
While there are several other such classification schemes for CAM, the most popular one among
CAM researchers, and the one also adopted by the Cochrane Collaboration CAM Field, is that
provided by the US National Centre for Complementary and Integrative Health (NCCIH), which
initially categorised CAM in into five specific classes [2]. In March 2015, NCCIH updated its cate-
gorisation of CAM from the initial five classes to three broader ones [11, 12], as follows (1) natural
products (formerly biologically-based therapies); (2) mind and body practices (a combination of
the former manipulation and body-based methods and mind-body interventions classes); and (3)
other complementary health approaches (an amalgamation of the initial alternative medical sys-
tems and energy therapies classes). The details of this classification system and the relevance of
each of the categories to the research reported in this thesis are summarized in Table 1.1.
Generally, medication-based therapies are called CAM products; while non-medication-based
therapies are called CAM practices [13]. Although the classical CAM products include herbal
medicines, Bach flower remedies, dietary supplements, megavitamins and special diets; the ambit
of CAM products can be broadened to include homeopathic products and essential oils. While
these products are utilised as part of such CAM practices as aromatherapy, homeopathy and
various forms of massage, they still are essentially medication-based therapies in their own right.
Described as such, some authors [14, 15] have more aptly identified these therapies as Natural
Product CAM (NP-CAM), Pharmaceutical-type Complementary and Alternative Medicines (PT-
CAMs), or simply Complementary and Alternative Medicines (CAMs). In view of the practical
impossibility of studying all CAM types in-depth within the time frame of the doctoral research
and the pharmaceutical background of the student this research is largely restricted to CAM
products or CAMs, except where the exigencies of a given aspect of the research dictate otherwise.
Chapter 1. General Introduction 3
Table 1.1: NCCIH categorisation of CAM therapies and relevance to current research
 
NCCIH categorisation of CAM Sub-types General comments Relevance to current 
research Current Initial 
1. Natural 
products 
1. Biologically-
based therapies 
Bach flower therapy 
Chelation therapy 
Dietary supplements 
Essential oils 
Herbal medicines 
Home remedies 
Hydrotherapy 
Megavitamins & minerals 
Prolotherapy 
Special diets 
Essentially medication-
based therapies 
 
Primarily entail the use 
of medicinal products 
(natural products)  
Will be the sole focus 
of the research 
reported in chapters 2 
and 3; and the major 
aspect of the research 
reported in chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Mind and body 
practices 
2. Mind-body 
interventions 
Acupuncture 
Art therapy 
Aromatherapy* 
Bio-feedback 
Breathing techniques 
Dance therapy 
Guided imagery 
Humour therapy 
Hypnotherapy 
Meditation techniques 
Music therapy 
Play therapy 
Prayer therapy 
Yoga 
Essentially non-
medication-based except 
for *. Some may stand 
alone or form part of 
another sub-type 
 
*This involve the use of 
essential oils, which 
often have medicinal 
properties (natural 
products) 
Will be considered only 
in the research 
reported in chapter 4; 
but essential oils will 
also form part of the 
research reported in 
chapters 2 and 3 
4. Manipulation & 
Body-based 
methods 
Acupressure 
Alexander technique 
Chiropractic 
Feldenkrais 
Massage 
Osteopathy 
Reflexology 
Rolfing 
Therapeutic touch 
Trager approach 
Essentially non-
medication-based  
 
Some of these may 
stand alone or form part 
of another sub-type 
 
Will be considered only 
in the research 
reported in chapter 4 
 
 
 
 
 
 
 
 
 
 
3. Other 
complementary 
health approaches 
4. Alternative 
medical systems 
Acupuncture† 
Anthroposophy* 
Ayurveda* 
Homeopathy* 
Naturopathy* 
Traditional Chinese 
 Medicine (TCM)* 
Kampo* 
Other indigenous 
 traditional health 
 practices* 
Essentially non-
medication-based except 
for * 
 
*These may also involve 
the use of medicinal (or 
natural) products 
 
†May also be part of 
categories 2 and/or 4 
The natural product 
components (*) will 
be specifically focused 
on in the research 
reported in chapters 2 
and 3; but all sub-
types will be included 
in the research 
reported in chapter 4 
5. Energy therapies - Bio-field therapies: 
Healing (Faith, distant, 
 etc.) 
Qi gong 
Reiki 
Tai chi 
- Bio-electromagnetic-
based therapies:  
Involves the 
unconventional use of 
pulse, magnetic, 
alternating or direct 
current fields 
Essentially non-
medication-based  
 
Some of these may 
stand alone or form part 
of another sub-type 
 
Will be considered only 
in the research 
reported in chapter 4 
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This exception, however, applies to a significant degree only to the aspect of the research reported
in chapter four of this thesis. For clarity, therefore, the terms CAM product(s) or CAMs are used
inter-changeably throughout this thesis to distinguish natural product pharmaceutical-type CAM
therapies from CAM practices in particular, or all CAM therapies in general.
1.1.2 CAM as a public health intervention
The role of CAM in public health has been increasingly acknowledged in recent times, and
underpins the WHO’s efforts towards the acceptance and integration of CAM therapies into health
care systems globally [16–19]. As the field of Public Health is ”the science and art of preventing
disease, prolonging life and promoting health through the organized efforts and informed choices
of society, organizations, public and private, communities and individuals” [20]; and CAM has
been defined as ‘the sum total of knowledge, skills and practices based on the theories, beliefs and
experiences indigenous to different cultures, whether explicable or not, used in the maintenance
of health; as well as in the prevention, diagnosis, improvement or treatment of physical and
mental illnesses’[4]; their shared attributes and intersecting paradigms are quite obvious [21].
Public health interventions are focused at preventing and managing diseases, injuries and other
health conditions through such simple and often non-medical methods as surveillance of cases
and health promotion at the personal, community and global levels. The optimization of self-care
capabilities of individuals and families through case management [22], a key aspect of public
health interventions, has been the cornerstone of CAM use in various health conditions [23–27].
Some other aspects of public health interventions that are also applied in CAM research include
adverse event surveillance [28–30]; population screening and case finding to determine prevalence
and characteristics of use [31–33]; and collaboration and coalition building to enhance CAM
research. Such collaboration has resulted in various networks such as the Network of Researchers
in the Public Health of CAM (norphCAM) [18] and CAMbrella, a 3-year pan-European, EU-
funded project that investigated the state of CAM use and research in Europe [19, 34, 35]. The
CAMbrella project culminated in the release of a road map for CAM research in Europe [36], key
aspects of which include:
(i.) the identification of CAM as a neglected research area in Europe;
(ii.) the need for research methods that reflect real-world health care settings in Europe;
(iii.) the need for an EU research strategy for CAM that prioritizes an approach that reflects the
needs of its citizens and providers of CAM.
The current work builds on these public health aspects of CAM research.
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1.1.3 CAMs: Popularity, effectiveness, and safety
In virtually all surveys of CAM use world-wide, CAM products have consistently been found to
be the most popular CAM type used –even among paediatric populations [37, 38]. Also, against
the back-drop of the limited evidence for the effectiveness of CAM therapies generally, CAM
products, with the notable exception of homeopathic remedies, are generally associated with a
significantly greater basis of evidence than many CAM practices [39]. This is particularly true for
many herbal medicinal products [40], the ethno-medicinal claims and efficacy of many of which
have been validated and affirmed in literature reports of experimental and quasi-experimental,
pre-clinical and clinical studies –including randomized controlled trials, RCTs [15, 41, 42]. In
spite of these advantages, however, CAMs –especially herbals- are plagued with the problems
of large-scale adulteration [43–45], and a high tendency of often unfavourable interactions with
conventional drugs [46, 47]. Homeopathic products, on the other hand, despite many clinical
trials in various health conditions, are still plagued with the problem of controversial efficacy
[48, 49], although widely acknowledged as safe [50, 51]. These drawbacks have grave implications
for patient safety, and have raised concerns as to the over-all safety and effectiveness of these
unconventional medicines. These concerns have been the subject of various studies [52, 53], and
have also been highlighted for their use in paediatric subjects [28, 29].
In spite of many negative reports about the hazards of unguided and/or misguided CAM use,
literature reports highlight their continued and increasing use world-wide in both adults and
children [54, 55], suggesting that public opinion on CAM use has not been adversely affected.
Moreover, studies have consistently associated high CAM use with both higher education and
higher economic status [56, 57]; which finding undermines the allegations of ignorance or poverty
as chief contributing factors to increased CAM use. Whether the continued popular use of these
products is purely based on their widely reported anecdotal claims; or due to some hitherto
unrecognised positive outcomes they yield to their users, is still the question of debate in various
sectors. Also, even in the instance of an unrecognised positive benefit in terms of user-perceived
effectiveness, one further wonders if these therapies are actually safe. While various studies have
documented the high rates of adverse drug events associated with the widespread unlicensed and
off-label medication use in children [58, 59], very little work has been published on paediatric CAM
safety –particularly in the UK. This informed this doctoral research to determine the bases for
-and implications of- this popularity by assessing user-focused outcomes in terms of effectiveness
and safety in Scotland.
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1.2 Outcomes research
1.2.1 Definition, history and scope
Health service outcomes have been described as the effects of health services on patients’ health,
as well as patients’ evaluation of their health care [60]. As the well-being of the patient is the
goal of all health services and interventions, outcomes research (OR) focuses to a large extent
on patient-reported end-results of health services and interventions by identifying and analysing
the patient’s experiences, preferences and values [61, 62]. There is, therefore, a de-emphasis on
the biomarkers and surrogate end-points that have traditionally characterised clinical medicine,
in preference for the perceptions and preferences of treated patients. It is one of the dividends
of the WHO’s definition of health as ‘a state of complete physical, mental and social well-being,
and not merely the absence of disease or infirmity’ [63].
Although first recognized in the 1850s through the work of Florence Nightingale on mortality
rates following medical interventions, modern OR was founded by Avedis Donabedian when, in
1966, he published the landmark essay on evaluating quality of medical care [64]. He stated that
‘outcomes, by and large, remain the ultimate validation of the effectiveness and quality of medical
care’. Building on Donabedian’s work, Ellwood later introduced the term ‘outcomes management’
[65], in which he suggested that patient management should be driven by the experience of how
similar patients fared following alternative therapies. In its present form, OR aims at generating
evidence for best practices and policies for the benefit of all stake-holders in medical care, by
providing evidence on which interventions are best suited for each patient and/or circumstance
[66, 67].
While OR emphasizes patient outcomes such as readmission or mortality rate, as well as patients’
healthcare experiences or cost, system-related outcomes that can affect the patient experience
–such as patient access to health care (waiting times), training of health professionals, or im-
plementation of health care policies- are also studied. All these frontiers are embodied in the
seven themes of OR as recognized by the Institute of Medicine -safety, effectiveness, patient-
centeredness, system responsiveness, timeliness, efficiency and equity [67, 68]. These themes have
been studied by means of primary epidemiological studies (such as RCTs, cross-sectional observa-
tional studies, etc.) or secondary epidemiological data from either published studies (systematic
reviews and/or meta-analyses) or patient/consumer electronic health records (database studies)
[69, 70]. The research reported in this thesis applies aspects of both of these methods to focus
on the first 2 themes of OR in the context of CAM use among children in the Aberdeen area of
North-east Scotland.
Chapter 1. General Introduction 7
1.2.2 Health outcomes measurement
Health outcome measurement focuses on the results of health care –or the effects of a health care
intervention- on the overall health, morbidity, disability and/or quality of life of the patient [71].
Described as such, it is intricately related to the health-related quality of life (HRQoL) of patients,
as it focuses on their perceptions on their health status within the context of other aspects of their
life in terms of changes in their symptoms and functioning, and their preferences and values, as
well as their satisfaction with their treatment [66, 72]. In epidemiological studies, such outcome
measures are determined essentially by means of either generic or (disease-, condition-, function-,
population-, or treatment-) specific patient questionnaires [73, 74], usually based on the item-
response theory [75, 76]. Such questionnaires are usually multi-dimensional in order to cover the
various components considered important to patients, which can also affect them positively or
negatively [77]. These components are often determined from the patients and care-givers directly,
usually through one-on-one in-depth interviews and/or focus group discussions. The inputs from
the patients are then combined with general findings from literature into a draft questionnaire
that is deemed capable of assessing the outcome concerned [78, 79] –thus achieving face validity.
The resulting instrument is then pre-tested in a purposive sample, not only to identify areas that
could be unclear or difficult to understand, but also to ensure that the data eventually realised
would meet the objectives of the survey. This is achieved conventionally by simply piloting the
instrument; but other more in-depth methods, such as cognitive interviews, behaviour coding,
response latency, vignette analyses and statistical modelling, have also been used [80, 81]. By
these means the content validity of the items is determined.
Following pre-testing, the questionnaire is revised appropriately and subjected to item reduction,
and, for health status outcomes instruments, further subjected to detailed psychometric anal-
yses to determine its construct and criterion validity, reliability and sensitivity to change [79].
Conventionally, item reduction is achieved through expert review of the pool of items initially
generated following feedback received from a field test to determine the acceptability of the in-
strument [82]. However, it could also be achieved by testing scaling assumptions, conducting a
component factor analysis and determining the internal consistency of the various scales in the
instrument [83]. As it is not the objective of this doctoral research to measure specific health
status in patients with particular health conditions, a generic outcomes instrument is utilised
in the aspect of the research reported in chapter four of this thesis, and detailed psychometric
analyses are not conducted. Also conventional methods of validation are employed as applicable.
1.2.3 Outcomes measures instruments in CAM research
The theories and philosophies that under-pin CAM use are different from those associated with
conventional medicine [84, 85]. It is, therefore, not strange that applying the same methodologies
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that have been found useful in the assessment of the effectiveness of conventional medicines has
not yielded much positive evidence for CAM therapies [86, 87]. In recent years, there have been
repeated calls and proposals for the development of different strategies for the validation of CAM
therapies as well as whole systems of integrative medicine [88–91]. As CAM use is primarily
patient/user-driven [92–96], an emphasis on the reliance on patient-reported outcomes (PROs)
-a conceptual framework of outcomes that reflect patients’ lived experiences- is central to the
strategies proposed for its proper evaluation [97]. Also proposed is a system of research that
emphasizes the relevance of the context of the treatment –that aims at answering the question:
“Which treatment works for whom, when and why?”, rather than the traditional question: “Which
treatment works?” [98]. In view of this emphasis on patient-specific outcomes, a variety of novel
methodologies has been proposed, such as the inclusion of qualitative methods in RCTs [99,
100], whole systems research (WSR) [89], aptitude-treatment interaction (ATI) research [98],
CAM systems research [101], and complex interventions research [102, 103], among others. One
consistent theme that runs through all these designs is the combination of appropriate qualitative
and quantitative methods in CAM research methodology [104, 105]. The research reported in
chapter four of this thesis follows that same approach in line with recent research on CAM use
[106].
1.3 Effectiveness of health interventions
1.3.1 Definition, classification and assessment
Efficacy and effectiveness are two closely related terms used in the evaluation of healthcare inter-
ventions. Historically, efficacy studies were the backbone of clinical research, being accepted as
the ‘gold standard’ for determining whether or not a treatment worked [107]. From the turn of
the 21st century, however, there has been a shift of emphasis towards effectiveness studies, which
differ from efficacy studies in that they focus on real-world use of interventions as against an
ideal-setting perspective [108, 109]. In other words, efficacy studies can be described as explana-
tory, and effectiveness studies as pragmatic [110, 111]. Despite these distinctions, there is still
sufficient confusion among researchers over the right terminology to warrant mislabelling of some
‘effectiveness’ studies as ‘efficacy’ studies, and vice versa. As a result, many systematic reviews
of ‘effectiveness’ studies often mistakenly include studies that are actually ‘efficacy’ studies. To
guard against this common error, Gartlehner et al, in a research carried out for the Agency of
Healthcare Research and Quality of the US Department of Health and Human Services, have
identified six criteria by which effectiveness studies can be distinguished with high specificity and
sensitivity from efficacy studies during systematic reviews [112, 113].
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The effectiveness of a health intervention can be evaluated from two major perspectives –ob-
jectively: from the clinician’s/experimenter’s perspective (clinical effectiveness, CE), or subjec-
tively: from a patient’s/consumer’s perspective (perceived effectiveness, PE) [114, 115]. The
cost-effectiveness/cost-benefit of the intervention can then be obtained by deducing the economic
implications of achieving or improving the effectiveness data realised from these two perspec-
tives relative to those for another intervention [116, 117]. While CE focuses on the attainment
of clinical/therapeutic outcomes/goals/end-points –and is best judged by carefully designed and
well conducted pragmatic ’real world’ randomized (controlled) trials (RCTs), PE focuses on the
attainment of humanistic outcomes through assessing the receiver’s own perception of –satisfac-
tion/ contentment with- the treatment, or his own assessment of his health-related quality of
life (HRQoL) following the treatment. It is best assessed using observational studies –essentially
cross-sectional surveys, cohort or case-control studies, and qualitative research.
Although evidence obtained from well-conducted RCTs is generally accorded greater recognition
by healthcare scientists and professionals, and is placed on a higher level in the popular hier-
archies of evidence in the evaluation of healthcare interventions [118], studies have shown that
observational studies are not particularly inferior to randomized trials in methodological qual-
ity [119, 120]. Rather, observational studies have been found to actually be superior to them
in studies where opinions, attitudes and perceptions about interventions are being investigated
[121, 122]. As the current research focuses on effectiveness from the users’ perspective, an obser-
vational approach is, therefore, justified.
1.3.2 Importance of the patient/user’s perspective
Conventionally, the effectiveness of a treatment or other health intervention is determined with
respect to physiological and/or clinical end-points, such as infection/disease control, results of
laboratory tests, and survival. While such objective measures yield very useful and accurate
evidence on the effectiveness of interventions in many circumstances, there are other conditions
–such as pain, fatigue, or visual acuity- in which objective measures are not either feasible or
reliable. Determining effectiveness of interventions in such circumstances, therefore, has to rely
on subjective data from the patient [123, 124]. Moreover, even in circumstances where objective
measures are feasible and reliable, situations often arise where improvement in physiological
indices do not translate into (significant) clinical response; or where clinical response does not
result in patient satisfaction vis-a-vis the peculiarities of the patient’s external circumstances
[125]. In such circumstances, the patient has the final say; as the relevance of physiological and
clinical measures ultimately diminish in view of the patient’s perception of changes in his/her
health status, and the effect of such changes on quality of life [126]. Another scenario in which the
importance of the patient’s judgement cannot be over-emphasized is in comparative effectiveness
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studies [62], where there is need to determine which of two or more effective treatment options
gives the greatest overall benefit to the patient. In coming to this decision, not only the direct
benefit of the intervention is considered, but also the patient’s perception of any adverse events
that may be associated with it [127].
In view of the above, the patient is ultimately the best judge of the impact of health interventions,
and, thus, absolutely relevant in the assessment of their effectiveness. The recognition of this has
resulted in a shift of emphasis in healthcare delivery, assessment, and research in various parts of
the world. Patient-reported outcome Measures (PROMs) have become incorporated into the NHS
since April 2009 [128]. Also, NHS regulations are now based on national surveys of patient expe-
riences [129]. In 2009, the US Food and Drug Administration, following a draft guideline in 2006,
finally released definitive guidance on the use of patient-reported outcomes (PROs) to support
labelling claims [130]. Also, the drug industry has now recognized the value of including PROs
in labelling efficacy claims in improving consumer-targeted marketing [131]. All these reflect a
realization of the profound impact of patient-centred care on the outcome of healthcare deliv-
ery, and have opened up a new field in healthcare research. The US Patient-centered Outcomes
Research Institute (PCORI), a non-governmental institute charged with examining the ‘relative
health outcomes, clinical effectiveness and appropriateness’ of different medical treatments by
evaluating existing studies and carrying out its own, is a notable example. It is similar to the
NHS National Institute for Health and Care Excellence (NICE) in England and Wales. However,
PCORI differs from NICE in its de-emphasis on the cost-effectiveness of health interventions in
establishing a recommendation. The data mining of (usually) health outcomes-related patient
data and healthcare information systems represents another novel research method that is espe-
cially appealing due to its low cost [132, 133]. In addition to applying this novel approach, the
research reported in this thesis follows the PCORI approach by placing the patient squarely at
the centre of the study, while de-emphasizing the cost implications of the interventions concerned.
1.3.3 CAM effectiveness -resolving the controversy
As earlier stated, despite their high popularity, and in spite of the calls by the WHO for their
integration into national health systems world-wide, there is still a lot of controversy surrounding
the effectiveness of many CAM therapies. This is so even for such CAMs as herbal medicines
that have been found to have some evidence base [134]. Generally, there is a great divide among
medical practitioners and researchers on CAM effectiveness, and the rationale for their clinical
use. While studies have shown that more than 70% of GPs recommend and/or refer their patients
to some therapies [135–137], a qualitative study has shown that scepticism and uncertainty are
prominent among medical doctors with a dual academic and clinical role [138]. Studies have also
shown a similar attitude among medical students, with the scepticism growing as they progress in
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pre-medical training [139, 140]. The views of other health professionals are generally more positive
[141–143]. Although there are a number of studies to the contrary [144, 145], the primary basis for
the scepticism and uncertainty among medical practitioners is the little, ambiguous, or outright
lack of empirical evidence on the clinical efficacy of CAM therapies based on RCTs [146–148].
On the other hand, practitioners of, and many researchers in, complementary medicine contend
that the various peculiarities of the philosophy and practice of CAM do not recommend them
to assessment using RCTs [149], as proposed by the evidence-based medicine paradigm. They
recommend instead the use of different and novel methodologies that take into consideration
some of the dimensions over-looked in randomized trials. The common distinctive features of the
new methodologies proposed are the reliance on real life, observational effectiveness studies and
a greater consideration and incorporation of the perspectives of patients that use CAM in the
assessment process, as well as the introduction of a holistic perspective in CAM use [86, 150]. A
recent survey of clinicians and primary care trust managers in the NHS has shown, however, that
clinical research evidence, rather than patient perspectives, is a greater factor in their professional
decisions on their patients [151].
With the continued and growing popularity of CAM use, however, the importance of resolving
the on-going controversy cannot be over-emphasized. This is especially so since the greatest
casualties of the conflict are the patients, who are continually barraged from all sides with dif-
ferent ‘expert’ opinions [152]. While each side of the argument has its own merits, it is obvious
that practical utility should not be marginalised in deference to dogma, as has been canvassed
by various authors in recent times [152–154]. The advent of comparative effectiveness studies
and patient-centred healthcare research, therefore, avails healthcare professionals and researchers
on both sides a good opportunity to resolve the controversy by adopting a balanced and more
tolerant, patient-focused approach [155, 156]. In other to achieve such balance, epidemiological
outcome studies of subjective patient-reports can be compared with database outcomes studies of
CAMs and other patient hospital records [157–159]. With many CAMs having been reported to
be efficacious in specific disease conditions, the importance of patient-centred effectiveness studies
in assessing their over-all usefulness cannot be over-emphasized. This is especially important for
homeopathic products, as patient-centred effectiveness studies can help to resolve the controver-
sies generated by the many conflicting results of efficacy studies. Only in this way can a truly
patient-led healthcare system be achieved. The research embodied in this thesis, particularly the
triangulation of research findings reported in chapter five, contributes towards this.
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1.4 Medication safety and pharmacovigilance
1.4.1 Introduction and basic principles
Despite great advances in the field of surgery, the use of medications remains the most com-
mon intervention in allopathic medicine, being the preferred initial intervention in most health
conditions, as well as an essential component of post-surgical management. Understandably,
therefore, adverse outcomes following medicine use constitute the greatest proportion of medical
errors in both adults and young people [160, 161]. These include the generally preventable med-
ication errors (MEs) and the not always predictable adverse drug reactions (ADRs). Although
the importance of reducing MEs is well noted, the key factor in the achievement of medication
safety is the early detection and subsequent prevention of ADRs. This involves the use of not
only hospital-based medication safety assessment techniques, but also the broader principles of
pharmacovigilance (PV) techniques [162, 163].
Originating in the 1960s as a concerted response to the thalidomide disaster, PV is the pharmaco-
logical science that focuses on the detection, assessment, understanding and prevention of ADRs
[162, 164]. Its ultimate goal is to ensure a rational and safe use of medicines, which is generally
achieved via monitoring for, collecting, characterizing, assessing and evaluating information on
adverse effects of medications and related health products both during the drug development pro-
cess and after regulatory approval (post-marketing surveillance). Such information is obtained
through various means, including spontaneous reporting, prescription event monitoring, record
linkage, case-control surveillance, and cohort follow-up studies, among others [162, 165], New
regulatory and scientific processes, such as conditional approval, risk management plans, trans-
parency and increased patient involvement in suspected ADR reporting have also been introduced
to improve effectiveness [164]. It is, however, not clear how these have affected the PV of CAMs.
In spite of these varieties of methods and policies, surveillance schemes based on national spon-
taneous reporting system databases, such as the Yellow Cards Scheme (YCS) of the Medicines
and Healthcare products Regulatory Agency (MHRA), have become the cornerstone for the early
detection of hints that suggest the possibility of hitherto unknown ADRs. Such hints are called
‘signals’; and refer to a set of clinical, pharmacological, pathological, or epidemiological data that
supports a hypothetical argument for a significant public health risk [166, 167]. They are iden-
tified by statistical analysis of the data generated in the database over a given period. Various
methods have been utilised in signal generation, including frequentist and Bayesian statistical
measures of association, such as Chi squared (Yates correction, X2), proportional reporting ratio
(PRR), reporting odds ratio (ROR), Yule’s Q measure (Q), Poisson probability, sequential prob-
ability ratio test (SPRT), information component (IC), empirical Bayes method, and alternative
generation criterion for the empirical Bayes method (EBP) [168]. Using two-by-two contingency
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tables, these quantitative methods essentially measure the disproportionality (or ‘unexpected-
ness’) in the frequency of the report of a given ADR in association with a particular drug relative
to the totality of the reports of that ADR in the database [169–171].
Variations (or combinations) of these methods have been used in different national and interna-
tional pharmacovigilance agencies. For instance, while the WHO Collaborating Centre for Inter-
national Drug Monitoring in Uppsala, Sweden, uses the Bayesian Confidence Propagation Neural
Network method (BCPNN) to measure the IC of drug-event combinations; the US FDA’s Ad-
verse Event Reporting System (AERS) employs the multiple gamma-poisson shrinkage (MGPS)
method [172, 173]. On the other hand, a combination of PPRs and Yates X2 have been utilised
in the UK’s YCS database [174, 175]; while RORs and logistic regression have been used in Dutch
Lareb centre [176]. While comparative studies have not found any particular measure to yield
significantly better results [177], it has been reported that sensitivity is generally higher when
point estimates (PPR, ROR, Yule’s Q, etc.) are used in combination with estimators of the pre-
cision of point estimates (X2, the lower limits of the 95% confidence intervals of point estimates,
etc.) [169]. Although the objective of the doctoral research is not to generate signals for CAM
products, these statistical principles are applied to PV data on CAMs in the research reported in
chapter three of this thesis so as to provide a standard descriptive summary of suspected ADRs
reported for CAM products in our target population.
1.4.2 Importance of patient-reporting of adverse drug reactions
In appraising the various methods that have been utilised in the detection of adverse effects
and measurement of medication safety in adults and children, several studies have highlighted
the importance of surveillance methods involving interaction with in-patients and outpatients
[178, 179]. Apart from cases where diagnosis was required, or where patient consciousness, judge-
ment or communication was impaired [180, 181], the information realised from such interaction
–essentially through patient interviews and surveys- was found to be not only in concord with
that reported by clinicians, but also complementary to it [182, 183]. In addition to the improved
generation of information about the experiences of past patients for the benefit of future patients
in both hospital and community settings, potential advantages of such methods include earlier
detection of adverse effects, and additional toxicity data to compare with efficacy during regula-
tory review [184]. A 2011 HTA of patient-reporting of ADRs in the UK’s YCS [185] found that
patient reports contained a higher median number of suspected ADRs per report, and described
reactions in greater detail, often including the effects of reported ADRs on their quality of life.
Although it noted that patient reports were better at potential signal generation when used in
combination with those from healthcare professionals, it concluded that ADR reporting by pa-
tients or consumers has a great potential to add value to pharmacovigilance in various interesting
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respects. An earlier literature review of patient-reporting of ADRs [186], and another study in
Sweden [187] also arrived at similar conclusions.
Thus, in spite of initial criticism and scepticism [188, 189], the active role of ‘users’ or ‘consumers’
in the assessment of healthcare quality has become firmly established as a ‘sine qua non’ not
only in the achievement of individual patient medication safety, but also in the improvement
of pharmacovigilance efforts for entire populace [190, 191]. However, the general reluctance
of patients to voluntarily report adverse drug events [192, 193], greatly emphasizes the need
for frequent, well-designed and innovative epidemiological studies with a view to eliciting ADE
reports, as such specific proactive projects have been shown to yield more comprehensive results
than the spontaneous reporting scheme (SRS) activities of pharmacovigilance centres [194, 195].
Apart from this intensive monitoring of both hospitalized and out-patients as well as consumers,
the utilization of database studies on adverse drug events based on retrospective medication
and hospitalization-related patient data represents another avenue for quick and inexpensive
generation of additional ADR data [159, 196]. The current work explores these two avenues in
the context of paediatric CAM use.
1.4.3 Pharmacovigilance of CAMs
CAMs are generally promoted as being as effective as -or even more effective and less toxic than-
conventional medicines [197]. Although there is limited information on the safety profiles of
most CAMs, there is documented evidence of better safety profiles for some herbal products and
dietary supplements relative to standard conventional drugs for the specific conditions concerned
[198, 199]. Also, various studies have associated homeopathic medicines with low frequencies of
adverse effects [50, 200]. However, there is also evidence of the association of many widely used
CAMs with both serious and non-serious ADRs [201, 202]. Therefore, in view of the widely held
view that CAMs are natural, and, thus, safe, there is great need to ensure the screening of CAMs
for ADRs. This need is further emphasized by other complicating factors, such as the lack of
standardization of products, the high degree of adulteration of botanicals, and the high risk of
interaction with conventional drugs; as well as the high degree of under-reporting of ADRs due
to CAM use [203, 204]. In Europe, this need has been further underlined by the EU directive
on herbal medicines (established in 2004, but fully effective as from May, 2011) banning the sale
of unlicensed traditional herbal medicinal products within the region (Directive 2004/24/EC).
Another significant development in this regard is the European Medical Agency (EMA)’s four-
year programme (2012-2015) for review of herbal medicines by its Committee on Herbal Medicinal
Products [205].
In spite of these significant milestones, the development of PV practices for CAMs has been
beset by various challenges. A 20-year retrospective analysis of the suspected herbal ADRs
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reported to the WHO Uppsala Monitoring Centre (UMC) published in 2000 highlighted the
problem of confusion over the nomenclature, classification and content of the herbal products
involved, and emphasized the need for international cooperation in ensuring the use of a precise
and consistent nomenclature in national pharmacopoeias [206]. Barnes [207] further highlighted
the problems of public perception, source, utilization, and regulation of herbal medicines, as well
as the difficulties with applying the traditional PV methods to herbal medicines, In addition
to proposing the institution of stricter regulations, and the development of modified methods
and/or new tools for monitoring the safety of herbal medicines, the need to improve public
communication on herbal medication safety, as well as the advantages of widening the reporter
base for herbal ADRs to include herbal medicine practitioners and patients/consumers were also
highlighted. The conclusions of these studies have led to an increase in PV efforts in CAMs
world-wide -even in such areas as Korea and India that have been greatly associated with their
long-term use; and where they enjoy high degrees of acceptance. Among the methods that have
been proposed and utilised in the monitoring and detection of ADRs in CAMs are assessing
historical use [208], controlled clinical trials, systematic and narrative reviews [209], SRS [210],
epidemiological investigations, including primary and secondary data outcomes studies [211], and
new signal detection tools [199]. This doctoral research focuses on the safety outcomes of CAM
use in children as determined from both primary and secondary epidemiologic data.
1.5 Paediatric research
1.5.1 Introducing the paediatric patient
Providing a globally acceptable definition of the paediatric age group has proved difficult. While
paediatrics is defined as the branch of medicine that deals with the medical care of infants,
children, and adolescents/young people [212, 213], there is no general consensus on the upper
paediatric age limit. Generally, based on the guidelines of international health bodies, the age
limit ranges from as low as 14 years to as high as 24 years; with many national paediatrics asso-
ciations preferring not to state a specific cut-off age. While the WHO states that the paediatric
population is typically considered to be between 0 and 14 years of age [214], and the European
Medicines Agency’s Paediatric Committee defines “paediatric population” as “the part of the
population aged between birth and 18 years” [215]; the UN specifies a much higher age limit
for them, defining “youth” as subjects aged 15-24 years, and “young people” as adolescents and
youth aged from 10 to 24 years [216]. The UN definition for “young people” is striking in view of
the definition of “paediatrics” by the Royal College of Paediatrics and Child Health (RCPCH) as
“a medical specialty that manages health conditions affecting babies, children and young people”
[217]. While the RCPCH does not specify an upper age limit for the “young people” included
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in the definition, it is generally understood to cover adolescents up until their 18th birthday,
probably based on the age of majority in the UK and most parts of the world. This traditional
understanding largely agrees with the definition of the United Nations Children’s Fund (UNICEF)
in its Convention on the Rights of the Child, where it defines a child as ‘every human being below
the age of 18 years, unless, under the law applicable to the child, majority is attained earlier’
[218]. It, however, slightly disagrees with the paediatric age specified on the NICE website for
the British National Formulary for Children (BNFC), on which it states that the BNFC “covers
the use of drugs in children of all ages from new-born infants, including those born prematurely,
to individuals aged 18 years” [219].
To manage this controversy for the purposes of this research report, the term “paediatric” will,
in line with the traditional definition, be used to describe “infants, children and adolescents from
birth to age 17 years”, or “up until their 18th birthday”. This position is in line with many
paediatric studies in literature [220–224]. The only exception to the application of this rule in
this thesis is in the aspect of the research reported in chapter two of this thesis, where the word
is used to refer to subjects aged up to 21 years. As that chapter reports the systematic review of
current literature on the perceived effectiveness of paediatric CAM use, this exception is justified
by the goal of not automatically excluding “paediatric” studies conducted in settings where a
broader definition of the word applies.
1.5.2 Identifying the “user” of paediatric medicines
Although medicines are ‘used’ for the basic purpose of improving health, the ‘user’ varies depend-
ing on the type of medication and the context in which it is used. While prescribers must take
the decision to ‘use’ prescription drugs to improve the health status of their patients (clients), the
patients themselves at the same time must accept to ‘use’ them by taking them as prescribed,
for their own personal benefit. Any deviation from this pattern would be termed a misuse or an
abuse of prescription drugs, as appropriate [225]. For non-prescription or self-prescribed over-the-
counter medicines or medicinal products such as CAMs, however, the decision to ‘use’ them often
lies invariably with the consumer, who then goes ahead to also purchase and take them as s/he
deems fit [226, 227]. Here also, the potential for abuse and misuse exists [228, 229]. While this
pattern generally holds true for all adults and some late adolescents, a slightly different pattern
obtains in the context of paediatric subjects. Here, for most infants and young children, the deci-
sion to ‘use’ medicines lies more-often-than-not with the parents/guardians, usually the mothers,
rather than the children who actually take them [230, 231]. Various factors buttress this trend.
For one, because paediatric subjects, irrespective of their actual age, have not reached the “age
of consent”, they are not usually considered “old enough” to take important health care decisions
for themselves [232]. Also, because most paediatric patients are still the responsibilities of their
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parents/guardians, psychological factors and pragmatic considerations by parents play significant
roles in child health decision-making [233, 234]. Additionally, as young paediatric subjects are still
trying to develop their own identifies, their views and perceptions are often coloured by those
of their parents/guardians [235, 236]. With the transition from childhood to adolescence and
early adulthood, however, due to the growing influence of peer pressure and self-efficacy, young
people tend to gradually become more self-opinionated and assertive; and usually come to the
point where they assume full responsibility of their health care decisions [237, 238]. But even at
such a “mature” stage in life, many have been found to still be influenced by the ‘health culture’
established by their parents and families [239, 240]. In view of these trends, in this thesis, the
term ‘user’, while referring where ever possible to the young person actually using the CAM, will
largely refer to the parents/guardians or carers of the paediatric-aged CAM users. This pattern
is in line with literature reports of similar studies in this demographic [241–243].
1.5.3 Specific application to current study
In view of the above, the current research aims at systematically determining the perceived
effectiveness and safety outcomes of CAM use among children in the general population within and
around Aberdeen metropolis through parent users. Also, to get an unbiased view of the general
inclination of parent residents within the Aberdeen metropolitan area towards child CAM use,
their views, opinions and attitudes on/towards CAM use in children are determined irrespective
of their use of CAM in their children. To improve the validity of the findings, and also properly
situate them with respect to current realities, the data reported is generated from both primary
and secondary epidemiologic sources in line with standard public health research methodologies.
1.6 Purpose and plan of study
1.6.1 Research questions
The goal of the research embodied in this thesis is to provide adequate answers to the following
research questions:
1. What is the strength and quality of published literature relating to user-reported effec-
tiveness and safety outcomes of paediatric CAM product use in terms of methodologies,
methods and models?
2. What are the key findings of published literature on the impact of paediatric CAM product
use in terms of user-reported effectiveness and safety outcomes?
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3. What is the extent and nature of the pharmacovigilance data on paediatric CAM product
use in the UK?
4. What is the nature and demography of the use and user-reported outcomes of paediatric
CAM products and practices in the Aberdeen area of NE Scotland with respect to perceived
effectiveness and safety?
5. What implications do the findings have for research and/or health policy and planning in
Scotland?
1.6.2 Aims and objectives of the study
The specific objectives developed to achieve these aims include the following:
1. to identify and systematically review all published literature on user-reported effectiveness
and safety outcomes of paediatric CAM products, using clear inclusion/exclusion criteria;
2. to determine and characterise the MHRA data on paediatric CAM product use with a view
to deducing the associated safety outcomes;
3. to develop suitable and validated user-reported outcomes measures instruments for the
study;
4. to carry out a survey on paediatric CAM use in Aberdeen metropolitan area using the
pre-tested instruments;
5. to carry out descriptive and inferential statistical and regression analyses of the data ob-
tained, as appropriate;
6. to tie together the findings of the various aspects of the research in order to generate valid
consolidated study outcomes; and
7. to draw out conclusions and recommendations from the findings of the study.
1.6.3 General outline of the thesis
This doctoral research is in three sections. The first section reported in chapter two features a
systematic review of the current literature in the field. It sets the global context on the area
of research to provide standard parameters against which the findings of the more local studies
will be compared. The second section documented in chapter three is a report of an exploratory
database analysis of PV data on paediatric CAM product use in the UK. Chapter four details
the findings of the last major aspect of the research, a cross-sectional survey of parents within
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the Aberdeen metropolitan area on the user-perceived and safety outcomes of paediatric CAM
use. Finally, after a triangulation of the findings of these separate strands of the research in
chapter five, the thesis concludes in chapter six with an outline of the associated and resultant
key recommendations of the study for health care policy and planning in Aberdeen, as well as
the whole of Scotland.

Chapter 2
User-Perceived Effectiveness and
Safety Outcomes of Paediatric
Complementary & Alternative
Medicines - A Systematic Literature
Review
2.1 Introduction
The growing popularity of CAM use world-wide has resulted in a surge in the number of publi-
cations on the subject in recent years. As studies focused specifically on CAM use in paediatric
populations are fewer than those for adult populations, there have also been much fewer system-
atic reviews (SRs) on paediatric CAM use studies. On the specific subject of the user-perceived
effectiveness and safety (UPES) outcomes of CAM use in paediatric populations, there is no SR
as yet, as the available SRs have focused mostly on prevalence of CAM use. This chapter aims
at filling this knowledge gap. The SR was mainly aimed at determining the quantity and quality
of available evidence on the outcomes associated with the use of paediatric CAM products (or
CAMs) as published in the English Language in peer-reviewed journals from January 2000 to
July 2011. Special emphasis was placed on the methods used in identified studies with a view to
informing further phases of the doctoral research.
After a general introduction to SR methodology, the peculiarities of SRs of public health inter-
ventions in general are highlighted; before narrowing down to an overview of SRs on CAM use as
a specific public health intervention. The specific aims and objectives of the current SR are then
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outlined, followed by a detailed description of the methods followed in the SR process. Finally,
the findings are reported and discussed in detail. In line with section 1.5 above, so as not to
exclude studies carried out in parts of the world that have a broader definition of the paediatric
population, an upper paediatric age limit of 21 years is used in the SR. Thus the term “paediatric”
is used in this chapter to refer to infants, children and adolescents aged up to 21 years.
An overview of the findings of this first SR on UPES outcomes generally indicates a low method-
ological quality profile among the 46 eligible studies identified, which studied a cumulative pop-
ulation of 9,087 paediatric subjects. The low methodological quality profile identified was found
to be due to a preponderance of study designs with a high tendency to bias and confounding,
and scant use of piloted or standardized data collection tools. Most of the studies included were
primarily descriptive and hospital-based, and utilised mainly self-completion or face-to-face inter-
view methods to collect data usually by proxy report. In addition to the wide variety of definitions
used for CAM therapies among the studies, many different and non-specific constructs were also
used to describe UPES outcomes. While these factors complicated a meta-analytic synthesis of
the outcomes findings reported, an overview of the findings reported indicated a high report of
positive health outcomes by majorities of CAM user sub-populations among the studies (with
the notable exception of three of the five the UK studies included), as well as a low report of
adverse outcomes. These generally positive findings were, however, not evident in the conclusions
and recommendations made by many studies, as study findings on outcomes were often either
disregarded altogether, or reported partially or in negative light. One reason for this could be
the observed high degree of non-application of inferential statistics to UPES outcomes data, even
where such were used for the non-outcomes data reported by the same studies, and for the same
study samples, suggesting a possible selective reporting and/or confirmation bias among study
authors. While the various limitations acknowledged by study authors are note-worthy, the ap-
parent tendency to selective reporting and/or confirmation bias in the studies could imply that
the opinions and perspectives of patients who use CAM are probably not being given sufficient
consideration by health care providers with respect to their (the users’) health-related quality of
life. This raises important ethical issues for social research generally; but more so in the light of
the current global trend towards patient-centred health care. The high report of positive health
outcomes for paediatric CAM use, however, highlight various implications for future research and
clinical practice, as were indicated in a summary of the Patient-Oriented Evidence that Matters
(POEM)-based recommendations made by many of the studies. These recommendations centred
on the need for greater cooperation in decision-making and collaboration in research between
health care providers and paediatric patients and/or their parents, as well as the need for greater
integration of CAM into conventional care settings. All in all, the findings of this review em-
phasize the need for more rigorous, methodologically superior, and user-focused research into
the UPES outcomes of paediatric CAM interventions -particularly in the UK; thus justifying the
inclusion of a survey component in the current doctoral research.
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2.1.1 Systematic Literature Reviews –from First Principles
A literature review in its simplest sense is a summary of the field of a subject that helps to
support the identification of specific research questions [244]. Thus, in addition to demonstrating
a reviewer’s knowledge about a particular field of study [245], literature reviews indicate the
directions for future research by highlighting the gaps in literature [246–248]. There are various
types of literature reviews depending on the perspective from which they are viewed or the purpose
for which they were intended [249]. Methodologically speaking, however, there are essentially two
types of literature reviews –the traditional narrative reviews (NRs) and the more recent SRs [250–
252]. (The other two main types of reviews –meta-analyses [253]and meta-synthesis [254]- are
actually special forms of SRs.). While the traditional NRs are often at best expert opinions given
based on a collection of studies selected and summarized by the author to buttress or showcase
a certain viewpoint, SRs are carried out through a much more objective and rigorous process
[255, 256].
The Cochrane Handbook for Systematic Reviews of Interventions [257] defines a SR as a collation
of all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific
research question. A SR uses explicit, systematic methods that are selected with a view to
minimizing bias and providing reliable findings from which conclusions can be drawn and decisions
made [258, 259]. Such methods generally include the following series of steps: formulating the
research question(s); specifying the inclusion and exclusion criteria and search strategy in a
detailed peer-reviewed protocol; searching for studies on the subject using the pre-defined search
strategy; screening identified studies using the pre-defined inclusion and exclusion criteria so as
to select the studies to be included in the review; extracting all relevant data from included
studies; assessing included studies for methodological quality; critically analysing results and
synthesizing new data from them either quantitatively (in meta-analyses) or narratively; and
finally, making recommendations for practice or future research [260–262]. Thus, a SR differs
from the traditional NR essentially in the robust and methodical manner in which the studies
included in it are identified, and their findings collated, analysed and synthesized in order to
answer the research question(s) that informed the process [263, 264].
SRs were developed as a way to make sense of the numerous publications of the results of various
interventions within the last 50 years. Following Archibald Cochrane’s proposal in 1972 that,
in view of the scarcity of resources, medical care should focus on interventions that have been
shown to work best, based on available evidence [265], it became necessary to develop ways of
achieving a critical appraisal and synthesis of research data on health interventions in order to
determine evidence-based best practices. The first result of such efforts was the development of
the method of meta-analysis in 1975, which statistically integrated data from several independent
“combinable” studies to enable a summary conclusion [266–268]. This method was first applied
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by Glass et al to research in the fields of education [269, 270] and psychotherapy [271]. Cochrane’s
continued calls for systematic reviews in medicine and health, were strengthened by Sackett and
colleagues’ formal definition of evidence-based medicine (EBM) in 1986 [272], and finally resulted
in the opening of the Cochrane Collaboration centre at Oxford in 1992 for the specific purpose
of “preparing, maintaining and disseminating systematic reviews of the effects of health care”
[273]. Although the Cochrane Collaboration has continued to promote and provide guidelines for
SRs of the effects of various health care interventions, with special emphasis on the use of RCT
study designs, the basic principles of SR methodology have come to find application in various
fields of research out with medical or effectiveness research. In each case, the main rationale
behind the application of the SR methodology is to efficiently integrate existing information and
provide data for the guidance of health care providers, researchers, and policy makers in rational
decision making [274–277]. As one of the objectives of the current research is to inform health
policy and planning in the context of CAM as a public health intervention, a SR of the subject
was considered relevant. Primarily, however, the SR was expected to set the context for the
whole doctoral research, by identifying and highlighting the global standards against with the
data generated from the ensuing research would be compared.
2.1.2 Systematic reviews of public health interventions –RCTs vs. observa-
tional studies
This section explains the rationale for not excluding cross sectional studies in the systematic
review: because of their high recognition in the evaluation of public health interventions.
Evidence-based public health (EBPH) differs from EBM in a number of ways, the most signif-
icant of which are the study designs used and the settings in which the intervention is applied
[278]. Medical research studies rely essentially on RCTs, which are considered the “gold stan-
dard” for evaluation of efficacy or clinical effectiveness [279]; while public health interventions
tend to rely a lot more on observational studies (cross-sectional, case-control, cohort, and case
series). While SRs focusing on RCT study designs have generally been accorded the highest
recognition in the standard hierarchy of evidence, the importance of observational study designs
has become increasingly recognized in recent times [280]. Apart from their utility in scenarios
where experimentation may be unnecessary, inappropriate, impossible, or inadequate [281], some
comparative pooled studies have also shown them to yield statistically similar outcomes as RCTs
in some cases[282–284]. Also, because RCTs tend to have high internal validity but low external
validity, the applicability of their findings to real life practice (generalisability) is often limited
[285–287]. Observational study designs therefore afford the opportunity to close the gap between
theory and practice -between what works in ideal conditions (efficacy) and what actually works
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in real life (effectiveness) [288, 289]; so they can supplement the findings of RCTs in this re-
spect [280, 290, 291]. In recognition of this potential contributions of observational studies in
the generation of comprehensive evidence, their inclusion in SRs of health interventions has been
encouraged wherever possible [292–294].
While the contributions of observational studies in general to SRs have been recognized [295], lon-
gitudinal study designs (cohort and case-control) have generally been preferred to cross-sectional
studies and case series for most medical decisions [296, 297]. As such, studies comparing obser-
vational studies with RCTs [282–284] have focused on longitudinal studies, which are ranked just
below RCTs in the hierarchy of evidence [298], rather than on cross sectional studies, which are
placed further down [299]. In EBPH, however, a different scenario obtains [278], as adequacy and
plausibility assessments of public health interventions using cross sectional study designs have
been shown to yield sufficient data to inform health policy decisions at local and/or international
levels [300–302]. Since the major objective of the assessment of the impact of public health inter-
ventions is to inform public health policy [303, 304], cross sectional studies are accorded greater
recognition in EBPH than in EBM [305, 306]. In view of this, a strict adherence to a standard
hierarchy of evidence irrespective of study context has been severally discouraged [121, 307, 308].
These considerations informed the inclusion of cross sectional and other observational studies in
the present review.
2.1.3 Systematic Reviews of CAM Interventions –An Overview
While there has been an upsurge in the publication of SRs on CAM interventions in recent
times, very few of them have been focused on paediatric studies. A scoping search of articles
indexed in Google Scholar conducted by the student in March 2014 shows that of the 62 SRs
on non-specific CAM use, only one was published before 2000; while 16 were published between
2000 and 2009, and the rest (45) were published between 2010 and March 2014. Also, only 6
of the 62 SRs were focused on paediatric studies. In addition, although about 60% of the SRs
(37 out of 62) focused on surveys, with most of them (27) summarizing research on prevalence of
CAM use in various countries, regions, and/or patient populations, none of them focused on user-
perceived effectiveness and safety (UPES) outcomes of CAM use. This same pattern of findings
was obtained when a scoping search of SRs on specific CAM products was conducted. While the
SRs identified for herbal medicines, Bach flower therapies, probiotics, and dietary supplements
focused predominantly on CAM efficacy or clinical effectiveness, also with much fewer studies
for paediatric subjects in each case; none focused on UPES outcomes of CAM use. The lack
of summary evidence on this aspect of CAM use is very significant considering the pivotal role
of perceived effectiveness (PE) as a global driver of CAM use through relationship marketing
and peer-to-peer reports [309–312]. Also, considering the greater vulnerability associated with
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paediatric populations in health and disease [313–315], as well as their significance as the future
generation [316–318], the observed paucity of SRs in that population is obviously troubling.
The above considerations informed the decision to conduct a SR of recent findings on UPES
outcomes of paediatric CAM use as part of the doctoral research on the outcomes associated
with paediatric CAM use. The SR was conducted in August 2011. To ensure a manageable,
contemporary and globally relevant study, the SR was proposed to focus on CAM products used
in infants, children and adolescents aged up to 21 years as published in English in peer-reviewed
journals in the period between January 2000 and July 2011. The specific findings sought to
be summarized by the SR were detailed to include user reports of the perceived outcomes of
their use of paediatric CAMs. More specifically, this included their experiences of paediatric
CAM use with respect to perceived effectiveness or other positive health outcomes (in terms of
perceived helpfulness, usefulness, satisfaction, benefits, improvement, etc.); as well as the adverse
experiences reported as encountered during such CAM use (in terms of user-reported toxic and/or
adverse effects, discomfort, harm, etc.). The study sought to answer the following questions:
1. What is the strength and quality of published literature relating to UPES outcomes of CAM
use in infants, children and adolescents aged up to 21 years in terms of methodologies,
methods and models?
2. What are the key findings of published literature on UPES outcomes of paediatric CAM
use?
In order to answer these questions, the following specific objectives were developed:
• To determine, outline and compare the strengths and weaknesses of all identified studies
on UPES outcomes of paediatric CAM use published in peer-reviewed journals in terms of
methodological quality and consistency of findings;
• To summarize and discuss key findings of the studies identified;
• To identify gaps in the literature to inform further phases of the doctoral research;
• To inform the most appropriate methodological approaches in further research;
• To obtain standard reference data on the subject with which to compare the findings of the
proposed research.
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2.2 Methods
2.2.1 Review Protocol
A review protocol was drafted for the review, and after under-going internal and external review
and a number of amendments, a final copy was adopted for the SR. The protocol was drawn up
in line with standard recommendations for SR as outlined in the guidelines by Centre for Reviews
and Dissemination, University of York [319], taking into consideration the limitations associated
with the doctoral research process [320]. While a full version of the review protocol including
the detailed search strategy used is provided in Appendix (i), a summary of the inclusion and
exclusion criteria of the SR outlined in the standard PICOS format is as follows:
Inclusion criteria
• Populations:
CAM studies focusing on paediatric subjects aged up to 21 years irrespective of health
status, and/or their parents.
• Interventions:
Studies that assessed natural product-based CAM (NP-CAM) modalities or complementary
and alternative medicines (CAMs) alone or in combination with other CAM types were
included. The specific modalities of interest included -herbal medicines, animal parts and/or
minerals, homeopathic medicines, dietary supplements, essential oils, probiotics, Bach flower
remedies, vitamin and mineral supplements, special diets, etc. Traditional Chinese Medicine
was also included as it involves a high application of Chinese medicines.
• Comparators:
No specific comparators or control groups were required for inclusion.
• Outcomes:
Studies reporting any views, opinions, perspectives and perceptions shared, given, or ex-
pressed by users of CAMs in children and adolescents (i. e. the subjects themselves and/or
their parents, guardians or carers) on the effectiveness (helpfulness, benefits, usefulness,
etc.) and safety (adverse or side effects, discomfort, harmfulness, etc.) outcomes of their
CAM use were included.
• Study designs:
Essentially survey, cohort and other observational studies were included, irrespective of
whether they were prospective/retrospective, or quantitative/qualitative in nature; provided
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they were published as full papers in the English language between January 2000 and July
2011.
Exclusion criteria
• Perception studies that focused only on health professionals or other non-user/consumers;
• Studies that focused on the general views, opinions, perspectives and perceptions of CAM
users as to the effectiveness and safety outcomes of NP-CAM, but did so from the perspective
of their expectations, reasons for use, or beliefs, rather than based on their experiences of
using them; and
• Perception studies that did not focus on user perspectives on CAM use, but rather on the
decision-making process involved
2.2.2 Identification and Selection of Studies
Three mega-databases were used to search for papers to be included in the review: the Knowl-
edge Network, EBSCO Host, and Pediatric Complementary and Alternative Medicine (Ped-
CAM). These three were selected because together they were found to hold articles indexed
by the major CAM databases, viz: Allied and Complementary Medicine Database (AMED),
Alt HealthWatch, Cumulative Index to Nursing and Allied Health Literature (CINAHL), CAB
Abstracts, International Pharmaceutical Abstracts (IPA), MEDLINE, EMBASE, PsychINFO,
Complementary and Alternative Medicine Evidence Online (CAMEOL), CAM on PubMed, In-
ternational Bibliographic Information on Dietary Supplements (IBIDS), Medicines Complete,
and Natural products Alert (NAPRALERT). The databases were searched from January 2000
to July, 2011 using the following search terms in various combinations as detailed in the re-
view protocol: “alternative medicin*”, “bach flower”, “Chinese medicin*”, “complementary
medicin*”, “dietary supplement”, “herbal medicin*”, “herbal remed*””, “herbal supplement”,
“holistic health”, “integrative medicin*”, “natural product”, “natural remed*”, “nonconventional
medicin*”, “hom?eopath*”, “megavitamin”, “traditional medicin*”, “unconventional medicin*”,
“adolescen*”, “baby”, “child”, “father”, “infant”, “minors”, “mother”, “p?ediatric” “parent*”,
“teen*”, “youth”, “adverse”, “benefi*”, “discomfort”, “effect*”, “efficacy*”, “harm*”, “help*”,
“improve*”, “opinion”, “perceive”, “perception”, “perspective”, “outcome”, “safe*”, satisf*”,
“use*”, and “view”.
At the conclusion of the search, the student screened the titles and abstracts of identified studies
in a step-wise sequential process to identify and select studies that met the pre-specified inclusion
criteria. One research supervisor independently reviewed a random sample of identified studies at
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each stage of the process, after which the results were compared with the student’s for inter-rater
agreement. Cases where there was lack of consensus were settled either by discussion or by the
opinion of a second supervisor. Where lack of consensus still persisted, the paper concerned was
retained for the next stage of the process. Duplicate studies were removed from the resulting pool
of studies, and a citation search was then carried out by title-screening the reference lists of the
studies for potentially relevant CAM studies. These were then searched for and abstract-screened;
and those that met the inclusion criteria were added to the pool of studies already selected for full
paper screening. Full papers of all studies in the cumulative pool were then assessed for eligibility
based on the pre-specified exclusion criteria. Ineligible studies were excluded from the final list
of studies for data extraction and critical appraisal.
2.2.3 Data Extraction
A data extraction form was developed by the student for the extraction of relevant details from the
selected papers, and was subsequently reviewed for completeness and utility by the review team.
The final version enabled the extraction of 27 different items from each included study. The items
were selected following a consideration of the recommendations in CRD’s guidance for undertaking
reviews in healthcare [319] and an overview of the items included in a random selection of SR
papers on CAM-related topics. The extracted items were of 5 distinct categories. First, general
information on each study was extracted, including the first author’s name and publication year,
the primary/corresponding author’s profession and the place (country) of the study, along with
its setting, geographical spread and duration. Then study sample-related data was collected,
including the target and eventual sample size and the sampling method used, the associated
sample size justification and response rate (RR) data; as well as the type of study participants
and age range of the paediatric subjects involved. The study design & procedure-related data
gathered included the study design, data collection method used, the level of adherence to ethical
considerations, and the transparency of participant recruitment and data collection methods;
as well as the associated study limitations acknowledged by the authors. Then the following
CAM-related data were extracted: level of standardization of the CAM data collection tool; the
type and description of the CAM therapies studied and the prevalence of their use among the
participants; the specific aspects or dimensions of user-perceived effectiveness outcomes focused
on in the study, with their associated level(s) of measurement; and the type of reporter involved.
Finally, the following results-related information was obtained: the specific findings reported
for UPES outcomes, and the level and type of statistical analysis conducted on the data; as
well as whether a valid summary of results and conclusion was provided for such data. Any
recommendations made based on the study findings on UPES outcomes were also recorded. To
ensure an ordered and systematic entry and summary, a specific range of coding categories was
drawn up for each item based on standard and expected report formats for observational studies.
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Any feature encountered in the course of the extraction process that had not been included in
the range of codes originally drawn up for the item concerned was discussed by the review team,
and a final decision was reached on either a suitable existing code or to create an extra one to
accommodate the new feature. The student extracted these data from the selected studies and
entered them into the extraction form; the entries were cross-checked and ratified by a supervisor.
2.2.4 Critical Appraisal & Methodological Quality Assessment
An initial 21-item checklist was developed for critical appraisal of included studies. It comprised
generally broad items drawn from various sources, including the guidelines published by CASP
(Critical Appraisal Skills Programme) and the CRD [319]; standard recommendations of the
STROBE (STrengthening the Report of OBservational studies in Epidemiology), ISPOR (In-
ternational Society for Pharmaco-economics and Outcomes Research) statements, and updated
PRISMA statements [321–323]; and the findings of a recent SR of the reporting of key quality
criteria for survey research in 117 recently published reports of self-administered surveys [324].
After further review by the team, a shortened checklist of 12 assessment criteria specific for ob-
servational studies was adopted for methodological quality assessment of included studies in line
with current recommendations [325, 326]. It comprised 12 fine-grained questions selected from
the 21 questions in the critical appraisal checklist, each of which aimed at determining the risk of
bias associated with various aspects of the study and its findings based on acceptable standards
reported in literature for observational studies. The 12 questions selected for methodological
quality assessment and the type of bias or quality criterion assessed by each are outlined in the
table 2.1.
Table 2.1: List of criteria used for methodological quality assessment during critical appraisal
QUALITY ASSESSMENT INDEX TYPE OF BIAS/QUALITY 
CRITERION ASSESSED 
Is the study design associated with a low tendency to bias and 
confounding? 
Internal validity 
Were study participants defined by clear inclusion/exclusion criteria? Selection bias; External validity 
Was a clear systematic method used for sampling/recruitment? Selection bias 
Were there efforts to obtain a representative sample? Selection bias; generalisability 
Was the sample size justified or ≥300? Selection bias 
Was a response rate ≥60 % achieved? Selection bias; Generalisability 
Was a standard, validated, or piloted (n≥12) CAM tool used? Information bias; internal validity 
Were UPES outcomes data analysed for inference or confounding? Confounding (External validity) 
Was a valid summary of UPES outcomes data provided? Selective outcome reporting 
(Confirmation bias)  
Was the generalisability of findings on UPES outcomes discussed? Generalisability/Applicability  
(External validity) 
Were valid conclusions drawn from study findings on UPES outcomes? Confirmation bias/Conclusion validity 
(External validity) 
Was any POEM bottom line recommendation) made based on UPES 
outcomes data? 
Practical relevance (Usefulness) 
 
The primary factor considered in determining the acceptable standards selected for quality as-
sessment was evidence from literature. Such acceptable standards were particularly relevant for
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the determination of a minimum sample size for a pilot study [327, 328]; and the RR threshold
[329, 330]. For the study sample size, the threshold of 300 participants was selected based on the
calculated sample size of 306 for a minimum study population estimate of 1500 at 95% confidence
interval with a 5% margin of error and 50% response distribution. However allowance was made
for smaller sample sizes provided a clear statistical justification was provided for its use. Efforts
considered indicative of the representativeness of the sample used included the use of multiple
centres [331, 332] or a population-based approach [333, 334], the use of a broad/large database
(rather than a local one) for participant recruitment for mail surveys [335]; and/or continuous
recruitment for at least 12 months [336, 337] to account for possible year-round variations. The
demonstration of the empirical generalisability of study findings was judged by the discussion of
the consistency or otherwise of the findings of the study to those of similar studies conducted
by other researchers [338]. The validity of the results summary or conclusion was based simply
on their being in line with the outcomes data reported in the study, with a view to detecting
confirmation bias [339, 340] or selective outcomes reporting bias [341, 342]. Such forms of bias
have been found to be common in controversial topics like CAM [343–345]; and their report in
systematic reviews is also required in the PRISMA updated guidelines [323]. Finally, as future
research and practice is usually informed by the main findings of previous studies, the report
of patient- and/or practitioner-oriented “bottom line” recommendations based on study findings
on UPES outcomes was considered important for the practical relevance and usefulness of study
findings in the context of Patient-Oriented Evidence that Matters (POEMs) [346, 347]. In this
vein, to align with the focus of the current SR, research-oriented recommendations were deemed
acceptable only where patient views/opinions were included.
The student and at least one supervisor critically appraised the selected studies in line with the
adopted checklists; and afterwards cross-checked their ratings to ensure inter-rater agreement.
In any case of variance, the case was reviewed together to facilitate an accord. Although each
question had two categorical response options, either YES or NO, in cases where there was
difficulty or lack of clarity in determining an unequivocal response with three assessors, the
basis for the difficulty was entered qualitatively for the given criterion instead of a categorical
response. As such only consensus ratings were reported. To enable a comparison of the quality
of included studies, the number of criteria met by each study was recorded. In line with current
recommendations [325, 326], an arbitrary standard of meeting a minimum of 67% of the quality
criteria (i. e. any 8 of the 12 criteria) was considered indicative of high methodological quality.
2.2.5 Data Analysis and Synthesis
To facilitate a narrative synthesis of the findings of this review, aspects of the extracted data
deemed relevant for addressing the specific objectives of the review were entered into SPSS
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(IBM R© SPSS R© Statistics Data Editor Version 21) for statistical analysis. Inter-rater agree-
ment during the screening stage was determined by Cohen’s Kappa. To highlight the similarities
and differences inherent in the selected studies, key characteristics were summarised using appro-
priate descriptive and/or univariate statistics. To determine whether research on the subject has
changed significantly over the years, any differences in study characteristics as well as methodolog-
ical quality between studies published by and after 2005 (the mid-point of the review period) were
analysed for statistical significant difference using univariate and bivariate statistics. Addition-
ally, the various factors associated with methodological quality were determined by appropriate
bivariate analysis. Since the conclusions that would be reached by authors from the findings of
their study would be mainly dependent on the way they summarised the findings of their study,
which in turn would be dependent on the way the findings were analysed statistically, odds ratios
were used to explore any tendency to confirmation bias by separately determining the strength
of any association between the use of inferential statistics for CAM outcomes and non-outcomes
data within the included studies, as well as the likelihood of the authors drawing a conclusion
in line with the data provided when the majority rating was positive or not. Studies with a
majority “positive” rating was described as those in which > 55% of the users surveyed reported
positive health outcomes. Similarly, a majority “negative” rating was associated with studies
where < 45% of the users reported positive health outcomes; while a “borderline” rating was
reserved for those with a PE rating of 45-55%. Percentage scores were rounded off to one decimal
place; and related pairs were compared for statistically significant differences, as appropriate, us-
ing the 2P (2 proportion) Binomial test in MiniTab R© (MiniTab 16). For comparisons, statistical
significant differences were tested for at p ≤ 0.05.
2.3 Results
2.3.1 Study search and selection
A primary search of the 3 selected mega-databases using the specified search terms and combi-
nations yielded a total of 2982 hits. Outputs of two searches made on EBSCO Host database
in August 2011 are provided in Appendix (ii). 21 additional papers were later identified from
other sources -a citation search of the studies initially selected after abstract screening (n=19)
and recommendation from members of the review team (n=2). Following the sequential screening
of titles and abstracts of the 3003 studies cumulatively identified, and the removal of duplicates,
67 papers were retained for full paper eligibility assessment, leading to the exclusion of 21 papers
for various reasons, as outlined in figure 1. The remaining 46 papers were included in the review
for data extraction and critical appraisal. The PRISMA flow chart summarising the study se-
lection process is outlined in figure 2.1. A Kappa coefficient of 0.91 was obtained for inter-rater
agreement for the 100 randomly selected papers screened at the abstract screening stage.
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Figure 2.1: PRISMA Flow Chart for Identification Of Papers For Critical 
Appraisal 
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Figure 2.1: PRISMA Flow Chart for Identification Of Papers For Critical Appraisal
2.3.2 Data Extraction
The 5 categories of items extracted from the included studies are summarised in tables 2.2 to
2.6; while the completed data extraction form (DEF) is presented in table 2.12 at the end of the
chapter. However, the ID numbers of studies with specific distinctive features are provided in
tables 2.2 to 2.6 to facilitate a cross reference with the DEF. The ID numbers correspond to the
serial numbers of the studies in the DEF.
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2.3.2.1 General information on included studies
The 46 studies identified for critical appraisal were contributed by 43 different primary authors
based in 16 different countries in 5 continents of the world. Except for 3 primary authors (April,
K. T. (Canada); Day, A. S. (Australia); and Sawni-Sikand, A. (USA)) who contributed 2 studies
each to the pool of included studies, each primary author contributed a single paper. Most
of the primary or corresponding authors were medical doctors, which profession contributed 32
(70%) of the 46 included studies. While there was no eligible study published in the year 2000,
and the year 2008 contributed most of the studies (9 studies), included studies were generally
uniformly distributed across the period of review (X2=9.478; df=10; p > 0.05). However, many
more studies (29; 63.0%) were published after the mid-point year of 2005 (X2 =3.130; df =1;
p=0.077). The included studies also differed significantly with respect to the country (X2=58.348;
df=15; p¡0.001) and continent (X2=28.348; df=4; p¡0.001) in which the studies were carried out;
with the USA, Canada and Mexico contributing among themselves 21 (46%) of the included
studies, skewing the continental distribution towards North America. The UK contributed 5
studies [348–352], which total was the highest among European countries. However, only 2 of
these studies (and the only ones carried out in Scotland) [351, 352], were published after the year
2005, with the latest published in 2008 [352]. Most of the included studies (38, 83%) were carried
out in clinic-based settings (X2=19.565; df=1; p < 0.001), with 74% of such studies (28 studies)
being carried out in outpatient departments. Only a few studies (12; 26%) recruited participants
from multiple centres/cities or broad databases (X2=10.552; df=1; p=0.001); and although the
recruitment period was not reported in many cases (14 studies; 30%), among the studies where it
was reported, the median study duration was shown to be six months [inter-quartile range (IQR):
2.6-9 months]. These facts are summarised in table 2.2.
2.3.2.2 Study sample-related data
Most of the sample-related data extracted were skewed; with 57% of actual sample size data (26
studies) being skewed towards lower limits of at most 200 respondents, while 65% of the studies
included paediatric subjects aged above 16 years. Also, 28 studies (61%) attained response rates
above 60%, with a mean RR of 78% among the 34 studies that reported such data. Skewing was
also observed with respect to the sampling method used, as well as the provision of a statistical
justification for the sample sizes used. While only 2 studies [348, 353] used the random sampling
method (4%; X2=17.913, df=1; p < 0.001), only 3 studies [348, 354, 355] provided statistical
justification for the sample size used (7%; X2=34.783, df=1; p < 0.001). Although cancer was
the health condition most studied (8 studies; 17%), the studies were uniformly distributed across
the 10 WHO ICD categories studied (X2 =12.143; df=9; p=0.217). However, only 2 studies (4%)
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reported in many cases (14 studies; 30 %), among the studies where it was 
reported, the median study duration was shown to be six months [inter-quartile 
range (IQR): 2.6-9 months]. These facts are summarised in table 2.2.
 
Table 2.2: General characteristics of included studies 
Study parameter 
 
 
Categorical distribution Frequency 
n (%) 
Statistical analysis 
(Descriptives/Χ2 
statistic & p value) 
Study ID number  
in data extraction form (DEF)  
Annual publication 
frequency 
2000 0 (0.0) Modal year of 
publication:  
2008 (9 studies); 
 
 
Study distribution 
around mid-point 
year (2005): 
By -17 (37.0 %); 
After -29 (63.0 %) 
[Χ2 =3.130; df =1; 
p=0.077] 
- 
2001 3 (6.5) 33;36;37 
2002 3 (6.5) 22;29;41 
2003 4 (8.7) 4;10;17;19 
2004 2 (4.3) 21;38 
2005 5 (10.9) 1;6;16;25;28 
2006 3 (6.5) 7;12;40 
2007 6 (13.0) 5;13;16;23;26;30 
2008 9 (19.6) 2;9;20;31;34;35;42;43;46 
2009 3 (6.5) 11;14;15 
2010 5 (10.9) 3;32;29;44;45 
2011 (July) 3 (6.5) 8;24;27 
First/corresponding 
author profession 
Medical doctor 32 (69.6) Modal author 
profession:  
Medical doctor  
(32 studies) 
See DEF 
Other core HCPs  
[Pharm. -2; RN -3] 
5  
(10.9) 
Pharm.: 2;18 
RN: 31;32;38 
Allied HCPs  
[Psych. -3; O. T.-2; Diet. -2]  
7  
(15.2) 
Psych.:13;30;39 ; 
O. T.: 14;15, Diet.: 33;43 
Unclear 2 (4.3) 3;37 
Study distribution by 
continent & country 
Africa  
[Nigeria (1)] 
1  
(2.2) 
Modal continent: 
North America 
 
Comparison across 
continents: 
Χ2 =28.348; df=4; 
p=0.000 
 
Modal country: 
USA 
 
Comparison across 
countries: 
Χ2 =58.348; df=15; 
p=0.000 
 
9 
Asia 
[Hong Kong (1); Israel (1); 
Jordan (1); Singapore (2); 
Turkey (3)] 
 
8  
(17.4) 
Hong Kong: 1, 
Israel: 40, Jordan: 32, 
Singapore: 11;12, 
Turkey: 3;8;31 
Australia  
[Australia (3)] 
3  
(6.5) 
 
16;21;22 
Europe 
[Denmark (1); Ireland (1); 
Switzerland (1); Italy (2); 
Germany (3); UK (5)] 
 
13  
(28.3) 
Denmark: 10, Ireland: 18,  
Swiss: 45, Italy: 24;44, 
Germany: 20;42;46, 
Scot: 26;43. Engld: 19;36;38 
North America  
[Mexico (1); Canada (6);  
USA (14)] 
 
21  
(45.7) 
Mexico: 23, 
Canada: 6;7;14;15;28;37 
USA –See DES 
Type of study setting 
 
Clinic-based  
[OPD (28); ED (3); Hospital 
records (6); Hospital-based 
health  centre (1)] 
 
 
38  
(82.6) 
Comparison across 
type of study 
setting: 
Χ2 =19.565;  
df=1; 
p=0.000 
Modal study setting: 
Outpatient clinics 
(28 studies) 
OPD: See DEF, 
ED: 5;28;45:  
Records: 3;15;21;34;35;38; 
Health centre: 12 
Non clinic-based 
(Registry (4); Online/web 
database (2); Health 
management centre (1); 
School (1)] 
 
8  
(17.4) 
 
Registry: 33;36;37;42; 
Online: 3;39 
Health centre: 20; 
School: 29  
Geographical spread 
of recruitment 
Single centre/local database  34 (73.9) Χ2 =10.552; df=1; 
p=0.001 
See DEF 
Multi-centre/broad database 12 (26.1) 3;7;14;15;20;33;36;37;39;41;42;46 
Study duration  
(Length of participant 
recruitment) 
Up to 6 months  18 (39.1) Median: 6 months;  
[Range:  
0.5-120 month; 
IQR: 2.63-9 month] 
See DEF 
6.5-12 months 10 (21.8) 2;4;5;14;19;24;28;31;32;42 
More than 12 months  4 (8.7) 20;43;44;46 
Not stated 14 (30.4) See DEF 
HCP –health care professional; Pharm. –pharmacist; RN: nurse; Psych. –clinical psychologist;  
O. T. –occupational therapist; Diet,: -dietitician; Scot. –Scotland; Engld. –England; OPD –outpatient 
department; ED –emergency department; 
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were conducted irrespective of participant health condition. These facts are summarised in table
2.3.
Table 2.3: Study sample-related data of included studies
57 
 
Table 2.3: Study sample-related data of included studies 
Study parameter Categorical distribution Frequency 
n (%) 
Statistical 
analysis 
(Descriptives/ 
Χ2 statistic &  
p value) 
Study ID number  
in data extraction form (DEF) 
Target sample size 
(Number of people 
invited to 
participate) 
Up to 200 participants  20 (43.5) Median: 
200 participants;  
[Range:  
39-1595; 
IQR: 101-350] 
See DEF 
201-400 participants  10 (21.7) 2;6;8;13;14;15;17;20;39;44 
401-1000 participants  6 (13.0) 5;10;24;26;27;28 
>1000 participants  3 (6.5) 36;41;42 
Not stated  7 (15.2) 1;3;4;9;10;40;45 
Number of 
respondents 
(Actual sample size 
attained) 
Up to 200 respondents  26 (56.5) Median: 
119 respondents; 
[Range: 36-994;  
IQR: 78.75-276] 
See DEF 
201-400 respondents  11 (23.9) 1;4;8;9;11;15;17;20;26;27;39 
401-1000 respondents  5 (10.9) 5;10;24;28;36 
Not stated  4 (8.7) 41;42;45;46 
Justification of 
sample size used 
Provided  3 (6.5) Χ2=34.783; df=1; 
p=0.000 
32;35;37 
Not provided  43 (93.5) See DEF 
Response rate 
attained 
21-40 %  1 (2.2) Mean (±SD)  
(n=34 studies): 
78.06 % 
(±16.655); 
13 
41-60 %  5 (10.9) 2;6;26;38;44 
61-80 %  13 (28.3) See DEF 
81-100 %  15 (32.6) See DEF 
Insufficient data  9 (19.6) 1;3;4;9;11;40;41;42;45 
Not applicable  3 (6.5) 34;39;46 
Sampling method 
used 
Consecutive  24 (52.2) Modal method: 
Consecutive   
(24 studies) 
See DEF 
Random  2 (4.3) 33;36 
Not described  20 (43.5) See DEF 
Upper age limit of 
paediatric subjects 
<16 years 7 (15.2) Modal upper  
age limit: 
16-18 years  
(27 studies)] 
12;15;23;24;37;42;44 
16-18 years  27 (58.7) See DEF 
19-21 years  3 (6.5) 2;35;39 
Not stated  9 (19.6) 1;4;9;13;27;31;40;41;45 
Disease conditions 
studied  
[International 
classification of 
diseases (ICD) 
classification] 
Neoplasms  8 (17.4) Modal ICD 
category: 
Neoplasms  
(8 studies) 
 
Comparison 
across the 10 
valid ICD classes 
(n=35 studies): 
Χ2 =12.143; 
df=9; 
p=0.217 
12;23;32;33;37;38;40;42 
Endocrine, nutritional and 
metabolic diseases 
3  
(6.5) 
2;20;31 
Mental & behavioural 
diseases 
6  
(13.0) 
3;7;13;16;34;39 
Nervous system diseases 2 (4.3) 6;17 
Ear & mastoid process 
diseases 
1  
(2.2) 
24 
Respiratory system diseases 3 (6.5) 4;29;44 
Digestive system diseases  3 (6.5) 21;22;43 
Skin & subcutaneous tissue 
diseases  
4  
(8.7) 
1;18;19;46 
Musculoskeletal & 
connective tissue diseases  
4  
(8.7) 
14;15;30;35 
Genitourinary system 
diseases 
1  
(2.2) 
25 
Nonspecific/mixed 9 (19.6) 5;9;10;11;26;27;28;45 
No health condition  2 (4.3) 8;36 
2.3.2.3 Study Design & procedure-related data
The study design and procedure-related data of included studies are summarised in table 2.4.
Although most of the included studies (40; 87%) were cross sectional studies, three prospective
longitudinal studies [356–358], a case-control study [359], and a case series [360] were also included.
There was also a secondary study that analysed paediatric data from an on-going, broader online
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survey on autism spectrum disorders [361]. While a variety of data collection methods was used,
face-to-face self-completion questionnaires (19 studies, 41%) and interviews (12 studies, 26%)
were particularly favoured. Although there was high report of adherence to ethical considerations
among included studies, with only 2 studies (4%) [354, 362] not reporting any such considerations
whatsoever, only 14 studies (30%) showed evidence of fully considering the 3 basic ethical factors
required for health and social research involving children –Research Ethics Committee (REC)
approval, informed consent and confidentiality/anonymity [363]. Many studies, however, reported
only obtaining REC approval and informed consent from participants (18 studies; 39%). Also,
only about a third (35%) of the studies transparently reported participant recruitment and data
collection methods, another ethical requirement for research integrity [364].
Table 2.4: Study design and procedure-related data of included studies
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Table 2.4: Study design and procedure-related data of included studies 
Study 
parameter 
Categorical distribution Frequency 
n (%) 
Statistical analysis 
(Descriptives/Χ2 
statistic & p value) 
Study ID number  
in data extraction form (DEF)  
Study design Longitudinal study [Prospective] 3 (6.5) Χ2= 129.217; df=4; 
p=0.000; 
Modal design: 
Cross sectional 
study 
14;44;46 
Case-control study  1 (2.2) 7 
Cross sectional study  40 (87.0) See DEF 
Case series  1 (2.2) 34 
Secondary study (data analysis) 1 (2.2) 39 
Data 
collection 
method 
Interview  
[f-2-f -12; telephone -4;  
medical consultation –1] 
 
17  
(37.0) 
 
Χ2=20.652; 
df=2; 
p=0.000 
 
Modal method: 
Self-completion 
questionnaire 
F2f –See DEF; 
Telephone: 7;12;33;37, 
Medical consultation: 44 
Self-completion questionnaire  
[f-2-f -19; postal -7; Online -1] 
27  
(58.7) 
F2f –See DEF; Online: 3, 
Postal: 13;14;21;35;36;38;42 
Other methods  
 [Patient medical records -1;  
data analysis -1] 
 
2  
(4.3) 
 
Patient medical records: 34 
data analysis: 39 
Transparency 
of data 
collection 
procedure 
Who did it? How? Where exactly? When? & For how long?) 
Transparent (Fully described)  16 (34.8) Χ2= 4.261;  
df=1; 
p=0.039 
 
See DEF Not transparent (Partially 
described)  
30 (65.2) 
Level of 
report of 
adherence to 
ethical 
requirements 
None reported  2 (4.3) Χ2=19.652; 
df =4; 
p=0.001 
12;37 
No REC approval but some 
others reported 
[informed consent -5;   
anonymity/confidentiality -2; 
Both -1 study] 
8 (17.4) Informed consent: 
2;3;18;26;44, 
anonymity/confidentiality: 
11;13, 
Both: 27 
REC approval only 4 (8.7) 1;8;29;34 
REC approval & informed 
consent only 
18 (39.1) See DEF 
Fully considered all ethical 
considerations above  
14 (30.4) See DEF 
f2f –face-to-face: REC –research ethics committee 
 
2.3.2.4 CAM-related data 
Although CAM was described to study participants mostly by providing examples 
or a list of therapies (28 studies), various definitions were used among the 
studies. However, in 7 studies (15 %) {{118 Johnston 2003; 173 Losier 2005; 
874 Hughes 2007; 78 Arykan 2009; 919 Zebracki 2007; 917 AlQudimat, M.R. 
2010; 1662 Zuzak 2010;}}, there was no report whatsoever of any CAM 
definition or description being provided to participants. Although many studies 
reported a previous use or pilot of the CAM outcomes data collection tool used, 
with 17 of them (37 %) reporting a revision of the tool after a pilot, only 4 
studies {{833 Hurvitz 2003; 729 Dannemann 2008; 917 AlQudimat, M.R. 2010; 
1954 Rossi 2010;}} utilised validated instruments for collecting CAM outcomes 
data. However, 21 studies (46 %) provided no information whatsoever on the 
level of standardisation of the instrument used. Although various different terms 
were used to describe the positive health outcomes studied, the most popular 
terms were perceived improvement (14 studies; 30 %), perceived 
effectiveness/efficacy (10 studies; 22 %) and perceived helpfulness (8 studies; 
17 %). Although outcomes were reported predominantly by proxy (37 studies; 
80 %), and were measured mostly at a nominal and/or ordinal levels (23 
studies; 50 %), higher levels of measurement as well as more direct forms of 
2.3.2.4 CAM-related data
Although CAM was described to study participants mostly by providing examples or a list of
therapies (28 studies), various definitions were used among the studies. However, in 7 studies
(15%) [349, 355, 365–369], there was no report whatsoever of any CAM definition or description
being provided to participants. Although many studies reported a previous use or pilot of the
CAM outcomes data collection tool used, with 17 of them (37%) reporting a revision of the tool
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after a pilot, only 4 studies [355, 358, 370, 371] utilised validated instruments for collecting CAM
outcomes data. However, 21 studies (46%) provided no information whatsoever on the level of
standardisation of the instrument used. Although various different terms were used to describe
the positive health outcomes studied, the most popular terms were perceived improvement (14
studies; 30%), perceived effectiveness/efficacy (10 studies; 22%) and perceived helpfulness (8
studies; 17%). Although outcomes were reported predominantly by proxy (37 studies; 80%),
and were measured mostly at a nominal and/or ordinal levels (23 studies; 50%), higher levels of
measurement as well as more direct forms of outcome report were also used. These characteristics
of the studies are summarised in table 2.5.
Table 2.5: CAM-related data of included studies
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outcome report were also used. These characteristics of the studies are 
summarised in table 2.5.
Table 2.5: CAM-related data of included studies 
Study 
parameter 
Categorical distribution Frequency 
n (%) 
Statistical 
analysis 
(Descriptives/Χ2 
statistic & p 
value) 
Study ID number  
in data extraction form (DEF) 
CAM definition  
/description to 
participants 
None reported  7 (15.2) Χ2=42.304; 
df =2; 
p<0.001 
18;19;28;30;31;32;45 
Definition provided  
[Only defined -8; examples/list 
of therapies also provided -28] 
 
36  
(78.3) 
 
See DEF 
No definition needed  3 (6.5) 1;44;46 
Dimension of 
perceived 
effectiveness 
measured 
Effectiveness/efficacy  10 (21.7) Χ2=17.913; 
df=6 
p=0.007 
2;4;20;21;24;26;29;38;43;45 
Helpfulness  8 (17.4) 6;13;16;27;28;30;35;36 
Usefulness  2 (4.3) 8;23 
Satisfaction  4 (8.7) 5;31;37;41 
Improvement  14 (30.4) See DEF 
Benefits  6 (13.0) 7;9;14;15;25;32 
Positive effects/experiences  2 (4.3) 10;17 
Level of 
standardization 
of CAM 
outcomes data 
collection tool 
No report of pilot or validation 21 (45.7) Χ2=51.565; 
df=5; 
p=0.000 
See DEF 
Tool previously used  2 (4.3) 5;8 
Developed and reviewed  2 (4.3) 21;22 
Piloted & revised  17 (37.0) See DEF 
Piloted & validated  3 (6.5) 17;20;32 
Standard tool  1 (2.2) 44 
Level of 
outcome 
measurement 
Not described  18 (39.1) Χ2=44.931; 
df=6; 
p=0.000 
See DEF 
Nominal scale  8 (17.4) 1;6;8;13;19;23;26;36 
Ordinal scale  14 (30.4) See DEF 
Interval scale  2 (4.3) 38;44 
Ratio scale  2 (4.3) 35;46 
Mixed [Nominal & Ordinal]  1 (2.2) 3 
Qualitative report 1 (2.2) 37 
Type of UPES 
outcomes 
report 
Not stated/Unclear 3 (6.5) Χ2=105.739; 
df=4; 
p=0.000 
2;36;44 
Self-report  1 (2.2) 29 
Proxy report  37 (80.4) See DEF 
Mixed report 4 (8.7) 10;19;40;46 
Joint report  1 (2.2) 35 
 
2.3.2.5 Results-related data 
Except in 3 studies (7 %) in which study findings on UPES outcomes were 
reported as mean ratings of PE and AE of therapies {{921 Molassiotis, A. 2004; 
3061 Keil 2008; 920 Rouster-Stevens 2008;}}, outcomes findings were reported 
mainly as percentages of users rating PE or AE. While in most cases, these 
percentages were presented for overall CAM use by participants, in 13 studies, 
they were more specifically presented either for the individual CAM therapies 
used {{918 Neuhouser 2001; 66 Madsen 2003; 151 Soo 2005; 102 Wong 2006; 
677 Hanson 2007; 34 Senel 2010; 922 Christon 2010; 907 Huillet 2011;}}, or 
for the episodes/experiences of CAM use {{760 Simpson, N. 2001; 118 Johnston 
2003; 1376 April 2009; 356 April 2009; 729 Dannemann, K. 2008;}}. One study 
{{910 Ben 2006;}}, however, reported PE outcomes based on both user 
percentage and the therapies used; while another study {{922 Christon 
2010;}}, in addition to presenting PE outcomes as percentages of the degrees of 
2.3.2.5 Resul s-r lated data
Except in 3 studies (7%) in which study findings on UPES outcomes wer reported as mean
ratings of PE and AE of therapies [350, 357, 372], outcomes findings were reported mainly as
percentages of users rating PE or AE. While in most cases, these percentages were presented for
overall CAM use by participants, in 13 studies, they were more specifically presented either for the
individual CAM therapies used [220, 353, 359, 361, 373–376], or for the episodes/experiences of
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CAM use [348, 349, 356, 371, 377]. One study [378], however, reported PE outcomes based on both
user percentage and the therapies used; while another study [361], in addition to presenting PE
outcomes as percentages of the degrees of user ratings for respective therapies, also distinctively
applied odds ratios to determine the general direction of PE ratings for respective therapies, in
terms of the degree of improvement reported by users.
The results-related data of included studies are summarised in tables 2.6 and 2.7. Table 2.6 shows
that, the proportion of users reporting positive outcomes following CAM use ranged from as low
as 35% [349] to as high as 99% [379], with a median PE rating of 72.5%. Discounting the 3 studies
that utilised mean PE ratings, the outcomes of CAM use were generally perceived as positive by
over 55% of users in 34 of 43 studies (79%). While AE outcomes were not studies in 27 of the
studies (59%), of the 19 studies that studied it, the AE outcomes reported ranged from 0-11.9%,
with a median of 4%, and a mean of 4.3%. While these outcomes data were validly summarised
in 34 studies (74%), valid conclusions were reached in only 21 of the cases (46%), indicating a
high degree of disparity. Detailed analysis based on study categorisation based on the majority
outcomes rating by users suggests this disparity to be due to the disregard of positive outcomes
reported by majority of the users sampled. With respect to providing a valid summary of the
outcomes data reported, for instance, 92% of the 12 studies in which outcomes data were either
not summarised at all or not validly summarised (11 studies) reported positive outcomes by a
majority of CAM user samples surveyed. Similarly, 22 of the 25 studies (88%) which either did not
provide any conclusion based on the outcomes data reported or made ambivalent or misleading
conclusions also reported positive outcomes by > 55% of CAM users in the study samples.
Table 2.6 also shows that there was a disparity in the type and degree of statistical analyses
applied to the outcomes and non-outcomes data reported in the studies. While there was a
uniform spread in the level of statistical analyses used for non-outcomes data in included studies
(X2=4.957; df=3; p=0.175), with a generally high use of inferential statistics; the statistical
analyses applied to outcomes data in the studies were highly skewed towards descriptive statistics
(X2=68.783; df=4; p=0.000), with scant use of inferential statistics. Thus, while CAM UPES
outcomes data were mostly presented using only descriptive statistics (31; 67%), non-outcomes
data were mostly presented using inferential statistical analyses (40 studies; 87%). Also, among
the 15 studies in which multivariate analyses were applied to non-outcomes data, such analyses
were extended to UPES outcomes data in only 3 cases [357, 358, 370]. A comparative analysis
reported in table 2.7 confirms the statistical significance of these observations, as the application
of inferential statistics was found to differ significantly between outcomes and non-outcomes
data (87% vs. 30%; z = 6.72; p < 0.001). Table 2.7 also highlights the statistically significant
disparity between the proportion of studies that validly summarised the outcomes data reported
and the proportion that provided a valid conclusion for the study based on the outcomes data
they reported.
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user ratings for respective therapies, also distinctively applied odds ratios to 
determine the general direction of PE ratings for respective therapies, in terms of 
the degree of improvement reported by users.  
 
Table 2.6: Results-related data of included studies 
Study parameter Categorical distribution Frequency 
n (%) 
Statistical analysis 
(Descriptives/Χ2 
statistic & p value) 
Study ID number  
in data extraction form (DEF) 
Level & type of 
statistical analysis 
used for non-
outcomes data 
Only descriptive statistics  6 (13.0) Χ2=4.957;  
df=3; 
p=0.175 
2;3;16;18;22;37 
Descriptive & univariate  15 (32.6) See DEF 
Descriptive & bivariate  10 (21.7) 7;9;10;12;19;23;29;35;38;40 
Descriptive & multivariate 15 (32.6) See DEF 
Level & type  
of statistical 
analysis used  
for  
outcomes data 
No statistical analysis  1 (2.2) Χ2=68.783;  
df=4; 
p=0.000 
3 
Only descriptive statistics  31 (67.4) See DEF 
Descriptive & univariate  9 (19.6) 1;5;8;10;23;24;35;38;45 
Descriptive & bivariate  2 (4.3) 29;43 
Descriptive & multivariate 3 (6.5) 17;44;46 
Proportion of users 
reporting PE  
[Majority  
rating among 
users] 
Data unclear or N/A  
(Uncl/NA) 
4  
(8.7) 
Mean (SD): 
71.1 (15.7) %; 
Median: 72.5 % 
[Range:35-99 %; 
IQR: 57.5-84.5 %] 
Modal category:  
>55 %  
[Mostly positive] 
Unclear: 9;  
N/A: 35;38;46 
<45 %  
[Mostly negative (-VE)]  
4  
(8.7) 
13;18;19;45 
45-55 %  
[Borderline (Bordl.)] 
4  
(8.7) 
6;31;41;43 
>55 %  
[Mostly positive (+VE)] 
34  
(73.9) 
See DEF 
Proportion of users 
reporting AEs 
0 % (none reported)  3 (6.5) Mean (SD):  
4.2 (3.3) %; 
Median: 4.0 % 
[Range: 0-11.9 %; 
IQR: 1.5-6.3 %] 
Modal category: 
 Not studied 
22;44;46 
1-5 %  6 (13.0) 6;8;25;27;34;42 
6-10 % 4 (8.7) 9;10;12;45 
>10 % 1 (2.2) 20 
Qualitative report  1 (2.2) 3 
Data unclear  4 (8.7) 33;35;37;43 
Not studied  27 (58.7) See DEF 
Validity of 
summary provided 
on outcomes data 
[Majority rating 
type]  
No summary provided 
[+VE -8] 
8 (17.4) Χ2= 34.609;  
df=2; 
p=0.000 
4;10;11;28;29;36;40 
Not validly summarised in line 
with data provided 
[+VE -3; Uncl -1] 
4  
(8.7) 
+VE: 5;;21;32; 
Uncl: 9 
Validly summarised in line with 
data provided 
[+VE -23; Bordl. -4; 
-VE -4; N/A -3] 
34  
(73.9) 
+VE: See DEF; 
Bordl.: 6;31;41;43; 
-VE: 13;18;19;45; 
Not applicable: 35;38;46 
Type of conclusion 
made on UPES 
findings 
[Majority rating 
type] 
No conclusion provided  
[+VE 18; Bordl -2; -VE -1] 
21 (45.7) Χ2= 12.565;  
df=2; 
p=0.002 
+VE: See DEF; 
Bordl.: 41;43; -VE: 13 
Ambivalent or misleading 
[+VE -4] 
4  
(8.7) 
2;3;7;39 
Valid conclusion in line with 
data reported 
[+VE -12; Bordl. -2;  
-VE -3; Uncl/NA -4] 
21  
(45.7) 
+VE: See DEF; 
Bordl.: 6;31; 
-VE: 18;19;45; 
Uncl/NA: 9; 35;38;46 
Type of POEM-
based 
recommendation 
made based on 
outcomes data 
reported 
None made 
[None on outcomes -18; 
None related to practice or 
outcomes research -7]  
25 (54.3) Χ2= 21.652;  
df=3; 
p=0.000 
See DEF 
Calling for (improved) 
outcomes research  
6  
(13.0) 
3;9;30;35;40;46 
Directed at HCPs  6 (13.0) 1;16;24;28;38;44 
Both practice & research-
oriented  
9  
(19.6) 
7;13;14;15;17;20;32;33;37 
PE –perceived effectiveness; AE –adverse effects; N/A –not applicable; UPES –user-perceived effectiveness & 
safety outcomes; HCP –health care professionals; POEM –patient-oriented evidence that matters; 
+VE rating –positive outcomes rating by >55 % of users; Bordl. Rating –positive outcomes rating by 45-55 % 
of users; -VE rating –positive outcomes rating by <45 % of users
 
The results-related data of included studies are summarised in tables 2.6 and 
2.7. Table 2.6 shows that, the proportion of users reporting positive outcomes 
following CAM use ranged from as low as 35 % {{118 Johnston 2003;}} to as 
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Table 2.7: 2-Proportion Binomial test for disparities in some results-related data among in-
cluded studies
27 
 
summarised the outcomes data reported and the proportion that provided a valid 
conclusion for the study based on the outcomes data they reported. 
 
Table 2.7: 2-Pro rtion Binomial test for disparities in some results-
related data among included studies 
Parameter tested ≠ of 
studies 
with 
parameter 
≠ of 
studies 
tested  
Proportions 
to be 
tested 
 
Test for 
difference  
[z score] 
95% CI for 
difference 
 
P 
value 
 
Valid summary of results 34 46 74 % 74 % vs. 46 %; 
[Z = 2.89] 
(0.091-0.474) 
 
0.004 
Valid conclusion drawn 21 46 46 % 
Use of inferential/Multivariable 
statistics in paper 
40 46 87 %  
87 % vs. 30 %; 
[Z = 6.72] 
 
(0.400 -0.730) 
 
 
0.000 
 Use of inferential/Multivariable 
statistics for UPES outcomes 
14 46 30 % 
 
Although the outcomes reported were validly summarised in 34 studies (74 %), 
valid conclusions were made in only 21 studies (46 %), with the 2 proportions 
differing significantly (74 % vs. 46 %;z =2.89; p<0.05). Following from the 
results reported in table 2.7, the odds of drawing a valid conclusion based on a 
valid summary of the outcomes data reported was determined as a test of a 
possible confirmation bias, and the output is displayed in tables 2.8 and 2.9. 
 
Table 2.8: Cross-tabulation of odds of drawing valid conclusions from a 
valid summary of outcomes data 
Was a valid summary of outcomes data provided? * 
Were valid conclusions drawn from study findings on 
UPES outcomes?  
Cross-tabulation 
Were valid conclusion 
drawn from study 
findings on UPES 
outcomes? 
Total 
Yes No 
 
Was a valid summary 
of outcomes data 
provided? 
 
Yes 
Count 19 15 34 
% within Was a valid summary of 
outcomes data provided? 
55.9 % 44.1 % 100 % 
 
No 
Count 2 10 12 
% within Was a valid summary of 
outcomes data provided? 
16.7 % 83.3 % 100 % 
Total  Count 21 25 46 
 % within Was a valid summary of 
outcomes data provided? 
45.7 % 54.3 % 100 % 
 
 
Table 2.9: SPSS risk estimate output for test of confirmation Bias  
PARAMETER TESTED Value Confidence 
Interval 
Implication 
Lower Upper 
Odds Ratio for: was a valid summary of outcomes data 
presented? (Yes/No) 
6.333 1.201 33.385 Significant 
association 
Relative Risk for cohort: Were valid conclusions drawn 
for study findings on UPES outcomes? (Yes) 
3.353 0.914 12.302 Non-significant 
association 
Relative Risk for cohort: Were valid conclusions drawn 
for study findings on UPES outcomes? (No) 
0.529 0.336 0.835 Significant 
association 
Although the outcomes reported were validly summarised in 34 studies (74%), valid conclusions
were made in only 21 studies (46%), with the 2 proportions differing significantly (74% vs. 46%;z
=2.89; p < 0.05). Following from the results reported in table 2.7, the odds of drawing a valid
conclusion based on the type of majority PE rating reported for the study was determined as a
test of possible confirm tion bias, and the output is displayed in tables 2.8 a d 2.9.
Table 2.8: Cross-tabulation of the odds of drawing valid conclusions based on the type of
majority PE rating reported in the study
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Although the outcomes reported were validly summarised in 34 studies (74 %), 
valid conclusions were made in only 21 studies (46 %), with the 2 proportions 
differing significantly (74 % vs. 46 %; z =2.89; p<0.05). Following from the 
results reported in table 2.7, the odds of drawing  valid conclusion based on the 
type of the majority PE rating reported for the study was det rmined as a test of 
a possible confirmation bias, and the output is displayed in tables 2.8 and 2.9. 
 
Table 2.8: Cros tabulati n of odds of drawing valid conclusions based 
on the type of the majority PE rating reported inn study 
Were valid conclusions drawn from outcomes data provided? * 
Was a POSITIVE majority rating of PE outcomes (PE >55 %) 
reported for the study?  
Cross-tabulation 
Was a POSITIVE majority 
rating of PE outcomes (PE 
>55 %) reported for the 
study?  
Total 
Yes No 
 
Were valid 
conclusions drawn 
from outcomes data 
reported? 
 
Yes 
Count 12 9 21 
% within Were valid conclusions drawn 
from outcomes data reported? 
57.1 % 42.9 % 100 % 
 
No 
Count 22 3 25 
% within Were valid conclusions drawn 
from outcomes data reported? 
88.0 % 12.0 % 100 % 
Total  Count 34 12 46 
 % within Were valid conclusions drawn 
from outcomes data reported? 
73.9 % 26.1 % 100 % 
 
 
Table 2.9: SPSS risk estimate output f r test of confirmation Bias  
PARAMETER TESTED Value Confidence 
Interval 
Implication 
Lower Upper 
Odds Ratio for: Were valid conclusions drawn from outc mes 
data reported? (Yes/No) 
0.182 0.041 0.802 Significant 
association 
Relative Risk for cohort: Was a POSITIVE majority rating of 
PE outcomes (PE >55 %) reported for the study? (Yes) 
0.649 0.436 0.966 Significant 
association 
Relative Risk for cohort: Was a POSITIVE majority rating of 
PE outcomes (PE >55 %) reported for the study? (No) 
3.571 1.108 11.156 Significant 
association 
 
Table 2.9: SPSS risk estimate output for test of confirmation Bias
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valid conclusions were made in only 21 studies (46 %), with the 2 proportions 
differing significantly (74 % vs. 46 %; z =2.89; p<0.05). Following from the 
results reported in table 2.7, the odds of drawing a valid conclusion based on the 
type of the majority PE rating reported for the study was determined as a test of 
a possible confirmation bias, and the output is displayed in tables 2.8 and 2.9. 
 
Table 2.8: Cross-tabulation of odds of drawing valid conclusions based 
on the type of the majority PE rating reported inn study 
Were valid conclusions drawn from outcomes data provided? * 
Was a POSITIVE majority rating of PE outcomes (PE >55 %) 
reported for the study?  
Cross-tabulation 
Was a POSITIVE majority 
rating of PE outcomes (PE 
>55 %) reported for the 
study?  
Total 
Yes No 
 
Were valid 
conclusions drawn 
from outcomes data 
reported? 
 
Yes 
Count 12 9 21 
% within Were valid conclusions drawn 
from outcomes data reported? 
57.1 % 42.9 % 100 % 
 
No 
Count 22 3 25 
% within Were valid conclusions drawn 
from outcomes data reported? 
88.0 % 12.0 % 100 % 
Total  Count 34 12 46 
 % within Were valid conclusions drawn 
fr  outcomes data reported? 
73.9  26.1 % 100 % 
 
 
Table 2.9: SPSS risk estimate output for test of confirmation Bias  
PARAMETER TESTED Value Confidence 
Interval 
Implication 
Lower Upper 
Odds Ratio for: Were valid conclusions drawn from outcomes 
data reported? (Yes/No) 
0.182 0.041 0.802 Significant 
association 
Relative Risk for cohort: Was a POSITIVE majority rating of 
PE outcomes (PE >55 %) reported for the study? (Yes) 
0.649 0.436 0.966 Significant 
association 
Relative Risk for cohort: Was a POSITIVE majority rating of 
PE outcomes (PE >55 %) reported for th  study? (No) 
3.571 1.108 11.156 Significant 
association 
 
Odds ratio estimates clearly show the much reduced odds of drawing valid conclusions from
outcomes data reported by the studies (OR 0.18; 95 % C I: 0.041- 0.802). This finding was also
shown to be associated with reduced chances of drawing valid conclusions when the majority PE
rating was positive (P >55 %) (RR 0.649; 95 % C I: 0.436-0.966); and about 4-fold likelihood of
doing same when the majority PE rating was not positive (RR 3.571; 95 % C I: 1.108-11.156)
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-that is, when the majority PE rating was either borderline (PE= 45-55 %) or negative (PE <45
%).
Only 21 studies (46%) made POEM-based recommendations on the UPES outcomes findings
they reported. The full extracts of all the recommendations made based on UPES outcomes
are included in the data extraction form in table 2.12. A coherent synthesis of the POEM-
based recommendations made by the various studies, however, goes as follows: in view of the
predominantly positive UPES outcomes reported for CAM use in children, the time has come for
healthcare researchers and providers not only to become sensitive to parental attitudes towards
CAM [375] and respect their wishes to use CAM even if its efficacy is not yet proved [371], but also
to aim to work together with parents who choose to use CAM [380] by adapting to and supporting
their needs [354], and helping them to properly evaluate the benefits of CAM [365, 374, 375]. In
this way, health professionals can practically evaluate the use of CAM in children [356, 377] with
a view to identifying safe and potentially helpful therapies [354], and optimising the positive
outcomes reported for such therapies [380]. While further research is needed to substantiate
apparent benefits of CAM [359] in terms of improved clinical outcome or enhanced quality of life
among pediatric patients [353], it should be understood that potential interactions and benefits of
CAM cannot be determined without adequate information on patient and parent CAM behaviour
[355]. As such, future research, rather than aiming to understand why patients turn to CAM
in general [354], should focus instead on therapies that parents feel are helpful and low in side
effects [372]; and must consider effectiveness in relation to users’ expected outcomes [354]. In
other words, clinical trials should be aimed at establishing the validity of parents’ claims, and
assessing the safety of CAM therapies for children [381]. While such research continues, the use
of therapies with high safety profiles that have been found to be consistently associated with
positive and beneficial effects [350] should be encouraged in conditions where they have been
found useful [380]. This is particularly so for children with high health care needs [356, 377]
such as recurrent conditions like acute otitis media [382] or paediatric respiratory ailments [358];
chronic conditions like physical disabilities [377], cerebral palsy [370]; or incurable conditions like
cancer [350]. This would ensure that patients’ (and parents’) desires to “leave no stone unturned”
[362] is considered, and that they are not denied any therapy that could prove helpful when
integrated into their conventional treatments [350, 370]. To facilitate this integration process,
health care providers need to gain some familiarity with CAM therapies most often reported as
useful [382, 383], communicate with patients about various treatment options, and make referrals
wherever appropriate [353]. Additionally, they should try to understand what factors make CAM
modalities desirable and effective either directly, on their own [370], or indirectly, by differentially
affecting the child’s medical and psychological status and, thus, contributing to a positive outcome
and optimal overall functioning [368]; so as to consider how these factors can be woven into the
“standard care” that children currently receive [370].
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2.3.3 Quality Assessment
The results of the quality assessment of included studies based on the 12 quality indices se-
lected are outlined in table 2.10; while a summary of the overall performance of included studies
presented is in table 2.11. Generally, included studies fared poorly in terms of methodological
quality, with an overall quality rating of 45% (251/552 points) across the studies, and only 9
studies (20%) meeting the pre-set minimum of 8 quality indices indicative of high quality.
Table 2.10: Results of quality assessment of included studies
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Table 2.10: Results of quality assessment of included studies 
ID 
no 
Low 
tendency 
to bias & 
confoundi
ng? 
Clear 
inclusion/ 
exclusion 
criteria? 
Clear 
systematic 
sampling 
method? 
Efforts 
towards 
representati
ve sample? 
Sample 
size 
justified 
or 
≥300? 
RR 
≥60 
%? 
CAM 
tool 
validate
d/ 
piloted 
(n=12)? 
Inferential 
statistical 
analyses/ 
confounding
? 
Valid 
summar
y of 
outcome
s data? 
Discussed 
generalisa
bility? 
Valid 
conclusi
ons 
drawn? 
POEM 
recomm
endation
? 
QA 
Score 
(x/ 
12) 
1 No No No No No NR No Yes Yes Yes No Yes 4 
2 No No No No No No No No Yes No No No 1 
3 No No Yes Yes No No No No Yes Yes No Yes 5 
4 No No No No Yes NR No No No No No No 1 
5 No Yes No No Yes Yes Yes Yes No Yes No No 6 
6 No Yes No No No No No No Yes Yes Yes No 4 
7 Yes Yes No Yes No Yes No No Yes No No Yes 6 
8 No No No No No  Yes Yes Yes No Yes No No 4 
9 No Yes No No Yes NR NRn No No Yes Yes Yes 5 
10 No Yes Yes No Yes Yes No Yes No No No No 5 
11 No No No No Yes NR No No No No No No 1 
12 No Yes No No No Yes No No Yes Yes Yes No 5 
13 No No No Yes No No No No Yes No No Yes 3 
14 Yes Yes No Yes No Yes NRn No Yes Yes Yes Yes 8 
15 No Yes No Yes No Yes No No Yes Yes Yes Yes 7 
16 No Yes No No No Yes No No Yes Yes No Yes 5 
17 No Yes Yes No No Yes Yes Yes Yes No Yes Yes 8 
18 No No No No No Yes No No Yes Yes Yes No 4 
19 No Yes Yes No No Yes No No Yes Yes Yes No 6 
20 No Yes No Yes No Yes Yes No Yes Yes Yes Yes 8 
21 No No Yes Yes No Yes NRn No No Yes No No 4 
22 No No No No No Yes NRn No Yes Yes No No 3 
23 No No Yes No No Yes NRn Yes Yes Yes Yes No 6 
24 No Yes Yes Yes Yes Yes No Yes Yes Yes No Yes 9 
25 No Yes No No No Yes No No Yes Yes No No 4 
26 No No Yes No Yes No No No Yes No No No 3 
27 No No Yes No Yes Yes No No Yes Yes Yes No 6 
28 No Yes No No Yes Yes Yes No No No No Yes 5 
29 No Yes Yes No No Yes NRn Yes No No No No 4 
30 No Yes Yes No No Yes No No Yes No Yes Yes 6 
31 No Yes Yes Yes No Yes No No Yes No Yes No 6 
32 No Yes No No Yes Yes Yes No No No No Yes 5 
33 No Yes Yes Yes No Yes No No Yes Yes No Yes 7 
34 No Yes Yes No No NR. No No Yes No Yes No 4 
35 No Yes Yes No No Yes No Yes Yes Yes Yes Yes 8 
36 No Yes Yes Yes Yes Yes NRn No No No No No 5 
37 No Yes Yes Yes Yes Yes No No Yes No Yes Yes 8 
38 No Yes Yes No No No No Yes Yes Yes Yes Yes 7 
39 No Yes Yes Yes No No No Yes Yes Yes No No 6 
40 No Yes Yes No No NR No No No Yes Yes Yes 5 
41 No No No Yes Yes Yes NRn No Yes Yes No No 5 
42 No Yes Yes Yes Yes NR No No Yes Yes No No 6 
43 No Yes Yes Yes No Yes Yes Yes Yes Yes No No 8 
44 Yes No Yes Yes No No Yes Yes Yes Yes Yes Yes 9 
45 No Yes No No Yes NR Yes Yes Yes No Yes No 6 
46 Yes Yes Yes Yes No Yes No Yes Yes Yes Yes Yes 10 
Total 
(%) 
4  
(8.7) 
31  
(67.4) 
24  
(52.2) 
17  
(37.0) 
15 
(32.6) 
30 
(65.2) 
9  
(19.6) 
15 
(32.6) 
33 
(71.7) 
29 
(63.0) 
21 
(45.7) 
21 
(46.7) 
251 
(45.5) 
RR –response rate; NR –Not reported; NRn - no “n” reported for pilot 
as meeting only 1 quality index (3 studies) to meeting 10 indices (1 study). 
Bivariate analyses showed that 6 quality indices were significantly correlated with 
attaining high methodological quality status. Of these, the indices most 
significantly correlated were the type of study design used (r=0.431; p=0.003) 
and the presence of a POEM-based recommendation (0.428; p=0.003); while the 
indicator least significantly correlated was the provision of a valid summary of 
CAM outcomes data (r=0.293; p=0.048). Only the use of a justified sample size 
Apart from the report of a valid summary of outcomes data (74%), the use of clear inclusion and
exclusion criteria in participant recruitment (67%), the attainment of a RR ≥ 60% (65%), and
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Table 2.11: Summary of quality indices attained by included studies
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or a sample size ≥300 was inversely correlated to attaining high quality status, 
albeit non-significantly (r=-0.109; p=0.47). As to how the studies fared across 
the years in the period of review, the only quality index significantly correlated 
with the year of study publication was the use of a validated or piloted tool for 
CAM data collection (r=-0.377; p=0.01); although it was also significantly 
correlated with the level of outcomes measurement (r=-0.316; p=0.033), one of 
the 27 items extracted from included studies (not shown in table).  Being 
published after the mid-point year of 2005 was significantly correlated with only 
one quality index -drawing valid conclusions from outcomes data reported (r= 
0.340; p=0.021). It was, however, inversely correlated with many of the quality 
Quality assessment 
index 
 # (%) 
of 
studies  
meeting 
criterion 
(n=46) 
Χ2 
statistic; 
p value 
Pearson’s correlation 
[r; p value] 
Distinctive categories 
Possessing  
8 or more 
quality 
indices) 
Year of 
publication 
Publication 
after mid-
point year 
(2005) 
Is the study design 
associated with a low 
tendency to bias and 
confounding? 
4  
(8.7) 
31.391; 
p=0.000* 
r= 0.431; 
p=0.003* 
r= -0.193; 
p=0.199 
r= 0.076; 
p=0.614 
Case-control -1;  
Prospective cohort -2;  
Prospective parallel cohort -1 
Were study participants 
defined by clear 
inclusion /exclusion 
criteria? 
31  
(67.4) 
5.565; 
p=0.018* 
r= 0.226; 
p=0.131 
r= 0.104; 
p=0.494 
r=-0.052; 
p=0.730 
 
Was a clear systematic 
method used for 
sampling/recruitment? 
24  
(52.2) 
0.087; 
p=0.883 
r= 0.253; 
p=0.090 
r= 0.082; 
p=0.590 
r= -0.012; 
p=0.938 
All eligible -14;  
Consecutive - 8;  
Simple random -2 
Were there efforts to 
obtain a representative 
sample? 
17  
(37.0) 
2.174; 
p=0.184 
r= 0.391; 
p=0.007* 
r= -0.079; 
p=0.600 
r= 0.060; 
p=0.891 
Recruitment period ≥ 1 year 
-9; Multi-centre/city -4;  
Broad/multi-centre database 
-5a 
Was the sample size 
justified or ≥300? 
15 
(32.6) 
5.565; 
p=0.018* 
r= -0.109; 
p=0.470 
r= 0.008; 
p=0.956 
r= -0.044; 
p=0.772 
Justified -3 
Sample size ≥300 -13a 
Was a response rate 
≥60 % achieved? 
30 
(65.2) 
42.174; 
p=0.000* 
r= 0.263; 
p=0.077 
r= 0.244; 
p=0.102 
r= -0.244; 
p=0.102 
 
Was a validated, or 
piloted (n≥12) CAM use 
survey tool used? 
9  
(19.6) 
19.304; 
p=0.000* 
r= 0.253; 
p=0.090 
r= -0.377; 
p=0.010* 
r= 0.250; 
p=0.094 
Standard -1;  
Validated -4;  
Piloted (n≥12) -4 
Were UPES outcomes 
data analysed for 
inference or 
confounding? 
15 
(32.6) 
5.565; 
p=0.018* 
r= 0.358; 
p=0.014* 
r= -0.167; 
p=0.266 
r= 0.052; 
p=0.730 
Univariate inferential analysis 
-9; 
Bi-/multivariate analysis -6 
Was a valid summary of 
UPES outcomes data 
provided? 
34 
(73.9) 
10.522; 
p=0.001* 
r= 0.293; 
p=0.048* 
r= -0.140; 
p=0.353 
r= 0.161; 
p=0.287 
For positive outcomes –31 
For non-positive outcomes -3 
Was the generalisability 
of findings on UPES 
outcomes discussed? 
29 
(63.0) 
3.130 
p=0.077 
r= 0.151; 
p=0.318 
r= -0.177; 
p=0.240 
r= 0.160; 
p=0.287 
 
Were valid conclusions 
drawn from study 
findings on UPES 
outcomes? 
21 
(46 %) 
0.348; 
p=0.555 
r= 0.318; 
p=0.031* 
r= -0.163; 
p=0.278 
r= 0.340; 
p=0.021* 
For positive outcomes –19 
For non-positive outcomes -2 
Was any POEM “bottom 
line” recommendation 
made based on 
outcomes data? 
21 
(45.7) 
0.348; 
p=0.555 
r= 0.428; 
p=0.003* 
 
r= -0.088; 
p=0.560 
r= -0.022; 
p=0.887 
Research-oriented –23 
Practice-oriented –10 
Parent-oriented -2 
Attained high quality 
status 
(8 or more indices) 
9 
(19.6) 
- 1.00 r= 0.151; 
p=0.318 
r= -0.153; 
p=0.311 
 
the discussion of the generalisability of the UPES outcomes data reported (63%), most of the
included studies failed to meet the quality indices selected. Overall, the number of quality indices
attained was normally distributed among included studies with two close modes of 5 and 6 indices
attained by 10 studies apiece, a median of 5 quality indices, and a mean of 5.46. Individually,
however, the quality of included studies ranged from as low as meeting only 1 quality index (3
studies) to meeting 10 indices (1 study). Bivariate analyses showed that 6 quality indices were
significantly correlated with attaining high methodological quality status. Of these, the indices
most significantly correlated were the type of study design used (r=0.431; p=0.003) and the pres-
ence of a POEM-based recommendation (0.428; p=0.003); while the indicator least significantly
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correlated was the provision of a valid summary of CAM outcomes data (r=0.293; p=0.048). Only
the use of a justified sample size or a sample size ≥ 300 was inversely correlated to attaining high
quality status, albeit non-significantly (r=-0.109; p=0.47). As to how the studies fared across
the years in the period of review, the only quality index significantly correlated with the year of
study publication was the use of a validated or piloted tool for CAM data collection (r=-0.377;
p=0.01); although it was also significantly correlated with the level of outcomes measurement
(r=-0.316; p=0.033), one of the 27 items extracted from included studies (not shown in table).
Being published after the mid-point year of 2005 was significantly correlated with only one qual-
ity index -drawing valid conclusions from outcomes data reported (r= 0.340; p=0.021). It was,
however, inversely correlated with many of the quality indices, as well as attaining high quality
status, but in all these cases, non-significantly.
2.4 Discussion
2.4.1 Summary of findings
This is the very first SR on UPES outcomes of paediatric CAM use. The systematic search
strategy and step-wise screening process yielded 46 eligible studies that studied a cumulative
population of 9,087 paediatric subjects aged up to 21 years. An overview of the findings of the
review generally indicates a low methodological quality profile among studies, due mainly to a
preponderance of study designs with a high tendency to bias and confounding, and scant use of
piloted or standardized data collection tools. Most of the studies included were primarily descrip-
tive and hospital-based, and utilised mainly self-completion or face-to-face interview methods to
collect data usually by proxy report. Although about one-fifth of the studies did not study a
specific health condition, the specific disease category for which CAM use was most studied was
cancers, closely followed by mental & behavioural disorders. In addition to a variety of definitions
used for CAM therapies among the studies, many different and non-specific constructs were also
used to describe UPES outcomes. While these points make it difficult to draw a specific conclu-
sion from the outcomes findings reported, a general overview indicates a high report of positive
outcomes by majorities of CAM users in the studies (with the notable exception of the UK studies
included), as well as a low report of negative outcomes. However, there was far less emphasis
on the report of negative outcomes among the studies, as CAM-related adverse effects were not
studied in more than half of the studies. These generally positive findings were, however, not
evident in the conclusions and recommendations of many studies, as study findings on outcomes
were either disregarded altogether, or reported partially or in negative light.
One reason for this is the high degree of non-application of inferential statistics to UPES out-
comes data, even where such were used for the non-outcomes data reported by the same studies
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and for the same study samples, suggesting some tendency to confirmation bias among study
authors. While the various limitations acknowledged by study authors are note-worthy, the ap-
parent tendency to confirmation bias in the studies suggests that the opinions and perspectives
of patients who use CAM are probably not being given sufficient consideration by health care
providers with respect to their (the users’) health-related quality of life. This raises important
ethical issues for social research generally; but more so in the light of the current global trend
towards patient-centred health care. The high report of positive outcomes for paediatric CAM
use, however, raises a number of implications for future research and clinical practice, as were
prominently portrayed in the POEM-based recommendations made by the studies. These rec-
ommendations centred on the need for greater cooperation in decision-making and collaboration
in research between health care providers and their patients and/or their parents, as well as the
need for greater integration of CAM into conventional care settings.
2.4.2 General characteristics of studies
A comparison of the included studies by the geographical regions in which they were conducted
indicates a relatively high concentration of research publications on outcomes of paediatric CAM
use in North America, with the USA and Canada contributing more studies individually than
any other country. In all, 5 of the 6 inhabited continents of the world were represented, with no
publication included from South America, probably because of the language restriction in this
review to the English Language. Also, as the languages most often affected by such restriction
have been found to be German and French [384], the language bias in the present study may
very likely have contributed to the relatively fewer publications retrieved from Europe, as well
as other parts of the world. The importance of non-restriction in the language of publication
in systematic reviews in general has already been noted in literature, particularly for CAM
interventions [384, 385]. This is therefore an important recommendation for future systematic
reviews on the subject.
The quality of research as well as its reporting is generally expected to improve with the passing
years in line with the discovery of better techniques and the development of standard reporting
standards. As the STROBE statement was published in 2007 with the aim of improving the
quality of observational health research studies [386, 387], a significant positive difference in
study quality was expected for studies published after 2005, the mid-point year of the review.
The findings however indicate that the year of publication had no significant effect on the quality
of included studies, being significantly correlated with only two study features, and even then
only negatively. Table 2.5 suggests the negative correlation to be due to the high non-report of
these two features in latter years. As the present study was not primarily aimed at evaluating
the effectiveness of any reporting standard in influencing research quality, these findings can only
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suggest the need for such evaluative research for the STROBE statement, as has been done for
other standard checklists [388, 389]. They also emphasize the necessity of greater adherence to
the STROBE checklist by study authors and journal editors, as has been noted for standard
reporting guidelines in general [390]. This is especially needful in CAM outcomes research, where
its adoption has been noted to be particularly relevant [391, 392].
The relative paucity of research on paediatric CAM interventions has already been acknowledged
[393, 394]. However, the relative paucity of UK research studies on paediatric CAM outcomes
found from the current review, and the fact that the latest eligible UK study (which also happens
to have been carried out in Scotland) [352] was published in 2008, not only greatly emphasize
the need for such research within the UK, but also the relevance of the current doctoral research.
Also striking is the marked deviation of the UK studies included in this review from the generally
reported predominantly positive outcomes of paediatric CAM use. Although the oldest UK study
included [348] reported a high PE outcomes rating (85%), 3 of the remaining 4 studies reported
poor to average PE ratings, including the poorest rating reported among included studies -35%
[349]. A SR of prevalence of paediatric CAM use in the UK that included data on perceived
effectiveness found an average PE of 48.3% (range 14-61%) for included studies [395]. Method-
ologically sound studies are therefore needed to determine a more reliable and current estimate
of paediatric CAM UPES among the UK public.
2.4.3 Methodological Quality
Like has already been found in many systematic reviews of CAM interventions [48, 396, 397],
most of the studies included in the current review were of poor methodological quality, with only
9 studies (< 20%) meeting 8 (67%) of the 12 quality requirements assessed, the pre-set standard
for high quality status. As the strongest predictors of high quality status were type of study
design and the presence of a POEM-based recommendation, future studies on UPES outcomes
need to give special consideration to these particular indices.
A significant difference has been demonstrated for the use of high quality study designs in paedi-
atric research relative to adult research [398]. Because of the many ethical issues associated with
paediatric research [399], observational effectiveness studies have many advantages over RCTs in
that population [400, 401]. However, because of their high tendency to confounding and bias,
cross sectional studies are lowly rated among observational effectiveness study designs used in
outcomes research [299]. This is especially so when they are purely descriptive in design; in-
stead of the analytical cross sectional studies that are sometimes considered an acceptable source
of evidence for systematic reviews of health outcomes, alongside longitudinal and case-control
studies [402, 403]. Such analytical studies are designed to facilitate the application of inferential
and multivariable statistical analyses of outcomes data [404, 405]. The high proportion of cross
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sectional studies with purely descriptive statistical analysis of outcomes therefore contributed to
the low quality rating among the studies.
The importance of POEMs has been emphasized for health outcomes studies [347, 406], as the
main objective of such studies is to optimise the delivery of quality patient care [407]. Under-
standably, this objective is especially important for user-led interventions like CAM [408]. The
call for greater cooperation of health care providers with parents and patients in decision-making
to optimise their use of CAM is justified, as various studies have pointed to its value and inade-
quacy in both conventional care hospitals [97, 409, 410] and pharmacies [411, 412]. The various
barriers to such helpful interaction have also been reviewed [413, 414]. While patient collabora-
tion in CAM outcomes research appears to have increased in recent years, as evidenced by the
increased use of patient-reported outcomes (PRO) tools in the assessment of the outcomes of
CAM interventions [415, 416], the poor clinical meaningfulness of the assessments made –that is,
what effect they would really have on the quality of patient care, and/or any practical changes
that are required to ensure better quality of patient care- has also been reported [416]. In the
systematic review of methodological quality assessment in CAM interventions, Efficace et al [396],
found that, although many PRO tools had been used among the 44 RCTs included in their re-
view, only 20% of the studies reported on the clinical significance of their findings. This agrees
with the 21% found in the current review. It is therefore clear that future studies need to place at
least as much emphasis on the clinical significance of their findings as they do on their statistical
significance [77, 417].
Another predictor of high quality status among included studies in the current review was the
efforts made to achieve a representative population sample. While the relevance of the represen-
tativeness of a study sample is well recognized, as it is indicative of the generalisability of the
resulting findings [418], its reporting in survey reports is generally poor. The current review found
that only 37% of included studies (17 studies) demonstrated efforts to achieve a representative
sample. Although this was a poor outcome that significantly contributed to the low quality of
included studies, an overview of recent reviews indicates that this finding was better than for
many. This could be because most reviews either did not specifically include or report this fea-
ture [395, 419, 420], or made it an inclusion criterion in order to improve the quality of included
studies [421, 422]. However, for those that did report it, none was found that reported a better
outcome than did the current review. The SR most related to the current, Bishop et al’s review
of prevalence of paediatric CAM use [423], reported that only 11% of included studies (3 studies)
demonstrated efforts to achieve representative samples. Also, Bennett et al’s SR [324] of the
quality of reporting of key quality criteria for survey research in 117 reports of self-administered
health care research surveys published in 34 high impact factor journals also reported that only
13 studies (11%) described the representativeness of the samples used. The best outcome en-
countered was for Blagojevic et al’s review and meta-analysis of the risk factors for the onset
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of osteoarthritis in older adults [424] which reported 32% population representativeness among
included studies (27 studies). Clearly there is need for greater effort in this aspect of research
quality.
2.4.4 Adherence to Procedural Research Ethics
Research ethics generally refer to a set of principles by which research should be conducted
[425, 426]; or, more specifically, a set of methods, procedures, or perspectives for analysing
complex problems and issues [427]. Adherence to research ethics is important for a study and its
findings to be acceptable to the research community and other users of the research results. Such
ethical considerations are particularly important for research involving vulnerable populations
like children and their families [428]. In addition to obtaining approval for the study from an
ethics board, typical ethical considerations relevant to social research involving children include
informed consent during participant recruitment [429, 430], assurance of confidentiality of data
[431, 432], and, more generally, transparency in reporting procedures, methods and findings [433].
Although there was high report of adherence to ethical considerations among included studies,
only 14 studies (30%) reported them fully including assuring the maintenance of confidentiali-
ty/anonymity. Maintaining confidentiality or anonymity is important in any data collection [434],
particularly in sensitive or controversial topics where social desirability factors could play a high
role. This is the case for the use of unconventional medicine [392, 435, 436], especially when it is
researched in a conventional health care setting. Moreover, its assurance (or the lack of such) has
been shown to significantly affect the type and quality of responses gotten from paediatric public
health surveys [437, 438]. Thus, the lack of emphasis placed on this ethical factor by authors
of included studies is worrisome, as it could very well have impacted on the study outcomes. A
SR on standards and ethics in e-health also found that much less emphasis was paid to assuring
maintenance of confidentiality than in obtaining informed consent [439]. Although confidentiality
matters seemed to be highly reported in Caplan et al’s SR of ethics in rheumatology literature
[440], that was only because it was not considered separately, but rather grouped along with
informed consent as autonomy, based on Beauchamp and Childress’ framework of ethical princi-
ples [441]. Future SRs need to consider this important aspect of ethics, especially in CAM use
research.
About two thirds of included studies did not provide a transparent report of the participant
recruitment and data collection methods used. The transparent report of research methods in-
creases the reliability, utility, and impact of the research, the major objective of the EQUATOR
(Enhancing the QUAality & Transparency Of health Research) network [442]. The lack of trans-
parency among the studies is evidenced by the high degree of non-report of the sampling method
used (20 studies, 43%) and the duration of data collection (14 studies, 30%), as well as significant
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missing data in the target and actual sample sizes and RR (see table 2.3). The poor report
of the procedures used to recruit participants and collect data further illustrates the fact that
the impact of the standard reporting guidelines on improving study quality is happening slowly
[388, 443]. As several calls have been made for greater transparency in research involving human
participants [444–446], future SRs on clinical and social research need to focus on this neglected
aspect of research ethics.
2.4.5 Tendency towards Non rigorous Research
Although the included studies were heterogeneous in many respects, an overview highlights a
number of trends in paediatric UPES CAM research in the period of review. The most obvious
trend is a tendency towards non-rigorous research, as is characterised by a high dependence on
descriptive cross sectional study designs carried out mainly by medical doctors on conveniently
accessible patient participants in mostly single-centre, hospital settings. Also, such studies tended
to rely predominantly on proxy report of PE outcomes using non-validated instruments that gave
with little emphasis to safety outcomes report. A less obvious trend is an apparent tendency
towards confirmation bias against affirming benefit from CAM use, both in terms of unbalanced
application of statistical methods within studies and selective reporting of positive outcomes.
Single-centre studies, while simple and inexpensive to execute, have been associated with several
limitations [331]. Although the most obvious limitation associated with such studies is poor
external validity, which reduces the generalisability of the findings [447], single-centre studies
have also been found to show slightly larger intervention effects than multicentre studies when
the outcomes were continuous [448]. Although most of the UPES outcomes reported in included
studies were categorical rather than continuous, the high use of single-centre studies could belie
the predominantly positive outcomes associated with the studies.
Over 80% of included studies were carried out in clinic-based settings. While the key attraction of
hospital-based studies is convenient access to study participants, this is particularly so where at
least one of the researchers is a medical doctor and affiliated with the healthcare setting concerned
[449]. With the high representation of medical doctors among the primary/corresponding authors
of included studies (table 2.2), the preponderance of hospital-based studies seen in the current
SR is therefore not strange. A recent SR of prevalence studies on CAM use by paediatric patients
between 2000 and 2011 identified 11 eligible studies covering 17,631 patients within the UK alone
[395]. Hospital-based studies are, however, associated with a number of challenges. For one, they
tend to overestimate the prevalence of CAM use [450, 451], essentially skewing the prevalence
data obtained from them [452]. Also, and more relevant to the current study, hospital-based
studies could affect the level of report of positive outcomes associated with CAM use [453]. This
is especially so for self-care CAM therapies like CAM products [454], which are the focus of the
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current SR. An underestimation of reported outcomes is understandable given the reported high
level of nondisclosure of CAM use to medical doctors [455, 456], most probably due to social
desirability issues [457]. In the current review, the lowest proportion of users reporting positive
outcomes for CAM use (35%) was arrived at from interviews by the patients’ doctors either
before or during the course of their outpatient consultation [349]. Although the study authors
reported efforts to assure participating patients of the confidentiality of their responses, as well as
its not affecting their treatment, the fact that it still might have affected them cannot really be
ruled out, a limitation that the authors duly acknowledged. However, those same factors could
also account for an overestimation of the outcomes reported [458]. This could explain why the
highest proportions of users rating CAM as effective in the current review (96% and 99%) were
gotten from patients at a Homeopathic hospital [358] and a TCM clinic [379], respectively, in
the course of their routine clinical visits. All these factors significantly compromise the external
validity of the studies [459], making them inferior to population-based studies for such measures
[460, 461]. Although this issue is mostly associated with face-to-face interview studies, and some
of the studies tried to minimize the possibility by either using research assistants or avoiding the
use of the participants’ paediatricians [220, 377, 462], future studies need to concentrate on the
general population (like [348]) so as to avoid these highlighted methodological flaws.
8 in every 10 of the included studies relied solely on proxy report for UPES outcomes measure-
ment, with 5 other studies combining proxy report with self-report either as mixed or joint report
(table 2.5). The high reliance on proxy report is understandable because of the ethical and other
methodological challenges of surveying paediatric subjects [431, 463, 464]. However, while an ear-
lier SR found that parent-proxy health assessments may agree with child self-reports with respect
to observable health behaviours, the same study also found that that their assessments differ sig-
nificantly in abstract issues like social and emotional health matters [465]. More recent primary
studies have confirmed clinically significant differences between the perceptions of general health,
frequency and amount of body pain, experience of mental health, and other measures of health
status [466, 467], many of which concerns would have been considered in the PE outcomes ratings
provided in included studies in the current review. The consensus, therefore, is that whenever
a child can provide valid and reliable data, paediatric self-report should be used [468]. Studies
have shown the youngest such age to be from 4-6 years [469, 470]. This recommendation was
not followed in most included studies, the seriousness of which failure is particularly heightened
by the fact that an upper paediatric age limit of at least 16 years was an inclusion criterion for
about two thirds of included studies. This somewhat questions the credibility of the outcomes
reported. This is further strengthened by the fact that parents have also been associated with
greater social desirability bias than their children in certain contexts, including the report of child
health matters [471–473]. Within the context of ethical provisions according “(every) child who
is capable of forming his or her own views the right to express those views freely in all matters
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affecting the child” [474], future studies need to seriously consider including child self-report at
least for adolescents.
About 60% of included studies did not study patient-reported adverse effects. This is very
striking, given that one of the cardinal ethical considerations in the practice of medicine is to
“first do no harm” [475], a fact that has also been emphasized for CAM interventions [476, 477].
While the reasons for this development are not obvious, it certainly goes against the clarion call
of the Institute of Medicine in its landmark 1999 report “To Err is Human: Building a Safer
Health System” [478]. It also disregards the huge concerns for patient safety expressed about
CAM therapies by several health professions and stakeholders over the years [479, 480], especially
in the context of their use in children [481, 482]. This suggests that the positive impact of the
publication of the IOM report on safety considerations in published literature reported by a
previous SR [483] is yet to be significantly evident in paediatric CAM research.
2.4.6 Tendency towards Confirmation/Selective Reporting Bias
Significant differences were demonstrated between the application of inferential and multivariable
statistics to outcomes and non-outcomes data within studies, as well as between providing a valid
summary of outcomes findings and drawing valid conclusions from them. These suggest a subtle
tendency to confirmation or selective reporting bias among study authors, as also buttressed by
the odds ratio tests carried out. Confirmation/selective reporting bias describes the tendency for
scientists to search for or interpret new information in such a way as to confirm their own prior
beliefs or theories; or to steer clear of or ignore data or evidence that may contradict those prior
beliefs [484, 485]. The occurrence of these biases in primary studies and SRs has been highlighted
in various reviews [486–488]; and both traits were obvious in included studies.
A comparison of the likelihood of authors reaching a valid conclusion based on a valid summary
of the findings reported for their study showed that authors were so much wary of drawing
wrong conclusions that they often ignored valid ones. This tendency was observed much more
when the findings were mainly positive –that is, in favour of CAM use- than in cases where the
majority rating of perceived outcomes was either borderline or lower than 45% of users surveyed.
This fact is buttressed by the fact that 11 of the 12 studies for which no valid summary of
outcomes was provided were all associated with positive outcomes reported by 56-91% of CAM
users surveyed. Likewise, of the 25 studies for which no valid conclusions were drawn, only in
3 instances [352, 374, 489] were positive outcomes reported by less than 55% of the participants
surveyed. While many of the 12 studies without valid outcomes data summaries did not provide
any summary whatsoever of the outcomes findings reported, and as such did not discuss the
outcomes data reported further, 4 of them [355, 462, 490, 491] omitted key aspects of the study
outcomes data in their summaries, resulting in their providing a negative data summary of the
Chapter 2. Systematic Review 53
positive outcomes findings they reported. Furthermore, except for 3 cases in which authors drew
ambivalent conclusions from their findings [359, 361, 375], and a single case in which the authors
drew a completely misleading one [492], most of the study authors drew no conclusions whatsoever
from the findings of their studies on outcomes data, while drawing conclusions from other data
obtained in their studies. As a researcher’s ability to draw a conclusion from study findings is
facilitated by the type of statistical analyses carried out on the data obtained [493, 494], the
unbalanced application of inferential and multivariate statistical tests in the studies somewhat
facilitated this trend.
While there are no obvious reasons for this development, a couple of possibilities exist. Firstly,
as the prominence of scepticism and uncertainty about the value of CAM has been reported for
medical doctors in general [138], the high proportion of medical practitioners among the authors
could offer an explanation. This professional bias has also been observed at the student level, as
nursing [495, 496] and pharmacy [497, 498] students have been reported to have more positive
attitudes to CAM use and integration than medical students [499, 500]. However, CAM has been
reported to be better appreciated by younger medical doctors [501], as well as with those who
either use it themselves or practise one or more forms of CAM [138, 502]. This is obvious from
the findings of this review, as the highest positive outcomes were reported by medical doctors
practising TCM [379] and Homeopathy [358], respectively. Moreover, other health professional
also contributed to the problem observed [355, 366, 492], indicating that it is not specific to the
medical profession.
Another possibility is the study design used, or the various limitations in study design acknowl-
edged by authors. While it is true that cross sectional studies are not highly regarded in EBM
because they are usually fraught with many limitations, it would certainly be unfair to disregard
the findings of a study because of the design used to elicit them. That would imply that the
study had been designed to fail ab initio. While the findings of cross sectional studies are not
regarded as evidence, they serve the purpose of formulating hypotheses that could be verified or
otherwise by more internally valid study designs [305, 503]. Defaulting authors could therefore
have formulated hypothesis from their findings, and called for more valid study designs to verify
them –as many of the other authors did.
A possible explanation for the unbalanced application of statistical analysis between UPES out-
comes and non-outcomes data could be that the sample sizes used in the studies were too small
to support such detailed analyses. This view could be supported by the fact that 8 of the stud-
ies that applied inferential and/or multivariate analyses reported more than 100 CAM users
[220, 358, 361, 369, 370, 382, 504, 505]. However, although up to 10 authors acknowledged small
sample size as one of their study limitations [350, 353, 355, 359, 360, 362, 368, 371, 373, 492], only
in one case [371] was this limitation attributed to the level of statistical analyses carried out. The
relevance of sample size in statistical analyses has well established [506, 507], with the general
Chapter 2. Systematic Review 54
discouragement of using sample sizes less than 100 for certain tests, like the goodness-of-fit test
[506]. However, certain exact statistical tests, like Fisher’s test, for instance, have been designed
specifically for small sample sizes [508, 509]. As such, 7 of the included studies were still able to
carry out inferential statistical analyses even with CAM user sample sizes of 16-88 participants
[350, 352, 357, 372, 383, 489, 510]. Also, some of the studies for which inferential statistical
analyses were not carried out for UPES outcomes data also reported high CAM user sample sizes
of more than 150 participants [348, 379, 489]. Finally, while small sample sizes may not yield
statistically significant findings, they have been associated with more clinically significant results
[511, 512], with well-designed but small studies having been shown to be sufficient for detecting
meaningful change [513]. Thus, an argument for non-conclusion based on small population of
CAM users does not really hold up to scrutiny.
Whatever the reason for the bias observed, its presence raises ethical issues; as it implies that the
views and opinions of research participants –and patients- are not being given due consideration.
The benefits of considering the perspectives, views and opinions of patients in the planning and
development of healthcare, particularly for long-term health conditions, has been documented in
earlier SRs [514–516]. Moreover, considering the inconveniences participants have to put up with
in social/public health research, any disregard of their views would amount to a great travesty
that could endanger future health research and practice [517–519]. This is particularly relevant
in the context of the current patient-centred healthcare dispensation [520, 521].
2.4.7 Limitations of the Review
The current SR is associated with a number of limitations. The most obvious is the language bias
due to the restriction to English language studies, which has been reported to be very significant
for SRs of CAM interventions [384, 385]. This has also been confirmed by a recent SR [522].
However, since the exclusion of languages other than English from SRs of CAM interventions
has been associated with a reduced positive outcomes [384], it is likely that a more inclusive SR
would have yielded an even higher report of positive outcomes than observed in the current one.
Another limitation could also be the non-inclusion of grey literature in this review. This has been
reported to be associated with exaggerated estimates of intervention effectiveness [523]. Also, a
recent SR has recommended the need to search for trials in both the published and grey literature
in order to help minimise the effects of publication bias in health care intervention reviews [524].
Future SRs therefore need to take this into consideration.
Thirdly, there is the limitation of the datedness of the review relative to the completion of the
manuscript of the doctoral thesis in which it is contained. As the SR was conducted in 2011
with the main purpose of informing further phases of the doctoral research, an update of the SR
was not considered necessary during the final phase of the research. However, in order to keep
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track of possibly eligible studies published in the intervening period, ZETOC R© alerts were set up
for key search terms, and have yielded 12 eligible studies based on title and abstract screening.
An overview of the findings of these studies as reported in their abstracts does not indicate any
deviation from the general trends observed in the studies included in the current review. That
notwithstanding, the necessity of an updated SR on the subject cannot be denied.
2.5 Conclusion
The findings of this review generally emphasize the need for more rigorous research into the UPES
outcomes of paediatric CAM interventions. While this is needed globally, it is needed particularly
in the UK, which is behind her North American counterparts in this area of research. Such future
studies should be suitably designed to reflect the practical uses of CAM by paediatric patients and
their parents in real life circumstances, taking into consideration the peculiar objectives for such
use. Greater emphasis should also be laid on identifying any negative outcomes associated with
paediatric CAM interventions; as well as in always providing conclusions that are congruent with
the reported perceptions of users. This would enable the verification of the predominantly positive
outcomes generally reported by past studies, and prepare the way for a better appreciation of
the benefits (if any) of CAM interventions and their possible integration into conventional care.
It would also overcome the ethical and social issues highlighted in this review, and give patients
their due recognition as partners in healthcare decision making. As the paucity of research on
this subject in the UK and Scotland justifies the inclusion of a survey component in the current
doctoral research, all these findings will be taken into consideration in the design of the study so
as to avoid the many methodological flaws of past studies. Given that the UK studies included
in this review varied widely in the PE outcomes reported -from as low as 35%, the lowest in
the review, [349] to as high as 85% [348], with 2 of the remaining 3 UK studies reporting either
borderline (48%) [352] or average (61%) [351] PE ratings, a major objective of that survey will
be to determine what the current opinion of the UK public is on the UPES of paediatric CAM
use.
Table 2.12: Completed data extraction form for included studies
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Table 2.12: Completed data extraction form for included studies
8 4  
S t u d y  
( Y e a r )  
C o u n t r y  
[ P r o f e s s i o n  o f  
p r i m a r y /  
c o r r e s p o n d i n
g  a u t h o r ]  
S a m p l e  s i z e  
( o f  p a e d i a t r i c  
s u b j e c t s  
w h e r e  
p o s s i b l e )  
N u m b e r  o f  
r e s p o n d e n t s  
[ R e s p o n s e  
R a t e ,  R R ]  
T y p e  o f  
p a r t i c i p a n t s  
[ A g e  r a n g e  o f  
p a e d i a t r i c  
s u b j e c t s ]  
S a m p l i n g  
m e t h o d   
[ J u s t i f i c a t i o n  
o f  s a m p l e  
s i z e  u s e d ]  
S t u d y   
d e s i g n  
[ D a t a   
c o l l e c t i o n  
m e t h o d  u s e d ]  
E x t e n t  o f  
v a l i d a t i o n  o f  
C A M  d a t a  
c o l l e c t i o n  t o o l  
L e v e l  o f  
a d h e r e n c e  t o  
e t h i c a l  
c o n s i d e r a t i o n s  
S t u d y  s e t t i n g ,  
d i s t r i b u t i o n  &  
s p r e a d   
[ S t u d y  
d u r a t i o n ]  
T y p e  o f  C A M  
s t u d i e d  a n d  t h e  
d e f i n i t i o n  p r o v i d e d  
t o  s t u d y  
p a r t i c i p a n t s  
P r e v a l e n c e  o f  C A M  
u s e             
( t y p e ;  n u m b e r  o f  
u s e r s )  
S p e c i f i c  t y p e  o f  
C A M  U P E S  
o u t c o m e ( s )  
s t u d i e d  
T y p e  o f  r e p o r t   
( S e l f ,  P r o x y ,  
M i x e d  o r  J o i n t )  
T y p e  ( l e v e l )  o f  
m e a s u r e m e n t  
s c a l e  u s e d  f o r  
U P E S  o u t c o m e s  
( D e s c r i p t i o n )   
T y p e  o f  s t a t i s t i c s  
u s e d  f o r  o u t c o m e s  
d a t a  
P r o p o r t i o n  ( n u m b e r )  o f  C A M  
u s e r s  r e p o r t i n g  P E  
( * O R  M e a n  P E  r a t i n g  o f  C A M  
t h e r a p i e s  b y  u s e r s )         
P r o p o r t i o n  ( n u m b e r )  o f  C A M  
u s e r s  r e p o r t i n g  A E  
( * O R  M e a n  A E  s e v e r i t y  r a t i n g  
o f  C A M  t h e r a p i e s  b y  u s e r s )   
A u t h o r s   s u m m a r y  o f  s t u d y  
f i n d i n g s / c o n c l u s i o n s  b a s e d  o n  
U P E S  o u t c o m e s  d a t a  
[ R e c o m m e n d a t i o n s  m a d e  b a s e d  o n  
U P E S  o u t c o m e s  d a t a ]  
L i m i t a t i o n s  a c k n o w l e d g e d  
1 .  H o n  e t  a l   
( 2 0 0 5 )  
[ 3 8 3 ]  
C o n d u c t e d  i n  
H o n g  K o n g  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
S a m p l e  s i z e  
n o t  s t a t e d  
C a r e g i v e r s  o f  
c h i l d r e n  w i t h  
a t o p i c  
d e r m a t i t i s  
[ A g e  r a n g e  
n o t  s t a t e d ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
u s e d  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l  o n l y  
o b t a i n e d  
T r a d i t i o n a l  C h i n e s e  
M e d i c i n e ;  b u t  n o  
d e f i n i t i o n  p r o v i d e d  
P e r c e i v e d  
i m p r o v e m e n t ;  
A E  n o t  s t u d i e d  
N o m i n a l  s c a l e :  
3  c a t e g o r i e s  
( Y e s / N o / N o t  s u r e )  
P E :  
5 7  %  ( 3 8  u s e r s ) ;   
N o  s i g n i f i c a n t  d i f f e r e n c e  
( p = 0 . 1 3 )  i n  P E  w i t h  r e s p e c t  
t o  d i s e a s e  s e v e r i t y   
F i n d i n g s  o n  o u t c o m e s  s u m m a r i s e d ,  
b u t  n o  c o n c l u s i o n s  r e p o r t e d  
[ R E C :  A  n u m b e r  o f  s t u d i e s  h a v e  
s h o w n  t h e  u s e f u l n e s s  o f  T C M  i n  
t h e  t r e a t m e n t  o f  c o m m o n  s k i n  
c o n d i t i o n s  s u c h  a s  e c z e m a  a n d  
p s o r i a s i s ,  a n d  t h u s  i t  i s  w o r t h w h i l e  
f o r  d e r m a t o l o g i s t s  t h r o u g h o u t  t h e  
W e s t  t o  g a i n  s o m e  f a m i l i a r i t y  w i t h  
t h i s  m e t h o d ]  
2 2 7  
r e s p o n d e n t s  
[ R R  d a t a  n o t  
a v a i l a b l e ]  
S a m p l i n g  
m e t h o d  u s e d  
n o t  d e s c r i b e d  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  
o u t c o m e s  
t o o l  
O u t p a t i e n t  
c l i n i c ;  s i n g l e  
c e n t r e  
[ F o r  4  m o n t h s ]  
P r e v a l e n c e :  3 0  %  
( 1 2 - m o n t h ;  6 7  
r e s p o n d e n t s )  
P r o x y  r e p o r t  D e s c r i p t i v e  ( % )  
a n d  i n f e r e n t i a l  
s t a t i s t i c s  
( P e a r s o n  s  ! 2 ,  
p < 0 . 0 5 ) ;  
u n i v a r i a t e  a n a l y s i s  
( f r e q u e n c y  t a b l e )  
A E  n o t  s t u d i e d  N o  l i m i t a t i o n s  a c k n o w l e d g e d  
2 .  M u r r a y  e t  
a l   
( 2 0 0 8 )  [ 4 9 2 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r   -
P h a r m a c i s t ]  
2 4 7  
p a e d i a t r i c  
s u b j e c t s  
P a t i e n t s  a n d  
g u a r d i a n s  o f  
p a t i e n t s  w i t h  
c y s t i c  f i b r o s i s  
[ a g e d  0 . 4 9 -
1 9  y e a r s ]  
C r o s s  
s e c t i o n a l   
s t u d y  d e s i g n  
u s e d  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l  &  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
D i e t a r y  
s u p p l e m e n t s ;  
d e f i n e d  t o  
p a r t i c i p a n t s ;  
e x c l u d e d  
m u l t i v i t a m i n  
p r e p a r a t i o n s  o r  
p r e s c r i b e d  h i g h  
c a l o r i e  n u t r i t i o n  
s u p p l e m e n t s  
P e r c e i v e d  
e f f e c t i v e n e s s ;  
A E  n o t  s t u d i e d  
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
P E :   
5 0 - 9 0  %  ( 1 5 - 2 7  u s e r s ) :  
{ S o m e w h a t  e f f e c t i v e  -       
4 0  %  ( 1 2  u s e r s ) ;  
A v e r a g e l y  e f f e c t i v e  -    
3 0  %  ( 9  u s e r s ) ;  
E x t r e m e l y  e f f e c t i v e     
2 0  %  ( 6  u s e r s ) }  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  t h e  c o n c l u s i o n s  
w e r e  m i s l e a d i n g :  D i e t a r y  
s u p p l e m e n t  u s e  i n  p a e d i a t r i c  
p a t i e n t s  w i t h  c y s t i c  f i b r o s i s  w a s  
c o m m o n ,  a l t h o u g h  f e w  p e r c e i v e d  i t  
a s  e f f e c t i v e  
[ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
1 2 1  
r e s p o n d e n t s   
[ R R  4 9  % ]  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  
o u t c o m e s  
t o o l  
O u t p a t i e n t  
c l i n i c ;  s i n g l e  
c e n t r e  
[ F o r  7  m o n t h s ]  
P r e v a l e n c e :  2 5  %  
( e v e r  u s e d ;  3 0  
r e s p o n d e n t s ) :  
( 1 9  %  - c u r r e n t ;   
1 0  %  - p a s t )  
R e p o r t e r  t y p e  
n o t  s t a t e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % )  o n l y ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S m a l l  s a m p l e  s i z e  
2 .  R e c a l l  b i a s  
3 .  U s e  o f  s u r v e y  d e s i g n  
4 .  I n t e r v i e w e r  b i a s  
5 .  L a c k  o f  i n f o r m a t i o n  o n  p o s s i b l e  
c o n f o u n d e r s  
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3. Senel                      
(2010) 
[375] 
Conducted in 
Turkey 
[Profession of 
primary 
author 
unclear] 
 
400-500
children 
 
Parents of 
children with 
autism 
spectrum 
disorders 
(ASD) 
[aged 0-18 
years] 
Cross 
sectional 
study design 
[E-mail 
survey 
method] 
Ethical issues 
not specifically 
described; but 
informed 
consent implied 
 
A list of 18 specific 
CAM treatments 
(arranged 
alphabetically from 
acupuncture to 
yoga) 
 
Perceived 
improvement; 
perceived 
benefits 
/positive 
changes; 
harmfulness 
Ordinal and 
Nominal scales 
used: 
PE: 
(Ordinal rating) 
(Worse/ No 
change/ Little/ 
Great 
improvement); 
Positive changes: 
(Nominal rating) 
(Sleeps better/ 
Eats better/ 
behaves better/ 
Communicates 
better/ Healthier/ 
Other);  
Negative effects: 
(Nominal rating) 
(Nothing/ Difficult 
to use/ Harmful 
/Expensive /Other) 
PE  
No summary count for all 
CAM use 
PE for specific CAM products: 
Herbals- 
7 of 10 users (70 %) 
Little: 5; Great: 2]; 
Vitamins/minerals-  
27 of 32 users (84.4 %) 
[Little: 12; Great: 15]; 
Special diets-  
-24 of 30 users (80 %) 
[Little: 12; Great: 12]; 
Other dietary supplements- 
15 of 19 users (78.9 %) 
[Little: 7; Great: 8] 
Positive effects: 
Most rated positive effects in 
decreasing order of report: 
Improved communication, 
learning, health, and 
behaviour 
Findings on outcomes validly 
summarised; but the following 
ambivalent conclusion was 
reached: It can be said that the 
results showed that parents 
ratings were optimistic. In general 
the results show that there is no 
treatment which brought 100 % 
improvement without any negative 
sides  
[REC: Parents should have realistic 
expectancy, and then to learn all 
the negative sides, from large 
experienced groups before trying 
any CAM. For further research, 
meta-analysis should be 
considered for analysing the 
researches relevant to these 
treatments. It would be beneficial 
to study details of what kinds of 
negative sides or risks parents had 
experienced with any CAM, 
preferably through large sample of 
parent group] 
44 
respondents      
[RR data not 
clear] 
Convenience 
sampling                  
(All eligible 
participants) 
[Sample size 
not justified] 
CAM 
outcomes 
tool piloted 
and revised 
E-mail 
communication 
support group 
for ASD; 
database 
coverage not 
described 
[For 2 months] 
Prevalence: 86 %  
(ever used; 38 
respondents) 
Proxy report 
used 
Neither descriptive 
nor inferential 
statistics used 
(Data simply 
stated) 
Negative effects 
Most rated negative effects in 
decreasing order of report: 
Nothing; expensive; difficulty 
to use; harmful   
Limitations acknowledged: 
1. Questionnaire bias (possible 
linguistic barrier in 
comprehension) 
2.Subjective report 
3. Small sample size 
4. Social desirability bias 
4. Braganza 
et al  
(2003) 
Conducted in 
the USA 
[Profession of 
primary 
author -
Medical 
doctor] 
 
Target 
sample size 
not stated 
Parents of 
children with 
asthma 
[Age range 
not specified] 
Cross 
sectional 
study design 
[Face to face 
interview 
method] 
Ethics 
committee 
approval and 
informed 
consent 
obtained. 
Anonymous? 
A compiled list of 
26 commonly 
available CAM 
therapies, 
especially those 
reportedly used for 
asthma 
Perceived 
effectiveness; 
AE not studied 
 
Type of outcomes 
measurement not 
described 
 
PE: 
59 % -at least as effective as 
asthma medicines;  
44 % used CAM as first 
treatment of an asthma 
attack  
(number of users not 
provided) 
Findings on outcomes not 
summarised; nor were any 
conclusions reported 
[No recommendations made on 
UPES outcomes data] 
 
310 
respondents 
[RR data not 
available] 
Sampling 
method not 
described 
[Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of survey 
Inner-city 
outpatient 
clinic; single 
centre 
[For 7 months] 
Prevalence: 89 %                              
(12-month; 276 
respondents) 
Proxy report
used 
Descriptive 
statistics (%); 
outcomes data not 
statistically 
analysed 
AE not studied Limitations acknowledged: 
1. Cross sectional study design 
2. Social desirability bias 
3. Non validation of instrument 
4. Single centre 
C
h
ap
te
r
2.
S
ys
te
m
a
ti
c
R
ev
ie
w
5
8
 
8 6  
 
C A M  
o u t c o m e s  
t o o l  
5 .  S a w n i  e t  a l   
( 2 0 0 7 )  
[ 4 6 2 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
6 5 0  
p a e d i a t r i c  
s u b j e c t s  
E n g l i s h -
s p e a k i n g  
p a r e n t s / c a r e -
g i v e r s  o f  
c h i l d r e n  o n  
e m e r g e n c y  
c a r e  
[ a g e d  0 - 1 8  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
C A M  d e f i n e d  a s  
a n y  t h e r a p y  f o r  a  
m e d i c a l  i l l n e s s  t h a t  
t h e  c h i l d  s  r e g u l a r  
d o c t o r  d i d  n o t  
p r e s c r i b e ,  
e x c l u d i n g  O T C  
m e d i c a t i o n s  a n d  
m u l t i v i t a m i n s .  
E x a m p l e s  o f  C A M  
w e r e  a l s o  p r o v i d e d  
S a t i s f a c t i o n  
w i t h  C A M  
t h e r a p y ,  a l o n e  
a n d  r e l a t i v e  t o  
c o n v e n t i o n a l  
t h e r a p y ;  A E  
n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
 
 
P E :  
S a t i s f a c t i o n  w i t h  C A M  -  
 7 6  %   
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
S a t i s f a c t i o n  r e l a t i v e  t o  
c o n v e n t i o n a l  t h e r a p y    
6 6  %  u s e d  C A M  a l o n g  w i t h  
c o n v e n t i o n a l  t h e r a p y ,  a n d  3 7  
%  f e l t  r e s u l t s  w e r e  b e s t  
w h e n  b o t h  C A M  a n d  
c o n v e n t i o n a l  m e d i c i n e  w e r e  
i n t e g r a t e d  ( p < 0 . 0 0 1  
F i n d i n g s  o n  o u t c o m e s  p a r t i a l l y  
s u m m a r i s e d  ( d a t a  o n  s a t i s f a c t i o n  
n o t  r e p o r t e d ) ,  a n d  n o  c o n c l u s i o n s  
w e r e  r e a c h e d  o n  t h e  d a t a  r e p o r t e d  
[ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
 
 
6 0 2  
r e s p o n d e n t s  
( 9 3  % )  
C o n v e n i e n c e  
s a m p l i n g  
( i n t e r v i e w s  
c o n d u c t e d  o n  
r a n d o m  d a y s  
a n d  t i m e s )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
C A M  
o u t c o m e s  
t o o l  p i l o t e d  
a n d  
p r e v i o u s l y  
u s e d  
E m e r g e n c y  
d e p a r t m e n t ;  
s i n g l e  c e n t r e  
[ F o r  7  m o n t h s ]  
P r e v a l e n c e  :  1 5  %   
( e v e r  u s e d ;  8 8  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  ( % )  
a n d  i n f e r e n t i a l  ( p  
v a l u e s )  s t a t i s t i c s ;  
u n i v a r i a t e  a n a l y s i s  
( F i s h e r  ! 2 ;  
s i g n i f i c a n c e  l e v e l  
n o t  s t a t e d )  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :   
1 .  S a m p l i n g  b i a s  ( c o n v e n i e n c e  
s a m p l i n g )  
2 .  U s e  o f  p r o x y  r e p o r t  
3 .  E x c l u s i o n  b i a s  ( l a n g u a g e )  
4 .  N o n - g e n e r a l i s a b i l i t y  ( n o n -
d i v e r s e  s a m p l e  u s e d )  
5 .  N o n  v a l i d a t i o n  o f  i n s t r u m e n t  
6 .  S o o  e t  a l             
( 2 0 0 5 )  
[ 3 7 3 ]  
C o n d u c t e d  i n  
C a n a d a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
2 2 8 e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
F a m i l i e s  o f  
c h i l d r e n  
a t t e n d i n g  t h e  
n e u r o l o g y  
c l i n i c  
[ a g e d  2 - 1 8  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y  
m e t h o d ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
o b t a i n e d ;  &  
c o n f i d e n t i a l i t y  
a s s u r e d  
 
 
D i f f e r e n t  C A M  
t y p e s  w e r e  
c l a s s i f i e d  b a s e d  o n                  
T a t a r y n  s  
f r a m e w o r k  o f  
b o d y ,  m i n d ,  
e n e r g y  a n d  s p i r i t  
p a r a d i g m  
P e r c e i v e d  
h e l p f u l n e s s ;  
P e r c e i v e d A E  
 
 
N o m i n a l  s c a l e :  
2  c a t e g o r i e s  
( H e l p f u l / N o t  
h e l p f u l )  
 
P E  f o r  a l l  C A M  t h e r a p i e s :  
5 4  %  ( 5 7  o f  1 0 6  u s e r s ) ;  
P E  f o r  C A M  p r o d u c t s :  
H e r b a l  r e m e d i e s    
6 7  %  ( 6  o f  9  u s e r s ) ;  
D i e t a r y  t h e r a p y    
7 7  %  ( 1 0  o f  1 3  u s e r s ) ;  
V i t a m i n s / M i n e r a l s    
4 3  %  ( 3  o f  7  u s e r s ) ;   
N a t u r a l  s u p p l e m e n t s    
1 4  %  ( 1  o f  7  u s e r s ) ;  
A r o m a t h e r a p y    
6 0  %  ( 3  o f  5  U s e r s ) ;  
A q u a  t h e r a p y    
0  %  0  o f  2  u s e r s ) ;  
H o m e o p a t h y    
2 2  %  ( 2  o f  9  u s e r s )  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ,  a n d  l e d  t o  t h e  
f o l l o w i n g  c o n c l u s i o n :  T h e  m a j o r i t y  
o f  c a r e g i v e r s  f o u n d  C A M  t o  b e  
h e l p f u l ,  a n d  t h e  p o s i t i v e  a s p e c t s  o f  
C A M  u s e  w e r e  a u g m e n t e d  b y  t h e i r  
i n f r e q u e n t  s i d e - e f f e c t s .   
 [ R E C :  F u r t h e r  s t u d i e s  t o  
i n v e s t i g a t e  d r u g  i n t e r a c t i o n s ,  
e f f e c t i v e n e s s ,  a d v e r s e  e f f e c t s ,  a n d  
c o s t  b e n e f i t s  o f  C A M  a r e  r e q u i r e d .  
W i t h  t h a t  f o u n d a t i o n  o f  k n o w l e d g e  
i t  w o u l d  b e  p o s s i b l e  t o  a d v o c a t e  
c o v e r a g e  o f  e f f i c a c i o u s  t h e r a p i e s  
a n d  a v o i d  u n s a f e  t h e r a p i e s  f o r  
p a t i e n t s ]  
1 2 5  
r e s p o n d e n t s  
[ R R  5 5  % ]  
C o n v e n i e n c e  
s a m p l i n g  
( A l l  e l i g i b l e  
s u b j e c t s )  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
O u t p a t i e n t s  
c l i n i c ;  s i n g l e  
c e n t r e  
[ F o r  4  m o n t h s ]  
P r e v a l e n c e :  4 4  %   
( e v e r  u s e d ;  4 6  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
u n i v a r i a t e  a n a l y s i s  
o f  o u t c o m e s  d a t a  
A E :  2  %  ( 1  u s e r )  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S m a l l  s a m p l e  s i z e  
2 .  L o w  r e s p o n s e  r a t e  
3 .  P o s s i b l e  n o n - r e s p o n s e  b i a s  
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[Sample size 
not justified 
of CAM 
outcomes 
tool 
(frequency table)  
 
7. Wong and 
Smith 
(2006) 
[359] 
Conducted in 
Canada 
[Profession of 
primary 
author -
Medical 
doctor] 
108 
paediatric 
subjects 
(Case=55; 
Control=53) 
 
 
Parents of 
two sets of 
children, one 
diagnosed 
with ASD 
(case), and 
the other not 
(control) 
[aged 2-17 
years] 
 
Case-control 
study design 
[Interview 
method by 
telephone & 
face to face] 
 
 
Ethics 
committee 
approval and 
informed 
consent 
obtained 
 
CAM was reported 
as defined to 
participants but 
definition not 
stated. All CAM 
types were 
included, except 
regular 
multivitamins. A 
list of CAM types 
was also provided  
 
Perceived 
benefit; AE not 
studied 
 
 
Type of outcomes 
measurement not 
described 
 
 
PE reported for CAM 
therapies used:  
ASD group: 
75 %  
(45 of 60 users of all CAM 
therapies; including 33 of 44 
users of CAM products 
specifically); 
Control:  
88 %  
(22 of 25 users of all CAM 
therapies; including 19 of 19 
users of CAM products 
specifically) 
Results of statistical analysis 
not shown. 
 
Findings on outcomes validly 
summarised with the this 
ambivalent 
 conclusion: Although this study 
provides information about the 
attitudes of parents regarding the 
benefits and short-comings of 
various CAM therapies for their 
child, the study does not provide 
any objective evidence regarding 
the efficacy of these therapies 
 [REC: While further research is 
needed to substantiate apparent 
benefits of CAM therapies, 
physicians need to be aware of the 
prevalence of use, and be sensitive 
to parental attitudes towards CAM. 
Also, several others including 
parents] 
100 
respondents 
(50 per 
group) 
[RR:  
Case -91 %; 
Control -94 
%] 
Sampling 
method not 
described 
[Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of CAM 
outcomes 
tool 
Hospital-
based; 4 
centres in 
same city 
[Study 
duration not 
stated} 
 
Prevalence:  
ASD group - 
52 %                       
(ever used; 26 
respondents) 
Control group  
28 %  
(ever used; 41) 
Proxy report 
used 
Descriptive 
statistics (%); 
univariate analysis 
of outcomes data 
(frequency table) 
AE not studied Limitations acknowledged: 
1. Small sample size 
2. Non-generalisability (one 
geographical area studied) 
8. Araz and 
Bulbul 
(2011) 
[505] 
Conducted in 
Turkey 
[Profession of 
primary 
author -
Medical 
doctor] 
 
350 
paediatric 
subjects 
 
Parents of 
children 
attending 
outpatient 
clinic 
[1 month  
17 years] 
 
Cross 
sectional 
study design 
[Face to face 
interview 
method] 
 
Ethics 
committee 
approval only 
obtained 
 
CAM defined as 
practices and ideas 
which are outside 
the conventional 
treatment 
methods for 
preventing or 
treating illness, or 
promoting health; 
but no 
list/examples 
reported as 
provided 
Perceived 
Usefulness 
(benefit); 
Perceived 
harmfulness 
 
Type of outcomes 
measurement 
unclear: 
5 categories    (No 
benefit/ Slightly 
useful/ Fairly 
useful/ Just 
started/ Harmful) 
 
PE for Herbal natural 
products: 
76 % (119 users) 
{Slightly useful-  
57.7 % (90 users,  
C I 27.93-39.23);  
Fairly useful- 
18.6 % (29 users,  
C I 7.1-14.54)} 
  
Report of outcomes findings 
unclear; also, no conclusions were 
made based on outcomes data 
reported 
[Further studies should analyse 
theeffectiveness, safety and side 
effects of frequently preferred CAM 
therapies.] 
 
68 
respondents 
Sampling 
method not 
CAM 
outcomes 
Outpatient 
clinic; single 
Prevalence:59 %  
(12-month; 157 
Proxy report 
used 
Descriptive (%) 
and inferential  
AE  
4 % (0.47-4.01)                   
Limitations acknowledged: 
1. Non-generalisability (Only one 
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8 8  
 
[ R R  7 7  % ]  d e s c r i b e d  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
t o o l  p i l o t e d  i n  
a  p r e v i o u s  
s t u d y  
c e n t r e  
[ F o r  2  m o n t h s ]  
r e s p o n d e n t s )  ( C  I )  s t a t i s t i c s ;  
u n i v a r i a t e  a n a l y s i s  
o f  o u t c o m e s  d a t a  
( f r e q u e n c y  t a b l e )  
( 6  u s e r s )  r e g i o n  s t u d i e d )  
2 .  H o s p i t a l  s e t t i n g  b i a s  
3 .  P r o x y  r e p o r t  
 
9 .  O s h i k o y a  
e t  a l  ( 2 0 0 8 )  
[ 3 8 1 ]  
C o n d u c t e d  i n  
N i g e r i a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
T a r g e t  
s a m p l e  s i z e  
n o t  s t a t e d  
 
P a r e n t s  o f  
1 2 2  s u b j e c t s  
w i t h  e p i l e p s y ,  
7 8  w i t h  
a s t h m a ,  a n d  
1 2 2  w i t h  
s i c k l e  c e l l  
d i s e a s e   
[ P a e d i a t r i c  
a g e  r a n g e  
n o t  s p e c i f i e d ]  
 
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
o b t a i n e d ;  &  
c o n f i d e n t i a l i t y  
a s s u r e d  
 
 
C A M  d e f i n e d  
a c c o r d i n g  t o  
N a t i o n a l  I n s t i t u t e  
o f  H e a l t h  
c l a s s i f i c a t i o n ,  a n d  
a  l i s t  o f  c o m m o n l y  
u s e d  b i o l o g i c a l  
C A M  p r o d u c t s  a n d  
s a m p l e s  a n d  
p i c t u r e s  o f  o t h e r  
l o c a l  C A M  t y p e s  
w e r e  p r o v i d e d  
P e r c e i v e d  
b e n e f i t s ;  
p e r c e i v e d  A E  
 
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
 
P E :  
7 8  %  ( 7 8  u s e r s ) :              
{ S p e c i f i c -  4 6  % ;  I n e x p l i c a b l e  
- 3 2  % }  
( N B :  R e p o r t e d  d a t a  u n c l e a r  -
4 6  %  v s .  7 8  % ?  
A n d  i s  4 6  %  f o r   s p e c i f i c   o r  
 n o n - s p e c i f i c   b e n e f i t s ? )  
 
F i n d i n g s  o n  o u t c o m e s  p a r t i a l l y  
s u m m a r i s e d ,  r e s u l t i n g  i n  t h e  
f o l l o w i n g  c o n c l u s i o n :  P a r e n t s  
c o n s i d e r e d  C A M  t o  b e  b e n e f i c i a l  t o  
t h e i r  c h i l d r e n  
 R E C :  T h e  f a c t  t h a t  a p p r o x i m a t e l y  
h a l f  t h e  p a r e n t s  r e p o r t e d  s o m e  
b e n e f i t s  o f  C A M  t o  t h e i r  c h i l d r e n ,  
a l b e i t  n o n - s p e c i f i c ,  c a l l s  f o r  c l i n i c a l  
t r i a l s  o f  C A M s  t o  e s t a b l i s h  p a r e n t s '  
c l a i m s ,  a n d  a s s e s s  t h e  s a f e t y  o f  
t h e  t h e r a p y  f o r  c h i l d r e n . ]  
3 1 8  
r e s p o n d e n t s  
[ R R  d a t a  n o t  
a v a i l a b l e ]  
C o n v e n i e n c e  
s a m p l i n g  
( R a n d o m l y  
o n  
c o n s e c u t i v e  
p r e s e n t a t i o n )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
C A M  
o u t c o m e s  
t o o l  p r e t e s t e d  
a n d  r e v i s e d  
 
O u t p a t i e n t  
c l i n i c s ;  s i n g l e  
c e n t r e  
[ F o r  3  m o n t h s ]  
P r e v a l e n c e :  3 1  %   
( e v e r  u s e d ;  9 9  
r e s p o n d e n t s ) ;   
2 6  %   
( 6 - m o n t h ;  8 3  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E :  
 7  %  ( 7  u s e r s )  
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  C r o s s  s e c t i o n a l  s t u d y  d e s i g n  ( n o  
c o m p a r i s o n  / c o n t r o l  g r o u p )  
1 0 .  M a d s e n  
e t  a l  ( 2 0 0 3 )  
[ 2 2 0 ]  
C o n d u c t e d  i n  
D e n m a r k  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
 
6 7 4  
p a e d i a t r i c  
s u b j e c t s  
 
O u t p a t i e n t s  
a n d  
h o s p i t a l i z e d  
p a e d i a t r i c  
p a t i e n t s  a n d  
t h e i r  p a r e n t s  
[ a g e d  0 - 1 7  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
 
C A M  w a s  
c a t e g o r i z e d  i n t o  
A u t h o r i z e d  h e r b a l  
d r u g s  ( a c c o r d i n g  
t o  T h e  D a n i s h  
M e d i c i n e s  
A g e n c y ) ,  
A l t e r n a t i v e  
t h e r a p y ) ,  a n d  
C h i r o p r a c t i c .  T h e  
h e r b a l  d r u g s  
c a t e g o r y  a l s o  
i n c l u d e d  
v i t a m i n / m i n e r a l  
p r e p a r a t i o n s ,  
d i e t a r y  
s u p p l e m e n t s ,  a n d  
o t h e r  
m i 8 s c e l l a n e o u s  
p r e p a r a t i o n s  
P o s i t i v e  
e f f e c t s ;  
u n e x p e c t e d  
e f f e c t s ;  a n d  
s i d e  e f f e c t s  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
 
P E  f o r  a l l  C A M  t h e r a p i e s -  
N o t  a v a i l a b l e ;  
P E  f o r  P r o d u c t - b a s e d  C A M :  
P o s i t i v e  e f f e c t s   
5 6  %  ( 4 5 - 6 6  % ) ;  
U n e x p e c t e d  e f f e c t s    
1 6  %  ( 9 - 2 5  % )                  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
 
F i n d i n g s  o n  o u t c o m e s  n o t  
s u m m a r i s e d ;  n o r  w e r e  a n y  
c o n c l u s i o n s  r e p o r t e d  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
 
6 2 2  C o n v e n i e n c e  N o  r e p o r t  o f  P a e d i a t r i c  P r e v a l e n c e :  5 3  %   P r o x y  r e p o r t  D e s c r i p t i v e  ( % )  A E  f o r  a l l  C A M  t h e r a p i e s :  L i m i t a t i o n s  a c k n o w l e d g e d :  
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respondents 
[92 %] 
sampling 
(All patients 
were asked 
to 
participate) 
[Sample size 
not justified] 
validation, 
pilot or 
previous use 
of CAM 
outcomes 
tool 
department of 
a university 
hospital; single 
centre 
[For 2 weeks] 
(ever used; 327 
respondents);                       
20 %  
(1-month; 121 
respondents) 
used for 
babies; Joint 
report used for 
children and 
adolescents 
and inferential (95 
% C I) statistics; 
univariate analysis 
(Pearsons !2 @ 
p<0.05) 
6 % (8 of 121 users); 
AE for Product-based CAM 
therapies: 
2 % (0-8 %)                      
(number of users not 
provided) 
1. Non consideration of duration of 
CAM use (information bias) 
11. Loh  
(2009) 
[379] 
Conducted in 
Singapore 
[Profession of 
primary 
author -
Medical 
doctor] 
 
Target 
sample size 
not stated 
Parents of 
paediatric 
subjects 
[aged 1-18 
years] 
Cross 
sectional 
study design 
[Self-
administered 
survey] 
No ethical 
considerations 
reported; but 
survey 
described as 
anonymous 
Traditional Chinese 
Medicine, 
specifically 
acupuncture and 
herbal medicine, 
alone or in 
combination 
Perceived 
improvement; 
AE not studied 
Ordinal scale: 
3 categories 
(No change /Some 
improvement 
/Much 
improvement) 
PE: 
99 %  
(number of users not 
provided) 
{Much improvement  
75 %;  
Some improvement  
24 %} 
Findings on outcomes not 
summarised (emphasis rather 
placed on data from physician 
postal survey); no conclusions 
reported with respect to UPES 
outcomes 
 [No recommendations made on 
UPES outcomes data] 
300 
respondents                      
[RR data not 
available] 
Sampling 
method not 
described 
[Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of CAM 
outcomes 
tool 
TCM outpatient 
clinic; single 
centre 
[Study 
duration not 
stated] 
 
TCM (as above): 
87 %  
(ever used; 262 
respondents); 
Herbs: 84 %  
(253 
respondents); 
Acupuncture -3 %  
(9 respondents) 
Proxy report 
used 
Descriptive 
statistics (%); 
outcomes data not 
statistically 
analysed 
AE not studied 
 
Limitations acknowledged:  
1. Selection bias (non-
representative -limited to clinic 
attendees) 
2. Reporting bias (tending towards 
affirmation of TCM) 
12. Lim et al 
(2006) 
[362] 
Conducted in 
Singapore 
[Profession of 
primary 
author -
Medical 
doctor] 
73 paediatric 
patients in 
the CAM 
outcomes 
phase 
(Target 
sample size 
for the first 
phase not 
stated) 
 
Primary 
caregivers of 
paediatric 
cancer 
patients 
[aged 1-14 
years] 
2-stage Cross 
sectional 
study design 
[Face to face 
Interviews, 
followed by 
telephone, 
interviews -
for outcomes 
report] 
No ethical 
considerations 
reported 
 
All CAM types 
according to 
NCCAM 
classification, with 
a list of specific 
therapies 
Perceived 
improvement/b
enefits on 
physical health, 
quality of life 
(QoL), control 
over situation, 
and sense of 
hope; overall 
satisfaction; 
perceived AE  
 
Ordinal scale: 
Improvement in 
specific criteria 
rated based on 
degrees of 
agreement 
(Strongly agree 
/Agree /Disagree; 
Overall satisfaction 
(Very satisfied 
/Satisfied /Not 
satisfied); AE 
rating unclear 
Perceived benefits: 
Improved Physical health - 
88 % 
(Agree 64 %; Strongly agree 
24 %); 
Improved QoL -65 % (Agree 
47 %; Strongly agree 18 %); 
Improved Control -53 % 
(Agree 53 %); 
Improved psychological 
benefit (hope) -75 % 
(Agree 75 %) 
Perceived satisfaction: 
94 %  
(Satisfied -77 %; Very 
satisfied -18 %) 
(number of users not 
provided in all cases) 
Findings on outcomes validly 
summarised, with the following 
conclusion: CAM has a widening 
impact on every facet of the 
healthcare system and all 
specialties of medicine, including 
paediatric oncology 
[REC: Future research needs to 
clarify the distinction between 
potentially harmful alternative 
cancer cures and potentially 
beneficial complementary 
therapies employed as adjuncts to 
cancer treatment.] 
59 
respondents 
(for the CAM 
Sampling 
method not 
described 
CAM 
outcomes 
tool piloted 
Cancer centre 
of a local 
hospital; single 
Prevalence: 67 %  
(for condition; 49 
of 73 participants 
Proxy report 
used 
 Descriptive 
statistics (%); 
univariate analysis 
AE: 
6.1 % (3 of 49 users).  
NB: % not specifically 
Limitations acknowledged: 
1. Small sample size 
2. Non representative (so 
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9 0  
 
o u t c o m e s  
p h a s e )  
 [ R R  8 1  % ]  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
( i n  1 0  
p a t i e n t s )  a n d  
r e v i s e d  
 
c e n t r e  
[ F o r  3  w e e k s ]  
i n  s t a g e  1 )  o f  o u t c o m e s  d a t a  
( s t a c k e d  b a r  
c h a r t s )  
 
s t a t e d :  b u t  r e p o r t e d  i n  t h e  
d i s c u s s i o n  t h a t   
  9 4  %  o f  p a r t i c i p a n t s  
e x p e r i e n c e d  n o  i l l  e f f e c t s  
w i t h  C A M  )  
u n d e r p o w e r e d  t o  d e t e c t  r e g i o n a l l y  
u s e d  t h e r a p i e s )  
3 .  R e c a l l  b i a s  
4 .  E x c l u s i o n  b i a s  ( p a r e n t s  o f  
d e c e a s e d  p a t i e n t s )  
5 .  S i n g l e  c e n t r e  s t u d y  
1 3 .  H a n s o n  
e t  a l  ( 2 0 0 6 )  
[ 3 7 4 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -  
P s y c h o l o g i s t ]  
 
 
 
 
 
 
 
 
 
3 2 5  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  2 0  
%  o f  c h i l d r e n  
w i t h  A S D  
s e e n  1 9 9 7 -
2 0 0 3  
[ P a e d i a t r i c  
a g e  r a n g e  
n o t  s p e c i f i e d ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y ]  
 
N o  e t h i c a l  
c o n s i d e r a t i o n s  
r e p o r t e d ;  b u t  
s u r v e y  
d e s c r i b e d  a s  
a n o n y m o u s  
 
C A M  d e f i n e d  a s  a l l  
t h e r a p i e s  u s e d  
e x c e p t  E d u c a t i o n a l  
t e c h n i q u e s ,  
S e n s o r y  t h e r a p i e s ,  
a n d  P r e s c r i p t i o n  
d r u g s .  A  l i s t  w a s  
a l s o  p r o v i d e d .  
M u l t i v i t a m i n s  w e r e  
e x c l u d e d .  
P e r c e i v e d  
h e l p f u l n e s s ;  A E  
n o t  s t u d i e d  
 
N o m i n a l  s c a l e  
3  c a t e g o r i e s  
( H e l p f u l /  H a r m f u l /  
N o  c h a n g e )  
 
P E  f o r  A l l  C A M  t h e r a p i e s :  
S u m m a r y  d a t a  n o t  p r o v i d e d  
 P E  f o r  C A M  p r o d u c t  
t h e r a p i e s :  
 M o d i f i e d  d i e t    
4 1  %  ( 1 7  o f  4 1  u s e r s ) ;  
V i t a m i n s / M i n e r a l s    
4 1  %  ( 1 2  o f  2 9  u s e r s ) ;  
F o o d  S u p p l e m e n t s    
 5 8  %  ( 1 5  o f  2 6  u s e r s ) ;  
H e r b a l s    
7 3  %  ( 8  o f  1 1  u s e r s ) ;  
S e c r e t i n  ( s u p p l e m e n t s    
3 3  %  ( 3  o f  9  u s e r s )  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  n o  c o n c l u s i o n s  
r e a c h e d  o n  o u t c o m e s  d a t a  
r e p o r t e d   
[ R E C :  P r o v i d e r s  s h o u l d  b e  a b l e  t o  
h e l p  f a m i l i e s  w h o  d e c i d e  t o  u s e  
C A M  i n  h o w  t o  e v a l u a t e  t r e a t m e n t  
a n d  t r e a t m e n t  r e s p o n s e .  F u t u r e  
r e s e a r c h  w o u l d  e n t a i l  i n v e s t i g a t i n g  
m o r e  s p e c i f i c  c o m p a r i s o n s  o n  t h e  
p e r c e i v e d  e f f i c a c y / i n e f f i c a c y  o f  
C A M  f o r  c h i l d r e n  w i t h  A S D ]  
1 1 2  
r e s p o n d e n t s  
[ R R  3 5  % ]  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  
o u t c o m e s  
t o o l  
 
H o s p i t a l  p a t i e n t  
r e c o r d s ;  l o c a l  
d a t a b a s e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
 
P r e v a l e n c e :  
A l l  C A M    
7 4  %   
( p r e v a l e n c e  t y p e  
u n c l e a r ;  8 3  
r e s p o n d e n t s ) ;   
C A M  P r o d u c t s    
5 4  %   
( a s  a b o v e ;  6 0  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
u n i v a r i a t e  a n a l y s i s  
( f r e q u e n c y  t a b l e )  
A E  n o t  s t u d i e d  
 
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  Q u e s t i o n n a i r e  b i a s  ( p o o r  
c o m p r e h e n s i o n  o f  q u e s t i o n s )  
2 .  P o s s i b l e  m e a s u r e m e n t  b i a s  ( t o o  
f e w  c a t e g o r i e s  o n  s c a l e )  
3 .  R e p o r t i n g  b i a s  ( s o c i a l  
d e s i r a b i l i t y )  
4 .  L o w  r e s p o n s e  r a t e  
5 .  P o s s i b l e  n o n r e s p o n s e  b i a s  d u e  
t o  v a r i a t i o n  i n  p a r t i c i p a n t  i n t e r e s t  
6 .  L a c k  o f  d i v e r s i t y  o f  s a m p l e  
7 .  A n o n y m o u s  d e s i g n ,  t h u s  u n a b l e  
t o  v e r i f y  p a r e n t  r e p o r t  o f  d i a g n o s i s  
1 4 .  A p r i l  e t  a l  
( 2 0 0 9 a )  
[ 3 5 6 ]  
C o n d u c t e d  i n  
C a n a d a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -  
O c c u p a t i o n a l  
t h e r a p i s t ]  
2 5 4  
p a e d i a t r i c  
s u b j e c t s  ( 1 5 7  
i n  M o n t r e a l ,  
a n d  9 7  i n  
V a n c o u v e r )  
 
P a r e n t s  o f  
c h i l d r e n  w i t h  
J u v e n i l e  
i d i o p a t h i c  
a r t h r i t i s   
[ a g e d  2 - 1 8  
y e a r s ]  
 
L o n g i t u d i n a l  
( P r o s p e c t i v e  
c o h o r t )  
s t u d y   
[ S e l f -
c o m p l e t i o n  
a n d  p o s t a l  
s u r v e y ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
A  l i s t  o f  C A M  t y p e s  
p r o v i d e d  t o  
p a r t i c i p a n t s ;  
d e t a i l s  g i v e n  
 
P e r c e i v e d  
b e n e f i t ;  A E  n o t  
s t u d i e d  
 
O r d i n a l  s c a l e :  
4  c a t e g o r i e s  
( n o  
I m p r o v e m e n t /  
b e n e f i t  t o  m u c h  
i m p r o v e m e n t /  
v e r y  b e n e f i c i a l )  
P E :  
7 2  %   o f  a l l  e p i s o d e s  o f  C A M  
u s e   
( S o m e w h a t  b e n e f i c i a l    
2 3  % ;   
M o d e r a t e l y  t o  H i g h l y  
b e n e f i c i a l  - 4 9  % )  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h i s  c o n c l u s i o n :  
T h i s  s t u d y  s h o w e d  t h a t  C A H C  u s e  
i s  c o m m o n  i n  c h i l d r e n  w i t h  J I A  a n d  
t h a t  i t  i s  o f t e n  p e r c e i v e d  a s  b e i n g  
b e n e f i c i a l .  
[ R E C :  T h i s  m a k e s  i t  i m p o r t a n t  f o r  
h e a l t h  p r a c t i t i o n e r s  t o  e v a l u a t e  
C A M  u s e ]  
1 8 2  
r e s p o n d e n t s ,  
[ 7 2  % ] :  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
C A M  
o u t c o m e s  
t o o l  p i l o t e d  
O u t p a t i e n t  
c l i n i c s ;  2  
c e n t r e s  i n  
5 1  %  ( p a s t  u s e ) ;  
3 6  %  ( s t u d y  
p e r i o d ) :   
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
A E  n o t  s t u d i e d  
 
 
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  Q u e s t i o n n a i r e  b i a s  ( n o n -
v a l i d a t i o n ;  p o s s i b l y  i n c o m p l e t e  
C
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91 
 
Montreal, 120 
[76 %]; 
Vancouver, 
62  [64 %]  
[Sample size 
not justified] 
and revised 
 
 
different cities 
[Quarterly over 
a 12-month 
study period] 
Montreal  
42 % (study 
period);  
Vancouver  
25 % (study 
period) 
(specific data not 
provided) 
statistically 
analysed  
CAM list) 
2. Selection bias (only clinic 
attendees/non-CAM users) 
3. Social desirability bias 
4. Attrition (Migration bias) 
5. Confounding -previous CAM use 
15. April et al 
(2009b) 
[377] 
Conducted in 
Canada 
[Profession of 
primary 
author - 
Occupational 
therapist] 
277 
paediatric 
subjects 
Parents of 
children with 
physical 
disabilities 
[aged 0-6 
years] 
Cross 
sectional 
study design 
[Face to face 
interview 
method] 
Ethics 
committee 
approval; 
informed 
consent 
A list of CAM types 
provided to 
participants; 
details given 
Perceived 
benefit; AE not 
studied 
 
Ordinal scale: 
4 categories 
(no 
Improvement/ 
benefit to much 
improvement/ 
very beneficial) 
PE: 
83 % of episodes of use 
{(Slightly beneficial -30 %; 
Moderately beneficial  
-15 %;  
Highly beneficial -38 %)} 
(number of users not 
provided in each case) 
Findings on outcomes validly 
summarised, with this conclusion: 
Parents of children with physical 
disabilities who used CAM tended 
to perceive it as being helpful. 
[REC: It may be important for 
health professionals to evaluate 
the use of CAM in children, and 
their parents beliefs which led 
them to try it, especially if the 
child has high health needs] 
206 
respondents  
[RR 74 %] 
Sampling 
method not 
described 
[Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of CAM 
outcomes 
tool 
Patients on 
waiting list on 
referral from 2 
hospitals; 
multi-centre 
patients 
database 
[Study 
duration not 
stated] 
Prevalence: 15 %  
(ever used; 31 
respondents) 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE not studied Limitations acknowledged: 
1. Questionnaire bias 
(nonvalidation; possibly 
incomplete CAM list; CAM not well 
defined); 
2. Recall bias 
3. Lack of objective CAM use data 
4. Unable to check for confounders  
16. Sinha and 
Efron  
(2005) 
[380] 
Conducted in 
Australia 
[Profession of 
primary 
author -
Medical 
doctor] 
105 
paediatric 
subjects 
Parents of 
children with 
ADHD  
[aged 5-17 
years] 
Cross 
sectional 
study design 
[Postal 
survey] 
Ethics 
committee 
approval and 
informed 
consent 
obtained 
A list of therapies 
provided to 
participants; but 
its content not 
described. 
Perceived 
helpfulness; AE 
not studied 
 
Type of outcomes 
measurement not 
described 
PE for all CAM therapies: 58 
% (29 users) 
PE for CAM products:  
Herbals  
 22 % (2 of 9 users); 
Homeopathy  
30 % (3 of 10 users); 
Health products  
36 % (4 of 11 users); 
Dietary supplement  
36 % (5 of 12 users); 
Vitamin/Minerals  
21 % (3 of 14 users); 
Modified diet  
42 % (14 of 33 users); 
Aromatherapy  
Findings on outcomes validly 
summarised, but no conclusion 
was drawn therefrom 
 [REC: The authors believe that if 
the risk of harm from the use of 
CAM is small, then we should aim 
to work together with parents who 
use complementary (as opposed to 
alternative/replacing) therapies in 
an effort to optimise the outcome 
for their children. It is important to 
explain to parents that many of 
these therapies have not 
undergone research trials, and to 
be clear that we do not 
recommend ceasing prescribed 
C
h
ap
te
r
2.
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9 1  
 
M o n t r e a l ,  1 2 0  
[ 7 6  % ] ;  
V a n c o u v e r ,  
6 2   [ 6 4  % ]   
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
a n d  r e v i s e d  
 
 
d i f f e r e n t  c i t i e s  
[ Q u a r t e r l y  o v e r  
a  1 2 - m o n t h  
s t u d y  p e r i o d ]  
M o n t r e a l    
4 2  %  ( s t u d y  
p e r i o d ) ;   
V a n c o u v e r    
2 5  %  ( s t u d y  
p e r i o d )  
( s p e c i f i c  d a t a  n o t  
p r o v i d e d )  
s t a t i s t i c a l l y  
a n a l y s e d   
C A M  l i s t )  
2 .  S e l e c t i o n  b i a s  ( o n l y  c l i n i c  
a t t e n d e e s / n o n - C A M  u s e r s )  
3 .  S o c i a l  d e s i r a b i l i t y  b i a s  
4 .  A t t r i t i o n  ( M i g r a t i o n  b i a s )  
5 .  C o n f o u n d i n g  - p r e v i o u s  C A M  u s e  
1 5 .  A p r i l  e t  a l  
( 2 0 0 9 b )  
[ 3 7 7 ]  
C o n d u c t e d  i n  
C a n a d a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -  
O c c u p a t i o n a l  
t h e r a p i s t ]  
2 7 7  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
c h i l d r e n  w i t h  
p h y s i c a l  
d i s a b i l i t i e s  
[ a g e d  0 - 6  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w  
m e t h o d ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
A  l i s t  o f  C A M  t y p e s  
p r o v i d e d  t o  
p a r t i c i p a n t s ;  
d e t a i l s  g i v e n  
P e r c e i v e d  
b e n e f i t ;  A E  n o t  
s t u d i e d  
 
O r d i n a l  s c a l e :  
4  c a t e g o r i e s  
( n o  
I m p r o v e m e n t /  
b e n e f i t  t o  m u c h  
i m p r o v e m e n t /  
v e r y  b e n e f i c i a l )  
P E :  
8 3  %  o f  e p i s o d e s  o f  u s e  
{ ( S l i g h t l y  b e n e f i c i a l  - 3 0  % ;  
M o d e r a t e l y  b e n e f i c i a l   
- 1 5  % ;   
H i g h l y  b e n e f i c i a l  - 3 8  % ) }  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d  i n  e a c h  c a s e )  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ,  w i t h  t h i s  c o n c l u s i o n :  
P a r e n t s  o f  c h i l d r e n  w i t h  p h y s i c a l  
d i s a b i l i t i e s  w h o  u s e d  C A M  t e n d e d  
t o  p e r c e i v e  i t  a s  b e i n g  h e l p f u l .  
[ R E C :  I t  m a y  b e  i m p o r t a n t  f o r  
h e a l t h  p r o f e s s i o n a l s  t o  e v a l u a t e  
t h e  u s e  o f  C A M  i n  c h i l d r e n ,  a n d  
t h e i r  p a r e n t s   b e l i e f s  w h i c h  l e d  
t h e m  t o  t r y  i t ,  e s p e c i a l l y  i f  t h e  
c h i l d  h a s  h i g h  h e a l t h  n e e d s ]  
2 0 6  
r e s p o n d e n t s   
[ R R  7 4  % ]  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  
o u t c o m e s  
t o o l  
P a t i e n t s  o n  
w a i t i n g  l i s t  o n  
r e f e r r a l  f r o m  2  
h o s p i t a l s ;  
m u l t i - c e n t r e  
p a t i e n t s   
d a t a b a s e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
P r e v a l e n c e :  1 5  %   
( e v e r  u s e d ;  3 1  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  Q u e s t i o n n a i r e  b i a s  
( n o n v a l i d a t i o n ;  p o s s i b l y  
i n c o m p l e t e  C A M  l i s t ;  C A M  n o t  w e l l  
d e f i n e d ) ;  
2 .  R e c a l l  b i a s  
3 .  L a c k  o f  o b j e c t i v e  C A M  u s e  d a t a  
4 .  U n a b l e  t o  c h e c k  f o r  c o n f o u n d e r s   
1 6 .  S i n h a  a n d  
E f r o n   
( 2 0 0 5 )  
[ 3 8 0 ]  
C o n d u c t e d  i n  
A u s t r a l i a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
1 0 5  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
c h i l d r e n  w i t h  
A D H D   
[ a g e d  5 - 1 7  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
A  l i s t  o f  t h e r a p i e s  
p r o v i d e d  t o  
p a r t i c i p a n t s ;  b u t  
i t s  c o n t e n t  n o t  
d e s c r i b e d .  
P e r c e i v e d  
h e l p f u l n e s s ;  A E  
n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
P E  f o r  a l l  C A M  t h e r a p i e s :  5 8  
%  ( 2 9  u s e r s )  
P E  f o r  C A M  p r o d u c t s :   
H e r b a l s    
 2 2  %  ( 2  o f  9  u s e r s ) ;  
H o m e o p a t h y    
3 0  %  ( 3  o f  1 0  u s e r s ) ;  
H e a l t h  p r o d u c t s    
3 6  %  ( 4  o f  1 1  u s e r s ) ;  
D i e t a r y  s u p p l e m e n t    
3 6  %  ( 5  o f  1 2  u s e r s ) ;  
V i t a m i n / M i n e r a l s    
2 1  %  ( 3  o f  1 4  u s e r s ) ;  
M o d i f i e d  d i e t    
4 2  %  ( 1 4  o f  3 3  u s e r s ) ;  
A r o m a t h e r a p y    
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ,  b u t  n o  c o n c l u s i o n  
w a s  d r a w n  t h e r e f r o m  
 [ R E C :  T h e  a u t h o r s  b e l i e v e  t h a t  i f  
t h e  r i s k  o f  h a r m  f r o m  t h e  u s e  o f  
C A M  i s  s m a l l ,  t h e n  w e  s h o u l d  a i m  
t o  w o r k  t o g e t h e r  w i t h  p a r e n t s  w h o  
u s e  c o m p l e m e n t a r y  ( a s  o p p o s e d  t o  
a l t e r n a t i v e / r e p l a c i n g )  t h e r a p i e s  i n  
a n  e f f o r t  t o  o p t i m i s e  t h e  o u t c o m e  
f o r  t h e i r  c h i l d r e n .  I t  i s  i m p o r t a n t  t o  
e x p l a i n  t o  p a r e n t s  t h a t  m a n y  o f  
t h e s e  t h e r a p i e s  h a v e  n o t  
u n d e r g o n e  r e s e a r c h  t r i a l s ,  a n d  t o  
b e  c l e a r  t h a t  w e  d o  n o t  
r e c o m m e n d  c e a s i n g  p r e s c r i b e d  
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39 % (5 of 13 users) therapies] 
75 
respondents                 
[RR 71 %] 
Sampling 
method not 
described 
[Sample size 
not justified] 
CAM 
outcomes 
tool 
developed 
from those 
used in 
previous 
studies; but 
no report of 
validation or 
pilot  
Outpatients of 
Childrens 
hospital; single 
centre 
[For 5 months] 
Prevalence: 68 %  
(for condition; 50 
respondents) 
Proxy report 
used 
Descriptive 
statistics (%); 
univariate analysis 
of outcomes data 
(frequency table) 
AE not studied 
 
Limitations acknowledged: 
1. Cross sectional study design (no 
comparison /control group) 
2. Unable to detect confounding 
(small sample size) 
 
17. Hurvitz et 
al  
(2003) 
[370] 
Conducted in 
the USA 
[Profession of 
primary 
author -
Medical 
doctor] 
235 
paediatric 
subjects 
Families of 
children with 
cerebral 
palsy 
[aged 1-18 
years] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
Ethics 
committee 
approval; 
informed 
consent 
CAM was defined 
according to 
NCCAM, and a list 
of common CAM 
types provided, 
with free text 
space for entry of 
other CAM 
therapies not 
listed 
Perceived 
positive 
outcomes; AE 
not studied 
 
Type of outcomes 
measurement not 
described 
 
PE for all CAM therapies: 
56 % (number of users not 
provided) 
Association 
Families of CAM users in 
which the primary caregiver 
had used CAM were more 
likely to be pleased with the 
outcome of CAM for their 
child than for those families 
where there had been no 
such prior use (71 % vs. 43 
%, P <0.005 two-tailed) 
Regression 
Parental use of CAM was the 
only factor that was 
predictive of parental 
satisfaction with the childs 
CAM therapies (OR 3.3,  
95 % C I 1.5 to 7.0) 
Findings on outcomes validly 
summarised, with this conclusion: 
Parental use of CAM was highly 
associated with choosing CAM for 
the child, and for eventual 
satisfaction with the treatment. 
[REC: Further contemplation and 
research is required to determine 
what factors make CAM modalities 
desirable and effective, and to 
consider how these factors can be 
woven into the standard care 
that we give children with cerebral 
palsy, and indeed all children] 
 
213 
respondents 
[RR 91 %] 
Convenience 
sampling 
(Consecutive, 
eligible 
subjects were 
recruited) 
[Sample size 
not justified] 
CAM 
outcomes 
tool was 
validated by 
undergoing 
reviews by 
paediatric 
professionals 
and primary 
caregivers of 
children (for 
readability 
and ease of 
Outpatients at 
a university 
medical centre; 
single centre 
[Study 
duration not 
stated] 
 
Prevalence: 56 %  
(for condition; 
number of 
respondents not 
provided) 
Proxy report 
used 
Descriptive 
statistics (%); 
univariate, 
(frequency table) 
bivariate 
(Pearsons !2 @ 
p<0.05, 2-tailed), 
and multivariate 
(step-wise logistic 
regression) 
analyses 
AE not studied 
 
Limitations acknowledged: 
1. Clinic-based setting (might have 
caused the relatively low 
prevalence values seen) 
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9 3  
 
u s e ) ;  a n d  
a l s o  t h r o u g h  
c o g n i t i v e  
i n t e r v i e w s  
w i t h  f a m i l i e s  
1 8 .  H u g h e s  
e t  a l   
( 2 0 0 7 )  
[ 3 6 6 ]  
C o n d u c t e d  i n  
t h e  R e p u b l i c  
o f  I r e l a n d  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
P h a r m a c i s t ]  
8 0  p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
p a e d i a t r i c  
p a t i e n t s  w i t h  
a t o p i c  
d e r m a t i t i s  
[ a g e d  2  
m o n t h s    1 7  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
 
N o  m e n t i o n  o f  
e t h i c s  
c o m m i t t e e  
a p p r o v a l ;  b u t  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
 
N o  d e s c r i p t i o n  o r  
d e f i n i t i o n  o f  C A M  
p r e s e n t e d ;  n o r  
w a s  a n y  r e p o r t e d  
a s  p r o v i d e d  t o  
p a r t i c i p a n t s  
P e r c e i v e d  
i m p r o v e m e n t ;  
A E  n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
P E :  
4 4  %  ( 1 5  u s e r s )  r e p o r t e d  
s o m e  i m p r o v e m e n t   m o s t  
c o m m o n l y  a  r e d u c t i o n  i n  
r a s h .  M o s t  t r e a t m e n t s  w e r e  
r e p o r t e d  t o  s h o w  n o  
i m p r o v e m e n t  ( 5 8  % ) .  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ,  w i t h  t h i s  c o n c l u s i o n :  
A l t e r n a t i v e  t h e r a p i e s  a r e  l a r g e l y  
i n e f f e c t i v e  a n d  m a y  b e  v e r y  
e x p e n s i v e  
[ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
8 0  
r e s p o n d e n t s  
[ R R  1 0 0  % ]  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  
o u t c o m e s  
t o o l  
D e r m a t o l o g y  
o u t p a t i e n t  
c l i n i c  i n  a  
u n i v e r s i t y  
t e a c h i n g  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
A l l  C A M :  4 3  %   
( p r e v a l e n c e  t y p e  
u n c l e a r ;  3 4  
r e s p o n d e n t s )  
H e r b a l s :  4 1  % ;   
H o m e o p a t h y :  2 4  
%  
 ( n u m b e r  o f  u s e r s  
n o t  p r o v i d e d )   
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  
 
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  A s c e r t a i n m e n t  b i a s  ( s e l e c t i o n  o f  
p a t i e n t s  w i t h  m o d e r a t e  t o  s e v e r e  
e c z e m a )  
2 .  D e m o g r a p h i c  e f f e c t s / b i a s  ( l o w  
e c o n o m i c  s t a t u s ;  e d u c a t i o n 0  
1 9 .  J o h n s t o n  
e t  a l  
( 2 0 0 3 )  
[ 3 4 9 ]  
C o n d u c t e d  i n  
t h e  U K  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
1 0 0  
p a e d i a t r i c  
s u b j e c t s  
C h i l d r e n  w i t h  
a t o p i c  
d e r m a t i t i s  
a c c o m p a n i e d  
b y  t h e i r  
p a r e n t s  o r  
g u a r d i a n s  
[ a g e d  0 . 6 -
1 7 . 1  y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
o b t a i n e d ;  
c o n f i d e n t i a l i t y  
a s s u r e d  
N o  d e s c r i p t i o n  o r  
d e f i n i t i o n  o f  C A M  
m e n t i o n e d ,  n o r  
r e p o r t e d  a s  g i v e n  
t o  p a r t i c i p a n t s  
P e r c e i v e d  
i m p r o v e m e n t ;  
A E  n o t  s t u d i e d  
 
N o m i n a l  s c a l e :  
3  c a t e g o r i e s  ( S k i n  
b e t t e r  / N o  c h a n g e  
/ S k i n  w o r s e )  
P E  f o r  e p i s o d e s  o f  C A M  
t h e r a p i e s   u s e d :  
3 5  %  ( 2 6  o f  7 4  e p i s o d e s )  
{ 4 1  %  o f  p a t i e n t s  r e p o r t e d  
i m p r o v e m e n t }  
 
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h e  f o l l o w i n g  
c o n c l u s i o n :  W h i l e  m a j o r i t y  f e l t  t h a t  
C A M  w a s  s a f e r  t h a n  o r t h o d o x  
m e d i c i n e ,  t h e y  r e p o r t e d  t h a t  i t  d i d  
n o t  i m p r o v e  t h e i r  s k i n ,  a n d  t h a t  
t h e y  w o u l d  n o t  r e c o m m e n d  i t  t o  
o t h e r  p a t i e n t s  w i t h  A D .  H o w e v e r  a  
s i g n i f i c a n t  m i n o r i t y  r e p o r t e d  
b e n e f i t s  f r o m  C a m  a n d  w o u l d  
r e c o m m e n d  i t .  
[ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
1 0 0  
r e s p o n d e n t s  
[ R R  1 0 0  % ]  
C o n v e n i e n c e  
s a m p l i n g  
( C o n s e c u t i v e ,  
e l i g i b l e  
s u b j e c t s  w e r e  
r e c r u i t e d )  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
C A M  
o u t c o m e s  
t o o l  p i l o t e d  
( i n  1 0  
p a t i e n t s )  a n d  
r e v i s e d  
D e r m a t o l o g y  
o u t p a t i e n t  
c l i n i c  o f  a  
r e f e r r a l  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ F o r  9  m o n t h s ]  
P r e v a l e n c e :  4 6  %   
( f o r  c o n d i t i o n ;  4 6  
r e s p o n d e n t s )  
M i x e d  r e p o r t  
u s e d :  
S e l f - r e p o r t  
( o l d e r  
c h i l d r e n ) ;  
p r o x y  r e p o r t  
( i n f a n t s  a n d  
t o d d l e r s )   
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d ;  
S k i n  c o n d i t i o n  r e p o r t e d  a s  
w o r s e  w i t h  1 2  %  ( 9  o f  7 4 )  
t h e r a p i e s  
 
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S h o r t e r  d i s e a s e  c h r o n i c i t y  
2 .  P a r e n t a l  o v e r s i g h t  o f  c a r e  
3 .  S e l e c t i o n  b i a s  ( c o n v e n i e n c e  
s a m p l i n g ;  n o n r a n d o m i s e d )  
4 .  S e c o n d a r y  c a r e  s e t t i n g  ( h i g h e r  
d i s e a s e  s e v e r i t y )  
5 .  N o n - g e n e r a l i s a b i l i t y  ( h i g h  e t h n i c  
m i n o r i t y  c o m p o s i t i o n )  
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6. Differences between CAM users 
and non-CAM users 
7. Recall bias 
8. Medical interviewer effect 
20. 
Dannemann 
et al 
(2008) 
[371] 
Conducted in 
Germany 
[Profession of 
primary 
author -
Medical 
doctor] 
346 
paediatric 
subjects 
Parents of 
children with 
type 1 
diabetes 
mellitus 
[aged 1-18 
years] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval and 
informed 
consent 
obtained; 
anonymity 
maintained 
Provided a list of 
11 drug-based and 
13 non-drug based 
therapies, as well 
as a free text area 
for others 
 
Perceived 
efficacy 
(overall, and 
also relative to 
insulin);  
specific 
reported 
effects; 
reported AE or 
side effects 
 
Ordinal and 
Nominal scales: 
Overall PE 
Ordinal scale: 
5 categories (Very 
good /Rather good 
/No effect /Rather 
poor /Very poor); 
PE relative to 
Insulin -Nominal: 
Smaller than 
/Equal to /Greater 
than; 
Specific reported 
effects Nominal 
scale: 
Improved /No 
change 
/Deteriorated 
Overall PE:  
63 % 
{Very good -12.5 %; 
Rather good -50 %; (number 
not stated)} 
 
PE relative to Insulin: 
Greater than insulin  
3 % (1 user); 
Equal to insulin  
15 % (number of users not 
stated) 
Perceived improvement of 
specific reported effects: 
Well-being -68 %; 
Quality of life -43 %; 
Acceptance of diabetes -37 
%; 
Daily coping -34 %; 
Emotional stability -33 %; 
Metabolic control -26 %; 
Dealing with stress -24 % 
Findings on outcomes validly 
summarised, with this conclusion: 
Despite the lack of objective 
outcome, diabetic patients seem to 
show improvement in non-
quantitative vital measures once 
beginning alternative medical care.  
[REC: Respecting parents wishes 
to use CAM is important even if its 
efficacy is not proved and viewed 
with scepticism. ..Facing the 
limited evidence of efficacy, 
further prospective, randomized 
trials are required to determine the 
impact of alternative approaches 
on the personal burden and quality 
of life of type 1 diabetes patients] 
228 
respondents 
[66 %]  
Sampling 
method not 
described 
 [Sample size 
not justified] 
Face and 
content 
validity of the 
survey was 
carried out by 
a panel of 
experts; and 
a pre-test in 
volunteers 
(including 
people with 
diabetes) to 
test its 
performance, 
length and 
understand-
ing 
4 paediatric 
diabetes 
centres; multi-
centre; multi-
city 
[for 13 
months] 
 
Prevalence: 18 %  
(for condition; 42 
respondents) 
Proxy report 
used 
Descriptive 
statistics (%); 
univariate analysis 
(frequency table) 
 
 
 
 
AE: 
11.9 % (5 users) 
{With these comments:  
Only five patients 
experienced short-term side 
effects, such as increased 
blood glucose levels or 
tiredness..However, 
in our study, no severe side 
effects were stated.]  
 
Limitations acknowledged: 
1. Small number of CAM users 
(limited the statistical analyses 
that could be carried out); 
2. Lack of control group 
3. Volunteer bias (self-selection) 
4. Recall bias 
 
 
 
21. Day et al 
(2004) 
60 eligible 
paediatric 
Parents of 
patients with 
Cross 
sectional 
Ethics 
committee 
A list of CAM 
therapies 
Perceived 
effectiveness; 
Type of outcomes 
measurement not 
PE:  
62 % (16 of 26 users):  
Findings on outcomes not validly 
summarised (only the top-most 
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[ 4 9 0 ]  
C o n d u c t e d  i n  
A u s t r a l i a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
s u b j e c t s  i n f l a m m a t o r y  
b o w e l  d i s e a s e  
( I B D )  
[ a g e d  1 - 1 8  
y e a r s ]  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y ]  
 
a p p r o v a l  
o b t a i n e d ;  
i n f o r m e d  
c o n s e n t  i m p l i e d   
&  a n o n y m i t y  
m a i n t a i n e d  
p r o v i d e d .  P a r e n t s  
a l s o  r e q u e s t e d  t o  
r e p o r t  a w a r e n e s s  
o f  t h e r a p i e s  w i t h  
p o t e n t i a l  r o l e s  i n  
t h e  m a n a g e m e n t  
o f  I B D   
A E  n o t  s t u d i e d  
 
d e s c r i b e d  ( V e r y  e f f e c t i v e  / E f f e c t i v e  - 1 2  
%  ( 3  u s e r s ) ;  
P a r t i a l l y  e f f e c t i v e    
5 0  %  ( 1 3  u s e r s )  
 
b a n d  w a s  i n c l u d e d ) ;  n o  
c o n c l u s i o n s  m a d e  o n  t h e  d a t a  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
4 6  
r e s p o n d e n t s   
[ R R  7 7  % ]  
C o n v e n i e n c e  
s a m p l i n g  
( A l l  e l i g i b l e  
s u b j e c t s  w e r e  
r e c r u i t e d )  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
C A M  
o u t c o m e s  
t o o l  w a s  
d e v e l o p e d  
f r o m  a n  
e a r l i e r  o n e ,  
a n d  t h e n  a  
f e w  p a r e n t s  
w e r e  a s k e d  
t o  r e v i e w  
r a n d o m  
q u e s t i o n s  
C l i n i c  b o o k i n g  
r e c o r d s /  
d a t a b a s e ;  l o c a l  
d a t a b a s e ,  
s i n g l e  c e n t r e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]   
P r e v a l e n c e :  7 2  %   
( c u r r e n t  u s e ;  3 3  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  
 
N o  l i m i t a t i o n s  a c k n o w l e d g e d  
2 2 .  D a y  
( 2 0 0 2 )  
C o n d u c t e d  i n  
A u s t r a l i a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
1 1 5  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  
a c c o m p a n y i n
g  c h i l d r e n  t o  
t h e i r  c l i n i c  
a p p o i n t m e n t s                  
[ a g e d  6  
m o n t h s    1 6  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
o b t a i n e d ;   
a n o n y m i t y  
m a i n t a i n e d  
 
S p e c i f i c  e x a m p l e s  
o f  C A M  t h e r a p i e s  
w e r e  l i s t e d ,  w i t h  
e m p h a s i s  o n  
p r o b i o t i c s  
P e r c e i v e d  
i m p r o v e m e n t / b
e n e f i t ;  
p e r c e i v e d  
d e t r i m e n t a l  
e f f e c t  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
P E  f o r  C A M :  
8 3 . 3  %  ( 2 2  u s e r s ) :   
{ I m p r o v e m e n t    
6 2 . 5  %  ( 1 5  u s e r s ) ;   
S l i g h t / p o s s i b l e  b e n e f i t s    
2 0 . 8  %  ( 5  u s e r s ) }  
S e v e r a l  p a r e n t s  c o m m e n t e d  
i n  f u r t h e r  d e t a i l  t h a t  p r o b i o t i c  
t h e r a p i e s  h a d  p r o v e d  t o  b e  
b e n e f i c i a l  f o r  t h e i r  c h i l d r e n  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  n o  c o n c l u s i o n s  
m a d e  o n  t h e  d a t a  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
 
9 2  
r e s p o n d e n t s  
[ R R  8 0  % ]  
C o n v e n i e n c e  
s a m p l i n g  
( A l l  e l i g i b l e  
s u b j e c t s  w e r e  
r e c r u i t e d )  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
D e v e l o p e d  
C A M  
o u t c o m e s  
t o o l  w a s  
r e v i e w e d  b y  
a  r a n d o m  
s e l e c t i o n  o f  
p a r e n t s ,  a n d  
t h e n  r e v i s e d  
G a s t r o e n t e r o l o
g y  o u t p a t i e n t  
c l i n i c ;  s i n g l e  
c e n t r e  
[ F o r  1  m o n t h ]  
P r e v a l e n c e :  
C A M :  3 6  %   
( r e c e n t / c u r r e n t  
u s e ;  3 3  
r e s p o n d e n t s ) ;  
P r o b i o t i c s :  2 4  %   
( e v e r  u s e d ;  2 0  o f  
8 5  r e s p o n d e n t s  - 1  
p a s t  u s e r  a n d  1 9  
r e g u l a r  u s e r s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E :  
0  %   
( N o  u s e r s  r e p o r t e d  
d e t r i m e n t a l  e f f e c t s  d u e  t o  
t h e  a l t e r n a t i v e  a g e n t s )  
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S t u d y  d u r a t i o n  p r o b a b l y  t o o  
s h o r t  
2 .  R e p o r t i n g  b i a s  
3 .  N o n - u s e  o f  i n t e r v i e w  m e t h o d  
4 .  Q u e s t i o n n a i r e  b i a s  ( p o s s i b l e  
l i n g u i s t i c  b a r r i e r  i n  
c o m p r e h e n s i o n )  
2 3 .  G o m e z -
M a r t i n e z  e t  a l  
( 2 0 0 7 )  
[ 5 1 0 ]  
C o n d u c t e d  i n  
M e x i c o  
1 1 0  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s /  
g u a r d i a n s  o f  
p a e d i a t r i c  
c a n c e r  
p a t i e n t s  
[ a g e d  0 . 7 6  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l  a n d  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
C A M  d e f i n e d  a s  
 a n y  a g e n t  o r  
p r a c t i c e  i n i t i a t e d  
s i n c e  d i a g n o s i s  
t h a t  d o e s  n o t  
c o n s t i t u t e  p a r t  o f  
P e r c e i v e d  
u s e f u l n e s s  
/ l e v e l  o f  
s a t i s f a c t i o n ;  A E  
n o t  s t u d i e d  
 
N o m i n a l  s c a l e :  
4  c a t e g o r i e s  ( V e r y  
u s e f u l  / U s e f u l  
/ N o n - e f f e c t i v e  / D o  
n o t  k n o w )  
 
P E :  
7 9  % :  
{ U s e f u l  - 2 6  % ;  
V e r y  u s e f u l  - 5 3  % ;  ( n u m b e r  
o f  u s e r s  n o t  p r o v i d e d ) } .  T h e  
p r o p o r t i o n  o f  u s e r s  t h a t  r a t e d  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h e  f o l l o w i n g  
c o n c l u s i o n :  T h i s  s t u d y  
d e m o n s t r a t e s  a  h i g h  l e v e l  o f  
s a t i s f a c t i o n  w i t h  C A M .  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
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[Profession of 
primary 
author -
Medical 
doctor] 
months  
15.6 years] 
the standard of 
care for a child 
with cancer. A list 
of definitions for 
each CAM type 
was provided 
CAM as useful was 
significantly (p=0.0001) 
different from those that 
either rated it as non-
effective (8 %) or did not 
know (13 %)  
UPES outcomes data] 
 
110 
respondents 
[RR 100 %] 
Convenience 
sampling 
(Consecutive, 
eligible 
subjects were 
recruited) 
 [Sample size 
not justified] 
Survey was 
piloted for 1 
month, and 
revised based 
on parental 
feedback 
Tertiary care 
hospital 
providing 
health 
coverage for 
Western region 
of Mexico; 
single centre 
[For 6 months] 
70 %  
(for condition; 77 
respondents) 
Proxy report 
used 
Descriptive (%) 
and inferential (p 
value) statistics; 
univariate analysis 
(!2 test @ p<0.05)  
AE not studied 
 
 
 
Limitation acknowledged: 
1. Non-consideration of herb-drug 
interaction 
24. Marchisio 
et al 
(2011) 
[382] 
Conducted in 
Italy 
[Profession of 
primary 
author -
Medical 
doctor] 
850 eligible 
paediatric 
subjects  
Parents 
/guardians or 
care-givers of 
children with 
recurrent 
acute otitis 
media 
[aged 1-7 
years] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval and 
informed 
consent 
obtained 
 
Homeopathy and 
herbal medicine; 
specified 
 
Perceived 
effectiveness; 
AE not studied 
 
Ordinal scale;                         
4 categories  
(Very good /Good 
/Moderate /Poor) 
 
PE: 
68 % (number of users not 
stated.  
Responses regarding good 
effectiveness were, for all 
CAM therapies studied, 
significantly more common 
than any other response. C I 
ranges not quoted. 
Findings on outcomes validly 
summarised; but no conclusions 
made on the data 
 [REC: Paediatricians need to be 
urgently involved in educational 
programmes specifically aimed at 
increasing their knowledge of 
evidence-based strategies for 
preventing AOM in order to reduce 
the number of new RAOM episodes 
in otitis-prone children] 
850 
respondents 
[RR 100 %] 
Convenience 
sampling 
(Consecutive, 
eligible 
subjects were 
recruited) 
 [Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of CAM tool 
Outpatient 
clinic of a 
medical referral 
centre; single 
centre 
[For 12 
months] 
Prevalence: 46 %  
(12-month; 391 
respondents) 
Proxy report 
used 
Descriptive (%) 
and inferential (95 
% C I) statistics; 
univariate analysis 
(!2 test @ p<0.05)  
AE not studied Limitations acknowledged: 
1. Recall bias 
2. Sampling bias 
3. Non-generalisability (a single 
geographical area) 
4. Narrow focus of study (not all 
CAM types/health conditions) 
25. Super et 
al 
(2005) 
Conducted in 
the USA 
[Profession of 
primary 
author -
Medical 
doctor] 
117 eligible 
paediatric 
subjects 
 
English-
speaking 
parents/ 
guardians or 
care-givers of 
paediatric 
patients 
presenting at 
nephrology 
clinic 
[aged 0.5-18 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval; 
informed 
consent 
(implied) & 
anonymity 
 
Cranberry 
(specifically asked, 
with product 
details) 
Perceived 
benefit (alone, 
and in 
combination 
with 
antibiotics; 
perceived side 
effects 
 
Ordinal scale: 
4 categories 
(Provided a cure 
/Very beneficial 
/Somewhat 
beneficial /Neither 
helped or harmed 
/Harmful) 
 
PE Overall:  
83 % (25 of 30 users) 
{Cured -3 % (1 user); Very 
beneficial  
67 % (20 users); 
Somewhat beneficial 
13 % (4 users) 
PE with antibiotics: 
Nearly half of users felt that 
cranberry plus antibiotics 
combined were more 
Findings on outcomes validly 
summarised; but no conclusions 
made on the data 
 [REC: RCTs are urgently needed 
to assess the effectiveness of 
cranberry juice in preventing and 
treating paediatric urinary tract 
infections] 
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9 7  
 
y e a r s ]  e f f e c t i v e  t h a n  e i t h e r  a l o n e  
1 1 7  
r e s p o n d e n t s  
[ R R  1 0 0  % ]  
C o n v e n i e n c e  
s a m p l i n g   
( b u t  t h e  
e x a c t  m e t h o d  
n o t  
d e s c r i b e d )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
S u r v e y  w a s  
p i l o t e d  ( i n  1 0  
p a t i e n t s )  a n d  
r e v i s e d  t o  
s i m p l i f y  
l a n g u a g e  
O u t p a t i e n t  
c l i n i c  o f  a  
c h i l d r e n  s  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ F o r  1 0  w e e k s ]  
P r e v a l e n c e :  2 9  %   
( f o r  c o n d i t i o n ;  3 4  
r e s p o n d e n t s )   
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;  
u n i v a r i a t e  a n a l y s i s  
( f r e q u e n c y  t a b l e )  
A E :  
H a r m f u l  3  %  ( 1  u s e r )  
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S e t t i n g  b i a s  ( n e p h r o l o g y  c l i n i c )  
2 .  S h o r t  d a t a  c o l l e c t i o n  p e r i o d  
3 .  N o n - g e n e r a l i s a b i l i t y  ( l o c a l  
s t u d y )  
4 .  R e s p o n s e  b i a s  ( i n a c c u r a c i e s )  
2 6 .  S h a k e e l  
e t  a l  
( 2 0 0 7 )  
[ 3 5 1 ]  
C o n d u c t e d  i n  
t h e  U K  
( S C O T L A N D )  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
5 5 4  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s   
E n g l i s h -
l i t e r a t e  
p a r e n t s  o r  
c a r e g i v e r s  o f  
c h i l d r e n   
[ 0 - 1 6  y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
N o  m e n t i o n  o f  
e t h i c s  
c o m m i t t e e  
a p p r o v a l ;  b u t  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
A  l i s t  o f  4 9  C A M  
p r o d u c t s  o r   
t h e r a p i e s  w a s  
p r o v i d e d ,  a l o n g  
w i t h  s p a c e  
p r o v i d e d  f o r  e n t r y  
o f  a n y  o t h e r  C A M  
t y p e  u s e d   
P e r c e i v e d  
e f f e c t i v e n e s s ;  
A E  n o t  s t u d i e d  
 
N o m i n a l  s c a l e :  
3  c a t e g o r i e s  
( E f f e c t i v e  / N o t  
e f f e c t i v e  / U n s u r e )  
P E :  
6 1  %  ( 5 7  u s e r s )  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  n o  c o n c l u s i o n s  
m a d e  o n  t h e  d a t a  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
3 2 7  
r e s p o n d e n t s  
[ R R  5 9  % ]  
C o n v e n i e n c e  
s a m p l i n g  
( c o n s e c u t i v e ,  
e l i g i b l e  
o u t p a t i e n t s ,  
a n d  a l l  
e l e c t i v e  
a d m i s s i o n s  
w e r e  
r e c r u i t e d )  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  t o o l  
 
O t o l a r y n g o l o g y  
o u t p a t i e n t  
c l i n i c  a n d  
s u r g i c a l  w a r d  
o f  a  s e c o n d a r y  
a n d  t e r t i a r y  
c a r e  h o s p i t a l  
p r o v i d i n g  
h e a l t h  
c o v e r a g e  f o r  
N o r t h - E a s t  o f  
S c o t l a n d ;  
s i n g l e  c e n t r e  
[ F o r  3  m o n t h s ]  
P r e v a l e n c e :  2 3  %   
( e v e r  u s e d ;  9 3  
r e s p o n d e n t s ) ;  
2 0  %   
( 1 2 - m o n t h ;  1 8  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  R e l a t i v e l y  h i g h  n o n r e s p o n s e  
r a t e  ( 4 1  % ;  d u e  t o  t i m e  p r e s s u r e ,  
a n d  p o o r  s u r v e y  d i s t r i b u t i o n )  
2 .  I n c o m p l e t e  r e s p o n s e s  ( d u e  t o  
s e l f - c o m p l e t i o n  s t u d y  d e s i g n ;  
p o s s i b l e  n o n r e s p o n s e  b i a s )  
3 .  N o n - g e n e r a l i s a b i l i t y  ( p o s s i b l e  
c o n f o u n d i n g  d u e  t o  r e l a t i v e  l o c a l  
a f f l u e n c e ;  e t h n i c  v a r i a t i o n s )  
4 .  N o n  c o l l e c t i o n  o f  d a t a  o n  
e t h n i c i t y  
2 7 .  H u i l l e t  e t  
a l  
( 2 0 1 1 )  
[ 3 7 6 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
M e d i c a l  
d o c t o r ]  
4 6 1  
p a e d i a t r i c  
s u b j e c t s   
E n g l i s h -
l i t e r a t e ,  
p r i m a r y  
c a r e g i v e r s  o f  
p r e s e n t i n g  
c h i l d r e n  
[ P a e d i a t r i c  
a g e  r a n g e  
n o t  s p e c i f i e d ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
 
N o  m e n t i o n  o f  
e t h i c s  
c o m m i t t e e  
a p p r o v a l ;  b u t  
a n o n y m o u s  &  
i n f o r m e d  
c o n s e n t  
o b t a i n e d  
 
A  l i s t  o f  2 5  
c a t e g o r i e s  o f  C A M  
t h e r a p i e s  p r o v i d e d  
 
P e r c e i v e d  
h e l p f u l n e s s ;  
p e r c e i v e d  s i d e  
e f f e c t s  
O r d i n a l  s c a l e :  
4  c a t e g o r i e s   
( P E    
N o t  / S o m e w h a t  
/ M o d e r a t e  / V e r y  
h e l p f u l ;   
A E    
N o n e  / M i l d  
/ M o d e r a t e  
/ S e v e r e )  
P E :  
N o t  f u l l y / c l e a r l y  r e p o r t e d :  
P r o d u c t - t y p e  C A M  t h e r a p i e s  
m o s t  c o m m o n l y  r e p o r t e d  a s  
 v e r y  h e l p f u l    D i e t ,  6 7  % ;  
M e l a t o n i n ,  5 7  % ;  M e g a -
v i t a m i n s ,  5 0  %  
( N o  d a t a  f o r  M o d e r a t e  o r  
S o m e w h a t  h e l p f u l ;  a l s o  t h e  
s p e c i f i c  c o h o r t  o f  u s e r s  
r e f e r r e d  t o  i n  e a c h  c a s e  w a s  
n o t  s p e c i f i e d )   
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ,  w i t h  t h i s  c o n c l u s i o n :  
W i t h  t h e  f e w  n o t e d  s i d e  e f f e c t s  
a n d  p a r e n t a l  i m p r e s s i o n  o f  
e f f i c a c y ,  i t  i s  l i k e l y  t h a t  C A M  u s e  
w i l l  c o n t i n u e  
[ N o  c l e a r  r e c o m m e n d a t i o n  m a d e  
o n  U P E S  o u t c o m e s  d a t a ]  
 
3 4 4  
r e s p o n d e n t s  
C o n v e n i e n c e  
s a m p l i n g  
D e v e l o p e d  
s u r v e y  w a s  
2  g e n e r a l  
p a e d i a t r i c  
P r e v a l e n c e :  2 3  %   
( 1 2 - m o n t h ;  6 3  o f  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
A E :  
4  %   
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  N o n - s t a n d a r d i z a t i o n  o f  s u r v e y  
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[RR 78 %] 
 
Also 255  
additional 
survey data 
for children 
at home 
(Consecutive, 
eligible 
subjects were 
recruited) 
 [Sample size 
not justified] 
piloted 
(among 10 
parents) to 
ensure 
understandab
ility 
 
clinics located 
at a large 
military 
treatment 
facility; single 
centre 
[For 4 months] 
278 respondents) 
{66 (19 %) of the 
recruited sample 
was incomplete, 
and so discarded.} 
22 % 
(12-month; among 
244 additional 
children) 
{11 of the 255 
responses were 
incomplete, and so 
discarded} 
outcomes data not 
statistically 
analysed 
(the specific cohort of users 
referred to was not specified) 
instrument 
2. Non-generalisability (local 
study) 
3. Broad definition of CAM 
including faith healing (but not 
prayer), and dance and 
environmental therapies (although 
excluded in the final analysis to 
avoid confusion) 
 
28. Losier et 
al 
(2005) 
[365] 
Conducted in 
Canada 
[Profession of 
primary 
author -
Medical 
doctor] 
800 
paediatric 
subjects 
Parents/ 
guardians of 
children at 
emergency 
department 
[aged 0-16 
years] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval; 
informed 
consent & 
anonymity 
 
No CAM definition 
specifically 
reported; but 
questionnaire was 
reported to have 
been adapted from 
Fermandez et al, 
1998, which 
provided a list of 
therapies 
Perceived 
helpfulness; AE 
not studied 
 
Type of outcomes 
measurement not 
described 
 
PE: 
91 % (63 of 69 users) 
(found CAM helpful or very 
helpful for child) 
 
Findings on outcomes not 
summarised; nor were any 
conclusions made on UPES 
outcomes data 
[REC: Continuing education of 
parents and families is important] 
 
621 
respondents 
[RR 78 %] 
Convenience 
sampling 
(random 
families in 
waiting 
room) 
[Sample size 
not justified] 
Adapted 
partly from 
an earlier tool 
used, piloted 
(in 20 
families) and 
revised 
Emergency 
department of 
health centre 
for women, 
children and 
families; single 
centre 
[For 8 months] 
Prevalence: 13 %  
(ever used, 75) 
 
 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE not studied Limitations acknowledged: 
1. Nonresponse bias (with respect 
to CAM use) 
2. Non representative sample (low 
representation of rural population; 
large proportion of highly 
educated, high income, 
Caucasians)  
29. Reznik et 
al 
(2002) 
[504] 
Conducted in 
the USA 
[Profession of 
primary 
author -
Medical 
doctor] 
200 eligible 
paediatric 
subjects, as 
identified 
from an 
earlier 
screening 
study 
Adolescent 
high school 
students with 
asthma 
[aged 13-18 
years] 
 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval only 
 
Defined as 
medical 
interventions not 
taught widely at 
US medical schools 
or not generally 
available in 
hospital, such as 
herbal use, 
chiropractic and 
massage therapy, 
with a list of 
common therapies 
for asthma 
Perceived 
efficacy  
(relative to 
conventional 
treatment); AE 
not studied 
 
Type of outcomes 
measurement not 
described 
PE: 
Satisfaction with CAM 
73 %  
(number of users not 
provided) 
CAM as effective as 
conventional treatment 
59 % 
(number of users not 
provided) 
Comparisons 
Those who perceived CAM to 
be as effective as 
conventional treatment were 
Findings on outcomes not 
summarised; nor were any 
conclusions made on UPES 
outcomes data 
[No recommendations made based 
on UPES outcomes data] 
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9 9  
 
p r o v i d e d ;  a n d  t h e  
o p p o r t u n i t y  t o  
i n c l u d e  a n y  
t h e r a p i e s  p o s s i b l y  
o m i t t e d .  
m o r e  l i k e l y  t o  r e p o r t  t h a t  
t h e y  w o u l d  u s e  C A M  a g a i n  
( 9 6  %  v s .  2 2  % ;  p < 0 . 0 0 1 )   
 
1 6 0  
r e s p o n d e n t s  
[ R R  8 0  % ]  
C o n v e n i e n c e  
s a m p l i n g   
( A l l  a v a i l a b l e  
e l i g i b l e  
s u b j e c t s  w e r e  
s u r v e y e d )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
S u r v e y  w a s  
d e v e l o p e d ,  
p i l o t e d  a n d  
t h e n  m o d i f i e d  
A n  u r b a n  h i g h  
s c h o o l ;  s i n g l e  
c e n t r e  
[ F o r  1  m o n t h ]  
P r e v a l e n c e :  8 0  %   
( 1 2 - m o n t h ;  1 2 8  
r e s p o n d e n t s )  
S e l f - r e p o r t  
u s e d  
D e s c r i p t i v e  ( % )  
a n d  i n f e r e n t i a l  ( p  
v a l u e )  s t a t i s t i c s ;   
b i v a r i a t e  a n a l y s i s  
( P e a r s o n  s  ! 2 ,  o r  
F i s h e r  s  e x a c t  t e s t ;  
s i g n i f i c a n c e  l e v e l  
n o t  s t a t e d )  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  U s e  o f  s e l f  r e p o r t  b y  
a d o l e s c e n t s   ( i n f o r m a t i o n  n o t  
v e r i f i e d ;  p o s s i b l e  r e s p o n s e  b i a s )  
2 .  P o s s i b l e  n o n - r e s p o n s e  b i a s  ( d u e  
t o  a b s e n c e  f r o m  s t u d y )  
3 .  P o s s i b l e  c o n f o u n d e r s  ( s o c i o -
e c o n o m i c  f a c t o r s )  
3 0 .  Z e b r a c k i  
e t  a l  
( 2 0 0 7 )  
[ 3 6 8 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  -
C l i n i c a l  
p s y c h o l o g i s t ]  
3 9  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
L a t i n o  
c h i l d r e n  w i t h  
j u v e n i l e  
i d i o p a t h i c  
a r t h r i t i s  o r  
a r t h r a l g i a  
[ a g e d  6 - 1 6  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
 
C A M  u s e  d e f i n e d  
a s   u t i l i z i n g  a t  
l e a s t  o n e  t y p e  o f  
C A M  i n  c o n j u n c t i o n  
w i t h  c o n v e n t i o n a l  
m e d i c a l  
t r e a t m e n t  ;  b u t  n o  
s p e c i f i c  C A M  
d e f i n i t i o n  r e p o r t e d  
a s  p r o v i d e d  
P e r c e i v e d  
h e l p f u l n e s s ;  A E  
n o t  s t u d i e d  
 
O r d i n a l  s c a l e :  
3  c a t e g o r i e s  ( V e r y  
/ S o m e w h a t  / N o t  
h e l p f u l )  
 
P E :  
N o t  c l e a r l y  r e p o r t e d  
8 0  %  f o u n d  i t  s o m e w h a t  
h e l p f u l  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
 
F i n d i n g s  o n  o u t c o m e s  s u m m a r i s e d  
w i t h  t h i s  c o n c l u s i o n :  C A M  w a s  
v i e w e d  b y  p a r e n t s  a s  s o m e w h a t  
h e l p f u l  i n  m i n i m i z i n g  s y m p t o m s  
a n d  s e q u e l a e  o f  J I A  o r  a r t h r a l g i a .  
 [ R E C :  F u t u r e  r e s e a r c h  s h o u l d  
a s s e s s  r e a s o n s  f o r  n o n d i s c l o s u r e  o f  
C A M  u s e ,  a n d  e x a m i n e  w h a t  C A M  
t r e a t m e n t  f a c t o r s  d i f f e r e n t i a l l y  
a f f e c t  t h e  c h i l d  s  m e d i c a l  a n d  
p s y c h o l o g i c a l  s t a t u s ,  a n d  
c o n t r i b u t e  t o  a  p o s i t i v e  o u t c o m e  
a n d  o p t i m a l  o v e r a l l  f u n c t i o n i n g ]  
3 6  
r e s p o n d e n t s  
[ R R  9 2  % ]  
C o n v e n i e n c e  
s a m p l i n g   
( A l l  e l i g i b l e  
s u b j e c t s )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  t o o l  
 
R h e u m a t o l o g y  
c l i n i c  o f  a  
t e r t i a r y  c a r e  
c h i l d r e n  s  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]   
P r e v a l e n c e :  5 6  %   
( p r e v a l e n c e  t y p e  
u n c l e a r ;  n u m b e r  
o f  r e s p o n d e n t s  n o t  
p r o v i d e d )  
P r o x y  r e p o r t  
u s e d  
 
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S m a l l  s a m p l e  s i z e  
2 .  C r o s s  s e c t i o n a l  s t u d y  d e s i g n  
3 .  R e l i a n c e  o n  p a r e n t - p r o x y  r e p o r t  
3 1 .  A r y k a n  e t  
a l  
( 2 0 0 8 )  
[ 3 6 7 ]  
C o n d u c t e d  i n  
T u r k e y  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  
N u r s e ]  
1 2 3  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
( 7  o f  1 3 0  
s u b j e c t s  w e r e  
i n e l i g i b l e )  
P a r e n t s  o f  
d i a b e t i c  
c h i l d r e n  w i t h  
t y p e  1  
d i a b e t e s  
[ P a e d i a t r i c  
a g e  r a n g e  
n o t  s p e c i f i e d ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ F a c e  t o  f a c e  
i n t e r v i e w ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  &  
c o n f i d e n t i a l i t y  
 
C A M  r e p o r t e d  a s  
d e f i n e d  t o  
p a r t i c i p a n t s ;  b u t  
t h e  s p e c i f i c  
d e f i n i t i o n  n o t  
p r o v i d e d  
 
S a t i s f a c t i o n ;  
A E  n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
 
P E :  
5 4  %  ( 2 8  u s e r s )  
 
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h i s  c o n c l u s i o n :  
S e v e r a l  C A M  p r a c t i c e s  a n d  h e r b a l  
r e m e d i e s  s h o w  p o t e n t i a l  p r o m i s e  
f o r  d i a b e t e s  t r e a t m e n t  
[ R E C :  . . f u r t h e r  r i g o r o u s  s t u d y  i s  
n e e d e d  t o  e s t a b l i s h  s a f e t y ,  e f f i c a c y  
a n d  m e c h a n i s m  o f  a c t i o n ]  
1 0 0  
r e s p o n d e n t s  
C o n v e n i e n c e  
s a m p l i n g   
N o  r e p o r t  o f  
v a l i d a t i o n ,  
E n d o c r i n e  
o u t p a t i e n t  
P r e v a l e n c e :  5 2  %  
( f o r  c o n d i t i o n ;  5 2  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  R e l i a n c e  o n  s u b j e c t i v e  r e p o r t  
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100 
 
[RR 81 %] (All available 
eligible 
subjects were 
surveyed) 
[Sample size 
not justified] 
pilot or 
previous use 
of CAM tool 
 
 
 
 
clinic of a large 
teaching 
hospital; single 
centre 
[For 12 
months] 
respondents)  outcomes data not 
statistically 
analysed 
(non use of objective data to verify 
claimed beneficial effects) 
2. PE may not be specific to CAM 
therapies 
3. Non record of AEs 
32. Al-
Qudimat et al 
(2010) 
[355] 
Conducted in 
Jordan 
[Profession of 
primary 
author 
Nurse] 
84 eligible 
paediatric 
subjects 
Parents of 
paediatric 
cancer 
patients 
[aged 0-18 
years] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
Ethics 
committee 
approval; 
informed 
consent 
 
CAM reported as 
described to 
participants; but 
specific definition 
not provided 
 
Perceived 
benefit 
/satisfaction; 
AE not studied 
 
Ordinal scale: 
4 categories 
(No benefits /Low 
benefits /Good 
benefits /Excellent 
benefit) 
PE: 
91 % (40 users): 
{Excellent benefit 
16 % (7 users); 
Good 46 % (20 users); 
Low -30 % (13 users)} 
Findings on outcomes partially 
summarised (only the middle band 
reported); no conclusions drawn 
on the data obtained 
 [REC: Potential drug-CAM 
interactions need to be discussed 
as well as potential benefits from 
CAM therapies.Potential 
interactions and benefits cannot be 
determined without adequate 
information on patient and parent 
CAM behaviour] 
69 
respondents 
[RR 82 %];  
but non-
responders 
and 
responders 
with 
incomplete 
surveys were 
not 
distinguished 
Convenience 
sampling  
(All eligible 
subjects were 
surveyed) 
[Sample size 
justified 
statistically] 
Survey was 
developed 
and piloted 
(in 6 parents 
from the 
centre); then 
tested for 
content 
validity (a 
panel of 
experts); and 
reliability 
(Cronbachs 
alpha -0.79) 
Outpatient 
department at 
a Paediatric 
cancer centre 
that treats 80 
% of all 
paediatric 
cases in 
Jordan;  single 
centre 
[For 9 months] 
 
Prevalence: 65 %  
(for condition; 45 
respondents) 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE not studied 
 
Limitations acknowledged:  
1. Small sample size 
2. Localized studied (one Middle 
Eastern country) 
 
33. 
Neuhouser et 
al 
(2001) 
[353] 
Conducted in 
the USA 
[Profession of 
primary 
author 
Dietician] 
101 eligible 
paediatric 
subjects 
English-
speaking 
parents of 
living children 
with cancer 
Aged 0-18 
years] 
Cross 
sectional 
study design 
[Computer-
assisted, 
telephone 
interview] 
Ethics 
committee 
approval; 
informed 
consent 
 
CAM defined using 
the 7 categories of 
alternative 
medicine described 
by the NCCAM 
collapsed into 3 
sub-groups (with 
examples) for 
cognitive ease of 
participants 
Perceived 
improvement;  
reported AEs 
Ordinal scale: 
4 categories 
(PE  
Strongly agree to 
Strongly disagree;  
AE  
Very mild to Very 
severe) 
PE: 
Data presentation unclear 
About 6090% of users 
reported improvements in 
health and well-being (for 
the whole range of CAM 
therapies studied) 
(number of users not 
provided) 
Findings on outcomes validly 
summarised; but no conclusions 
drawn on the data obtained 
 [REC: Further research is needed 
to clarify whether specific 
alternative treatments are 
associated with improved clinical 
outcome or enhanced quality of life 
among pediatric oncology patients. 
Clinicians should remain informed 
about therapies that may dhow 
harm or benefit, communicate with 
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1 0 1  
 
p a t i e n t s  a b o u t  v a r i o u s  t r e a t m e n t  
o p t i o n s ,  a n d  m a k e  r e f e r r a l s  
w h e r e v e r  a p p r o p r i a t e ]   
7 5  
r e s p o n d e n t s  
[ R R  7 4  % ]  
S i m p l e  
R a n d o m  
[ N o n e  
p r o v i d e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  C A M  t o o l  
 
C a n c e r  
S u r v e i l l a n c e  
S y s t e m  f o r  
w e s t e r n  
W a s h i n g t o n  
s t a t e ;  1 3 -
c o u n t y - w i d e ,  
b r o a d  d a t a b a s e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]   
P r e v a l e n c e  d a t a  
u n c l e a r  
7 3 . 3  %   
( 1 2 - m o n t h ;  5 5  o f  
7 5  r e s p o n d e n t s ) ;  
d a t a  o n  C A M  u s e  
f o r  c o n d i t i o n  
u n c l e a r  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E :  
D a t a  u n c l e a r  
[  V e r y  s e v e r e  A E   r e p o r t e d  
b y  2  p a r t i c i p a n t s ;  b u t  t h e  
d a t a  w a s  n o t  p r e s e n t e d . ]  
Q :  W e r e  t h e s e  t h e  o n l y  A E s  
r e p o r t e d ?  W h a t  a b o u t  t h e  
d a t a ?  
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S m a l l  s a m p l e  s i z e  
2 .  P o s s i b l e  n o n - r e s p o n s e  b i a s  
3 .  N o n - g e n e r a l i s a b i l i t y  ( l i m i t e d  t o  
o n l y  l i v i n g  c h i l d r e n  w i t h  f i r s t  
p r i m a r y  c a n c e r s ,  a n d  t o  
W a s h i n g t o n  s t a t e )   
4 .  P o s s i b l e  r e s p o n s e  b i a s  
5 .  P o s s i b l e  o v e r l a p s  i n  C A M  
c l a s s i f i c a t i o n  
3 4 .  A n d e r s e n  
e t  a l  
( 2 0 0 8 )  
[ 3 6 0 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  
M e d i c a l  
d o c t o r ]  
1 0 7  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
c h i l d r e n  w i t h  
a u t i s m  
s p e c t r u m  
d i s o r d e r s  
t r e a t e d  w i t h  
m e l a t o n i n  
[ a g e d  2 - 1 8  
y e a r s ]  
C a s e  s e r i e s  
[ C h a r t  r e v i e w  
a n d  p a r e n t a l  
s l e e p  d i a r i e s ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l  o n l y  
 
 
C A M  s t u d i e d  w a s  
m e l a t o n i n ,  w h i c h  
h a d  b e e n  
p r e s c r i b e d  b y  t h e  
p a e d i a t r i c i a n  f o r  
s l e e p  p r o b l e m s  
P e r c e i v e d  
i m p r o v e m e n t ;  
r e p o r t e d  A E s  
 
O r d i n a l  s c a l e :  
4  c a t e g o r i e s   
( S l e e p  n o  l o n g e r  a  
p r o b l e m  
/ I m p r o v e d  s l e e p  
b u t  w i t h  c o n t i n u e d  
p a r e n t a l  c o n c e r n  
/ S l e e p  c o n t i n u e s  
t o  b e  a  c o n c e r n  
/ W o r s e n e d  s l e e p  
P E :  
8 5  %  ( 9 1  u s e r s )  
{ S l e e p  n o  l o n g e r  a  c o n c e r n    
2 5  %  ( 2 7  u s e r s ( ;  I m p r o v e d  
s l e e p  w i t h  c o n t i n u e d  p a r e n t a l  
c o n c e r n    
6 0  %  ( 6 7  u s e r s ) }  
 
F i n d i n g s  o n  o u t c o m e s  s u m m a r i s e d  
w i t h  t h i s  c o n c l u s i o n :  M e l a t o n i n  
m a y  b e  a  s a f e  a n d  e f f e c t i v e  
t r e a t m e n t  o f  i n s o m n i a  f o r  c h i l d r e n  
w i t h  a u t i s m  s p e c t r u m  d i s o r d e r s  
[ R E C :  F u t u r e  p r o s p e c t i v e  
r a n d o m i s e d ,  b l i n d e d  p l a c e b o  
c l i n i c a l  t r i a l s  a p p e a r  w a r r a n t e d ]  
 
1 0 7  
p a r t i c i p a n t s  
[ R R  n o t  
a p p l i c a b l e  
n o t  a  p r i m a r y  
s t u d y ]  
C o n v e n i e n c e  
s a m p l i n g  
( a l l  e l i g i b l e  
c h i l d r e n )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
N o  r e p o r t  o f  
v a l i d a t i o n ,  
p i l o t  o r  
p r e v i o u s  u s e  
o f  t o o l  u s e d  
t o  e x t r a c t  
C A M  d a t a  
E l e c t r o n i c  
m e d i c a l  
r e c o r d s  o f  a  
p a e d i a t r i c i a n  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
P r e v a l e n c e  o f  C A M  
u s e  n o t  r e l e v a n t  a s  
u s e  o f  m e l a t o n i n  
h a d  b e e n  a n  
i n c l u s i o n  c r i t e r i o n  
P r o x y  r e p o r t   D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E :  
3  %  ( 3  u s e r s )  
 
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  D e s i g n  b i a s  ( r e t r o s p e c t i v e ,  n o n  
R C T )  
2 .  H e t e r o g e n e i t y  
3 .  C o n f o u n d e r s  ( o t h e r  
m e d i c a t i o n s ,  d o s e  v a r i a b i l i t y ,  e t c . )  
4 .  S m a l l  s a m p l e  s i z e   
5 .  S u b j e c t i v e  r e p o r t  b i a s  
3 5 .  R o u s t e r -
S t e v e n s  e t  a l  
( 2 0 0 8 )  
[ 3 7 2 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  
M e d i c a l  
d o c t o r ]  
7 6  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
c h i l d r e n  w i t h  
j u v e n i l e  
i d i o p a t h i c  
a r t h r i t i s  ( J I A )  
[ a g e d  0 - 2 1  
y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y  - w i t h  
m o n e t a r y  
i n c e n t i v e ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  &  
a n o n y m i t y  
 
A n  e x t e n s i v e  l i s t  o f  
c o n v e n t i o n a l  a n d  
C A M  t h e r a p i e s  
c o m p i l e d  f r o m  
l i t e r a t u r e  a n d  l o c a l  
a n d  s t a t e - w i d e  
e x p e r i e n c e  o f  J I A  
m a n a g e m e n t  w a s  
p r o v i d e d   
P e r c e i v e d  
h e l p f u l n e s s ;  
p e r c e i v e d  s i d e  
e f f e c t s   
 
R a t i o  s c a l e :  
4  l e v e l s  f r o m  0 - 3    
( P E     
N o t  / S o m e w h a t  
/ M o d e r a t e l y  / V e r y  
h e l p f u l ;   
A E    
N o n e  / M i l d  
/ M o d e r a t e  
/ S e v e r e )  
* P E  f o r  C A M  t h e r a p i e s  a s  a  
w h o l e :  
M e d i a n  ( m e a n )  r a t i n g  
3  ( 2 . 5 )  
T h e r e  w a s  n o  s i g n i f i c a n t  
d i f f e r e n c e  b e t w e e n  t h e  m e a n  
h e l p f u l n e s s  r a t i n g s  f o r  
c o n v e n t i o n a l  m e d i c a t i o n s  a n d  
C A M  t h e r a p i e s  
{ 2 . 7  v s .  2 . 5  ( p = 0 . 2 9 ) }  
F i n d i n g s  o n  o u t c o m e s  s u m m a r i s e d  
w i t h  t h i s  c o n c l u s i o n :  E v e n  t h o u g h  
p a r e n t s  v i e w e d  s o m e  c o n v e n t i o n a l  
m e d i c a t i o n s  a s  b e i n g  m o r e  h e l p f u l  
f o r  t h e i r  c h i l d r e n  s  J I A  t h a n  s o m e  
C A M  t h e r a p i e s  o v e r a l l ,  t h e  u s e  o f  
C A M  w a s  p e r c e i v e d  a s  b e i n g  
s i m i l a r l y  h e l p f u l  a s  c o n v e n t i o n a l  
m e d i c a t i o n s .  
[ R E C :  F u t u r e  s t u d i e s  o f  C A M  
t h e r a p i e s ,  p a r t i c u l a r l y  t h o s e  t h a t  
p a r e n t s  f e e l  a r e  h e l p f u l  a n d  l o w  i n  
s i d e  e f f e c t s ,  s u c h  a s  v i t a m i n  D ,  a r e  
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patients about various treatment 
options, and make referrals 
wherever appropriate]  
75 
respondents 
[RR 74 %] 
Simple 
Random 
[None 
provided] 
No report of 
validation, 
pilot or 
previous use 
of CAM tool 
 
Cancer 
Surveillance 
System for 
western 
Washington 
state; 13-
county-wide, 
broad database 
[Study 
duration not 
stated]  
Prevalence data 
unclear 
73.3 %  
(12-month; 55 of 
75 respondents); 
data on CAM use 
for condition 
unclear 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE: 
Data unclear 
[Very severe AE reported 
by 2 participants; but the 
data was not presented.] 
Q: Were these the only AEs 
reported? What about the 
data? 
Limitations acknowledged: 
1. Small sample size 
2. Possible non-response bias 
3. Non-generalisability (limited to 
only living children with first 
primary cancers, and to 
Washington state)  
4. Possible response bias 
5. Possible overlaps in CAM 
classification 
34. Andersen 
et al 
(2008) 
[360] 
Conducted in 
the USA 
[Profession of 
primary 
author 
Medical 
doctor] 
107 eligible 
paediatric 
subjects 
Parents of 
children with 
autism 
spectrum 
disorders 
treated with 
melatonin 
[aged 2-18 
years] 
Case series 
[Chart review 
and parental 
sleep diaries] 
 
Ethics 
committee 
approval only 
 
 
CAM studied was 
melatonin, which 
had been 
prescribed by the 
paediatrician for 
sleep problems 
Perceived 
improvement; 
reported AEs 
 
Ordinal scale: 
4 categories  
(Sleep no longer a 
problem 
/Improved sleep 
but with continued 
parental concern 
/Sleep continues 
to be a concern 
/Worsened sleep 
PE: 
85 % (91 users) 
{Sleep no longer a concern  
25 % (27 users(; Improved 
sleep with continued parental 
concern  
60 % (67 users)} 
 
Findings on outcomes summarised 
with this conclusion: Melatonin 
may be a safe and effective 
treatment of insomnia for children 
with autism spectrum disorders 
[REC: Future prospective 
randomised, blinded placebo 
clinical trials appear warranted] 
 
107 
participants 
[RR not 
applicable 
not a primary 
study] 
Convenience 
sampling 
(all eligible 
children) 
[Sample size 
not justified] 
No report of 
validation, 
pilot or 
previous use 
of tool used 
to extract 
CAM data 
Electronic 
medical 
records of a 
paediatrician 
[Study 
duration not 
stated] 
Prevalence of CAM 
use not relevant as 
use of melatonin 
had been an 
inclusion criterion 
Proxy report  Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE: 
3 % (3 users) 
 
Limitations acknowledged: 
1. Design bias (retrospective, non 
RCT) 
2. Heterogeneity 
3. Confounders (other 
medications, dose variability, etc.) 
4. Small sample size  
5. Subjective report bias 
35. Rouster-
Stevens et al 
(2008) 
[372] 
Conducted in 
the USA 
[Profession of 
primary 
author 
Medical 
doctor] 
76 eligible 
paediatric 
subjects 
Parents of 
children with 
juvenile 
idiopathic 
arthritis (JIA) 
[aged 0-21 
years] 
Cross 
sectional 
study design 
[Postal 
survey -with 
monetary 
incentive] 
Ethics 
committee 
approval; 
informed 
consent & 
anonymity 
 
An extensive list of 
conventional and 
CAM therapies 
compiled from 
literature and local 
and state-wide 
experience of JIA 
management was 
provided  
Perceived 
helpfulness; 
perceived side 
effects  
 
Ratio scale: 
4 levels from 0-3   
(PE   
Not /Somewhat 
/Moderately /Very 
helpful;  
AE  
None /Mild 
/Moderate 
/Severe) 
*PE for CAM therapies as a 
whole: 
Median (mean) rating 
3 (2.5) 
There was no significant 
difference between the mean 
helpfulness ratings for 
conventional medications and 
CAM therapies 
{2.7 vs. 2.5 (p=0.29)} 
Findings on outcomes summarised 
with this conclusion: Even though 
parents viewed some conventional 
medications as being more helpful 
for their childrens JIA than some 
CAM therapies overall, the use of 
CAM was perceived as being 
similarly helpful as conventional 
medications. 
[REC: Future studies of CAM 
therapies, particularly those that 
parents feel are helpful and low in 
side effects, such as vitamin D, are 
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w a r r a n t e d ]  
5 2  
r e s p o n d e n t s   
[ R R  6 8  % ]  
C o n v e n i e n c e  
s a m p l i n g   
( A l l  e l i g i b l e  
s u b j e c t s )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
D e v e l o p e d  
C A M  t o o l  w a s  
p i l o t e d  f o r  
c l a r i t y  i n  t w o  
J I A  
a d o l e s c e n t s  
n o t  p a r t  o f  
t h e  s a m p l e .  
N o  r e v i s i o n s  
w e r e  
r e q u i r e d .  
 
P a t i e n t  m e d i c a l  
r e c o r d s  o f  a  
u n i v e r s i t y  
c h i l d r e n  s  
h o s p i t a l ;  l o c a l  
d a t a b a s e  
[ F o r  2  m o n t h s ]  
P r e v a l e n c e :  9 2  %   
( 3 0 - d a y ;  4 8  
r e s p o n d e n t s )  
 
 
 
J o i n t  r e p o r t  
( P a r e n t s  i n  
c o n s u l t a t i o n  
w i t h  t h e i r  
c h i l d r e n )  
D e s c r i p t i v e  
{ m e d i a n  r a t i n g  
( m e a n ) }  a n d  
i n f e r e n t i a l  ( p  
v a l u e s )  s t a t i s t i c s ;  
u n i v a r i a t e  a n a l y s i s  
( W i l c o x o n  s i g n e d -
r a n k  @  p < 0 . 0 5 )  
A E  C A M  t h e r a p i e s  a s  a  
w h o l e :  
M e d i a n  ( m e a n )  r a t i n g  
 0  ( 0 . 2 9 )  
M e a n  p e r c e i v e d  A E  r a t i n g s  
f o r  c o n v e n t i o n a l  m e d i c a t i o n s  
w a s  s i g n i f i c a n t l y  h i g h e r  t h a n  
t h o s e  f o r  C A M  t h e r a p i e s  
{ 1 . 0  v s .  0 . 2 9  ( p = 0 . 0 0 2 ) }  
L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S i n g l e  c e n t r e  s t u d y  
2 .  N o n - g e n e r a l i s a b i l i t y  ( g e o g r a p h i c  
v a r i a t i o n s  i n  C A M  l i c e n s i n g  a n d  
p r a c t i c e )  
3 .  T o o  s h o r t  a  p e r i o d  s u r v e y e d  f o r  
C A M  u s e  ( l a s t  3 0  d a y s )  
4 .  N o n - i n s u r a n c e  o f  j o i n t  r e p o r t  
s t a t u s  o f  t h e  o u t c o m e s  r e p o r t e d  
5 .  A n o n y m i t y  ( i m p o s s i b l e  t o  v e r i f y  
p a r e n t a l  r e p o r t s  o f  m e d i c a t i o n s  
u s e d )  
6 .  P o s s i b l e  ( T y p e  I )  e r r o r s  i n  
s t a t i s t i c a l  a n a l y s e s  d u e  t o  s m a l l  
s a m p l e  s i z e  
3 6 .  S i m p s o n  
a n d  R o m a n  
( 2 0 0 1 )  
[ 3 4 8 ]  
C o n d u c t e d  i n  
t h e  U K  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  
M e d i c a l  
d o c t o r ]  
1 1 3 4  c h i l d r e n  N o t  s p e c i f i e d  
( P a r e n t s /  
g u a r d i a n s  
o f ? )  
P a e d i a t r i c  
s u b j e c t s   
[ A g e d  u p  t o -
1 6  y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l  o n l y ;  
b u t  i m p l i e d  
c o n s e n t  i m p l i e d  
 
C A M  d e f i n e d  
i n c l u s i v e l y  a s  
 v a r i o u s  t h e r a p i e s  
f o r  w h i c h  y o u  s e e  
a  t h e r a p i s t ,  s u c h  
a s  a  h o m e o p a t h ,  
a n d  v a r i o u s  s e l f -
t r e a t m e n t s  s u c h  a s  
h e r b s ,  w h i c h  y o u  
b u y  y o u r s e l f .   
P e r c e i v e d  
h e l p f u l n e s s ;  A E  
n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
P E :  
8 5  %  ( 1 9 7  o f  2 3 1  e p i s o d e s  
o f  u s e )  
 
F i n d i n g s  o n  o u t c o m e s  n o t  
s u m m a r i s e d ;  n o r  w e r e  a n y  
c o n c l u s i o n s  m a d e  o n  U P E S  
o u t c o m e s  d a t a  
[ N o  r e c o m m e n d a t i o n s  m a d e  b a s e d  
o n  U P E S  o u t c o m e s  d a t a ]  
 
 
9 9 4  
r e s p o n d e n t s  
[ R R  7 9 . 7  % ]  
S i m p l e  
r a n d o m  
s a m p l i n g  
[ S a m p l e  s i z e  
j u s t i f i e d  
s t a t i s t i c a l l y ]  
C A M  t o o l  
d e v e l o p e d  
a n d  p i l o t e d  
( n  n o t  
s t a t e d ) .  
S a m p l e  
g e n e r a t e d  f r o m  
a  c h i l d  h e a l t h  
d a t a b a s e ;  
r e g i o n a l  
d a t a b a s e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
P r e v a l e n c e :  1 8  %  
( e v e r  u s e d ,  1 6 2  
r e s p o n d e n t s )  
T y p e  o f  
r e p o r t ( e r )  n o t  
s p e c i f i e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  P o s s i b l e  c o n f o u n d i n g  d u e  t o  
s o c i - e c o n o m i c  f a c t o r s  
3 7 .  B o l d  a n d  
L e i s  
( 2 0 0 1 )  
[ 3 5 4 ]  
C o n d u c t e d  i n  
C a n a d a  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r  
U n c l e a r ]  
4 8  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s   
P a r e n t s  o f  
l i v i n g  c h i l d r e n  
w i t h  c a n c e r  
[ 0 - 1 4  y e a r s  
a t  t i m e  o f  
d i a g n o s i s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ S e m i -
s t r u c t u r e d  
t e l e p h o n e  
i n t e r v i e w s ]  
N o  e t h i c a l  
c o n s i d e r a t i o n s  
r e p o r t e d  
 
U n c o n v e n t i o n a l  
t h e r a p i e s  w e r e  
d e f i n e d  a s  t h o s e  
t h e r a p i e s ,  o t h e r  
t h a n  m e d i c a l  
t r e a t m e n t s  t h a t  
a r e  c o n s i d e r e d  
s t a n d a r d  i n  
S a s k a t c h e w a n ,  
t h a t  p a t i e n t s  
S a t i s f a c t i o n ;  
p r o b l e m s  
 
N o  r a t i n g  s c a l e  
u s e d .  O u t c o m e s  
w e r e  r a t e d  
q u a l i t a t i v e l y  
 
P E :  
R e p o r t e d  b y  m o r e  t h a n   
8 0  %  o f  u s e r s   
( d e s c r i b e d  a s :  t h e r a p y  h a d  
h e l p e d  i n  s o m e  w a y ;  t h e  
p r o v i d e r  w a s  v e r y  g o o d ;  
a n d / o r  t h e  c h i l d  h a d  b e e n  
t r e a t e d  v e r y  w e l l )  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
F i n d i n g s  o n  o u t c o m e s  s u m m a r i s e d  
w i t h  t h i s  c o n c l u s i o n :  P a r e n t s  w h o  
u s e d  u n c o n v e n t i o n a l  t h e r a p i e s  
e x p r e s s e d  s a t i s f a c t i o n  w i t h  t h e m ,  
a n d  r e p o r t e d  v e r y  f e w  p r o b l e m s .  
I n  g e n e r a l  p a r e n t s  d e s c r i b e d  q u i t e  
p o s i t i v e  e x p e r i e n c e s  i n  u s i n g  
u n c o n v e n t i o n a l  t h e r a p i e s  
[ R E C :  I t  i s  t i m e  t o  m o v e  b e y o n d  
t r y i n g  t o  u n d e r s t a n d  w h y  p a t i e n t s  
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received 
specifically for 
their cancer and/or 
associated 
symptoms or 
conditions, 
regardless of type 
of provider 
 turn to unconventional therapies. 
Rather the health system needs to 
adapt to and support patients and 
families needs to identify safe and 
potentially helpful therapies when 
they choose to do so. There is 
need for more research into the 
effectiveness of individual 
unconventional therapies using 
appropriate questions and 
methods. Evaluations must 
consider effectiveness in relation 
to users expected outcomes] 
44 
respondents 
[RR 92 %] 
Convenience 
sampling  
(All eligible 
subjects) 
[A 2-year 
period was 
adjudged 
from the past 
annual 
entries as 
adequate in 
providing a 
sufficient 
number of 
subjects for 
descriptive 
and 
associational 
statistical 
analyses] 
Interview 
schedule 
adapted from 
a previous 
cancer survey 
in adults; but 
no report of 
validation or 
pilot. 
Province-wide 
mandatory and 
comprehensive 
cancer 
registry; state-
wide database 
[Study 
duration not 
stated] 
 
 
Prevalence: 36 %  
(for condition; 16 
respondents) 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE: 
Unsure -data unclear: 
three quarters of parents 
reported no problems 
implying that about a quarter 
did? 
No limitations acknowledged 
38. 
Molassiotis 
and Cubbin 
(2004) 
[350] 
Conducted in 
the UK 
[Profession of 
primary 
author 
Nurse] 
96 eligible 
paediatric 
subjects 
Parents of 
children with 
cancer 
receiving 
conventional 
treatment                          
[aged 5-18 
years] 
Cross 
sectional 
study design 
[Postal 
survey] 
Ethics 
committee 
approval; 
informed 
consent & 
confidentiality 
 
CAM defined 
according to Ernst 
and Cassileth, 
1998, p. 777: 
diagnosis, 
treatment and/or 
prevention which 
complements 
mainstream 
medicine by 
contributing to a 
common whole, by 
Perceived 
effectiveness 
/benefits; AE 
not studied 
 
Interval scale 
and qualitative 
report: 
Helpfulness  
10-level scale, 
from  1 (not 
helpful at all) to 10 
(very helpful); 
Benefits -
qualitatively 
 
*PE: 
No general rating for all CAM.  
Mean PE rating (SD) for 
specific CAMs: 
Multivitamins  
6.71 (1.7); 
Diet  
7.17 (0.98); 
Aromatherapy  
8 (1.46); 
Herbal medicine 1*; 
Homeopathy -1*; 
Findings on outcomes validly 
summarised with this conclusion: 
Most parents who used some form 
of CAM for their children were 
satisfied with their chosen therapy 
in relation to the benefits it 
provided for their child.  
[REC: The fact that the use of CAM 
has been reported as having both 
positive and beneficial effects for 
children with cancer suggests that 
CAM use should perhaps be an 
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s a t i s f y i n g  a  
d e m a n d  n o t  m e t  
b y  o r t h o d o x y ,  o r  
b y  d i v e r s i f y i n g  t h e  
c o n c e p t u a l  
f r a m e w o r k s  o f  
m e d i c i n e   
M e g a v i t a m i n s  - 1 * ;  
V e g e t a b l e  j u i c e s  - 1 0 *  
( * S D  n o t  s t a t e d ) .  
C o r r e l a t i o n s  
A  s i g n i f i c a n t  c o r r e l a t i o n  w a s  
s h o w n  b e t w e e n  u s i n g  d i e t s  
a n d  t h e  p e r c e p t i o n  o f  
i m p r o v i n g  t h e  c h i l d  s  i m m u n e  
f u n c t i o n  ( r s  = 0 . 7 3 ,  p < 0 . 0 0 1 )  
a s  w e l l  a s  w i t h  u s i n g  
m u l t i v i t a m i n s  ( r s  = 0 . 6 8 ,  
p = 0 . 0 0 4 ) .  
  P e r c e i v e d  b e n e f i t s :  
I n c r e a s e d  c o n f i d e n c e  ( n = 2 ) ;  
p a i n  r e l i e f  ( n = 6 )  a n d  
r e l a x a t i o n  ( n = 5 )  
i n t e g r a l  p a r t  o f  t h e  t r e a t m e n t  t h a t  
c h i l d r e n  r e c e i v e  f o r  t h e i r  c a n c e r ]  
 
4 9  
r e s p o n d e n t s  
[ 5 1  % ]  
C o n v e n i e n c e  
s a m p l i n g   
( A l l  e l i g i b l e  
s u b j e c t s )  
[ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
D e v e l o p e d  
C A M  t o o l  w a s  
p i l o t e d  i n  f o u r  
p a r e n t s  w h o  
w e r e  n o t  p a r t  
o f  t h e  f i n a l  
s a m p l e ,  a n d  
t h e n  r e v i s e d  
P a t i e n t  
d a t a b a s e  o f  t h e  
o n c o l o g y  u n i t  
o f  a  h o s p i t a l ;  
l o c a l  d a t a b a s e  
[ S t u d y  
d u r a t i o n  n o t  
s t a t e d ]  
P r e v a l e n c e :  3 3  %  
( f o r  c o n d i t i o n ;  1 6  
r e s p o n d e n t s )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  { m e a n  
r a t i n g s  ( S D ) }  a n d  
i n f e r e n t i a l  ( p  
v a l u e s )  s t a t i s t i c s ;  
b i v a r i a t e  a n a l y s i s  
( S p e a r m a n  s  
c o r r e l a t i o n ;  
s i g n i f i c a n c e  l e v e l  
n o t  s t a t e d )   
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  S m a l l  s a m p l e  s i z e  ( d i f f i c u l t  t o  
g e n e r a l i s e  r e s u l t s )  
2 .  C r o s s  s e c t i o n a l  s t u d y  d e s i g n  ( n o  
t i m e  e l e m e n t  c o n s i d e r e d )  
3 .  N o n r e s p o n s e  b i a s  ( p o s s i b l y  
s k e w e d  t h e  r e s u l t s )  
3 9 .  C h r i s t o n  
e t  a l  
( 2 0 1 0 )  
[ 3 6 1 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r   
C l i n i c a l  
p s y c h o l o g i s t ]  
2 4 8  e l i g i b l e  
p a r e n t s  
( N u m b e r  o f  
p a e d i a t r i c  
s u b j e c t s  n o t  
s t a t e d )  
P a r e n t s  o f  
c h i l d r e n  w i t h  
a u t i s m  
s p e c t r u m  
d i s o r d e r s  
w h o  h a d  
p a r t i c i p a t e d  
i n  a  l a r g e r  
s t u d y  
[ a g e d  2 1  
m o n t h s - 2 1  
y e a r s ]  
D a t a  a n a l y s i s  
o f  a  s u b - s e t  
o f  
r e s p o n d e n t s  
t o  a n  o n l i n e  
c r o s s  
s e c t i o n a l  
s u r v e y   
[ S e c o n d a r y  
s t u d y ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
 
A  l i s t  o f  b o t h  
c o n v e n t i o n a l  a n d  
C A M  t h e r a p i e s  
( i n c l u d i n g  
b i o l o g i c a l  a n d  n o n -
b i o l o g i c a l  
t r e a t m e n t s )  w a s  
p r o v i d e d  t o  
p a r t i c i p a n t s  
 
P e r c e i v e d  
i m p r o v e m e n t ;  
o u t c o m e -
r e l a t e d  r e a s o n  
f o r  s t o p p i n g  
t h e r a p y ;  A E  
n o t  s t u d i e d  
 
O r d i n a l  s c a l e :  
5  c a t e g o r i e s  
( M u c h  
i m p r o v e m e n t  t o  
M u c h  w o r s e )  
 
P E  ( a v e r a g i n g  a c r o s s  
t r e a t m e n t s ) :  
5 6  %    
( M u c h  i m p r o v e m e n t  - 1 8  % ;  
S o m e  i m p r o v e m e n t  - 3 8  % )  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
O d d s  o f   I m p r o v e m e n t   
r a t i n g :  
T h e  o d d s  o f  p a r e n t s  r a t i n g  
t h e  o u t c o m e  o f  t h e i r  u s e  o f  
v a r i o u s  p r o d u c t - b a s e d  C A M  
t h e r a p i e s  a s  a n  i m p r o v e m e n t  
( m u c h / s o m e w h a t )  r a t h e r  
t h a n  a s  n o  i m p r o v e m e n t  ( n o  
c h a n g e / w o r s e )  w e r e  a s  
f o l l o w s :  
 A n i m a l  t h e r a p y  - 1 . 8 ;  
C h e l a t i o n  - 1 . 7 ;  
S e c r e t i n  - 0 . 4 ;  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  t h e  f o l l o w i n g  
a m b i v a l e n t  c o n c l u s i o n  w a s  
r e a c h e d :  P a r e n t s  v a r y  c o n s i d e r a b l y  
i n  t h e i r  a s s e s s m e n t  o f  w h e t h e r  t h e  
C A M  t h e r a p i e s  a c t u a l l y  h e l p e d  
t h e i r  c h i l d :  t h e  m o s t  f r e q u e n t  
r e a s o n  f o r  s t o p p i n g  a  t r e a t m e n t  
w a s  t h a t ,  i n  t h e  p a r e n t s   v i e w ,  i t  
d i d  n o t  w o r k .  I t  i s  l i k e l y  t h a t  s o m e  
o f  t h e  C A M  t r e a t m e n t s  w e r e  
h e l p f u l  f o r  s o m e  o f  t h e  c h i l d r e n ,  
a n d  t h a t  t h e  t r e a t m e n t s  h a d  n o  
e f f e c t  f o r  s o m e  o f  t h e  c h i l d r e n ;  i t  
i s  p o s s i b l e  t h e y  h a r m e d  s o m e  
c h i l d r e n .  W i t h o u t  v a l i d  a s s e s s m e n t  
o f  e f f i c a c y ,  w e  d o  n o t  k n o w    
[ R E C :  C l e a r l y  m o r e  
m e t h o d o l o g i c a l l y  s o u n d  r e s e a r c h  
n e e d s  t o  b e  d o n e  o n  C A M  
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Special diets -1.4; 
Special vitamins -3.2 
Proportion of users that 
stopped therapy because it 
did not work 
(averaging across therapies): 
Stopped using CAM  
54 % of users; 
Stopped because CAM did 
not work  
27 % of users  
treatments] 
 
248 
respondents 
[RR not 
appropriate 
not a primary 
study] 
Convenience 
sampling 
(All eligible 
subjects) 
[Sample size 
not justified] 
Online survey 
was 
developed 
using the 
Inquisite 
programme; 
but no report 
of validation 
or pilot 
Database of 
participants in 
a larger online 
survey 
recruited 
through notices 
placed in 
parent 
newsletters by 
county-, state- 
and nation-
wide autism 
organizations; 
broad database 
[Study 
duration not 
stated] 
Prevalence: 71 % 
(ever used; 176 
respondents) 
51 %  
(current use; 127 
respondents) 
Proxy report 
used 
Descriptive 
statistics  
(%, OR); 
univariate analysis 
(frequency table) 
AE not studied Limitations acknowledged: 
1. Response bias (subjective and 
not clearly specific to specific 
therapies) 
2. Non representative sample 
(required computer/online access, 
and membership of autism 
organization) 
3. Outcomes ratings not validated  
40. Ben 
Arush et al 
(2006) 
[378] 
Conducted in 
Israel 
[Profession of 
primary 
author  
(Medical 
doctor] 
Target 
sample size 
not stated 
Adolescents 
and parents 
of children 
presenting 
for oncology 
treatment, 
hospitalizatio
n or follow-up 
[Paediatric 
age range 
not specified] 
Cross 
sectional 
study design 
 [Face-to-
face 
interview] 
 
Ethics 
committee 
approval; 
informed 
consent 
 
CAM was defined 
as any practice not 
prescribed by a 
physician or not 
considered as a 
proven medical 
treatment. A list of 
CAM therapies was 
also provided 
Perceived 
improvement; 
AE not studied 
 
Type of outcomes 
measurement not 
described 
 
PE: 
69 % (42 users);  
for 63 % of 165 different 
treatments and remedies 
Specific benefits reported: 
General improvement in well-
being  
70-85 % of treatments; 
Strengthening immune 
system  
68 % of treatments 
Although no distinct summary 
statement was made on the 
outcomes findings reported, the 
following conclusion was reached: 
The optimal use of complementary 
therapies may improve quality of 
care, especially its impact on well-
being 
[REC: Potential benefits and harms 
of CAM treatments have to be 
scientifically studied, verifying 
their impact on therapeutic trials] 
100 
respondents 
[RR data not 
available] 
Convenience 
sampling 
 (All parents 
or 
adolescents 
Developed 
CAM tool was 
piloted (in 10 
patients) and 
then revised 
Oncology 
department of 
childrens 
hospital at a 
secondary and 
Prevalence: 61 %  
(prevalence type 
unclear; 61 
respondents) 
 
Mixed report 
used: 
Adolescents -
self-report; 
Children 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed 
AE not studied No limitations acknowledged 
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1 0 6  
 
w h o  c a m e  o n  
t h e  s p e c i f i c  
i n t e r v i e w i n g  
d a y s )  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
t e r t i a r y  r e f e r r a l  
c e n t r e  f o r  a  
m u l t i -
e t h n i c / c u l t u r a l  
p o p u l a t i o n  i n  
n o r t h e r n  
I s r a e l ;  s i n g l e  
c e n t r e  
[ F o r  6  m o n t h s ]  
 p a r e n t - p r o x y  
r e p o r t   
4 1 .  S a w n i -
S i k a n d  e t  a l  
( 2 0 0 2 )  
[ 4 8 9 ]  
C o n d u c t e d  i n  
t h e  U S A  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r    
( M e d i c a l  
d o c t o r ]  
1 0 4 5  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s / c a r e g
i v e r s  o f  
c h i l d r e n  
p r e s e n t i n g  a t  
p r a c t i c e s  
[ P a e d i a t r i c  
a g e  r a n g e  
n o t  s p e c i f i e d ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
 [ S e l f -
c o m p l e t i o n  
s u r v e y ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  &  
a n o n y m i t y  
 
C A M  d e f i n e d  a s  
a n y  t h e r a p y  f o r  a  
m e d i c a l  i l l n e s s  t h a t  
t h e  c h i l d  s  r e g u l a r  
d o c t o r  d i d  n o t  
p r e s c r i b e  
( e x c l u d i n g  o v e r -
t h e - c o u n t e r  
m e d i c a t i o n s  l i k e  
m u l t i v i t a m i n s ) ,  
w i t h  r e l e v a n t  
e x a m p l e s  
P e r c e i v e d  
s a t i s f a c t i o n  
o v e r a l l ,  a n d  
r e l a t i v e  t o  
c o n v e n t i o n a l  
m e d i c i n e ;   A E  
n o t  s t u d i e d  
 
T y p e  o f  o u t c o m e s  
m e a s u r e m e n t  n o t  
d e s c r i b e d  
 
P E :  
O v e r a l l  S a t i s f a c t i o n  -  
5 5  %  ( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d ) ;   
R e l a t i v e  t o  c o n v e n t i o n a l  
m e d i c i n e :  
5 2  %  r e p o r t e d  t h a t  r e s u l t s  
w e r e  b e s t  w h e n  C A M  i s  
i n t e g r a t e d  w i t h  c o n v e n t i o n a l  
m e d i c i n e )  
 
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  n o  c o n c l u s i o n s  
w e r e  d r a w n  f r o m  t h e m  
  [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
 
N u m b e r  o f  
r e s p o n d e n t s  
n o t  s t a t e d ;  
b u t  1 0 1 3  
v a l i d  
r e s p o n s e s  
( 6 7  % )  w e r e  
r e c e i v e d  
[ R R  d a t a  n o t  
a v a i l a b l e ]  
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
 
C A M  t o o l  
a d a p t e d  
p a r t l y  f r o m  
t o o l  u s e d  i n  
a n  e a r l i e r  
s t u d y ,  a n d  
t h e n  p i l o t e d  
3  U r b a n  a n d  3  
s u b - u r b a n  
g e n e r a l  
p a e d i a t r i c  
p r a c t i c e s ;  
m u l t i - c e n t r e ;  
m u l t i - c i t y  
[ F o r  5  m o n t h s ]  
P r e v a l e n c e :   
S u b - u r b a n  
p r a c t i c e s :                   
1 2  %   
( p r e v a l e n c e  t y p e  
u n c l e a r ;  n u m b e r  
o f  r e s p o n d e n t s  n o t  
p r o v i d e d ) ;  
U r b a n  p r a c t i c e s :  
1 4  %   
( p r e v a l e n c e  t y p e  
u n c l e a r ;  n u m b e r  
n o t  s t a t e d )  
P r o x y  r e p o r t  
u s e d  
D e s c r i p t i v e  
s t a t i s t i c s  ( % ) ;   
o u t c o m e s  d a t a  n o t  
s t a t i s t i c a l l y  
a n a l y s e d  
A E  n o t  s t u d i e d  L i m i t a t i o n s  a c k n o w l e d g e d :  
1 .  N o n - g e n e r a l i s a b i l i t y  ( r e g i o n a l  
d i f f e r e n c e s  i n  C A M  u s e ;  c l i n i c a l  
s e t t i n g )  
2 .  S o c i a l  d e s i r a b i l i t y  b i a s  
3 .  N o n - v a l i d a t i o n  o f  t o o l  ( r e l i a b i l i t y  
a n d  v a l i d i t y )  
4 2 .  L a e n g l e r  
e t  a l  
( 2 0 0 8 )  
[ 6 6 1 ]  
C o n d u c t e d  i n  
G e r m a n y  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r    
( M e d i c a l  
d o c t o r ]  
1 5 9 5  e l i g i b l e  
p a e d i a t r i c  
s u b j e c t s  
P a r e n t s  o f  
p a e d i a t r i c  
s u b j e c t s  w i t h  
c a n c e r  
r e g i s t e r e d  i n  
t h e  G e r m a n  
C h i l d h o o d  
C a n c e r  
R e g i s t r y  
[ 0 - 1 5  y e a r s ]  
C r o s s  
s e c t i o n a l  
s t u d y  d e s i g n  
[ P o s t a l  
s u r v e y ]  
 
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  &  
a n o n y m i t y  
 
C A M  d e f i n e d  a s  a l l  
t h e  t r e a t m e n t s  n o t  
c u r r e n t l y  
c o n s i d e r e d  
s t a n d a r d  o r  l a r g e l y  
a c c e p t e d  
e x p e r i m e n t a l  
m e t h o d s .  A  
 c o m p r e h e n s i v e   
l i s t  o f  t h e r a p i e s  
w a s  a l s o  p r o v i d e  
P e r c e i v e d  
i m p r o v e m e n t ;  
p e r c e i v e d  A E s  
 
 
T y p e  o f  o u t c o m e s  
r a t i n g  s c a l e s  n o t  
d e s c r i b e d ;  
p e r c e i v e d  b e n e f i t s  
r e p o r t e d  
q u a l i t a t i v e l y  
 
P E :  
 I m p r o v e m e n t   o r   M a r k e d  
i m p r o v e m e n t   w a s  r e p o r t e d  
i n  o v e r  5 0  %  o f  t h e  c a s e s  
w h e r e  t h e  m o s t  p o p u l a r  C A M  
t y p e s  ( m a i n l y  C A M  p r o d u c t s )  
w e r e  u s e d .  
P e r c e i v e d  B e n e f i t s :  
R e p o r t e d  b y  9 1  %  o f  u s e r s  
w i t h  p o s i t i v e  e x p e c t a t i o n s  o f  
C A M  u s e ,  a n d  6 8  %  o f  t h o s e  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d ;  b u t  n o  c o n c l u s i o n s  
w e r e  d r a w n  f r o m  t h e m  
 [ N o  r e c o m m e n d a t i o n s  m a d e  o n  
U P E S  o u t c o m e s  d a t a ]  
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with negative expectations.  
Most reported benefits for 
CAM products - 
1. Strengthening of the 
immune system 
2. Greater physical stability 
Number of 
respondents 
not stated; 
but 1063 
valid 
responses 
(67 %) were 
received 
[RR data not 
available] 
Convenience 
sampling 
(All eligible 
subjects) 
[Sample size 
not justified] 
CAM tool was 
previously 
piloted; but 
no report of 
validation 
German 
Childhood 
Cancer 
Registry; broad 
database 
[8.5 months] 
 
Prevalence: 35 %  
(for condition; 367 
respondents) 
 
 
Proxy report 
used 
Descriptive 
statistics (%);  
outcomes data not 
statistically 
analysed  
AE: 
 4 %  
(number of users not 
provided) 
No limitations acknowledged 
43. 
Gerasimidis 
et al 
(2008) 
[352] 
Conducted in 
the UK 
[SCOTLAND] 
[Profession of 
primary 
author 
Clinical 
nutritionist] 
104 of 135 
eligible 
paediatric 
subjects 
Guardians of 
paediatric 
patients with 
inflammatory 
bowel disease 
(IBD) 
[4.8-17.5 
years] 
Cross 
sectional  
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval; 
informed 
consent 
 
CAM was defined 
as unconventional 
remedies and 
treatments that 
are not normally 
taught in the 
British medical 
schools as 
established 
approaches to IBD 
management; and 
that were not 
reimbursed by the 
NHS nor 
recommended by 
medical staff, 
excluding exercise 
and prayer. 
Multivitamins and 
dietary 
modifications were 
included only 
where they had 
been purchased 
over-the-counter 
without having 
been 
recommended by 
medical staff. A list 
Perceived 
effectiveness; 
reported AEs 
 
Type of outcomes 
measurement not 
described 
 
PE: 
48 % (16 users) 
Association: 
A PE rating of Effective was 
reported to be associated 
with the CAM type used: 
CAM Therapist Users were 
reported to be more 
(p=0.022) associated with an 
Effective rating for CAM 
Self-prescribed CAM users: 
but data not presented. 
 
 
Findings on outcomes validly 
summarised; but no conclusions 
drawn on UPES data 
[No recommendations made on 
UPES outcomes data] 
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1 0 8  
 
o f  g r o u p e d  C A M  
t h e r a p i e s  w a s  a l s o  
p r o v i d e d .  
8 6  
r e s p o n d e n t s  
[ R R  8 3  % ]  
 
S a m p l i n g  
m e t h o d  n o t  
d e s c r i b e d  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
 
 
 
A d a p t e d  f r o m  
2  p r e v i o u s  
q u e s t i o n n a i r e
s ;  c h e c k e d  
f o r  f a c e  
v a l i d i t y ,  a n d  
t h e n  p i l o t e d  
i n  1 0  I B D  
p a t i e n t s  
O u t p a t i e n t  
d e p a r t m e n t  o f  
a  r e g i o n a l  I B D  
r e f e r r a l  c e n t r e  
i n  a n  u r b a n  
c h i l d r e n  s  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ F o r  1 3  
m o n t h s ]                  
P r e v a l e n c e :  6 1  %   
( e v e r  u s e d  - a s  
f r o m  3  m o n t h s  
p o s t  d i a g n o s i s ;  5 2  
r e s p o n d e n t s )  
3 7  %   
( c u r r e n t  u s e ;  
n u m b e r  o f  
r e s p o n d e n t s  n o t  
p r o v i d e d )  
P r o x y  r e p o r t  
u s e d  
 
 
D e s c r i p t i v e  ( % )  
a n d  i n f e r e n t i a l  ( p  
v a l u e s )  s t a t i s t i c s ;  
b i v a r i a t e  a n a l y s e s   
( O R  @  9 5  %  C I )  
A E :  
1  p a t i e n t  ( b u t  %  n o t  
p r o v i d e d ;  s o  d a t a  u n c l e a r ) .  
Q :  I s  t h i s  p a t i e n t  a m o n g  t h e  
e v e r  u s e r s  o r  r e c e n t  u s e r s  o f  
C A M ?  
N o  L i m i t a t i o n  a c k n o w l e d g e d   
4 4 .  R o s s i  e t  
a l  
( 2 0 1 0 )  
[ 3 5 8 ]  
C o n d u c t e d  i n  
I t a l y  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r    
( M e d i c a l  
d o c t o r ]  
3 3 7  
p a e d i a t r i c  
p a t i e n t s  
P a e d i a t r i c  
p a t i e n t s  w i t h  
r e s p i r a t o r y  
d i s e a s e s   
[ a g e d  0 - 1 4  
y e a r s ]  
P r o s p e c t i v e  
c o h o r t  s t u d y  
d e s i g n  
[ R o u t i n e  
m e d i c a l  
c o n s u l t a t i o n  -
P a t i e n t  r e p o r t  
o f  s y m p t o m s ]  
N o  m e n t i o n  o f  
e t h i c s  
c o m m i t t e e  
a p p r o v a l ;  b u t  
i n f o r m e d  
c o n s e n t  
o b t a i n e d   
 
H o m e o p a t h i c  
t h e r a p i e s ;  n o  
d e f i n i t i o n  n e e d e d ,  
a s  p a r t i c i p a n t s  
w e r e  p a t i e n t s  
p r e s e n t i n g  a t  
h o m e o p a t h i c  c l i n i c  
[ S i n g l e  c e n t r e ]  
O u t c o m e  o f  
t h e r a p y  
d e g r e e s  o f  
i m p r o v e m e n t ;  
A E s  r e p o r t e d   
 
 
I n t e r v a l  s c a l e :  
6  l e v e l s ,  n u m b e r e d  
f r o m  
 - 1  t o  4  
( S l i g h t  w o r s e n i n g  
/ N o n e  / S l i g h t  
i m p r o v e m e n t  
/ M o d e r a t e  
i m p r o v e m e n t  
/ I m p o r t a n t  
i m p r o v e m e n t  
/ C u r e d  o r  B a c k  t o  
n o r m a l )  
P E :  
D e g r e e  o f  I m p r o v e m e n t -  
9 6  %   
{ C u r e d / B a c k  t o  n o r m a l    
3 2  % ;  
I m p o r t a n t  i m p r o v e m e n t    
3 6  % ;  
M o d e r a t e  i m p r o v e m e n t    
1 5  % ;  
S l i g h t  i m p r o v e m e n t    
1 3  % }  
( n u m b e r  o f  u s e r s  n o t  
p r o v i d e d )  
R e g r e s s i o n    
O u t c o m e  w a s  s i g n i f i c a n t l y  
a s s o c i a t e d  w i t h  t y p e  o f  
d i s e a s e s  t r e a t e d  ( p = 0 . 0 0 5 )  
{ u p p e r  r e s p i r a t o r y  t r a c t  
i n f e c t i o n  [ 7 7  %  s u c c e s s ;  O R  
- 4 . 2  ( 1 . 6 - 1 1 . 4 ) ]  >  a l l e r g i c  
r h i n o c o n j u c t i v i t i s  [ 6 3  %  
s u c c e s s ;  O R  - 1 . 2  ( 0 . 3 - 4 . 6 )  >  
l o w e r  r e s p i r a t o r y  t r a c t  
i n f e c t i o n  [ 5 4  %  s u c c e s s ;  O R  
- 1 . 0  ( C  I  n o t  p r o v i d e d ) ] }  a n d  
t h e  d u r a t i o n  o f  f o l l o w - u p  a t  
w h i c h  e i t h e r  a n  i m p o r t a n t  
i m p r o v e m e n t  o r  a  r e s o l u t i o n  
w a s  r e p o r t e d  ( p < 0 . 0 0 1 )  
{ " 2 4  m o n t h s  [ 9 4  %  s u c c e s s ;  
O R  - 3 5 . 7  ( 8 . 5 - 1 5 0 . 0 ) ]  >  1 2 -
1 8  m o n t h s  [ 7 8  %  s u c c e s s ;  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h i s  c o n c l u s i o n :  
O u r  d a t a  e v i d e n c e  t h a t  n e a r l y  a l l  
p a t i e n t s  w i t h  f o l l o w - u p  r e p o r t e d  a  
p o s i t i v e  o u t c o m e  d e r i v i n g  f r o m  
h o m e o p a t h i c  t r e a t m e n t  o f  
r e s p i r a t o r y  d i s e a s e s ,  w i t h  t h e  
p r o b a b i l i t y  o f  r e p o r t i n g  a t  l e a s t  a n  
i m p o r t a n t  i m p r o v e m e n t  b e i n g  
h i g h e s t  f o r  u p p e r  r e s p i r a t o r y  t r a c t  
i n f e c t i o n s  a n d  t h e  l i k e l i h o o d  o f  
s u c c e s s  b e i n g  h i g h e r  i n  p a t i e n t s  
w i t h  f o l l o w - u p  o f  a t  l e a s t  o n e  y e a r .  
T h e s e  r e s u l t s  t e n d  t o  i d e n t i f y  a  
p o s i t i v e  t h e r a p e u t i c  e f f e c t  o f  
h o m e o p a t h y  i n  t h e  p a e d i a t r i c  a g e .  
[ R E C :  H o m e o p a t h i c  t r e a t m e n t  
s h o u l d  b e  e n c o u r a g e d ,  i n  
p a r t i c u l a r  f o r  r e s p i r a t o r y  d i s e a s e s ,  
w h i c h  a r e  t h e  m o s t  f r e q u e n t  i n  t h e  
p a e d i a t r i c  p h a s e  o f  l i f e ]  
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OR -6.3 (2.2-17.9)] > 6 
months [50 % success; OR -
1.2 (0.4-3.5)] > 2 months 
[38 % success; OR -1.0 (C I 
not provided)]}   
168 patients 
returning for 
follow-up 
[RR 50 %] 
 
Convenience 
sampling 
(Consecutive 
eligible 
subjects) 
[Sample size 
not justified] 
Glasgow 
Homeopathic 
Hospital 
Outcome 
Score 
(GHHOS); a 
standard 
outcomes 
tool 
Homeopathic 
clinic of a 
provincial 
hospital; single 
centre 
[For 10 years] 
Prevalence of CAM 
use not relevant as 
use of homeopathy 
use had been an 
inclusion criterion 
Report made 
by patient; but 
the specific 
report type 
(direct or 
proxy) not 
clearly stated 
Descriptive (%) 
and inferential 
statistics (p  
value); 
Logistic 
multivariate  
analysis (Adjusted 
OR;  
95 % C I)  
AE: 
No negative effects reported 
Limitations acknowledged: 
1. Non-comparison of results with 
a control group on conventional 
treatment 
Zuzak et al 
(2010) 
[369] 
Conducted in 
Switzerland 
[Profession of 
primary 
author  
(Medical 
doctor] 
Target 
sample size 
not stated 
Adults 
mainly 
parents- 
accompanyin
g their 
children for 
clinic visits 
[Paediatric 
age range 
not specified] 
Cross 
sectional 
study design 
[Self-
completion 
survey] 
 
Ethics 
committee 
approval; 
informed 
consent & 
anonymity 
 
A list of CAM 
therapies was also 
provided 
 
Experiences 
with CAM: 
frequency of 
perceived 
effect (CAM vs. 
conventional 
medicine, CM); 
comparative 
perceived 
effectiveness; 
AEs noticed 
(CAM vs. CM) 
Ordinal scale: 
Frequency of 
benefit  
4 categories 
(Always 
/Sometimes 
/Rarely /Never); 
Comparative 
effectiveness  
3 categories (More 
/Equivalent /Less 
effective); 
Perceived AEs - 
3 categories 
(Strong /Weak /No 
side effect) 
PE: 
Frequency of perceived effect 
(CAM vs. CM)- 
Always  
CAM -38 % (242 users) vs.  
CM -62 % (473 users); 
Sometimes  
CAM -52 % (331 users) 
vs. 
CM -34 % (262 users); 
Rarely  
CAM -3 % (19 users) 
vs. 
CM -1 % (11 users); 
Never  
CAM -5% (33 users) 
vs. 
CM -2 % (14 users) 
Comparison of mean value of 
ratings (CAM vs. CM): 
0.76 vs. 0.85 (p<0.001) 
Comparative effectiveness  
More effective  
49 % (370 users); 
Equivalent effect  
13 % (99 users); 
Less effective  
3 % (26 users) 
Findings on outcomes validly 
summarised with this conclusion: 
Although CAM may be slightly less 
effective than CM, its good 
performance in some clinical 
situations and the superior 
tolerability leads to a high 
satisfaction of the users. Taken 
together, the data shows that for 
adults accompanying paediatric 
patients presenting to the 
emergency department, the 
strongest difference between CM 
therapies and CAM therapies 
concerned the tolerability of the 
two types of medical systems, with 
clearly more seldom and weaker 
side effects being experienced with 
CAM therapies. 
These observations seem to justify 
the recommendation of CAM 
therapies in certain situations, if 
accompanied by an individual 
assessment of the patients risk 
situation by a medical doctor 
[No recommendations made on 
UPES outcomes data] 
Number of 
respondents 
not stated; 
Sampling 
method not 
described 
CAM tool was 
piloted (in 20 
families) to 
Urban 
paediatric 
emergency 
Prevalence: 58 % 
(ever used; 665 
respondents) 
Proxy report 
used 
 
Descriptive (%, 
mean ratings) and 
inferential (p 
AE: 
AEs noticed CAM vs. CM 
CAM -7 % (47 users) 
Limitations acknowledged: 
1. Lack of clinical data 
2. Exclusion of people not literate 
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1 1 0  
 
b u t  1 1 4 3  ( 7 1  
% )  r e s p o n s e s  
a v a i l a b l e  f o r  
a n a l y s i s  
[ R R  d a t a  n o t  
a v a i l a b l e ]  
 [ S a m p l e  s i z e  
n o t  j u s t i f i e d ]  
e n s u r e  
r e a d a b i l i t y  
a n d  q u e s t i o n  
c l a r i t y ;  a n d  
t h e n  r e v i s e d  
d e p a r t m e n t  i n  
a  t e r t i a r y  
h o s p i t a l ;  s i n g l e  
c e n t r e  
[ 6  m o n t h s ]  
 
 
 
 
 
 
v a l u e )  s t a t i s t i c s ;  
u n i v a r i a t e  a n a l y s i s  
( M a n n - W h i t n e y  
t e s t s  @  p < 0 . 0 5 )  
 
{ S t r o n g  - 1 . 4  %  ( 9  u s e r s ) ,  
W e a k  - 6  %  ( 3 8  u s e r s ) ,  
N o n e  - 9 3  %  ( 5 8 0  u s e r s ) }  
C M  - 4 8  %  ( 3 5 7  u s e r s )  
{ S t r o n g  - 1 0  %  ( 7 3  u s e r s ) ,  
W e a k  - 3 8  %  ( 2 8 4  u s e r s ) ,  
N o n e  - 5 2  %  ( 3 8 1  u s e r s )  
C o m p a r i s o n  o f  m e a n  v a l u e  o f  
r a t i n g s  ( C A M  v s .  C M ) :  
0 . 0 5  v s .  0 . 2 2  ( p < 0 . 0 0 1 )  
i n  G e r m a n ,  E n g l i s h ,  F r e n c h ,  o r  
I t a l i a n  
3 .  A  w i d e  d e f i n i t i o n  o f  C A M  
4 .  U s e  o f  a  s i n g l e  c e n t r e   
5 .  U s e  o f  c o l l e c t i v e  e x p r e s s i o n  
s u c h  a s   a l l  ,   n e v e r  ,  
 s o m e t i m e s  ,  e t c . ,  w i t h o u t  f u r t h e r  
n u m e r i c a l  d e f i n i t i o n  o f  w h a t  i s  
m e a n t  
4 6 .  K e i l  e t  a l  
( 2 0 0 8 )  
[ 3 5 7 ]  
C o n d u c t e d  i n  
G e r m a n y  
[ P r o f e s s i o n  o f  
p r i m a r y  
a u t h o r    
( M e d i c a l  
d o c t o r ]  
1 1 8  c h i l d r e n  
( 5 4  o n  
h o m e o p a t h y ;  
6 4  o n  
c o n v e n t i o n a l  
m e d i c i n e ,  
C M )  
P a t i e n t s  w i t h  
e c z e m a  a n d  
t h e i r  p a r e n t s  
[ a g e d  0 - 1 6  
y e a r s ]  
 
P r o s p e c t i v e ,  
c o m p a r a t i v e ,  
c o h o r t  s t u d y  
d e s i g n  
[ S e l f -
c o m p l e t i o n  
s u r v e y ]  
E t h i c s  
c o m m i t t e e  
a p p r o v a l ;  
i n f o r m e d  
c o n s e n t  
 
H o m e o p a t h y ;  b u t  
n o  d e f i n i t i o n  
n e c e s s a r y ,  a s  
p a t i e n t s  h a d  
a l r e a d y  c h o s e n  t o  
r e c e i v e  t r e a t m e n t  
a t  h o m e o p a t h i c  
c l i n i c s  
P e r c e i v e d  
i m p r o v e m e n t  
o f  s y m p t o m  
s e v e r i t y ;  
p e r c e i v e d  s i d e  
e f f e c t s  
I n  e a c h  c a s e  
C A M  v s .  C M )  
 
R a t i o  s c a l e :  
S y m p t o m  s e v e r i t y  
  
1 1 - p o i n t  n u m e r i c a l  
r a t i n g  s c a l e ,  
n u m b e r e d  f r o m  0  
( n o  s y m p t o m s )   
t o  1 0  ( w o r s t  
s y m p t o m s )  
* P E :  
M e a n  i m p r o v e m e n t  o f  
s y m p t o m s  
S y m p t o m s  i m p r o v e d  
g r a d u a l l y  o v e r  t i m e  i n  b o t h  
g r o u p s    
C A M   
{ [ B a s e l i n e  - 3 . 7  ( 3 . 1 - 4 . 3 ) ;  6 -
m o n t h  - 3 . 3  ( 2 . 7 - 4 . 0 ) ;  1 2 -
m o n t h  - 2 . 7  ( 2 . 1 - 3 . 4 ) ]  
p < 0 . 0 0 1 ,  u n a d j u s t e d } ;  a n d  
C M   
{ [ B a s e l i n e  - 3 . 4  ( 2 . 8 - 3 . 9 ) ;  6 -
m o n t h  - 2 . 7  ( 2 . 1 - 3 . 3 ) ;  1 2 -
m o n t h  - 2 . 1  ( 1 . 5 - 2 . 7 ) ]  
p < 0 . 0 3 7 ,  u n a d j u s t e d } ;  b u t  
m o r e  s e v e r e  c a s e s  t e n d e d  t o  
b e  f o u n d  m o r e  o f t e n  i n  t h e  
C A M  g r o u p  ( p = 0 . 0 7 7 ,  
u n a d j u s t e d )  t h a n  i n  t h e  C M  
g r o u p  ( p < 0 . 1 7 2 ,  
u n a d j u s t e d ) .  H o w e v e r ,  
t r e n d s  d i d  n o t  d i f f e r  b e t w e e n  
t h e  2  g r o u p s   
( p = 0 . 8 3 0 ,  u n a d j u s t e d ;  
p = 0 . 4 4 7 ,  u n a d j u s t e d )  
R e g r e s s i o n  
R e s u l t s  d i s p l a y e d  g r a p h i c a l l y  
F i n d i n g s  o n  o u t c o m e s  v a l i d l y  
s u m m a r i s e d  w i t h  t h i s  c o n c l u s i o n :  
C o m p a r i n g  h o m e o p a t h y  w i t h  
c o n v e n t i o n a l  t r e a t m e n t s  o v e r  a  
l o n g  p e r i o d  ( 1 2  m o n t h s )  i n  
e v e r y d a y  p r a c t i c e ,  b o t h  t h e r a p y  
g r o u p s  i m p r o v e d  s i m i l a r l y  
r e g a r d i n g  p e r c e p t i o n  o f  e c z e m a  
s y m p t o m s  a s s e s s e d  b y  p a t i e n t s  o r  
p a r e n t s .  
[ R E C :  F u r t h e r  r e s e a r c h  i s  n e e d e d  
r e g a r d i n g  t h e  c o m p a r i s o n  o f  t h e s e  
t h e r a p y  o p t i o n s  f o r  p a t i e n t s  w i t h  
e c z e m a  i n  r e l a t i o n  t o  d i f f e r e n t  
s t u d y  s e t t i n g s  a n d  p a t i e n t  
p o p u l a t i o n s  a s  w e l l  a s  e c o n o m i c  
e v a l u a t i o n s ]  
 
N u m b e r  o f  
r e s p o n d e n t s  
n o t  p r o v i d e d  
[ R R  f o r  a l l  3  
s u r v e y  p o i n t s  
( 0 ,  6 ,  1 2  
m o n t h s )  
N o  s a m p l i n g  
c a r r i e d  o u t  
( E l i g i b l e  
s u b j e c t s  
p r e s e n t i n g  a t  
t h e  s e l e c t e d  
s t u d y  c e n t r e s  
T o o l  
d e v e l o p e d  
s p e c i f i c a l l y  
f o r  t h e  s t u d y ;  
b u t  n o  r e p o r t  
o f  p i l o t  o r  
v a l i d a t i o n  
H o m e o p a t h i c  
a n d  
c o n v e n t i o n a l  
d o c t o r s   
p r a c t i c e s  i n  
u r b a n  a n d  
u r b a n - r u r a l  
P r e v a l e n c e  o f  C A M  
u s e  n o t  r e l e v a n t  a s  
u s e  o f  h o m e o p a t h y  
u s e  h a d  b e e n  a n  
i n c l u s i o n  c r i t e r i o n  
M i x e d  r e p o r t  
u s e d  S e l f  
r e p o r t  ( m o s t l y  
f o r  c h i l d r e n  
a g e d  8 - 1 6  
y e a r s )  o r  
p a r e n t - p r o x y  
D e s c r i p t i v e  ( m e a n  
r a t i n g s )  a n d  
i n f e r e n t i a l  
s t a t i s t i c s  ( 9 5  %  C  
I ) ;  u n i v a r i a t e  a n d  
l o g i s t i c  
m u l t i v a r i a t e  
M e a n  A E  r a t i n g  s c a l e  ( A E ) :  
N o n e  r e p o r t e d  f o r  b o t h  
g r o u p s  
N o  l i m i t a t i o n s  a c k n o w l e d g e d  
C
h
a
p
ter
2.
S
ystem
a
tic
R
eview
85
 
111 
 
-70 % for 
Homeopathy; 
and 75 % for 
CM] 
were 
recruited) 
[Sample size 
not justified] 
regions; multi-
centre, multi-
city 
[For 36 
months] 
or joint report 
(mostly for 
children aged 
0-7 years) 
analyses (@ 
p<0.05) 
 
 

Chapter 3
Yellow Card Reports Associated with
Paediatric Use of Natural Health
Products - An Exploratory Analysis
3.1 Introduction
The Yellow Card Scheme (YCS) is the main spontaneous adverse drug reaction (ADR) reporting
scheme in the UK. Established in 1964 under the Committee on Safety of Drugs (CSD), and
run since 2005 by the Commission on Human Medicines arm of the Medicines and Healthcare
products Regulatory Agency (MHRA), the scheme collates reports made to it by healthcare
professionals, patients and authorized bodies about suspected ADRs associated with the use of
medicines, medical devices, biologicals, vaccines, blood products, or herbal or complementary
products, whether self-medicated or prescribed. This includes suspected adverse drug reactions
associated with misuse, overdose and medication errors, or from use of unlicensed and off-label
medicines. A key finding of the SR reported in chapter two is the low report of adverse outcomes
by CAM users participating in population studies reported in peer-reviewed journals. Possible
reasons for this development could range from the failure of public health researchers to focus
on and pick up such negative outcomes of CAM use; to social desirability bias among CAM
users with regards to reporting negative outcomes from their elective therapies; to the actual
relative scarcity of CAM-related ADRs among the population. This chapter seeks to explore
the third possibility within the constraints and peculiarities of available data; while the other
possibilities will be investigated in the following chapter. As efforts to obtain suitable data on
CAMs from the Information Services Division of the Scottish NHS proved abortive, the data
for this study will be the reports made on the UK’s YCS from inception to July 2012. Also,
as ethical considerations based on the provisions of the Data Protection Act of 1998 precluded
87
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the isolation of Scotland-specific data; YCS reports for the whole of the UK will be used. Thus,
the primary research question for this retrospective study can be summarised as: how common
and serious are the suspected ADRs reported by the UK public for CAM products on the YCS,
and what are the associated factors? While a general overview will be given on CAM-related
ADRs among the UK population as a whole, these questions will be investigated in greater detail
among paediatric subjects (children aged 0-17 years); while aspects of the data relating to younger
children (subjects aged 0-11 years) and all adults (subjects aged over 17 years) will be presented,
where necessary, for the purpose of comparison.
After a general overview of the theoretical bases for pharmacovigilance (PV) and the YCS with
special focus on paediatric PV, this section will provide a historical overview of PV with emphasis
on the YCS, and a summary of the distinctive features of the PV of CAM products. Thereafter
a recap of previous research of the YCS data will be conducted to give the context of the current
study. The methods and results of the YCS data analysis will then be reported in two distinct
phases. Firstly, a general overview of the data will be provided by highlighting general distinctions
between CAM and non-CAM reports, as well as those between adult and paediatric CAM reports.
Then the specifics of paediatric CAM data will be investigated in greater detail by comparing the
different constituent age-groups.
3.1.1 Pharmacovigilance and the Yellow Card Scheme –A Historical Perspec-
tive
To facilitate the understanding of the MHRA’s YCS CAM data, it is helpful to have a historical
overview of PV in general, and the YCS in particular. The first recorded PV historical milestone
was a publication in The Lancet in 1893 reporting the findings of a commission on anaesthesia-
related deaths which was set up following the death of a 15-year old girl in Northeast England
from chloroform anaesthesia [525]. For a brief period following the incident, the commission had
invited doctors in Britain and its colonies to report suspected anaesthesia-related deaths, thus
becoming the fore-runner of the spontaneous reporting system for suspected ADRs [526]. This
one-off event was followed sometime later by the opening of a register of suspected ADRs by the
American Food and Drug Administration (FDA) following sudden deaths in 1937 associated with
poisoning by an elixir of sulphanilamide [527]. However, in spite of these sporadic developments,
the major historical event leading to the establishment of PV was the thalidomide tragedy in 1961.
In the years following this incident, particularly between 1961 and 1965, many national centres
monitoring suspected ADRs were established across the world. In the UK, the CSD was set up in
1963 to monitor new drugs and report on drug quality, efficacy, and safety [528]. Internationally,
that same year, the World Health Assembly adopted resolution WHA 16.36 reaffirming the need
to give more attention and surveillance to suspected ADRs. In 1968, the WHO launched the
Chapter 3. Yellow Card Scheme Data Analysis 89
Pilot Research Project for International Drug Monitoring, which subsequently developed into the
Programme for International Drug Monitoring, coordinated since 1978 by the Uppsala Monitoring
Centre (UMC) in Sweden [529]. The UMC now gathers suspected ADR reports (received since
1968) from over 100 WHO member countries into a global database of individual case safety
reports (ICSRs) called VigiBaseTM. More recently in 2001, the European Medicines Agency
(EMA) set up EudraVigilance as an international network tasked with gathering all reports of
suspected ADRs for drugs authorized in the EU forwarded to it by regulatory agencies and by
drug industries in the EU [530].
The UK’s YCS is one of the oldest national spontaneous ADR reporting schemes. Although
reports of a few suspected ADRs were received in 1963 following the establishment of the CSD,
the YCS was established in 1964. Some key historical milestones have significantly affected
suspected ADR reporting in the UK [531]. One of the most significant is the establishment of
the Black Triangle Scheme in 1976, for newly introduced drugs or drug indications/routes of
administration, which is still currently in use. Some other key milestones are: the establishment
of regional monitoring centres in the 1980s; the inclusion of the Yellow Card in GP prescription
pads and the BNF in 1986; the extension of the YCS reports to unlicensed herbal medicines in
1996 [532]; the broadening of ADR reporters to include pharmacists practising in hospitals (in
1997) and in the community (in 1999) [531]; the broadening of ADR reporters to include nurses,
initially for vaccines only in 1999, and more broadly in October 2002 [533]; and finally, the
national roll-out of patient-reporting in 2005 [186], and its formal launch in February 2008 [534].
The effects of these factors on the suspected ADRs reported for CAM products used in paediatric
subjects will be investigated in this study. However, a broad overview of the trends in yellow
card reporting shows that in the late 1970s and mid-1980s, and in the year 2000, ADR reporting
increased significantly; while there was a general decrease in the early 1990s [531, 535, 536]. The
current study will also verify whether the trends for ADR reporting for CAM products follow a
similar pattern.
The chief limitation associated with spontaneous reporting schemes is a high degree of under-
reporting [537]. Various factors have been identified for this development, ranging from physio-
logical and pharmacological factors to factors related to professional ethics and public health in
general to technological and educational factors [538, 539]. These factors have also been found to
be relevant to ADR reporting in the YCS [540, 541]. While these factors have not nullified the
utility of the YCS with respect to identifying specific important signals resulting in withdrawals
of marketing authorisations or restricted prescribing conditions of several medicinal products
since its inception [542, 543], they make it as unwise to draw specific conclusions about the UK
population from the data as it would be to draw conclusions from a survey sample that is unrepre-
sentative of its parent population [544]. Moreover, such data cannot be used to provide estimates
of risk, as, apart from the fact that the true number of cases involved is often under-reported
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reported, the denominator (i.e. all cases where the medicine was used within the period) is also
not known [545, 546]. Additionally, the danger of basing important therapeutic and regulatory
decisions on only one source of data has been highlighted [547]. Therefore, although every effort
will be made in the current analysis to extract as much information as possible from the YCS
data, the findings will be interpreted with caution with respect to the UK population.
3.1.2 Pharmacovigilance in children
ADRs are a significant problem among children in general [548, 549]. As such, while the report
of suspected ADRs associated with all medicinal products is generally encouraged, special em-
phasis is placed on the report of all ADRs experienced by paediatric subjects. Up until October
2014, this was required in the UK in every instance, irrespective of the marketing status of the
medicinal product concerned, or the perceived degree of seriousness of the suspected ADR [541].
Although the requirement in ADR reporting in children was restricted by the MHRA in October
2014 to ADRs that are serious, medically significant or life threatening/disabling, and all those
occurring in Black Triangle drugs [550], the importance of PV in that demographic is still high
[551]. Therefore, in the UK and many other countries, active (rather than passive) surveillance
schemes have been set up for paediatric ADRs [552]. While there are several reasons for this, the
British National Formulary for children (BNFC) summarizes them as being related essentially to
specific physiological and pathological differences between children (particularly the very young)
and adults; and the deficiency of drug-related data on, and appropriate drug formulations for,
paediatric subjects (BNFC 2014). These points not only emphasize the need to improve the
evaluation of paediatric drug safety, but also the importance of including age-specific and circum-
stantial data in such reports [553, 554]. Despite efforts to improve paediatric PV, the proportion
of YCS reports for under-18-year-olds has remained low, contributing 4.4% all UK ADR reports
received in 2011–2012 [539]. Whether CAM-related ADR reporting in children follows a similar
trend remains to be seen; and is one of the objectives of the current study. It is also helpful to
find out how such reports differ across paediatric age sub-categories. In view of this, in addition
to comparing the CAM-related YCS data received for paediatric subjects (0-17 years) with those
for the general adult population (< 17 years), this study will also consider the data with respect
to the following age subcategories – infants (less than 2 years old); pre-school children (2-5 years);
school-age children (6-11 years); and younger adolescents (12-17 years).
3.1.3 Pharmacovigilance of Complementary & Alternative Medicines
As CAM products differ from conventional medicines in various ways, the PV of CAM products
presents distinctive challenges, an appreciation of which is helpful in understanding this aspect
of the research. The first major challenge concerns the nature of the CAM products themselves;
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while the other relates to the peculiarities in their use. As most CAM products are natural
products that have been in use as food as well as home remedies for many centuries, and are
thus associated with various cultural lifestyles, they are widely perceived as both effective and
safe [31, 555]. Additionally, as they have not been subject to the same degree of regulation as
conventional medicines, there have been fewer barriers and restrictions to their availability and
use across the world [15, 556]. A major factor in this is that they are largely not available on
many national health systems; and as such are often either self-prescribed by users based on
their own (internet) search or experience, or used on the recommendation of family and friends
[312, 557]. Additionally, they can be easily accessed from various outlets, nullifying the influence
of gate-keepers associated with prescription medicines [101, 558]. In this last respect, the factors
affecting CAM products are similar to, but not identical with, those affecting non-prescription
conventional medicines [532, 559]. These factors negatively affect PV of CAM products, as users
are less likely to attribute negative outcomes to them; and even when they do, most would
be reluctant to report ADRs, as that would essentially amount to them reporting themselves
[560, 561].
In addition to the above, there is also the issue of general confusion as to nomenclature [562].
Although this is more prevalent with herbal medicinal products [204], there is a general confusion
as to where to draw the line between what can be normally called “food” and what actually is
CAM [563]. The CAM subcategory of nutritional therapies or the product category of nutraceu-
ticals makes this even more problematic [564, 565]. This factor affects such “special” foods as
Mediterranean diets, which are cultural in certain parts of the world and yet are still CAM; as
well as generally accepted foods like yogurts, which can also serve as CAM (probiotics). Also,
many substances that are classified as dietary supplements, such as multivitamins, melatonin or
ephedrine, are also used in conventional medicine [2]. Moreover, some dietary supplements are
not used so much to manage or cure an ailment as to maintain general health and well-being
–similar to a food item in a balanced diet [566]. To overcome the confusion in the definition of
CAM, it has been proposed that attention should be focused on CAM users with respect to their
purposes of use of CAM, rather than on the nature of the CAM products and practices them-
selves [567, 568]. From a PV point of view, however, this clarification is neither very helpful nor
particularly important, as the focus of the database is on suspected ADRs and not indications.
Indications would serve as a useful guide only where such specific details as would clarify the
purpose of use of the natural product concerned are strictly reported, as has been recommended
in the WHO guidelines on safety monitoring of herbal medicines in PV systems [569]. The extent
to which these recommendations have been adhered to remains to be seen; and will be one of
the objectives of the current analysis. For the purposes of clarity, however, CAM products will
be taken in this chapter to refer to the natural health products (NHPs) reported in the YCS
database, irrespective of their purpose of use. The NHPs to be studied will, therefore, include
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vitamins and minerals; probiotics; amino acids and essential fatty acids; traditional and home-
opathic medicines; synthetic duplicates of natural ingredients; various preparations of plants,
algae, bacteria, fungi, nonhuman animal materials; and medicinal products containing extracts
or isolates of plants, algae, bacteria, fungi, nonhuman animal materials as active ingredients [570]
. These will be included in the current analysis whether they were used alone or in combination,
or whether they were single or combination products [571].
Another key factor in the PV of CAM products is the fact they are frequently used in conjunction
with conventional medicines, a practice further encouraged by the global trend towards integrative
medicine [572, 573]. While the hazards of this practice have been particularly established with
herbal medicines in terms of herb-drug interactions [574], the peculiarities associated with the
general perception, understanding and use of CAM make it generally important for all CAM
products [575]. It has been suggested that “adverse reactions apparently due to a conventional
medicine, might in reality be due to a herbal medicine or a drug interaction between a herbal
medicine and a conventional drug” leading to confusion in spontaneous reporting systems [576].
It is necessary to verify this suggestion based on the YCS data, and will be one of the objectives
of the current study. Apart from being used along with conventional medicines, CAM products
are also often used together, either separately as multiple products or as combination products,
like poly-herbal formulations [577–579]. As poly-pharmacy has generally been associated with a
higher risk of ADRs in conventional medicines [580], another objective of the current study is to
understand the consequences of such combined use for CAM products with respect to adverse
effects [573].
3.1.4 Summary of previous research on the Yellow Card Scheme
While substantial research has been carried out on ADRs in adults, little such work has been
done for children, and much less for CAMs [204, 581]. Most previous studies either considered
all reports received during a particular period [535, 582]; or focused on specific drugs or drug
classes and/or health or physiological conditions [583–585]. Significantly, about the only YCS
study that focused on CAM products [586] was based on the NIMH Yellow Cards, and not the
whole YCS database. The paucity of reports on CAM-related ADRs is, however, not confined to
the UK. However, although an analysis by [206] of 20 years of ADR reports to the WHO found
“substantial evidence” that herbal medicines could cause serious ADRs; there is generally a lack
of information regarding the rates of occurrence of ADRs with CAM products [587].
The situation of pharmacovigilance research is worse for paediatric subjects. Although a recent
review of ADRs reported in children [588] indicated that the highest numbers of ADRs were
reported in national ADR databases rather than in studies monitoring inpatients and outpatients,
none of the eight database studies included in the review was carried out in the UK. Since a recent
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global ADR report analysis at the Uppsala monitoring centre shows that the UK ranks second
only to the US with respect to the total number of ADR reports received in both adults and
children [589], the non-representation of the UK in the review highlights the scarcity of research
on the YCS for paediatric subjects. While an overview of the literature in September, 2014 using
Google Scholar yielded three papers analysing UK YCS reports for paediatric subjects, only one
of them [590] covered all ADRs reported for paediatric subjects across the UK; with the other
two focusing on either a region of the country [552] or a subset of paediatric ADRs –fatal ADRs
[591]. Also, even the most comprehensive of the studies had a relatively short time span, focusing
only on ADR reports submitted within the period 2000-2009. And most importantly, none of the
studies focused on NHPs or CAMs. Thus, the relevance of the current study is not debatable.
3.1.5 Objectives of the current study
The aim of this study is to descriptively summarize the MHRA PV data for CAMs from the in-
ception of the YCS to July 2012 in terms of patient demography, CAM product types, nature and
clinical classification of reported events, and type of reporter involved. Data will be summarized
in terms of:
(i) number of reports for individual products as well as CAM product types;
(ii) date of report (annually and in 10-year bands), and associated trends in ADR reports
received;
(iii) patient characteristics (sex and age);
(iv) comparison of ADR reports (CAMs vs. non-CAMs; adults vs. paediatric subjects; and
among paediatric sub-categories);
(v) effect of relevant public health legislations on ADR reporting (immediate and sustained
effect);
(vi) reporter status;
(vii) MedDRA SOC distribution of paediatric ADRs;
(viii) reporter’s opinion as to seriousness of the reaction (outcome and severity);
(ix) CAM classification of products associated with paediatric ADRs;
(x) ATC (level 1) classification of products associated with paediatric ADRs
(xi) indications/purposes of NHP use
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(xii) most common ADRs (holistically, as well as for age & sex categories and CAM product
types);
(xiii) serious, fatal and most common severe and unresolved ADRs (holistically, as well as for age
& sex categories and CAM product types);
(xiv) reaction duration; and
(xv) richness of free text description of ADRs
The major research question that this study posed was: what is the number, frequency, and
nature of the suspected ADRs reported on the YCS for children and adolescents aged up to 17
years with respect to CAMs, and how are these affected by:
1. patient demography (sex and age category);
2. public health legislations (UK and Europe); and
3. product type and mode of use (single, multiple or combined)?
3.2 Methods
3.2.1 Acquisition of YCS data and dataset description
An application for the release of Category II YCS data for CAMs was made to the Independent
Scientific Advisory Committee for MHRA database research in July 2011. The application was
considered on October 7, 2011, and approval was granted subject to a number of conditions
with respect to computer security and data storage. After meeting the conditions, the data for
reports on CAM products from 1963 to July 2012 was released in August 2012 as a pass-worded
encrypted Excel file. The dataset provided contained 2167 data entries (in rows), with each
entry providing a range of information in columns that can be generally grouped into five broad
categories comprising a total of 31 specific items. The broad categories with their respective
constituent items are:
(i) seven patient health data-related items:-“age”, “age group”, “sex”, “medical history”,
“medical history comments”, “case narrative” and “medical history”;
(ii) eight reaction-related items:- “ADR number”, “date received”, “reaction + outcome”, “re-
action severity”, “reaction start date”, “reaction stop date”, “treatment description” and
“other drugs + indications”;
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(iii) five suspect drug-related items:- “suspect drug + indications”, “route of administration”,
“additional dosage form information”, “drug start date” and “drug end date”;
(iv) three reporter-related items:- “qualification”, “specialty” and “comment”; and
(v) eight Council for International Organisations of Medical Sciences (CIOMS)-related items:-
“reporter serious”, “any CIOMS serious”, “congenital abnormality”, “disability/incapac-
ity”, “hospitalization”, “life-threatening”, “other medically significant” and “patient died”.
Additional data on the total number of reports received annually for the period of the review
was obtained from the MHRA on July 11, 2013 and September 18, 2013 upon further requests.
Copies of the application form and approval letters for data release are provided in Appendices
(iii)-(vi); while a protocol drawn up to direct the database analysis is provided in Appendix (vii).
3.2.2 Data cleaning
To prepare the data for the current analysis, the data was cleaned in line with standard guidelines
for database research [592, 593]. This was done in two main stages as follows:
3.2.2.1 Extraction of appropriate paediatric data
Firstly, specific data for paediatric subjects was extracted from the parent dataset. This was
achieved essentially by filtering out entries for subjects aged > 17 years as well as those with no
age-related details. As age-related details were recorded in the “age” and “age-group” columns
of the dataset, specific data for paediatric subjects was extracted from the parent dataset using
the filter criteria “< 18” (for age) and “infant”, “child”, and “adolescent” (for the “age group”
category. To facilitate analysis, a single age-related data column was then created for the extracted
paediatric dataset by ascribing fixed standard values for the four “age group” entries for which
there were no corresponding “age” entries. As these entries were for “infant” (3 entries) and
“child” (1 entry), the standard values “0.5 years” and “5 years” were arbitrarily selected and
used for these specific entries, respectively. The “age group” column was thereafter deleted.
Also, in order to focus on ADRs in children as autonomous beings, entries in which the route
of administration was recorded as “transplacental” (3 entries) were excluded. Also, for the same
reason, another entry for which the ADR reported was described as “congenital” was also removed.
3.2.2.2 Data organisation
3.2.2.2.1 Separation of merged items In addition to merging the age-related details into a
single item, the data was further organised by unmerging the “reaction + outcome” and “suspect
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drug + indications” items. Additional columns were created beside each of these items, and the
contents of each column were copied into the adjoining new column. Then the contents of each
cell were edited in such a way as to separate the combined entries.
3.2.2.2.2 Introduction of additional item columns To facilitate the study of the effect
of CAM product type and mode of use on ADR number and outcome, as well as the richness of
the narrative provided, seven additional columns were created at strategic points in the dataset.
These enabled the generation of relevant additional information from the data. The columns were
titled as follows: “Number of items used together”; “CAM product type”; “CAM product ATC
(Anatomical, therapeutic and chemical classification) Code”; “ADR MedDRA SOC (System-
organ class)”; “Number of ADRs reported”; “ADR duration”; and “Richness of narrative”. CAM
suspect drugs were grouped using a series of standard definitions and other distinctive criteria
outlined in table 3.1 into one of seven CAM product categories in line with the study objectives.
Table 3.1: Classification scheme for suspect CAM products reported in the database
 
 
Table 3.1 Classification scheme for suspect CAM products reported in the 
database 
CAM product 
type 
Standard definition (reference) Distinctive criteria (reference) 
Aromatherapy 
(Essential oils) 
The use of concentrated essential oils 
extracted from herbs, flowers, and other plant 
parts to treat various diseases (Segen, 1998; 
Delgado, 2005) 
Essential oil must act through its volatile 
aromatic effect (the sensual perception of 
the aroma) –not just a local action (Cooke 
and Ernst, 2000) 
Dietary 
supplement 
A product, other than tobacco, used in 
conjunction with a healthy diet and containing 
one or more of the following dietary 
ingredients: a vitamin, mineral, herb or other 
botanical, an amino acid, a dietary substance 
for use by man to supplement the diet by 
increasing the total daily intake, or a 
concentrate, metabolite, constituent, extract, 
or combinations of these ingredients. 
(Maughan et al, 2007) 
These include vitamins, minerals, other 
nutrients, and botanical supplements, as 
well as ingredients and extracts of animal 
and plant origin (Cheema et al, 2001). The 
classification “Dietary supplement” was 
reserved for single products that are 
directly related to the diet, or combined 
products that are used regularly and/or for 
some specific “nontherapeutic” purpose (e. 
g.: weight loss, body-building, etc). 
Herbal Remedy  
-classically 
herbal medicinal 
products 
Medicinal products containing exclusively 
herbal drugs or herbal drug preparations as 
active substances (WHO, 1991; Silano et al, 
2004) 
This definition was restricted specifically to 
herbal medicines containing 1-3 herbs 
alone without any non-herbal 
products 
Herbal product Medicinal combination products containing one 
or more herbs along with non-herbal 
substances excluding conventional medicines. 
(WHO, 2004; Sahoo et al, 2010) 
The combination product must contain 
other substances apart from herbs, but 
not conventional medicines. 
Herb-drug 
combination 
Medicinal combination products containing one 
or more herbs along with one or more 
conventional medicines, with high probability 
of herb-drug interaction (Hu et al, 2005) 
Here, the suspect drug must contain one 
or more conventional medicines apart 
from herbs –whether used conjunctively or 
in combination.  
Homeopathic 
remedy 
Products derived from natural substances of 
plant, mineral, or animal origin, and prepared 
by sequential dilution and succussion in a 
series of steps. (Khuda-Bukhsh, 2006) 
Products are distinguished based on the 
“like cures like” homeopathic principle 
(Tedesco and Cicchetti, 2001) 
Traditional 
Chinese 
medicines (TCM 
natural products) 
Decoctions of mixtures of up to 20 herbs that 
are customized for each individual patient, 
thus with high potential for herb-herb 
interaction (Yuan and Lin, 2000; Yan et al, 
2014) 
Essentially combination herbal products of 
Chinese origin; but all poly herbal products 
(containing more than three herbs with no 
non-herbal components) are also placed in 
this category. (Viswanath et al, 2014) 
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Entries for products that could not be classified into any of these CAM product, types (2 entries)
were excluded from further analysis. Product ATC codes for herbal medicinal products (HATC
codes) were obtained from the Herbal ATC Index [594]; and the identified codes were further
grouped at the anatomical and/or therapeutic levels (where possible) using the Guidelines for
ATC Classification [595]. The ATC classification format used is outlined in table 3.2.
Table 3.2: Classification scheme for suspect CAM products reported in the database
 
 
Table 3.2: Herbal ATC Classification Guidelines (Levels 1 and 2) 
Main  
groups 
Anatomical classification (Level 1) Range 
(Level 2) 
Therapeutic classification (Level 2) 
HA Alimentary tract and metabolism HA01-11; 
13; 15; 16 
Stomatological preparations; Drugs for acid-related 
disorders; Drugs for functional gastro-intestinal 
disorders; Anti-emetics and Anti-nauseants; Bile and 
liver therapy; Laxatives; Anti-diarrhoeals, intestinal 
anti-inflammatory/anti-infective agents; Anti-obesity 
preparations (excluding diet products); Digestives 
(including enzymes); Drugs used in diabetes; Vitamins; 
Tonics; Appetite stimulants; Other alimentary tract and 
metabolism products 
HB Blood and blood forming organs HB05 Blood substitutes and perfusion products 
HC Cardiovascular system HC01, 02, 
04, 05, 10 
Cardiac therapy; Anti-hypertensives; Peripheral 
vasodilators; Vaso-protectives; Serum lipid-reducing 
agents 
HD Dermatologicals HD02-06; 
08, 10, 11 
Emollients and protective; Preparations for treatment of 
wounds and ulcers; Anti-pruritics (including anti-
histamines, anaesthetics, etc.); Anti-psoriatics; 
Antibiotics and chemotherapeutics for dermatological 
use; Antisceptics anddisinfectants; Anti-acne 
preparations; Other dermatological preparations 
HG Genitourinary system and sex 
hormones 
HG01-04 Gynaecological anti-infectives and antisceptics; Other 
gynaecologicals; Sex hormones and modulators of the 
genital system; Urologicals 
HH Systemic hormonal preparations 
excluding sex hormones 
HH03 Thyroid therapy 
HJ Anti-infectives for systemic use HJ01 Antibacterials for systemic use 
HL Antineoplastic and immuno-modulating 
agents 
HL01, 03 Antineoplastic agents; Immunostimulants 
HM Musculoskeletal system HM01-04 Anti-inflammatory & anti-rheumatic products; Topical 
products for joint & muscular pain; Muscle relaxants; 
Ant-gout preparations 
HN Nervous system HN01; 02; 
05-07 
Anaesthetics; Analgesics; Psycholeptics; Psych-
analeptics; Other nervous system drugs 
HP Anti-parasitic products HP01-03 Anti-protozoals; Anthelmintics; Ectoparasites 
(Scarbicides, insecticides & repellents) 
HR Respiratory system HR03, 05, 
07 
Drugs for obstructive airway disease; Cough and cold 
preparations; Other respiratory system products 
HS Sensory organs HS01 Ophthalmologicals 
HV Various HV03 All other therapeutic products 
 
 Where the specific indication of the suspect herbal remedy was not stated, the ATC code was
determined from a consideration of a number of other factors -such as the subject age and/or
sex, the products co-used with it (if a combination product or multiple product use), the dosage
form, the subject’s medical history, and/or the textual account of the event. Where no clear
conclusion could be arrived at, it was categorized as “Unclear”. For each herbal product or herb-
drug combination, the HATC code for the herbal component was given. Where more than one
herbal component with a related indication was involved, the Level 1 code was used; but where
indications are unrelated, it was categorized as “Unclear”. For poly-herbals with various unrelated
ATC codes, the term “Various” was used. ATCs for homeopathic products were generally not
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available (n. a.). The MedDRA primary SOCs were obtained from the Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0 [596]. ADRs were classified into SOCs based
on the format outlined in table 3.3.
Table 3.3: Classification scheme for suspect CAM products reported in the database
 
 
Table 3.3: The MedDRA Terminology System-Organ Class (SOC) List 
 System-Organ Classes 
1 SOC Blood and lymphatic system disorders 
2 SOC Cardiac disorders 
3 SOC Congenital, familial and genetic disorders 
4 SOC Ear and labyrinth disorders 
5 SOC Endocrine disorders 
6 SOC Eye disorders 
7 SOC Gastrointestinal disorders 
8 SOC General disorders and administration site conditions 
9 SOC Hepatobiliary disorders 
10 SOC Immune system disorders 
11 SOC Infections and infestations 
12 SOC Injury, poisoning and procedural complications 
13 SOC Investigations 
14 SOC Metabolism and nutrition disorders 
15 SOC Musculoskeletal and connective tissue disorders 
16 SOC Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
17 SOC Nervous system disorders 
18 SOC Pregnancy, puerperium and perinatal conditions 
19 SOC Psychiatric disorders 
20 SOC Renal and urinary disorders 
21 SOC Reproductive system and breast disorders 
22 SOC Respiratory, thoracic and mediastinal disorders 
23 SOC Skin and subcutaneous tissue disorders 
24 SOC Social circumstances 
25 SOC Surgical and medical procedures 
26 SOC Vascular disorders 
Courtesy: MedDRA Introductory Guide Version 14.0 13, March 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The indications recorded for the suspect products were classified into various organ systems
according to the general format for complete physical examination reports. The seriousness of the
ADRs reported was determined solely from the description of the reporter based on the CIOMS
criteria: no personal judgment was exercised. However, ADRs that could be interpreted as a
cause/reason for, or an outcome of, the event –e.g. “aggression worsened”; “drug interaction”;
*drug administration error”; “overdose”; etc. - were not included in the ADR count. Also, where
an ADR was recorded multiple times for any given case report, only one such record was retained,
and all other records for that specific case were deleted. In describing the ADR duration, “n. a.”
was used to indicate cases where there was absolutely no such record, or where the available record
was incomplete –i. e. either the “Reaction start date” or “Reaction end date” was not available.
On the other hand, “ERROR” was used to indicate cases where the START date reported was
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after the END date, which is obviously an error. Similarly, the richness of each case narrative
was categorised as “detailed” where the narrative described the details of the circumstances
leading to the ADR or its management; or as “Additional information” where it provided further
information on the ADR or suspect drug than were provided in earlier columns of the entry, but
did not also describe the conditions surrounding the case. Case narratives not providing any
further information on the ADR or suspect drug were classified as “Basic information”; while
the category “No case narrative” was reserved for entries for which absolutely no narrative was
recorded.
3.2.2.2.3 Additional categories introduced to facilitate data analysis Two additional
reorganisations were carried out to facilitate data analysis of the original and derived data. The
“Age” values were further broken into four paediatric subcategories (infants: < 2 years; pre-school
children: 2-5 years; school-age children: 6-11 years; and younger adolescents: 12-17 years), with
a fifth category (older adolescents: 18-21 years) added in order to facilitate the comparison of
reports in children (0-11 years) and adolescents (12-21 years), where appropriate. Also, the ADR
durations derived from the previous section were further grouped into six categories: Same day
(0 days); Up to 3 days (1-3 days); About 1 week (4-8 days); Up to 2 weeks (9-15 days); Up to 1
month (16-31 days); and More than 1 month (> 31 days).
3.2.3 Data analysis
Data analysis was carried out using the Student Excel package of Microsoft Excel 2010 c©. Prelim-
inary analysis was carried out on the original dataset, so as to provide an overview of the whole
dataset with respect to age and sex distribution of case reports, trends in annual ADR reports for
CAM and non-CAM suspect “drugs”, as well as comparisons between adult and paediatric CAM
reports. Population-based reporting ratios (PBRR), defined as the total number of ADR reports
collected per year per million inhabitants, were determined for CAM versus non-CAM products
according to the method of Srba et al [597]. Subsequent analyses were, however, focused on
the age-filtered data set in line with the demographic focus of the study. Descriptive univariate
and bivariate statistics (percentages, measures of central tendency, pictorial representations and
cross-tabulations based on pivot tables), as well as frequentist inferential statistics (P value and
confidence interval, C. I.) were determined in each case as appropriate. A significance level of
P ≤ 0.05 or 95% confidence interval was used for inference.
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3.3 Results
The results of the detailed analysis of ADR reports in the yellow cards received are presented
in tables 3.4 to 3.23 and figures 3.1 to 3.15. While a general summary of the findings will be
presented in section 3.4.1 as part of the discussion of results, a brief running textual summary of
the data presented in each table or figure will be provided along with their respective tables or
figures all through the results section.
3.3.1 Overview and descriptive statistics for whole dataset
Tables 3.4 to 3.6 and figure 3.1 provide a demographic summary of the original YCS dataset, as
well as the PBRRs for CAM and non-CAM suspect products.
A total of 2,167 individual case reports for CAMs were contained in the dataset for the period
1963 to July, 2012, amounting to 0.3% of all reports made to the database within the period.
These case reports were for a range of subjects aged from birth to 96 years (mean ± SD =
43.65± 20.89years;median = 43years;mode = 37years) , and amounted to a maximum PBRR
of 1.193 reports per year per million (rym) UK inhabitants for CAMs as against 369.61 rym for
non-CAMs. Less than 10% of the CAM-related reports (192 reports; corresponding to 0.03% of all
ADR reports) concerned paediatric subjects aged under 18 years; with reports from middle-aged
adults (aged 40-59 years) making up the highest proportion (one quarter) of the reports.
Although there were significantly more CAM-related reports for female subjects more than for
male subjects in the whole dataset (63.5% vs. 33.4%; p < 0.001), this was only true for the adult
population (> 17 years); as paediatric reports were uniformly distributed by gender (p=0.122).
However, there were significantly more reports for female paediatric subjects aged 3 years old
among (P = 0.001), just as there were for male subjects for infants in the first year of life
(p = 0.007). The age (±SD) of the paediatric subjects for whom the mean CAM-related reports
within the period was made was 6.59 (±5.49) years, with the highest number of single reports
being made for children aged 3 years (19; 9.8%). However, when full age bands were considered,
subjects in their first year of life (neonates and babies aged less than one year) accounted for the
highest proportion of ADRs (38; 19.8%).
Although infant children aged under 2 years accounted for the highest proportion of paediatric
reports (50; 26.1%), paediatric age categories did not differ significantly with respect to ADR
reports (P=0.974). The converse was, however, the case among adult subjects (p < 0.001). Also,
in about one fifth of the CAM-related ADR reports (442; 20.4%) there was no age-related data,
thus invalidating the associated reports with respect to further detailed analysis. When the 1725
age-valid CAM-related ADR reports were categorised based on age groups and compared with
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Table 3.4: Overview of the original MHRA data set by age and gender distribution over time
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(%)1=Relative to grand total of paediatric subjects (192) 
(%)2=Relative to grand total of CAM ADR reports (2167) 
(%)3=Relative to grand total of all ADR reports (698,638) 
(%)6=Relative to age group/sub-category grand total (various) 
a –Excluding unknown sex 
Age range 
(Age group/ 
sub-category) 
Number of reports in period of report 
covered  
Grand 
totals 
n (%) 
Χ2 
test  
P 
value 
Gender distribution 
n (%) 
Binomial 
test P 
valuea 1963-
1972 
1973-
1982 
1983-
1992 
1993-
2002 
2003-
2012 
FEMALE MALE N/A 
<2 years 
(Infants) 
- 
 
9 17 8 16 50, 
(26.0)1 
(2.3)2 
 
 
 
 
 
0.989 
20, 
(40.0)4 
29, 
(58.0)4 
1, 
(2.0)4 
0.064 
 
(2-5 years 
(Preschool 
age) 
1 
 
5 16 12 14 48, 
(25.0)1 
(2.2)2 
28, 
(58.3)4 
19, 
(39.6)4  
1, 
(2.1)4 
0.059 
 
6-11 years 
(School-age) 
 
- 
 
6 16 8 17 47, 
(24.5)1 
(2.2)2 
27, 
(57.5)4 
19, 
(40.4)4 
1, 
(2.1)4  
0.090 
 
12-17 years 
(Young 
adolescents) 
- 
 
3 19 8 17 47, 
(24.5)1 
(2.2)2 
27, 
(7.5)4 
20, 
(42.6)4 
- 0.144 
 
All Paediatric 
subjects 
(0-17 years) 
n (%) 
1, 
(0.52)1 
(0.05)2       
[0.000]3 
23, 
(11.98)1 
(1.06)2 
[0.003]3 
68, 
(35.42)1 
(3.14)2 
[0.01]3 
36, 
(18.75)1 
(1.66)2 
[0.005]3 
64, 
(33.33)1 
(2.95)2 
[0.009]3 
192, 
(100)1 
(8.86)2 
[0.03]3 
 
- 
102, 
(53.13)4 
87, 
(45.31)4 
3, 
(1.56)4 
0.122 
18-25 years 
(Emerging 
adults) 
- 
 
10 
 
47 
 
29 
 
50 
 
136, 
- 
(6.3)2 
 
 
 
 
 
 
 
0.000 
97, 
(71.32)4 
39, 
(28.68)4 
- 0.000 
26-39 years 
(Young adults) 
6 36 109 37 36 424, 
- 
(19.6)2 
296, 
(69.81)4 
 
127, 
(29.95)4 
 
1, 
(0.24)4 
0.000 
40-59 years 
(Middle-aged 
adults) 
3 38 106 182 216 545, 
- 
(25.2)2 
374, 
(68.62)4 
166, 
(30.46)4 
5, 
(0.92)4 
0.000 
60-74 years 
(Older adults) 
2  14 59 90 144 309, 
- 
(14.3)2 
192, 
(62.14)4 
114, 
(36.89)4 
3, 
(0.97)4 
0.000 
>74 years 
(The elderly) 
1 
 
13 16 32 57 119, 
- 
(5.5)2 
70, 
(58.82)4 
48, 
(40.34)4 
1, 
(0.84)4 
 
0.004 
All adults 
(>17 years) 
n (%) 
12, 
- 
(0.55)2 
[0.002]3 
111, 
- 
(5.12)2 
[0.016]3 
337, 
- 
(15.55)2 
[0.048]3 
470, 
- 
(21.69)2 
[0.067]3 
603, 
- 
(27.83)2 
[0.086]3 
1533, 
- 
(70.7)2 
[0.219]3 
 
- 
1029, 
(67.12)4 
494 
(32.22)4 
10, 
(0.65)4 
 
 
0.000 
Age not 
specified 
n (%) 
96, 
- 
(4.43)2 
87, 
- 
(4.01)2 
148, 
- 
(6.83)2 
43, 
- 
(1.98)2 
68, 
- 
(3.14)2 
442, 
- 
(20.40)2 
 
- 
244, 
(55.20)4 
142, 
(32.13)4 
 
56, 
(12.67)4 
 
 
0.000 
Grand total 
(CAM ADR 
reports) 
n (%) 
109, 
- 
(5.03)2 
[0.016]3 
221, 
- 
(10.20)2 
[0.032]3 
553, 
- 
(25.52)2 
[0.08]3 
549, 
- 
(25.33)2 
[0.079]3 
735, 
- 
(33.92)2 
[0.105]3 
2167, 
- 
(100.0)2 
[0.31]3 
 
- 
1375, 
(63.45)4 
 
723, 
(33.36)4 
 
69, 
(3.18)4 
 
 
0.000 
All Non CAM 
ADR reports 
n (%) 
27,093, 
- 
[3.87]3 
82,925, 
- 
[11.87]3 
163,604, 
- 
[23.42]3 
195,046, 
- 
[27.92]3 
227,803, 
- 
[32.61]3 
696,471 
- 
[99.69]3 
- - - - - 
GRAND TOTAL 
(All ADR 
reports) n (%) 
27,202, 
- 
[3.89]3 
83,146, 
- 
[11.9]3 
164,157, 
- 
[23.5]3 
195,595, 
- 
[28.0]3 
228,538, 
- 
[32.71]3 
698,638, 
- 
[100]3 
- - - - - 
Descriptive statistics for all age-specific subjects for whom CAM-related ADR reports were made: 
      Mean (SEM) ± SD: 43.65 (0.50) ± 20.89 years   
   Median: 43 year olds   
    Mode:  37 years  
 Range:  96 years 
Chapter 3. Yellow Card Scheme Data Analysis 102
Table 3.5: Population-based reporting ratios (PBRRs) for CAM and non-CAM-related products
 
 
Figure 3.1: Comparative age group distribution of age-valid CAM-related 
ADR reports relative to the normal UK population 
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Period of report 
(in decades) 
UK Population† 
(in millions) 
CAM 
ADRs  
PBRR Non CAM 
ADRs 
PBRR All ADRs PBRR 
1963-1972 55.1 109 1.98 27,093 491.71 27,202 493.68 
1973-1982 56.2 221 3.93 82,925 1475.54 83146 1479.47 
1983-1992 56.9 553 9.72 163,604 2875.9 164157 2885.01 
1993-2002 58.5 549 9.39 195,046 3335.83 195595 3345.22 
2003-July 2012 61.6 735 11.93 227,803 3698.1 228538 3710.03 
Total ADRs  2167  696,471  698,638  
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Figure 3.1: Comparative age group distribution of age-valid CAM-related ADR reports relative
to the normal UK population
the normal UK population according to the 2011 census (figure 3.1), it was found that while
the CAM-related ADR reports for most age groups generally aligned with expected proportions
of the population, the reports for paediatric subjects were found to be much less than expected
(12.3% vs. 23.8%; p < 0.043).
3.3.2 Comparison of trends of reports for CAMs and conventional medicines
Although CAMs contributed significantly less than one percent of all reports made to the database,
the trends of ADR reporting for CAMs and conventional medicines were seen to be generally sim-
ilar. However, while there was a general increase in the total number of ADR reports received
over the period, the increase was not as proportional for CAM-related reports as they were for
conventional medicines. This is clearly illustrated in the 10-year comparative trends displayed
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Table 3.6: Age and sex distribution of individual paediatric reports
 
 
Table 3.6: Age and sex distribution of individual paediatric reports 
Age 
(year) 
Total 
reports 
Proportion 
by age (%) 
Female Male N/A  Binomial test 
P value a 
0 1 0.52  1 
 
 
0.01 1 0.52  1 
0.05 1 0.52 1  
0.08 1 0.52 1  
0.09 1 0.52  1 
0.2 9 4.69 2 7 
0.3 4 2.08 1 3 
0.4 2 1.04  2 
0.5 7 3.65 3 3 1 
0.6 2 1.04 2  
 
0.7 5 2.60 1 4 
0.8 2 1.04 1 1 
0.9 2 1.04 1 1 
<1 38*†1    19.79* 13* 24* 1* 0.007 
1 10 5.21 6 4    
1.1 2 1.04 1 1 
1-<2 12* 6.25* 7* 5* 
2 8 4.17 3 4 1 
2.1 1 0.52 1   
2-<3 9* 4.69* 4* 4* 1* 
3 19†2 9.90 14 5  0.001 
4 10 5.21 7 3 
 
 
5 10 5.21 3 7 
6 9 4.69 4 5 
7 7 3.65 6 1 
8 7 3.65 6 1 
9 10 5.21 5 4 1 
10 6 3.13 2 4 
 
11 8 4.17 4 4 
12 9 4.69 6 3 
13 9 4.69 7 2 
14 3 1.56 2 1 
15 9 4.69 7 2 
16 9 4.69 3 6 
17 8 4.17 2 6 
Total 192 100.00 % 102 87 3 0.122 
Proportion by gender 53.13 %  45.31 % 1.56 %  
Descriptive statistics for paediatric subjects for whom CAM ADR reports were made: 
 Mean age (SEM) ± SD: 6.59 (0.40) ± 5.49 years  
 Median age: 5 years   
Mode (full years)†1:  < 1 year olds 
Mode (specific entries)†2:  3 year olds 
Range:  17 years 
* -Full age subtotal; 
† -Highest number of reports for full age bands (1) or specific entries (2); 
a –Excluding unknown sex 
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in figure 3.2, resulting in a plateau phase in the period between the 1980s and the 1990s. This
difference was, however, not so obvious at a more detailed annual level.
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Figure 3.2: Comparative trends of 10-year reports for complementary 
and conventional medicines (1963-2012) 
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Figure 3.2: Comparative trends of 10-year reports for complementary and conventional
medicines (1963-2012)
Figure 3.3 illustrates that annual ADR reports ranged in both cases from their lowest levels in
the 1960s to a peak in the year 2000, with smaller spikes in the late 1970s and mid-1980s and
a depression in the mid-1990s. Finally, the trends of annual reports increased equally in both
cases between 2008 and 2012, albeit more consistently for conventional medicines than for CAMs.
Unlike the sustained annual increase in the ADR reports for conventional medicines in the period
from the mid-1980s to the early 1990s, the spike in CAM-related ADR reports in the mid-1980s
was not sustained, leading to progressively less reports being received in that period, before the
depression in the latter 1990s that was common to both categories. This obviously explains the
absence of a plateau phase for reports associated with conventional medicines.
When the apparent effects of significant relevant public health policy milestones on annual ADR
reports are considered (table 3.7), it is seen that the percentage change in total reports was
generally greater for CAMs than for conventional medicines.
However, while this apparent advantage is possibly due the much smaller numbers of reports
available for CAM products than for conventional products, it is also seen to be significantly
more for immediate (1-year) than for sustained (2-year) changes in report totals, unlike the
case for reports for conventional medicines. While many of the policies resulted in sustained
increases in annual reports for conventional medicines, the only public health initiatives that
resulted in continued increases in reports for both conventional medicines and CAM products are
the introduction of the Black Triangle scheme in 1976 (from 34.8% to 141.8% for conventional
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Figure 3.3: Comparative trends in annual ADR reports for complementary and conventional medicines (1963-2012) 
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Table 3.7: Effects of relevant significant public health policy changes on ADR reporting for complementary and conventional medicines (Immediate
& Sustained Effect)
 
 
T a b l e  3 . 7 :  E f f e c t s  o f  r e l e v a n t  s i g n i f i c a n t  p u b l i c  h e a l t h  p o l i c y  c h a n g e s  o n  A D R  r e p o r t i n g  f o r  c o m p l e m e n t a r y  a n d  
c o n v e n t i o n a l  m e d i c i n e s  ( I m m e d i a t e  &  S u s t a i n e d  E f f e c t )  
 
S i g n i f i c a n t  E v e n t  D a t e  Y e a r s  
c o m p a r e d  
%  C h a n g e  i n  A D R  
R e p o r t s  R e c e i v e d  
B i n o m i a l  t e s t  
P ( 1 ) - P ( 2 )  
Y e a r s  
c o m p a r e d  
%  C h a n g e  i n  A D R  
R e p o r t s  R e c e i v e d  
B i n o m i a l  t e s t   
P ( 1 ) - P ( 2 )  
C o n v e n t i o n a l  C A M   E s t i m a t e  P  v a l u e  C o n v e n t i o n a l  C A M   E s t i m a t e  P  v a l u e  
E s t a b l i s h m e n t  o f  t h e  B l a c k  T r i a n g l e  
S c h e m e  
J a n u a r y ,  
1 9 7 6  
1 9 7 5  &  1 9 7 6  3 4 . 8  %  7 0 . 0  %  - 0 . 3 5  0 . 0 1 5  
 
1 9 7 5  &  
1 9 7 7  
1 4 1 . 8  %  1 9 0 . 0  %  - 0 . 4 8  0 . 0 0 0  
 
I n c l u s i o n  o f  t h e  Y e l l o w  C a r d  i n  G P  
p r e s c r i p t i o n  p a d s  a n d  t h e  B N F  
M a y ,  1 9 8 6  1 9 8 5  &  1 9 8 6  2 1 . 2  %  2 3 . 3  %  - 0 . 0 2  0 . 6 9 4  
 
1 9 8 5  &  
1 9 8 7  
3 3 . 4  %  - 3 . 3  %  0 . 3 6  0 . 0 0 0  
 
E s t a b l i s h m e n t  o f  t h e  N I M H *  Y e l l o w  
C a r d  S c h e m e  
J a n u a r y ,  
1 9 9 4  
1 9 9 3  &  1 9 9 4  - 3 . 8  %  - 2 6 . 5  %  - 0 . 2 4  0 . 0 0 2  
 
1 9 9 3  &  
1 9 9 5  
- 2 . 3  %  - - 1 1 . 8  %  - 0 . 0 9  0 . 0 8 6  
 
E x t e n s i o n  o f  S c h e m e  t o  u n l i c e n s e d  
h e r b a l  r e m e d i e s  
O c t o b e r ,  
1 9 9 6  
1 9 9 6  &  1 9 9 7  - 2 . 8  %  2 5 . 0  %  - 0 . 2 8  0 . 0 0 0  
 
1 9 9 6  &  
1 9 9 8  
5 . 4  %  2 . 8  %  0 . 0 3  0 . 3 2 7  
 
E x t e n s i o n  o f  A D R  r e p o r t i n g  t o  
c o m m u n i t y  p h a r m a c i s t s  
N o v e m b e r ,  
1 9 9 9  
1 9 9 9  &  2 0 0 0  7 9 . 3  %  1 3 8 . 3  %  - 0 . 5 9  0 . 0 0 0  
 
1 9 9 9  &  
2 0 0 1  
1 6 . 0  %  2 5 . 0  %  - 0 . 0 9  0 . 1 0 9  
 
E x t e n s i o n  o f  A D R  r e p o r t i n g  t o  N u r s e s ,  
M i d w i v e s  &  H e a l t h  v i s i t o r s  
O c t o b e r ,  
2 0 0 2  
2 0 0 2  &  2 0 0 3  9 . 1  %  1 0 . 9  %  - 0 . 0 2  0 . 6 3 7  
 
2 0 0 2  &  
2 0 0 4  
1 3 . 3  %  4 0 . 6  %  - 0 . 3 7  0 . 0 0 0  
 
A d o p t i o n  o f  E M A  d i r e c t i v e   
2 0 0 4 . / 2 4 /  E C  r e g u l a t i n g  h e r b a l  a n d  
h o m e o p a t h i c  m e d i c i n a l  p r o d u c t s  
A p r i l ,  2 0 0 4  2 0 0 3  &  2 0 0 4  3 . 9  %  2 6 . 8  %  - 0 . 2 3  0 . 0 0 0  
 
2 0 0 3  &  
2 0 0 5  
1 3 . 8  %  - 8 . 5  %  0 . 2 2  0 . 0 0 0  
 
E x t e n s i o n  o f  A D R  r e p o r t i n g  t o  p a t i e n t s  F e b r u a r y ,  
2 0 0 8  
2 0 0 7  &  2 0 0 8  1 8 . 1  %  2 5 . 0  %  - 0 . 0 7  0 . 2 0 4  
 
2 0 0 7  &  
2 0 0 9  
2 0 . 2  %  1 5 . 6  %  0 . 0 5  0 . 3 1 9  
 
* N I M H  – N a t i o n a l  I n s t i t u t e  o f  M e d i c a l  H e r b a l i s t s  
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medicines; and from 70.0% to 190.0% for CAMs); and the extension of ADR reporting to nurses,
midwives & health visitors in October 2002 (from 9.1% to 13.3% for conventional medicines;
and from 10.9% to 40.6% for CAMs). Judging solely from percentage changes in annual report
totals, the public health policy that yielded the greatest immediate (same year) improvement
in total annual ADR reports is the extension of reporting status to community pharmacists in
1999 (138.3% increase for CAMs vs. 79.3% increase for conventional medicines; P < 0.001).
However, the policy that yielded the most sustained effect over a 2-year span is the introduction
of the Black Triangle scheme in 1976 (190% increase for CAMs vs. 141% increase for conventional
medicines; P < 0.001). Also, the only public health policy changes for which there was apparently
no significant immediate difference in percentage change in annual reports between CAMs and
onventional medicines were the inclusion of Yellow Cards in GP prescription pads and the BNF
(23.3% vs. 21.2%; P=0.694), the extension of ADR reporting to nurses, midwives & health
visitors (10.9% vs. 9.1%; P=0.637) and the extension of ADR reporting to patients (25% vs.
18.1; P=0.204). Strikingly, of the three CAM-related public health initiatives introduced within
the period of analysis, the only one that did not yield any increase in CAM-related yellow card
reports was the establishment of the National Institute of Medical Herbalists (NIMH) Yellow Card
Scheme in January, 1994. However, while the other two CAM-related public health initiatives,
the extension of the YCS to unlicensed herbal remedies in October, 1996, and the adoption of the
European Medicines Agency directive 2004./24/ EC regulating herbal and homeopathic medicinal
products use within the EU in April, 2004, were associated with higher increases in CAM-related
ADR reports than for conventional medicines, these effects were not sustained beyond one year
of their institution. A similar pattern was noted for the extension of ADR reporting to patients.
3.3.3 Comparison of trends in CAM-related ADR reports for adult and pae-
diatric subjects
Figures 3.4 to 3.6 illustrate various comparisons of the trends in CAM-related ADR reporting
among different age categories of paediatric subjects; as well as between adult and paediatric
CAM ADR reports. Due to the much fewer number of CAM-related ADRs in the database, it
was not possible to compare annual trends for paediatric data: therefore, only 10-year trends
were compared.
Figure 3.4 shows that the plateau seen in CAM-related ADR reports is actually associated with
reports for paediatric subjects rather than those for adults.
Figure 3.5 shows that, while it is not obvious which paediatric age category is most associated with
the depression generally seen with paediatric subjects, it is least seen among preschool children.
Additionally, figure 3.6 shows that the depression is not as much associated with younger (12-17
year olds) or older adolescents (18-21 year olds), as it is with children aged less than 12 years.
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Figure 3.4: Comparative trends of 10-year CAM-related reports for adult 
and paediatric subjects (1963-2012) 
 
 
 
 
 
 
 
Figure 3.5: Comparative trends of 10-year CAM-related reports for 
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Figure 3.4: Comparative trends of 10-year CAM-related reports for adult and paediatric sub-
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Figure 3.5: Comparative trends of 10-year CAM-related reports for mong subcategories of
paediatric subjects (1963-2012)
3.3.4 Comparison of reporter profile for adult and paediatric CAM-related
ADRs
A comparison of adult and paediatric CAM-related ADR reports based on reporter profile shows
that, while both categories follow a similar trend: Doctor> Other Health care professional (Other
HCP)> Pharmacist > Patient > Nurse (table 3.8), only doctors (45.3% vs. 43.8%; p=0.683) and
nurses (1.0% vs. 1.9%; p=0.569) contributed about the same proportions of the total reports
for either category. Other HCPs contributed a significantly higher proportion of the reports
for paediatric subjects than for adults (40.6% vs. 27.5%; p < 0.001); while pharmacists (9.7%
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Figure 3.6: Comparativ  trends of 10-year CAM-related reports for 
children and adolescents aged up to 21 years (1963-2012) 
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Figure 3.6: Comparative trends of 10-year CAM-related reports for children and adolescents
aged up to 21 years (1963-2012)
vs. 16.2%; p < 0.001) and patients (3.7% vs. 10.1%; p < 0.001) contributed significantly lower
proportions. When the ADR reporter type for specific age sub-categories were compared, however,
it was found that while there were no significant differences (p < 0.05) among paediatric sub-
categories in the number of CAM-related ADRs reported by doctors, other HCPs or pharmacists;
the converse was the case among adult age categories for all ADR reporter types. Middle-aged
and young adults were the subjects of most of the ADRs reported by doctors, other HCPs and
patients; while young adults featured much less in the ADRs reported by pharmacists (19.7%) and
nurse (10.3%). Notably, alth ugh only 31 age-specific CAM-related ADR repor (1.8%) were
received from nurse reporters, subjects aged 60 years and over accounted for a high proportion of
such reports both among the adult population (17; 58.6%) and the whole population (19; 61.3%).
3.3.5 Overview of paediatric ADRs
To specifically analyse ADRs associated with paediatric reports, the 2167 individual case safety
report (ICSR) entries received rom the MHRA w re reduced to 186 pae tric I SRs through a
sequential screening process based on specified criteria (figure 3.6). Although the 186 paediatric
entries included more reports for female than male subjects, there were no significant differences
in the number of reports across paediatric age categories (p=0.991) or gender (p=0.059), nor
were there any significant differences in their distribution among paediatric age categories for
either sex (females, p= 0.674; males, p= 0.6). There were however two reports for subjects for
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whom the gender was not specified. These 186 entries yielded 332 specific ADRs for paediatric
subjects,171 (51.5%) of which were for female subjects (table 3.9).
 
 
Figure 3.7: Sequential screening process for selection of paediatric data 
for analysis 
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Table 3.8: Comparison of adult and paediatric CAM-related ADR reporters
 
 
Table 3.8: Comparison of adult and paediatric CAM-related ADR reporters 
Type of Reporter ADR report count by age categories n (% of grand total) Binomial test 
P(Paed)-P(Adult) PAEDIATRIC AGE CATEGORIES ADULT AGE CATEGORIES  
Infants 
 
(<2 yr) 
Preschool 
children 
(2-5 yr) 
School-age 
Children 
(6-11 yr) 
Younger 
adolescents 
(12-17 yr) 
Paediatric 
ADR Grand 
total 
Emerging 
adults 
(18-25 yr) 
Young 
adults 
(26-39 yr) 
Middle-aged 
adults 
(40-59 yr) 
Older 
adults 
(60-74 yr) 
The 
elderly 
(>74 yr) 
Adult ADR 
Grand 
total 
All ADR 
Grand 
total 
Estimate P value  
Doctor-reported 31, 
(16.15) 
21, 
(10.94) 
15, 
(7.81) 
20, 
(10.42) 
87, 
(45.31) 
58, 
(3.78) 
183, 
(11.94) 
257, 
(16.76) 
124, 
(8.09) 
48, 
(3.13) 
670, 
(43.75) 
756, 
(43.93) 
0.016 0.683 
Pharmacist-
reported 
2, 
(1.04) 
5, 
(2.60) 
6, 
(3.13) 
5, 
(2.60) 
18, 
(9.38) 
17, 
(1.11) 
49, 
(3.20) 
89, 
(5.81) 
63, 
(4.11) 
31, 
(2.02) 
249, 
(16.15) 
265, 
(15.40) 
-0.068 
 
0.003 
Nurse-reported - - 2, 
(1.04) 
- 
 
2, 
(1.04) 
1, 
(0.07) 
3, 
(0.20) 
8, 
(0.52) 
11, 
(0.72) 
6, 
(0.39) 
29, 
(1.90) 
31, 
(1.80) 
-0.009 0.569 
Other HCP-
reported 
14, 
(7.29) 
22, 
(11.46) 
23, 
(11.98) 
19, 
(9.90) 
78, 
(40.63) 
47, 
(3.07) 
134, 
(8.74) 
135, 
(8.81) 
79, 
(5.15) 
26, 
(1.70) 
421, 
(27.53) 
499, 
(28.99) 
0.131 0.000 
Patient-reported 3, 
(1.56) 
- 1, 
(0.52) 
3, 
(1.56) 
7, 
(3.65) 
13, 
(0.85) 
52, 
(3.39) 
52, 
(3.39) 
30, 
(1.96) 
8, 
(0.52) 
155, 
(10.07) 
161, 
(9.36) 
-0.064 0.000 
Other sources - - - - -  3, 
(0.20) 
4, 
(0.26) 
2, 
(0.13) 
 9, 
(0.59) 
9, 
(0.52) 
- - 
Grand total 50, 
26.04 % 
48, 
25.00 % 
47, 
24.48 % 
47,, 
24.48 % 
192, 
100 % 
136, 
8.87 % 
424, 
27.66 % 
545, 
35.55 % 
309, 
20.16 % 
119, 
7.76 % 
1529, 
100 % 
1721, 
100 % 
  
Chi squared test (Variability of doctor-reported ADRs across paediatric age categories) P value =0.102  
Chi squared test (Variability of doctor-reported ADRs across adult age categories) P value =0.000 
Chi squared test (Variability of pharmacist-reported ADRs across paediatric age categories) P value =0.572  
Chi squared test (Variability of pharmacist-reported ADRs across adult age categories) P value =0.000 
Chi squared test (Variability of nurse-reported ADRs across age paediatric categories) –Insufficient data 
Chi squared test (Variability of nurse-reported ADRs across adult age categories) P value =0.029 
Chi squared test (Variability of other HCP-reported ADRs across age paediatric categories) P value =0.473  
Chi squared test (Variability of other HCP-reported ADRs across adult age categories) P value =0.000 
Chi squared test (Variability of patient-reported ADRs across age paediatric categories) –Insufficient data 
Chi squared test (Variability of patient-reported ADRs across adult age categories) P value =0.000 
Chi squared test (Variability of ADR reports from other sources across adult age categories) –Insufficient data 
†-Fisher’s exact test 
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Table 3.9: Paediatric age group and gender distribution of subjects of CAM-related ADR
reports
 
 
 
Table 3.9  P diatric age group and gender distribution of subjects of 
CAM-related ADR reports 
 
Paediatric 
age sub-categories 
Number of ADRs reported, n (%) Binomial 
test  
P valuea 
ODDs of ADR 
report among 
female subjects 
Female 
subjects 
Male 
subjects 
Unknown 
sex 
Total 
(%) 
Infants  
(<2 years) 
28, 
(40.0) 
42, 
(60.0) 
- 70, 
(21.08) 
0.016 0.67 
Preschool 
Children 
(2-5 years) 
43, 
(51.2) 
40, 
(47.6) 
1, 
(1.2) 
84, 
(25.30) 
0.641 
 
1.08 
School-age 
Children 
(6-11 years) 
50, 
(61.0) 
31, 
(37.8) 
1, 
(1.2) 
82, 
(24.70) 
0.002 
 
1.61 
Younger 
Adolescents 
(12-17 years) 
50, 
(52.1) 
46, 
(47.9) 
- 96, 
(28.92) 
0.563 
 
1.09 
Grand total 
(%) 
171, 
(51.51) 
159, 
(47.89) 
2, 
(0.60) 
332, 
(100) 
0.350 1.08 
Χ2 test for independence of ADR report on paediatric age categories:  
P value =0.251 
Χ2 test for independence of ADR report on paediatric age category among female 
subjects: P value =0.056 
Χ2 test for independence of ADR report on paediatric age category among male subjects: 
P value =0.386 
a –Excluding unknown sex 
 
Although there was 1.08 times greater likelihood of ADRs reported being for female subjects
than for male subjects, the odds of ADR report among female infants was 0.33 times less than for
their male counterparts (p=0.016). However, there was a greater likelihood of the ADRs reported
being for female subjects for all other paediatric age categories, resulting in higher female ADR
counts for all such age categories. The paediatric age category associated with the highest odds of
ADR report among female subjects, and the thus the greatest difference in the number of ADRs
reported, was school-age children (p=0.002; odds =1.61).
In table 3.10, the 332 specific ADRs were categorised into their respective system-organ classes
(SOCs), and were found to belong to 20 (76.9%) of the 26 SOCs in the MedDRA terminology.
ADRs related to skin and subcutaneous disorders, SSD (86; 25.9%), nervous system disorders,
NSD (47; 14.2%), gastrointestinal disorders, GID (42; 12.7%) and general disorders & adminis-
tration site injuries, GDASI (38; 11.5%) accounted for the greatest proportions; while neoplasms
(1; 0.3%), nutrition & metabolic disorders (2; 0.6%) and ear and labyrinth disorders (3; 0.9%)
accounted for the least. Although, the total ADR counts were uniformly distributed across the
paediatric age categories (P=0.251), they were significantly skewed (P < 0.001) across SOCs,
with the SSD class accounting for over a quarter (86; 25.9%) of them. Also, all the four most
commonly reported SOCs were uniformly distributed across paediatric age categories. In terms
of gender, however, although only the SSD (P < 0.001) and the NSD (p=0.010) classes were not
uniformly distributed among the sexes, the odds of report were higher among female subjects for
the GDASI and SSD classes (1.38 and 1.97, respectively), and lower for the GID and NSD classes
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Table 3.10: Age and gender distribution of paediatric CAM-related ADRs by System-Organ
Classes
 
 
Table 3.10: Age and gender distribution of paediatric CAM-related ADRs 
by System-Organ Classes 
* -Includes subject of unknown sex 
 
Adverse drug 
Reaction  
System-Organ 
Classes  
(ADR SOCs) 
Infants 
 
 
(<2 yr) 
Preschool-
age 
children 
(2-5 yr) 
School-
age 
children 
(6-11 yr) 
Younger 
adolescents 
 
(12-17 yr) 
Grand 
total 
 
Χ2 
test  
p 
value 
for 
age 
GENDER 
SPREAD 
Binomial 
test p 
value 
for 
gender 
ODDs 
among 
FEMALE 
subjects 
(for 
Σn≥5) 
Female 
 
n  
(%) 
Male 
 
n  
(%) 
Number of ADRs, 
n (%) 
Blood & 
lymphatic 
System disorders
- 2 1 1 
4, 
(1.2) 
- 4 - - - 
Cardiac 
disorders 
1 - - 3 4, 
(1.2) 
- 1 3 - - 
Ear & labyrinth 
disorders 
- - 2 1 3, 
(0.9) 
- 2 1 - - 
Eye disorders 2 2 1 2 7, 
(2.1) 
- 4 3 - 1.33 
Gastrointestinal 
disorders 
6 11 8 17 42, 
(12.7 
0.087 18, 
(42.9) 
24, 
(57.1) 
0.186 
 
0.75 
General 
disorders & 
Administration 
site injuries 
8 8 12 10 38, 
(11.5 
0.674 22, 
(57.9) 
16, 
(42.1) 
0.163 
 
1.38 
Immune system 
disorders 
1 5 2 12 20,* 
(6.0) 
- 8 11 0.324 
 
0.73 
Infections & 
Infestations 
2 1 1 1 5, 
(1.5) 
- 4 1 - 4.00 
Injury, Poisoning 
& Procedural 
Complications 
7 5 - 3 15, 
(4.5) 
- 6 9 0.439 0.67 
Investigations 2 - 1 1 4, 
(1.2) 
- 2 2 - - 
Nutrition & 
Metabolic 
disorders 
1 - 1 - 
2, 
(0.6) 
- 2 0 - - 
Musculoskeletal 
& Connective 
tissue Disorders 
2 - 3 8 13, 
(3.9) 
- 7 6 0.264 
 
1.17 
Neoplasms –
benign, 
malignant or 
unspecified 
- - 1 - 1, 
(0.3) 
- 0 1 - - 
Nervous system 
disorders 
8 11 14 14 47,* 
(14.2 
0.550 17, 
(37.0) 
29, 
(63.0) 
0.010 0.59 
Psychiatric 
disorders 
1 5 4 1 11. 
(3.3) 
- 2 9 - 0.22 
Renal & Urinary 
disorders 
- 1 2 2 5, 
(1.5) 
- 4 
 
1 
 
- 4.00 
Reproductive 
system & Breast 
disorders 
- 2 2 1 
5, 
(1.5) 
- 3 2 - 1.50 
Respiratory, 
Thoracic & 
Mediastinal 
disorders 
4 5 1 6 16, 
(4.8) 
- 6 10 0.144 
 
0.60 
Skin & 
Subcutaneous 
disorders 
25 25 25 11 86, 
(25.9 
0.077 57, 
(66.3) 
29, 
(33.7) 
0.000 1.97 
Vascular 
disorders 
- 1 1 2 4, 
(1.2) 
- 2 2 - 1.00 
Total ADRs 
reported, (%) 
70, 
(21.08) 
84, 
(25.30) 
82, 
(24.70) 
96, 
(28.92) 
332, 
(100) 
0.251 171, 
(51.51) 
159, 
(47.8
9) 
0.350 
 
1.08 
Χ2 test for independence of ADR report on ADR system organ class:  
P value <0.001 
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Table 3.11: Age and sex distribution of skin and subcutaneous system-organ class ADRs
 
 
 T a b l e  3 . 1 1 :  A g e  a n d  s e x  d i s t r i b u t i o n  o f  s k i n  a n d  s u b c u t a n e o u s  s y t e r g a n  c l a s s  A D R s  
 
S p e c i f i c  r e a c t i o n s  
i n  t h e  S k i n  &  
s u b c u t a n e o u s  
d i s o r d e r s  M e d D R A  
S O C  
F E M A L E  S U B J E C T S  M A L E  S U B J E C T S  G r a n d  
T o t a l  
 
Σ n  
( % )  
O D D s  o f  A D R  
r e p o r t  a m o n g  
F E M A L E  
s u b j e c t s  
( f o r  Σ n ≥ 5 )  
I n f a n t s  
 
 
( < 2  y r |  
P r e s c h o o l -  
a g e  
c h i l d r e n  
( 2 - 5  y r )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  y r )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  y r )  
A l l  
f e m a l e  
s u b j e c t s  
 
I n f a n t s  
 
 
( < 2  y r |  
P r e s c h o o l -  
a g e  
c h i l d r e n  
( 2 - 5  y r )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  y r )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  y r )  
A l l  
m a l e  
s u b j e c t s  
C y a n o s i s  
 
0  0     1     1  1  -  
E c z e m a  
 
2  1  2  1  6  2  2  1  1  6  1 2  1 . 0 0  
E r y t h e m a  
 
1  1  2  1  5  1  2    3  8  1 . 6 7  
H y p e r h i d r o s i s  
 
0  0  1   1       1  -  
P e t e c h i a e   
 
0  0  1   1       1  -  
P h o t o s e n s i t i v i t y  
r e a c t i o n   
0  0      1    1  1  -  
P r u r i t u s  
 
0  3    3  1     1  4  -  
P u r p u r a   
 
0  2    2  1     1  3  -  
R a s h  
%  f o r  s e x ;  
( %  i n  S O C ) ;  
( %  o f  a l l  A D R s )  
9  1 0  1 0  8  3 7 ,  
6 4 . 9  %  
( 4 3 . 0  % )  
5  2  6   1 3 ,  
4 4 . 8  %  
( 1 5 . 1  % )  
5 0 ,  
 
( 5 8 . 1  % )  
( 1 5 . 1  % )  
2 . 8 5  
S k i n  e x f o l i a t i o n  
 
0  0  1   1       1  -  
T h e r m a l  b u r n  
 
0  0  1   1  2  1    3  4  -  
G r a n d  t o t a l  
%  b y  s e x ;  
( %  i n  S O C ) ;  
( %  o f  a l l  A D R s )  
1 2 ,  
2 1 . 0  %  
1 7 ,  
2 9 . 8  %  
1 8 ,  
3 1 . 6  %  
1 0 ,  
1 7 . 5  %  
5 7 ,  
1 0 0  %  
( 6 6 . 3  % )  
1 3 ,  
4 4 . 8  %  
8 ,  
2 7 . 6  %  
7 ,  
2 4 . 1  %  
1 ,  
3 . 5  %  
2 9 ,  
1 0 0  %  
( 3 3 . 7  % )  
8 6 ,  
 
( 1 0 0  % )  
( 2 5 . 9  % )  
1 . 9 7  
Χ 2  t e s t  P  v a l u e  ( a l l  
A D R s )  
P = 0 . 3 7    P = 0 . 0 1 8     
Χ 2  t e s t  P  v a l u e  
( r a s h )  
P = 0 . 9 6 1   I n s u f f i c i e n t  d a t a     
B i n o m i a l  t e s t  f o r  i n d e p e n d e n c e  o f  t o t a l  s k i n  a n d  s u b c u t a n e o u s  d i s o r d e r s  A D R  c o u n t  o n  s e x :  P  v a l u e  < 0 . 0 0 1   
B i n o m i a l  t e s t  f o r  r a s h  P ( F e m a l e ) - P ( M a l e ) :  E s t i m a t e  =  0 . 2 0 0 8 4 7 ;  P - V a l u e  =  0 . 0 7 3  
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(0.75 and 0.59, respectively). Although ADRs belonging to the SSD class had the highest odds of
report among female subjects (1.97) when the four most prevalent SOCs alone were considered,
ADRs in the infections and infestations (I & I) and renal and urinary disorders (RUD) classes
showed the highest odds of report among female subjects overall (4.00). These two classes, how-
ever, accounted for much fewer ADR reports than the SSD class (5 each; 1.5% vs. 86 ADRs;
25.9%).
Table 3.11 outlines the distribution of specific ADRs in the SSD class, indicating them to be
predominantly associated with rash (50; 58.1%), which alone accounted for 15% of all CAM-
related ADRs reported among children. Although this reaction was reported to about the same
degree in each sex (64.9% vs. 44.8%; p=0.073), it was almost three times more likely to be
reported among female subjects than among the males (odds =2.85), as well as more uniformly
distributed across female paediatric age categories (p=0.961). Among male subjects, however,
the 29 SSD ADRs reported were skewed (p=0.018) towards children aged up to 5 years (21 ADRs;
72.4%), particularly infants (13; 44.8%).
Table 3.12 outlines the distribution of specific ADRs in the NSD class. While no specific ADR
predominated, the high proportions of ADRs related to cognitive impairment (15; 31.9%), hy-
perkinesia (13; 27.7%), and abnormal sensation (10; 21.3%) were obvious. Also, while abnormal
sensation had the highest odds of being reported for female subjects, hyperkinesia had the least
such likelihood, being very highly reported for male subjects (p=0.001). At the specific ADR
level, convulsions were found to be the most recorded (6 reports), closely followed by burning
sensation and dizziness (5 reports each). While convulsions were predominantly reported for male
subjects; burning sensation was highly reported for female subjects. Although various specific
ADRs were reported exclusively in subjects of certain specific paediatric age categories, on the
whole ADRs in the NSD class were evenly spread across age categories for both sexes.
Table 3.13 outlines the 3 most commonly reported ADRs for male and female subjects per pae-
diatric age category. In addition to underlining the high incidence of the report of rash among
female subjects (37; 21.6%), it also highlights the co-dominance of NSD ADRs with SSD ADRs
among male subjects (29 each; 18.2%). Also, while rash was shown to be the most predomi-
nant ADR reported for each age category among female subjects, the incidence of report of NSD
ADRs among males generally increased with increasing age, albeit non significantly (p=0.565).
The report of ADRs in the GID class among males also followed the same trend.
A classification of the ADRs reported based on the associated CAM product types in table 3.14
shows a highly non-uniform distribution (P < 0.001), with herb-drug combinations and herbal
remedies together accounting for over half of the ADRs reported (192; 57.8%). Among spe-
cific CAM product types, there were significant differences in the distribution of reported ADRs
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Table 3.12: Age and sex distribution of nervous system disorders ADRs
 
 
T a b l e  3 . 1 2 :  A g e  a n d  s e x  d i s t r i b u t i o n  o f  n e r v o u s  s y s t e m  d i s o r d e r s  A D R s  
 
 
S p e c i f i c  r e a c t i o n s  g r o u p s  
i n  t h e  n e r v o u s  s y s t e m  
d i s o r d e r s  M e d D R A  S O C  
F E M A L E  S U B J E C T S  M A L E  S U B J E C T S  U N K N O W N  
S E X  
G r a n d  
T o t a l  
 
Σ n  
( % )  
B i n o m i a l  
t e s t   
P  v a l u e  
( g e n d e r  
s p r e a d )  
O D D s  o f  A D R  
r e p o r t  a m o n g  
F E M A L E  
s u b j e c t s  
( f o r  Σ n ≥ 5 )  
I n f a n t s  
 
 
( < 2  y r |  
P r e s c h o o l -  
a g e  
c h i l d r e n  
( 2 - 5  y r )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  y r )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  y r )  
A l l  
f e m a l e  
s u b j e c t s  
n  ( % )  
I n f a n t s  
 
 
( < 2  y r |  
P r e s c h o o l -  
a g e  
c h i l d r e n  
( 2 - 5  y r )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  y r )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  y r )  
A l l  
m a l e  
s u b j e c t s  
 
S c h o o l - a g e  
c h i l d  
( 6 - 1 1  y r )  
A b n o r m a l  s e n s a t i o n  1  1  3  2  7  2  -  -  1  3  -  1 0 .  
( 2 1 . 3 )  
0 . 1 7 9  2 . 3 3  
B u r n i n g  s e n s a t i o n 1 1 2 - 4 1 - - - 1 - 5  4 . 0 0  
H y p e r a e s t h e s i a  - - 1 - 1 - - - - - - 1   
H y p o e s t h e s i a - - - 2 2 - - - - - - 2   
P a r a e s t h e s i a - - - - - 1 - - 1 2 - 2   
C o g n i t i v e  i m p a i r m e n t  -  1  3  1  5  1  3  2  3  9  1  1 5 ,  
( 3 1 . 9 )  
0 . 1 1 5  0 . 5 6  
D i s o r i e n t a t i o n  - - 1 - 1 1 1 2 1 3   
D i s s o c i a t i o n  - - - - - 1 1 - 1   
D i z z i n e s s - 1 1 - 2 2 1 3 - 5  0 . 6 7  
H a l l u c i n a t i o n - - - - - 1 1 - 1   
N i g h t m a r e - - - - - 1 - 1 - 1   
S y n c o p e 1 1 2 1 - 1 - 3   
H y p e r k i n e s i a  -  1  -  1  2  2  4  3  2  1 1  -  1 3 ,  
( 2 7 . 7 )  
0 . 0 0 1  0 . 1 8  
A t a x i a - - - - - - 2 - - 2 - 2   
A D H D - - - - - - 1 - - 1 - 1   
C o n v u l s i o n - 1 1 1 1 1 2 5 - 6  0 . 2  
P s y c h o m o t o r  h y p e r a c t i v i t y - - - - - - - 2 - 2 - 2   
S t a t u s  e p i l e p t i c u s - - - - - 1 - - - 1 - 1   
T r e m o r - - - 1 1 - - - - - - 1   
V i s u a l  i m p a i r m e n t  -  -  -  -  -  -  1  1  1  3  -  3  -  -  
D i p l o p i a - - - - - - 1 - 1 2 - 2   
N y s t a g m u s - - - - - - - 1 - 1 - 1   
M i s c e l l a n e o u s  2  -  1  -  3  -  -  -  3  3  -  6  -  1 . 0 0  
C e r e b r a l  i n f a r c t i o n 1 - - - 1 - - - - - - 1   
C r a n i a l  n e r v e  d i s o r d e r - - - - - - - - 1 1 - 1   
D e p e n d e n c e 1 - - - 1 - - - - - - 1   
H e a d a c h e - - 1 - 1 - - - 1 1 - 2   
N e u r o l o g i c a l  s y m p t o m - - - - - - - - 1 1 - 1   
G r a n d  t o t a l  
%  o f  s e x  t o t a l  
%  o f  g r a n d  t o t a l  
3 ,  
1 7 . 7  %  
3 ,  
1 7 . 7  %  
7 ,  
4 1 . 2  %  
4 ,  
2 3 . 5  %  
1 7 ,  
1 0 0  %  
3 6 . 2  %  
5 ,  
1 7 . 2  %  
8 ,  
2 7 . 6  %  
6 ,  
2 0 . 7  %  
1 0 ,  
3 4 . 5  %  
2 9 ,  
1 0 0  %  
6 1 . 7  %  
1 ,  
 
2 . 1  %  
4 7 ,  
 
1 0 0  %  
0 . 0 1 0  0 . 5 8  
Χ 2  t e s t  P  v a l u e  ( a l l  
A D R s )  
0 . 4 7 0   0 . 5 6 5       
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Table 3.13: The 3 most common ADRs reported per paediatric age sub-category distributed
by sex†
 
 
Table 3.13: Th   most common ADRs reported per paediatric age s b-
category distributed by sex† 
 
Paediatric 
age 
category 
FEMALES MALES 
Major specific ADR  
or ADR SOC 
n  
(% for 
category) 
Major specific ADR  
or ADR SOC 
n  
(% for 
category) 
Infants 
(<2 years) 
Rash 9  
(32.1) 
Other skin & subcutaneous 
          disorders (excluding rash) 
8 
(19.0) 
General disorders &  
       administration site injuries 
3 
(10.7) 
Injury, poisoning & procedural          
 complications 
6 
(14.3) 
Nervous system disorders 3 
(10.7) 
Nervous system disorders 5 
(11.9) 
Category total 
(% for sex) 
28 ADRs  
(16.4) 
42 ADRs  
(26.4) 
Preschool-
age 
children 
(2-5 years) 
Rash 
 
10 
(23.3) 
Skin & Subcutaneous 
  disorders 
8 
(20.0) 
Other skin & subcutaneous 
       disorders (excluding rash) 
7 
(16.3) 
Nervous system disorders 
 
8 
(20.0) 
General disorders &  
      administration site injuries 
6 
(14.0) 
Gastrointestinal disorders 6 
(15.0) 
Category total 
(% for sex) 
43 ADRs  
(25.2) 
40 ADRs  
(25.2) 
School-age 
children 
(6-11 
years) 
Rash 10 
(20.0) 
Rash 
 
6 
(19.4) 
Other skin & subcutaneous 
      disorders (excluding rash) 
8 
(16.0) 
Nervous system disorders 
 
6 
(19.4) 
General disorders &  
administration Site Injuries 
8 
(16.0) 
Gastrointestinal disorders 4 
(12.9) 
Category total 
(% for sex) 
50 ADRs  
(29.2) 
31 ADRs  
(19.5) 
Younger 
Adolescents 
(12-17 
years) 
Rash 8 
(16.0) 
Nervous system disorders 
 
10 
(21.8) 
Gastrointestinal disorders 8 
(16.0) 
Gastrointestinal disorders 
 
9 
(19.6) 
Immune system disorders 7 
(14.0) 
General disorders &  
           administration site injuries 
5 
(10.9) 
Category total 
(% for sex) 
50 ADRs  
(29.2) 
46 ADRs 
(28.9) 
Paediatric 
 subjects 
(0-17 
years) 
Rash 37 
(21.6) 
Nervous system disorders  
 
29 
(18.2) 
General disorders &  
       administration site injuries 
22 
(12.9) 
Skin & Subcutaneous disorders 29  
(18.2) 
Other skin & subcutaneous 
       disorders (excluding rash) 
20 
(11.7) 
Gastrointestinal disorders 24 
(15.1) 
Category total 
(% for sex) 
171 ADRs  
(100) 
159 ADRs  
(100) 
% in population 51.7 %† 48.3 %† 
Χ2 test for independence of nervous system disorders ADRs on male paediatric age: P=0.565 
† -Excluding subjects of unknown sex 
across paediatric age categories. While ADRs associated with aromatherapy products were pre-
dominant among infants (64.3%; p < 0.001), those associated with homeopathic products were
predominant among younger adolescents (65.2%; p < 0.001), and those associated with dietary
supplements were predominant among school-age children (51.9%; p=0.004). For ADRs associ-
ated with herbal remedies and herb-drug combinations, however, although they were uniformly
distributed (p=0.163; p=0.961) among children aged over 2 years, they were much less associated
with infants (p=0.002; p=0.031). A comparison of the various modes of herbal medicinal prod-
uct use shows that the combined use of herbal medicines with conventional medicines, chemical
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Table 3.14: Distribution of ADR reports based on the associated CAM product types
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Table 3.15: Distribution of ADR reports based on the anatomical main 
group classification of associated CAM products 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAM product types  
(or specific modes of use) 
Infants 
 
 
(<2 yr) 
Preschool-
age 
children 
(2-5 yr) 
School-age 
children 
 
6-11 yr) 
Younger 
adolescents 
 
(12-17 yr) 
Grand 
total 
n  
(%) 
Χ2 test 
p value 
(all 
ages) 
Χ2 test 
p value 
(age 
>2 yr) 
Aromatherapy products 
(essential oils) 
27 9 5 1 42, 
(12.7) 
0.000 0.041 
Dietary Supplements 8 3 14 2 27, 
(8.1) 
0.004 0.001 
Herbal Products 6 3 0 2 11, 
(3.3) 
- - 
Herbal Remedies 7 30 23 17 77, 
(23.2) 
0.002 0.163 
Herb-Drug Combinations 15 34 34 32 115, 
(34.6) 
0.031 0.961 
Homeopathic Remedies 6 5 5 30 46, 
(13.9) 
0.000 0.000 
TCM/Poly-herbal 
formulations 
1 0 1 12 14, 
(4.2) 
- - 
TOTAL ADRs Reported 
(%) 
70, 
(21.08) 
84, 
(25.30) 
82, 
(24.70) 
96, 
(28.92) 
332, 
(100) 
  
Χ2 test for independence of ADR report on CAM types involved: P value <0.001 
Binomial test comparing ADR report based on the mode of herbal product use  
P(Herbal remedies)–P(Herb-drug combinations):  
Estimate = -0.114458; P-Value = 0.001 
Anatomical main group of 
associated CAM product 
(1St level ATC Classification) 
Infants 
 
 
(<2 yr) 
Preschool-
age 
children 
(2-5 yr) 
School-age 
children 
 
(6-11 yr) 
Younger 
adolescents 
 
(12-17 yr) 
Grand 
total 
n,  
% 
Χ2 test 
p value 
(for 
age) 
Alimentary system & 
metabolism products 
6 
 
23 
 
18 
 
12 
 
59 , 
31.67% 
0.012 
Blood & blood forming organ-
related products 
7  2 
 
4 
 
- 13, 
7.0 % 
- 
Dermatological products 4 
 
4 
 
8 
 
2 
 
18, 
9.7 % 
0.238 
Genito-urinary system & Sex 
hormonal products 
1 
 
- - 1 
 
2, 
1.1 % 
- 
Antineoplastic & immuno-
modulatory agents 
- 2 
 
2 
 
2 
 
6, 
3.2 % 
- 
Musculo-skeletal system 
agents 
6 
 
1 
 
- 1 
 
8, 
4.3 % 
- 
Nervous system agents 3 
 
- 1 
 
4 
 
8, 
4.3 % 
- 
Respiratory system agents 17 
 
7 
 
2 
 
2 
 
28, 
15.1 % 
0.000 
Products with multi-modal or 
non-specific indication(s) 
- 5 
 
6 
 
4 
 
15, 
8.1 % 
- 
Unclear (Insufficient/no 
information provided) 
- 1 
 
1 
 
1 
 
3, 
1.6 % 
- 
No ATC class currently 
available 
3 
 
3 
 
3 
 
18 
 
26, 
14.0 % 
- 
GRAND TOTAL, 
% 
46, 
100 % 
48, 
100 % 
45, 
100 % 
47, 
100 % 
186, 
100 % 
- 
Χ2 test for independence of ADRs reported on available† Anatomical main group of CAMs:  
P value <0.001 
† -excluding unavailable or unclear ATC codes 
 
 
products or more than two other herbal medicines resulted in more ADRs than the use of 1-3
herbs alone only when the additional agent was a conventional medicine. While herb- drug com-
binations were associated with a much higher proportion of ADRs than herbal remedies (34.6%
vs. 23.2%; estimate = −0.114458; p =0.001); herbal p oducts and poly-herb formu ations were
associated with much fewer proportions (3.3% vs. 23.2%; estimate = −0.198795; p < 0.001; 4.2%
vs. 23.2%; estimate = −0.189759; p < 0.001).
The level one ATC classification of the CAMs (table 3.15) shows a highly non-uniform distribution
(P < 0.001), with CAMs in the alimentary system & metabolism class accounting for almost one
third of the ADR reports and those in the genito-urinary system & sex hormones class accounting
for only 1% of them. Among products in the 3 anatomical main groups whose ADR reports were
associated with all paediatric age categories, only the ADRs reports for dermatological CAM
products were uniformly distributed across age categories (p=0.238). While ADR reports for
respiratory system CAM products were skewed (p < 0.001) towards infants; those for products
in the alimentary system & metabolism class were skewed against them (P=0.012).
Figure 3.8 illustrates the indications recorded for the CAM products used in the 186 paediatric
subjects for whom ADRs were reported, highlighting the high degree of non-inclusion of indica-
tions for the products used (83; 44.6%), as well as the high proportion of abdominal and rectal
conditions among the indications that were reported (54; 52.4%). This indication was followed
distantly by head, eye, ear, neck and throat conditions (16; 15.5%), skin conditions (11; 10.7%);
and allergy (10 cases; 9.7%), respectively. A detailed analysis of the specific indications consti-
tuting the abdominal and rectal conditions associated with the ADRs in figure 3.9 indicates that
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Table 3.15: Distribution of ADR reports based on the anatomical main group classification of
associated CAM products
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CAM product types  
(or specific modes of use) 
Infants 
 
 
(<2 yr) 
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age 
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(2-5 yr) 
School-age 
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6-11 yr) 
Younger 
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(12-17 yr) 
Grand 
total 
n  
(%) 
Χ2 test 
p value 
(all 
ages) 
Χ2 test 
p value 
(age 
>2 yr) 
Aromatherapy products 
(essential oils) 
27 9 5 1 42, 
(12.7) 
0.000 0.041 
Dietary Supplements 8 3 14 2 27, 
(8.1) 
0.004 0.001 
Herbal Products 6 3 0 2 11, 
(3.3) 
- - 
Herbal Remedies 7 30 23 17 77, 
(23.2) 
0.002 0.163 
Herb-Drug Combinations 15 34 34 32 115, 
(34.6) 
0.031 0.961 
Homeopathic Remedies 6 5 5 30 46, 
(13.9) 
0.000 0.000 
TCM/Poly-herbal 
formulations 
1 0 1 12 14, 
(4.2) 
- - 
TOTAL ADRs Reported 
(%) 
70, 
(21.08) 
84, 
(25.30) 
82, 
(24.70) 
96, 
(28.92) 
332, 
(100) 
  
Χ2 test for independence of ADR report on CAM types involved: P value <0.001 
Binomial test comparing ADR report based on the mode of herbal product use  
P(Herbal remedies)–P(Herb-drug combinations):  
Estimate = -0.114458; P-Value = 0.001 
Anatomical main group of 
associated CAM product 
(1St level ATC Classification) 
Infants 
 
 
(<2 yr) 
Preschool-
age 
children 
(2-5 yr) 
School-age 
children 
 
(6-11 yr) 
Younger 
adolescents 
 
(12-17 yr) 
Grand 
total 
n,  
% 
Χ2 test 
p value 
(for 
age) 
Alimentary system & 
metabolism products 
6 
 
23 
 
18 
 
12 
 
59 , 
31.67% 
0.012 
Blood & blood forming organ-
related products 
7  2 
 
4 
 
- 13, 
7.0 % 
- 
Dermatological products 4 
 
4 
 
8 
 
2 
 
18, 
9.7 % 
0.238 
Genito-urinary system & Sex 
hormonal products 
1 
 
- - 1 
 
2, 
1.1 % 
- 
Antineoplastic & immuno-
modulatory agents 
- 2 
 
2 
 
2 
 
6, 
3.2 % 
- 
Musculo-skeletal system 
agents 
6 
 
1 
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7 
 
2 
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Products with multi-modal or 
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4 
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8.1 % 
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1 
 
1 
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3 
 
3 
 
3 
 
18 
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- 
GRAND TOTAL, 
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- 
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Figure 3.8: Indications provided for CAM products associated with ADRs 
in paediatric subjects 
 
 
 
 
Figure 3.9: Details of abdominal and rectal conditions recorded as 
indications for CAM products associated with ADRs in paediatric subjects 
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Figure 3.8: Indications provided for CAM products associated with ADRs in paediatric subjects
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enterobiasis, the eradication of round worm infestation, accounted for over two thirds of them
(41; 76.0%).
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Figure 3.9: Details of abdominal and rectal conditions recorded as 
indications for CAM products associated with ADRs in paediatric subjects 
 
 
Figure 3.9: Details of abdominal and rectal conditions recorded as indications for CAM products
associated with ADRs in paediatric subjects
Tables 3.16 and 3.17 outline the period taken for the ADRs reported to resolve as recorded in the
database, and indicate that, although ADR duration was either not (validly) recorded for about
60% of the cases (190; 57.2%), in about 70% of the validly recorded cases, the ADRs reported
resolved within the first 3 days of the report (97; 68.3%), with a third of them resolving on the
very same day(47; 33.1%). When the SOC distribution of the ADRs reported was considered
(table 3.15), the ADR durations of ADRs in the respective SOCs were found to follow the same
general pattern as for the total ADRs reported, except for ADRs in the cardiac disorders; I & I;
injury, poisoning & procedural complications (IPPC); neoplasms; and psychiatric disorders (PD)
classes, for which most (or all) of the associated ADRs took more than 3 days to resolve. When
the CAM product types associated with ADRs were considered (table 3.16), the ADR resolution
periods for the various product types were also found to follow a similar pattern. Only the ADRs
associated with dietary supplements and herbal products were found to have taken more than 3
days to resolve. Strikingly, there was no record for records involving poly-herbal preparations.
Figure 3.10 illustrates the richness of the narrative associated with CAM-related paediatric ADR
report entries. Although a detailed case narrative was presented in about half of the cases
reported (88; 47.3%), no narrative whatsoever was provided in a third of the cases (64; 34.4%),
and some “additional information” in about one eighth of the cases (26; 14.0%). Most of the
additional information provided was in terms of further details of the ADR reported, including
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Table 3.16: Duration of CAM-related ADRs reported according to their respective system-organ
classes
 
 
Table 3.16: Duration of CAM-related ADRs reported according to their 
respective system-organ classes  
 
Adverse drug Reaction 
System-Organ Classes 
(ADR SOCs) 
Reported period of ADR resolution Reports with 
valid ADR 
duration data 
 
n (%) 
Reports with 
missing or 
erroneous ADR 
duration data 
n (%) 
All ADRs 
reported 
 
n 
(%) 
Same 
day 
1-3 
days 
4-7 
days 
8-15 
days 
16-31 
days 
>31 
days 
Blood & lymphatic System 
disorders 
1 
  
1 
    
2,  
(50.0) 
2, 
(50.0) 
4, 
(1.2) 
Cardiac disorders 
  
1 
   
1 
 
2,  
(50.0) 
2, 
(50.0) 
4, 
(1.2) 
Ear & labyrinth disorders 
 
1 
 
1 
    
2, 
(66.7) 
1, 
(33.3) 
3, 
(0.9) 
Eye disorders 1 
 
1 
    
1 
 
3, 
(42.9) 
4, 
(57.1) 
7, 
(2.1) 
Gastrointestinal disorders 6 
 
10 
 
2 
  
1 
 
3 
 
22, 
(52.4) 
20, 
(47.6) 
42, 
(12.7) 
General disorders & 
Administration site injuries 
4 
 
4 
 
1 
   
2 
 
11, 
(28.9) 
27, 
(71.1) 
38, 
(11.5) 
Immune system disorders 5 
 
3 
    
1 
 
9, 
(45.0) 
11, 
(55.0) 
20, 
(6.0) 
Infections & Infestations 
  
1 
   
1 
 
2, 
(40.0) 
3, 
(60.0) 
5, 
(1.5) 
Injury, Poisoning & 
Procedural Complications 
1 
  
1 
  
1 
  
3, 
(20.0) 
12, 
(80.0) 
15, 
(4.5) 
Investigations 
 
1 
 
1 
    
2, 
(50.0) 
2, 
(50.0) 
4, 
(1.2) 
Nutrition & Metabolic 
disorders       
0 
 
2, 
(100) 
2, 
(0.6) 
Musculoskeletal & connective 
tissue Disorders 
2 
 
2 
  
1 
   
5, 
(38.5) 
8, 
(61.5) 
13, 
(3.9) 
Neoplasms –benign, 
malignant or unspecified   
1 
    
1, 
(100)  
1, 
(0.3) 
Nervous system disorders 14 
 
11 
 
3 
 
1 
 
1 
 
1 
 
31, 
(66.0) 
16, 
(34.0) 
47, 
(14.2) 
Psychiatric disorders 1 
  
2 
 
2 
   
5, 
(45.5) 
6, 
(54.6) 
11. 
(3.3) 
Renal & Urinary disorders 
      
0 
 
5, 
(100) 
5, 
(1.5) 
Reproductive system & 
Breast disorders  
1 
     
1, 
(20.0) 
4, 
(80.0) 
5, 
(1.5) 
Respiratory, Thoracic & 
Mediastinal disorders 
5 
 
2 
     
7, 
(43.8) 
9, 
(56.3) 
16, 
(4.8) 
Skin & Subcutaneous 
disorders 
7 
 
14 
 
8 
 
4 
  
1 
 
34, 
(39.5) 
52, 
(60.5) 
86, 
(25.9) 
Vascular disorders       0 
 
4, 
(100) 
4, 
(1.2) 
TOTAL ADRs Reported 
(% of valid entries) 
(% of all entries) 
47, 
(33.1) 
(14.2) 
50, 
(35.2) 
(15.1) 
23, 
(16.2) 
(6.9) 
8, 
(5.6) 
(2.4) 
3, 
(2.1) 
(0.9) 
11, 
(7.7) 
(3.3) 
142, 
(100) 
(42.8) 
190, 
- 
(57.2) 
332, 
- 
(100) 
associated reactions and its onset and duration. Also included in some cases were further details
of the suspect drug, including the specific brand, the person who prescribed or recommended
it, its purpose of use, as well as any other co-administered agents. Finally, a few cases included
suggestions of possible causes of the reaction, such as an overdose, a drug interaction, etc.
3.3.6 Severity and outcome of paediatric ADRs
Table 3.18 outlines the severity and outcomes of the ADRs reported according to their respective
SOCs. While there was no report on the severity of about 92% of CAM-related ADRs reported
for paediatric subjects, about 6% of them (19, 5.7%) were described as severe. Among the nine
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Table 3.17: Duration of ADRs associated with various CAM product types
 
 
Table 3.17: Duration of ADRs associated with various CAM product types 
 
 
 
Figure 3.10: Richness of report narrative associated with paediatric case 
reports  
 
 
 
CAM product 
types  
(or specific 
modes of use) 
Reported period of ADR resolution Reports with 
valid ADR 
duration data 
 
n (%) 
Reports with 
missing or 
erroneous ADR 
duration data 
n (%) 
All ADRs 
reported 
 
n 
(%) 
Same 
day 
1-3 
days 
4-7 
days 
8-15 
days 
16-31 
days 
>31 
days 
Aromatherapy 
products 
10 
 
8 
 
2 
 
1 
 
1 
  
22, 
(15.5) 
20, 
(10.5) 
42, 
(12.7) 
Dietary 
supplements  
1 
  
3 
 
1 
  
5, 
(3.5) 
22, 
(11.6) 
27, 
(8.1) 
Herbal products 
 
1 
 
2 
    
3, 
(2.1) 
8, 
(4.2) 
11, 
(3.3) 
Herbal remedies 7 
 
19 
 
10 
  
1 
 
1 
 
38, 
(26.7) 
39, 
(20.5) 
77, 
(23.2) 
Herb-drug 
combinations 
23 
 
19 
 
8 
 
3 
  
6 
 
59, 
(41.5) 
56, 
(29.5) 
115, 
(34.6) 
Homeopathic 
remedies 
7 
 
2 
 
1 
 
1 
  
4 
 
15, 
(10.6) 
31, 
(16.3) 
46, 
(13.9) 
TCM/Poly-herbal 
formulations       
0, 
 
14, 
(7.4) 
14, 
(4.2) 
TOTAL ADRs 
reported 
47, 
 
50, 
 
23, 
 
8, 
 
3, 
 
11, 
 
142, 
 
190, 
 
332, 
 
(% of valid 
reports) 
(33.1) 
 
(35.2) 
 
(16.2) 
 
(5.6) 
 
(2.1) 
 
(7.7) 
 
(100) 
 
- 
 
- 
 
(% of all 
reports) (14.2) (15.1) (6.9) (2.4) (0.9) (3.3) (42.8) (57.2) (100) 
 
 
Table 3.17: Duration of ADRs associated with various CAM product types 
 
 
 
Figure 3.10: Richness of report narrative associated with paediatric case 
reports  
 
 
 
CAM product 
types  
(or specific 
modes of use) 
Reported period of ADR resolution Reports with 
l d ADR 
duration data 
 
n (%) 
Reports with 
missing or 
erroneous ADR 
duration data 
n (%) 
All ADRs 
reported 
 
n 
(%) 
Same 
day 
1-3 
days 
4-7 
days 
8-15 
days 
16-31 
days 
>31 
days 
Aromatherapy 
products 
10 
 
8 
 
2 
 
1 
 
1 
  
22, 
(15.5) 
20, 
(10.5) 
42, 
(12.7) 
Dietary 
supplements  
1 
  
3 
 
1 
  
5, 
(3.5) 
22, 
(11.6) 
27, 
(8.1) 
Herbal products 
 
1 
 
2 
   
3, 
2.1) 
8, 
(4.2) 
11, 
(3.3) 
He bal remedies 7 
 
19 
 
10 
  
1 
 
38, 
(26.7) 
39, 
(20.5) 
77, 
(23.2) 
Herb-drug 
combinations 
23 
 
19 
 
8 
 
3 
  
6 
 
59, 
(41.5) 
56, 
(29.5) 
115, 
(34.6) 
Homeopathic 
remedies 
7 
 
2 
 
1 
 
1 
  
4 
 
15, 
(10.6) 
31, 
(16.3) 
46, 
(13.9) 
TCM/Poly-herbal 
formulations       
0, 
 
14, 
(7.4) 
14, 
(4.2) 
TOTAL ADRs 
reported 
47, 
 
50, 
 
23, 
 
8, 
 
3, 
 
11, 
 
142, 
 
190, 
 
332, 
 
(% of valid 
reports) 
(33.1) 
 
(35.2) 
 
(16.2) 
 
(5.6) 
 
(2.1) 
 
(7.7) 
 
(100) 
 
- 
 
- 
 
(% of all 
reports) (14.2) (15.1) (6.9) (2.4) (0.9) (3.3) (42.8) (57.2) (100) 
Figure 3.10: Richness of report narrative associated with paediatric case reports
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SOCs which had at least 10 ADRs, the immune system disorders (ISD) class (2; 10.0%), GID
class (4; 9.5%) and PD class (1; 9.1%) had the greatest prevalence of severe ADRs, and were
followed distantly by other classes. The lowest incidences of severity were associated with the
two SOCs with the highest ADRs representation (SSD class - 5; 5.8% and NSD class -1; 2.1%).
Table 3.18: Distribution of paediatric adverse drug reactions by severity and outcome
 
 
Table 3.18: Distribution of paediatric adverse drug reactions by severity 
and outcome 
Adverse drug Reaction  
System-Organ Classes  
(ADR SOCs) 
SEVERITY Grand  
total 
n  
(100 %) 
OUTCOME 
Severe 
 
n (%) 
Not 
severe 
Not  
reported 
Fatal 
 
n (%) 
Not 
resolved 
n (%) 
Resolving/
resolved 
n (%) 
Not  
reported 
Blood & lymphatic system 
disorders 
1, 
(25.00)  
3 
 
4 
  
1, 
(25.00) 
2 
(50.00) 
1 
 
Cardiac disorders 
  
4 
 
4 
  
1, 
(25.00) 
3, 
(75.00)  
Ear & labyrinth disorders 
  
3 
 
3 
   
1, 
(33.33) 
2 
 
Eye disorders 1, 
(14,29)  
6 
 
7 
   
6, 
(85.71) 
1 
 
Gastrointestinal disorders 4, 
(9.52) 
2 
 
36 
 
42 
  
3, 
(7.14) 
35, 
(83.33) 
4 
 
General disorders & 
administration site injuries   
38 
 
38 
 
1, 
(2.63) 
6 
(15.79) 
25, 
(65.79) 
6 
 
Immune system disorders 2 
(10.00)  
18 
 
20 
   
17, 
(85.00) 
3 
 
Infections & infestations 
 
1 
 
4 
 
5 
 
1, 
(20.00)  
2, 
(40.00) 
2 
 
Injury, poisoning & procedural 
complications 
1, 
(6.67)  
14 
 
15 
 
4 
(26.67) 
2 
(13.33) 
9 
(60.00)  
Investigations 
  
4 
 
4 
   
3, 
(75.00) 
1 
 
Nutrition & metabolic 
disorders 
1, 
(50.0)  
1 
 
2 
    
2 
 
Musculoskeletal & connective 
tissue disorders   
13 
 
13 
  
1 
(7.69) 
10 
(76.92) 
2 
 
Neoplasms –benign, malignant 
or unspecified   
1 
 
1 
   
1, 
(100)  
Nervous system disorders 1 
(2.13) 
3 
 
43 
 
47 
 
1, 
(2.13) 
1 
(2.13) 
40, 
(85.11) 
5 
 
Psychiatric disorders 1 
(9.09)  
10 
 
11 
  
3, 
(27.27) 
8, 
(72.73)  
Renal & urinary disorders 
 
1 
 
4 
 
5 
   
5, 
(100)  
Reproductive system & Breast 
disorders 
1 
(20.00)  
4 
 
5 
  
1, 
(20.00) 
3, 
(60.00) 
1 
 
Respiratory, thoracic & 
mediastinal disorders 
1 
(6.25)  
15 
 
16 
   
14, 
(87.50) 
2 
 
Skin & subcutaneous disorders 5, 
(5.81) 
1 
 
80 
 
86 
  
6, 
(6.98) 
69 
(80.23) 
11 
 
Vascular disorders 
  
4 
 
4 
   
3, 
(75.00) 
1 
 
TOTAL ADRs Reported 
(% of grand total) 
19, 
(5.72) 
8, 
(2.41) 
305, 
(91.87) 
332, 
(100) 
7, 
(2.11) 
25, 
(7.54) 
256, 
(77.11) 
44, 
(13.25) 
In terms of the outcomes of the ADRs reported, over 75% of the ADRs reported (256; 77.5%) were
described as either resolving or fully resolved by the time of report, while only 2% of the ADRs
(7; 2.1%) were described as fatal. The highest incidence of fatality was seen in ADRs in the IPPC
class (4; 26.7%), while the lowest incidence was seen in ADRs in the NSD class (1; 2.1%). 25
ADRs (7.6%) were unresolved at the time of report; about half of which (12; 48.0%) were equally
contributed by the SSD and GDASI classes. Among SOCs with 10 or more ADRs, the prevalence
of non-resolved cases was highest for ADRs in the PD class (3; 27.3%); intermediate for those in
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the GDASI class (6; 15.8%) and IPPC class (2; 13.3%); and (like for severity status) lowest in
the NSD class (1; 2.1%). The degree of resolution of CAM-related ADRs seen was proportional
to the number of ADRs contributed by each SOC, with the four most highly represented SOCs
contributing about two thirds of resolved ADRs (169; 66.0%). At the individual SOC level,
however, and among classes with at least 10 ADRs, the highest prevalence of resolution was seen
with ADRs in the respiratory, thoracic & mediastinal disorders (RTMD) class (14; 87.5%). These
were closely followed by ADRs in the NSD class (40; 85.1%), the ISD class (17; 85.0%), the GID
class (35; 83.3%), and the SSD class (69; 80.2%); with the lowest prevalence being seen in the
IPPC class (9; 60.0%).
Tables 3.19 to 3.21 classify the fatal and unresolved ADRs reported based on subject age category
and sex, CAM product type, and specific CAM products, respectively. Table 3.19 shows that
most of the seven fatalities reported occurred in infants (6; 85.7%), without gender disparity.
Fat embolism was the most notable fatal ADR (4; 57.1%). Rash and device occlusion accounted
for over half of the 13 unresolved ADRs reported for female subjects (7; 53.9%); while abnormal
behaviour joined device occlusion in making up about 42% of male ADRs (5; 41.7%). Most of
the unresolved ADRs in male subjects were reported among preschool-age children (9; 75.0%);
while male infants were not at all associated with such ADRs. Although unresolved ADRs
were more widely distributed among female age categories, about half of them (6; 46.2%) were
reported for school-age children. Although there were no significant sex-related differences in the
proportion of unresolved ADRs reported in the two sexes (P(female)-P(male) Estimate =0.04; p
=0.777), unresolved ADRs were more frequently reported for female subjects (13; 52.0%), while
the converse held for fatal ADRs (3; 42.9%).
The classification of fatal and unresolved ADRs based on CAM product types in table 3.20 impli-
cates dietary supplements as the predominant culprits, accounting for (85.7%) of fatal ADRs and
32% of unresolved ADRs. Poly-herbal formulations and herbal products (i. e. products containing
herbs along with non-herbal substances other than conventional medicines) were not at all asso-
ciated with fatal and unresolved ADRs. Herbal remedies were most associated with unresolved
ADR%s (12; 48.0%), closely followed by dietary supplements (8; 32.0%). The overview of the
specific CAMs most associated with ADRs in table 3.21 indicates that while PRIPSEN R©, a herb-
drug combination of senna and piperazine, accounted for more than 25% of all ADRs reported,
the herbal remedy, senna, topped the CAM product list for unresolved ADRs, and the dietary
supplement, soybean oil, topped the list for CAMs associated with fatal outcomes. Although
PRIPSEN R© was highly associated with ADRs for every paediatric age category, KARVOL R©, an
aromatherapy product, was most associated with ADRs among infants by a wide margin. Sev-
eral products were associated with severity in the different age categories, without any particular
distinction.
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Table 3.19: Age and sex distribution of fatal and unresolved ADRs reported for paediatric subjects
 
 
 
 
Table 3.19: Age and sex distribution of fatal and unresolved ADRs reported for paediatric subjects 
Specific ADR 
Or 
ADR System-organ class (SOC) 
FEMALE SUBJECTS MALE SUBJECTS All 
Infants 
 
(<2 years) 
Preschool 
Children 
(2-5 years) 
School age 
Children 
(6-11 years) 
Younger 
Adolescents 
(12-17 years) 
All 
female 
subjects 
Infants 
 
(<2 years) 
Preschool 
Children 
(2-5 years) 
School age 
Children 
(6-11 years) 
Younger 
Adolescents 
(12-17 years) 
All 
male 
subjects 
paediatric 
subjects 
(<18 years) 
FATAL ADRs 
General disorders & administration 
site injuries 
        1 1 1, 
14.3 % 
Pneumonia 1 1   1 
Fat embolism 1 1 3 3 4, 
57.1 % 
Cerebral infarction 1 1   1 
Grand total (FATAL ADRs) 3, 
100 % 
3, 
100 % 
42.9 % 
3, 
75.0 % 
1, 
25 % 
4. 
100 % 
57.1 % 
7, 
 
100 % 
UNRESOLVED ADRs 
Aplastic anaemia    1 1, 
7.7 % 
     1, 
4.0 % 
Supraventricular tachycardia   1 1 1 
Anal injury 1 1   1 
Diarrhoea   1 1 1 
Mouth ulceration 1 1   1 
Application site reaction  1  1 1 
Device occlusion 1 1 1 3, 
23.1 % 
2 2 5, 
20.0 % 
Blister     1  1 1 
Chemical injury 1 1 1 
Arthropathy 1 1   1 
Attention-deficit hyperactivity   1 1 1 
Abnormal behaviour 3 3 3, 
12.0 % 
Perineal pain 1 1 1 
Erythema 1 1 1 
Rash  2 2 4, 
30.8 % 
  4, 
16.0 % 
Skin exfoliation 1 1 1 
Grand Total 3, 
23.1 % 
1, 
7.7 % 
6, 
46.2 % 
3, 
23.1 % 
13, 
100 % 
52.0 % 
0, 
0 % 
9, 
75.0 % 
2, 
16.7 % 
1, 
8.3 % 
12, 
100 % 
48.0 % 
25, 
100 % 
Binomial test of gender for unresolved ADRs, P(female)-P(male): Estimate=0.04; P value =0.777 
C
h
ap
te
r
3.
Y
el
lo
w
C
a
rd
S
ch
em
e
D
a
ta
A
n
a
ly
si
s
1
2
6
Table 3.20: Classification of fatal and unresolved ADRs reported based on the associated CAM product type
 
 
 
T a b l e  3 . 2 0 :  C l a s s i f i c a t i o n  o f  f a t a l  a n d  u n r e s o l v e d  A D R s  r e p o r t e d  b a s e d  o n  t h e  a s s o c i a t e d  C A M  p r o d u c t  t y p e
F a t a l  * *  a n d  5  m o s t  c o m m o n l y  r e p o r t e d  u n r e s o l v e d  s u s p e c t e d  A D R s  o r  S O C s  p e r  C A M  P r o d u c t  T y p e  [ n ,  ( % ) ]  
A r o m a t h e r a p y  
p r o d u c t s  
 
D i e t a r y  
s u p p l e m e n t s  
H e r b - d r u g  
c o m b i n a t i o n s  
H e r b a l  
p r o d u c t s  
H e r b a l  r e m e d i e s  T C M / P o l y - h e r b a l  
f o r m u l a t i o n s  
H o m e o p a t h i c  
r e m e d i e s  
T O T A L   
A  t o t a l  o f  7  F A T A L  A D R s  r e p o r t e d  ( 2 . 1  % )  
1  f a t a l  A D R s  
( 1 4 . 3  % )  
6  f a t a l  A D R s  
( 8 5 . 7  % )  
-  -  -  -  -  7  f a t a l  
A D R s  
( 1 0 0  % )  
P n e u m o n i a * * ,  
[ 1 ,  ( 1 0 0  % ) ]  
 
F a t  
e m b o l i s m * * ,  
[ 4 ,  ( 6 6 . 7  % ) ]  
      
G e n e r a l  
d i s o r d e r s * * ,  
[ 1 ,  ( 1 6 . 7  % ) ]  
C e r e b r a l  
i n f a r c t i o n * * ,  
[ 1 ,  ( 1 6 . 7  % ) ]  
A  t o t a l  o f  2 5  s u s p e c t e d  A D R s  r e p o r t e d  a s  U N R E S O L V E D  ( 7 . 5  % )  
W h e r e  > 5  u n r e s o l v e d  A D R  r e p o r t s  w e r e  r e c e i v e d  f o r  a n y  g i v e n  C A M  p r o d u c t  t y p e ,  t h e  5  m o s t  c o m m o n l y  r e p o r t e d  a r e  l i s t e d  
1  u n r e s o l v e d  
A D R s  
( 4 . 0  % )  
8  u n r e s o l v e d  
A D R s  
( 3 2 . 0  % )  
1  u n r e s o l v e d  
A D R  
( 4 . 0  % )  
-  1 2  u n r e s o l v e d  
A D R s  
( 4 8 . 0  % )  
-  3  u n r e s o l v e d  
A D R s  
( 1 2 . 0  % )  
2 5  A D R s  
 
( 1 0 0  % )  
R a s h ,  
[ 1 ,  ( 1 0 0  % ) ]  
 
D e v i c e  
o c c l u s i o n ,  
[ 5 ,  ( 6 2 . 5  % ) ]  
R a s h ,  
[ 1 ,  ( 1 0 0  % ) ]  
 G a s t r o i n t e s t i n a l  
d i s o r d e r s ,  
[ 3 ,  ( 2 5 . 0  % ) ]  
 A b n o r m a l  
b e h a v i o u r ,  
[ 2 ,  ( 6 6 . 7  % ) ]  
 
 A r t h r o p a t h y ,  
[ 1 ,  ( 1 2 . 5  % ) ]  
 S k i n  &   
s u b c u t a n e o u s   
d i s o r d e r s  
[ 2 ,  ( 1 6 . 7  % ) ]  
A t t e n t i o n - d e f i c i t  
/ H y p e r a c t i v i t y  
d i s o r d e r  
[ 1 ,  ( 3 3 . 3  % ) ]  
R a s h ,  
[ 1 ,  ( 1 2 . 5  % ) ]  
I n j u r y ,  p o i s o n i n g  
&   p r o c e d u r a l   
c o m p l i c a t i o n s ,  
[ 2 ,  ( 1 6 . 7  % ) ]  
 
S k i n  e x f o l i a t i o n  
[ 1 ,  ( 1 2 . 5  % ) ]  
B l o o d  &  l y m p h a t i c  
s y s t e m  d i s o r d e r s  
[ 1 ,  ( 8 . 3  % ) ]  
 A p p l i c a t i o n  s i t e  
r e a c t i o n  
[ 1 ,  ( 8 . 3  % ) ]  
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Table 3.21: Specific CAM products most commonly associated with severe, unresolved and
fatal ADRs among paediatric subjects
 
 
Table 3.21: Specific CAM products ost commonly associated with 
severe, unresolved and fatal ADRs among paediatric subjects 
 
Age 
categories 
Specific CAM products most associated with: 
All ADRs Unresolved ADRs Severe  ADRs Fatal ADRs 
Infants 
(<2 years) 
KARVOL 
[15, 21.4 %]; 
 
 
 
PRIPSEN  
[9, 12.9 %]; 
 
 
Soya bean oil 
[8, 11.4 %] 
  
(Total: 70 ADRs) 
ASHTON & PARSON'S 
TEETHING POWDER 
(Matricaria) 
[1, 33.3 %]; 
 
Eucalyptus, Menthol & 
Thymus combination 
[1, 33.3 %]; 
 
Soya bean oil  
[1, 33.3 %] 
 
(Total: 3 ADRs)  
KARVOL 
(1, 100 %] 
 
 
 
 
 
 
 
 
 
 
(Total: 1 ADR) 
Soya bean oil 
[5, 83.3 %]; 
 
 
 
KARVOL  
(1, 16.7 %) 
 
 
 
 
 
(Total: 6 ADRs) 
Preschool-
age 
children 
(2-5 years) 
PRIPSEN  
[30, 35.7 %]; 
 
Senna 
[15, 17.9 %]; 
 
Azadirachta, 
Lavandula 
angustifolia & 
Melaleuca 
combination 
[6, 7.1 %] 
 
 (Total: 84 ADRs) 
Senna 
[6, 60 %]; 
 
Hyoscyamus niger 
[3, 30 %]; 
 
Soya bean oil 
[1, 10 %] 
 
 
 
 
 
(Total: 10 ADRs) 
CERUMOL 
[1, 20 %]; 
 
Echinacea 
[1, 20 %];  
 
Hyoscyamus niger 
[1, 20 %]; 
 
 
 
 
 
(Total: 5 ADRs) 
None 
 
 
 
 
 
 
 
 
 
 
 
 
(Total: 0 ADR) 
School-age 
children 
(6-11 years) 
PRIPSEN 
[30, 35.7 %]; 
 
 
BALNEUM bath 
oil 
[9, 11.0 %]; 
 
EYE Q CHEWS 
[6, 7.3 %] 
 
(Total: 82 ADRs) 
EYE Q CHEWS 
[3, 37.5 %]; 
 
 
Soya bean oil 
[3, 37.5 %]; 
 
 
BALNEUM bath oil 
[1, 12.5 %]; 
 
 (Total: 8 ADRs) 
GOLDENSEAL 
COMPOUND 
[1, 50 %]; 
 
Podophyllum & 
Salicylic acid 
combination 
[1, 50 %] 
 
 
 
(Total: 2 ADRs) 
None 
 
 
 
 
 
 
 
 
 
 
(Total: 0 ADR) 
Younger 
adolescents 
(12-17 years) 
PRIPSEN 
[20, 20.8 %]; 
 
Phleum pratens 
[12, 12.5 %]; 
 
SWEAT SLEEPER 
 [11, 11.5 %] 
 
 
 
(Total: 96 ADRs) 
Echinacea 
[1, 25 %]; 
 
Senna  
[1, 25 %]; 
 
St. John’s Wort 
[1, 25 %]; 
 
 
 
(Total: 4 ADRs) 
SWEAT SLEEPER 
 [2, 33.3 %]; 
 
Dactylis glomerata 
allergy 
combination  
[1, 16.7 %]; 
 
Melaleuca 
[1, 16.7 %] 
 
(Total: 6 ADRs) 
1-Androstenediol,  
Ephedra, Ephedrine, 
Methyl-
testosterone,  
Naringin,  
Oxymetholone,  
Sida cordifolia,  
Testosterone 
combination 
[, 100 %] 
 
(Total: 1 ADR) 
All  
paediatric 
subjects 
(<18 years) 
PRIPSEN 
[89, 26.8 %]; 
 
Senna 
[22, 6.6 %]; 
 
KARVOL 
[21, 6.3 %] 
 
 
 
 
 
(Total: 332 ADRs) 
Senna  
[7, 28.0 %]; 
 
Soya bean oil 
[5, 20.0 %]; 
 
EYE Q CHEWS 
[3, 12.0 %] 
 
 
 
 
 
Total: 25 ADRs) 
Echinacea 
[2, 14.3 %]; 
 
KARVOL 
[2, 14.3 %]; 
 
SWEAT SLEEPER 
 [2, 14.3 %] 
 
 
 
 
 
(Total: 14 ADRs) 
Soya bean oil 
[5, 71.4 %]; 
 
KARVOL  
[1, 14.3 %];  
 
1-Androstenediol,  
Ephedra, Ephedrine, 
Methyl-
testosterone,  
etc combination 
[1, 14.3 %];  
 
(Total: 7 ADRs) 
Product proprietary (brand) names are CAPITALISED.
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3.3.7 Seriousness of paediatric ADRs
Table 3.22 classifies paediatric ADR reports based on the reporter’s perception of their seriousness.
Of the 332 ADRs reported for paediatric subjects, about a third (100; 30.1%) was deemed serious
by the reporter. An overview of the reporters involved outlined in figure 3.11 indicates that
almost 60% were doctors (58; 58.0%), and one fifth were pharmacists (20; 20.0%); while about
one tenth (9; 9.0%) of the serious ADRs were patient-reported. A classification of the serious
ADRs reported based on the Council for International Organizations of Medical Sciences (CIOMS)
ADR classification criteria is presented in figure 3.12. The findings show that, although only three
serious ADRs (3.0%) resulted in the death of the subject, 23% resulted in hospitalisation; 10%
was reported as life threatening; and 5% was considered disabling or incapacitating. However,
about six in ten of them (59; 59.0%) were considered medically significant for reasons other than
these. Understandably, the “congenital abnormalities” serious ADR marker was absent.
Table 3.22: Distribution of paediatric CAM-related adverse drug reactions based on reporter’s
opinion on their seriousness
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Adverse drug Reaction  
System-Organ Classes  
(ADR SOCs) 
Serious 
 
Not serious Not reported 
/Unknown 
Grand  
total 
Blood & lymphatic System disorders 1  3 4 
Cardiac disorders 3 1  4 
Ear & labyrinth disorders  1 2 3 
Eye disorders 3  4 7 
Gastrointestinal disorders 10 5 27 42 
General disorders & Administration site injuries 16 5 17 38 
Immune system disorders 8 1 11 20 
Infections & Infestations  2 3 5 
Injury, Poisoning & Procedural Complications 2 6 7 15 
Investigations 1  3 4 
Nutrition & Metabolic disorders 1 1  2 
Musculoskeletal & Connective tissue Disorders 3 3 7 13 
Neoplasms –benign, malignant or unspecified 1   1 
Nervous system disorders 13 6 28 47 
Psychiatric disorders 7 3 1 11 
Renal & Urinary disorders 1 2 2 5 
Reproductive system & Breast disorders 1 1 3 5 
Respiratory, Thoracic & Mediastinal disorders 9 2 5 16 
Skin & Subcutaneous disorders 19 15 52 86 
Vascular disorders 1  3 4 
TOTAL ADRs Reported 
(%) 
100, 
30.12 % 
54, 
16.27 % 
178,  
53.61 % 
332, 
100 % 
 
 
 
Figure 3.11: Reporter profile of serious ADRs 
 
 
 
 
 
The categorisation of the serious ADR report cases based on gender outlined in table 3.23
shows that, although much fewer serious ADRs were reported for female subjects than for males
(38.0% vs. 60.0%; p=0.001), the greater proportion of these were in the SSD class (14; 36.8%)
-predominantly rash (8; 57.1%); followed by ADRs in the GDASI class (7; 18.4%). The majority
of the serious ADRs reported for male subjects were, however, spread out among five SOCs –the
GDASI (9; 15.0%); GID (8; 13.3%); NSD (8; 13.3%); PD (7; 11.7%); and RTMD (7; 11.7%).
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Figure 3.12: Classification of serious ADRs according to the available† 
CIOMS markers of seriousness 
 
 
 
†The “congenital abnormalities” class of CIOMS serious ADRs was understandably not represented 
in the 100 ADRs considered serious by reporters
Figure 3.12: Classification of serious ADRs according to the available† CIOMS markers of
seriousness
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Table 3.23: Age group and sex distribution of serious adverse drug reactions
 
 
T a b l e  3 . 2 3 :  A g e  g r o u p  a n d  s e x  d i s t r i b u t i o n  o f  s e r i o u  a v e r s e  d r u g  r e a c t i o n s  
 
S e r i o u s  A d v e r s e  d r u g  R e a c t i o n s   
S y s t e m - O r g a n  C l a s s e s   
( A D R  S O C s )  
F E M A L E  S U B J E C T S  M A L E  S U B J E C T S  U N K N O W N  S E X  G r a n d  
t o t a l  
I n f a n t s  
 
 
( < 2  
y e a r s )  
P r e s c h o o l -
a g e  
c h i l d r e n  
( 2 - 5  y e a r s )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  
y e a r s )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  
y e a r s )  
A l l  
f e m a l e  
S u b j e c t s  
( 0 - 1 7  
y e a r s )  
I n f a n t s  
 
 
( < 2  
y e a r s )  
P r e s c h o o l
- a g e  
c h i l d r e n  
( 2 - 5  
y e a r s )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  
y e a r s )  
Y o u n g e r  
a d o l e s c e n t s  
 
( 1 2 - 1 7  
y e a r s )  
A l l  m a l e  
s u b j e c t s  
 
( 0 - 1 7  
y e a r s )  
P r e s c h o o l -
a g e  
c h i l d r e n  
( 2 - 5  
y e a r s )  
S c h o o l -
a g e  
c h i l d r e n  
( 6 - 1 1  
y e a r s )  
 
B l o o d  &  l y m p h a t i c  S y s t e m  d i s o r d e r s     1  1         1  
C a r d i a c  d i s o r d e r s    3  3  3  
E y e  d i s o r d e r s  1  1  1  1  2  3  
G a s t r o i n t e s t i n a l  d i s o r d e r s  1  1  2  3  5  8  1 0  
G e n e r a l  d i s o r d e r s  &  A d m i n i s t r a t i o n  
s i t e  i n j u r i e s  
1  3  2  1  7  2  3  4  9  1 6  
I m m u n e  s y s t e m  d i s o r d e r s     3  3   1   3  4  1  8  
I n j u r y ,  P o i s o n i n g  &  P r o c e d u r a l  
C o m p l i c a t i o n s  
1  1  1     1   2  
I n v e s t i g a t i o n s     1  1  1  
N u t r i t i o n  &  M e t a b o l i c  d i s o r d e r s  1  1    1  
M u s c u l o s k e l e t a l  &  C o n n e c t i v e  t i s s u e  
D i s o r d e r s  
 1  1  2  2  3  
N e o p l a s m s  – b e n i g n ,  m a l i g n a n t  o r  
u n s p e c i f i e d  
  1   1  1  
N e r v o u s  s y s t e m  d i s o r d e r s  2  2  4  2  2  4  8  1  1 3  
P s y c h i a t r i c  d i s o r d e r s     2  4  1  7   7  
R e n a l  &  U r i n a r y  d i s o r d e r s    1  1  1  
R e p r o d u c t i v e  s y s t e m  &  B r e a s t  
d i s o r d e r s  
1  1  2    1  
R e s p i r a t o r y ,  T h o r a c i c  &  M e d i a s t i n a l  
d i s o r d e r s  
2   2  2   1  2  7  9  
S k i n  &  S u b c u t a n e o u s  d i s o r d e r s  4  2  5  3  1 4  4    1  5  1 9  
 C y a n o s i s   1  1 1
 E c z e m a  1  1 1 2 1  1 2 4
 E r y t h e m a  1  1 2 1  1 3
 P u r p u r a    
2  
1  1
 R a s h  1 2 3 8 8
 T h e r m a l  b u r n    1 1 1  1 2
V a s c u l a r  d i s o r d e r s     1  1  1  
G R A N D  T O T A L  1 0  7  9  1 2  3 8 ,  
3 8 . 0  %  
1 3  7  1 1  2 9  6 0 ,  
6 0 . 0  %  
1  1  1 0 0 ,  
1 0 0  %  
Χ 2  t e s t  o f  i n d e p e n d e n c e  o f  s e r i o u s  
A D R s  o n  p a e d i a t r i c  a g e  c a t e g o r y  
P = 0 . 7 1 3   
 
 P = 0 . 0 0 0   
 
    
B i n o m i a l  t e s t  f o r  i n d e p e n d e n c e  o f   s e r i o u s  A D R s  o n  g e n d e r :  P  v a l u e  = 0 . 0 0 1  
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Among the paediatric age categories, the number of serious ADRs varied in both male and female
subjects according to the following pattern: younger adolescents > infants > school age children
> pre-school children. However, while serious ADRs among female subjects were uniformly
distributed across the various age categories (P=0.713), they were significantly associated with
adolescents aged 12-17 years (P=0.000) among male subjects.
Table 3.24 presents the categorisation of CAM product types according to their association with
serious ADRs. Serious ADRs were found to be dependent on CAM product type (p=0.03), with
herbal products accounting for only 4% of serious ADRs reported. Apart from aromatherapy
products, which were highly associated with hospitalisation (11; 73.3%) and accounted for almost
half of all hospitalised cases (47.8%), all other CAM product types were mainly associated with
ADRs besides the major CIOMS markers of ADR seriousness -death, hospitalisation, threat to
life, or disability/incapacity. Although dietary supplements were the product types associated
with fatalities (3%); herb-drug combinations (5%) and homeopathic remedies (5%) were the only
ones associated with life threatening serious ADRs. Herbal remedies, in addition to being the
product type most associated with serious ADRs (22%), also accounted for four fifths (4; 80%)
of the serious ADRs described as disabling or incapacitating by the reporter.
In terms of their potential for serious ADRs, while CAM products generally have less than 30%
potential of generating serious ADRs in paediatric subjects (52 of 186 ADRs reported; 28.0%),
the serious ADR potential was seen to be highest in dietary supplements (14 of 20 ADRs reported;
70.0%), and least in herb-drug combinations (8 of 59 ADRs reported; 13.6%). While the serious
ADR potentials of other CAM product types were roughly situated around that for all CAMs in
general, they ranged from as low as 23.9% for herbal remedies (11 of 46 episodes of use) to as
high as 34.8% for homeopathic remedies (8 of 23 episodes of use).
3.3.8 Comparison of CAM products based on their mode of use
The results of the comparison of ADR reports for CAM products based on their mode of use,
which was carried out in three phases, are illustrated in figures 3.13 to 3.15. In figure 3.13, the
outcomes of suspect products were compared according to whether they had been used alone (as
single products) or in combination (multiple products). In figure 3.14, the outcomes of specific
ADRs associated with various modes of use of herbal medicinal products were compared. Figure
3.15, however, presents a holistic ADR profile comparison at the specific product level for senna,
the CAM product with the highest number of reports in the database, based on the two most
commonly reported formulations with which it was associated: as the herb-drug combination
product, Pripsen R©, or as the single herbal medicine, senna.
Figure 3.13 illustrates that, although many more ADR reports were associated with combination
product use (115; 61.8%), in most of the cases, the ADRs reported were described as either
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Table 3.24: Classification of CAM product types with respect to their association with serious ADRs
 
 
T a b l e  3 . 2 4 :  C l a s s i f i c a t i o n  o f  C A M  p r o d u c t  t y p e s  w h  r e s p e c t  t o  t h e r  a s s o c a t i o n  w i t h  s e r i o u s  A D R s  
 
 
 
C A M  p r o d u c t  t y p e s  S e r i o u s  A D R s  
c a u s i n g  
h o s p i t a l i s a t i o n  
L i f e -  
t h r e a t e n i n g  
s e r i o u s  
A D R s   
D i s a b l i n g  o r  
i n c a p a c i t a t i n g  
s e r i o u s  A D R s   
F a t a l   
s e r i o u s  
A D R s  
O t h e r   
m e d i c a l l y  
s i g n i f i c a n t  
s e r i o u s  
A D R s  
A l l  
s e r i o u s  
A D R s  
A l l   
A D R  
r e p o r t s  
E p i s o d e s  o f  
u s e  
a s s o c i a t e d  
w i t h  s e r i o u s  
A D R s   
E p i s o d e s  
o f  u s e    
a s s o c i a t e d  
w i t h  a n y  
A D R s  
S e r i o u s  
A D R  
p o t e n t i a l  
( % )  
A r o m a t h e r a p y  
p r o d u c t s  
1 1 ,  
7 3 . 3 3  %  
4 7 . 8 3  %  
 
 
  4 ,  
2 6 . 6 7  %  
6 . 7 8  %  
1 5 ,  
1 0 0  %  
1 5 . 0 0  %  
4 2 ,  
-  
1 2 . 6 5  %  
8  2 7  2 9 . 6 3  %  
 
 
D i e t a r y  s u p p l e m e n t s  3 ,  
1 6 . 6 7  %  
1 3 . 0 4  %  
3 ,  
1 6 . 6 7  %  
1 0 0  %  
1 2 ,  
6 6 . 6 7  %  
2 0 . 3 4  %  
1 8 ,  
1 0 0  %  
1 8 . 0 0  %  
2 7 ,  
-  
8 . 1 3  %  
1 4  2 0  7 0 . 0 0  %  
 
 
H e r b a l  p r o d u c t s  2 ,  
5 0 . 0 0 %  
8 . 7 0  %  
 2 ,  
5 0 . 0 0  %  
3 . 3 9  %  
4 ,  
1 0 0  %  
4 . 0 0  %  
1 1 ,  
-  
3 . 3 1  %  
2  7  2 8 . 5 7  %  
 
 
H e r b a l  r e m e d i e s  5 ,  
2 2 . 7 3  %  
2 1 . 7 4  %  
4 ,  
1 8 . 1 8  %  
8 0 . 0 0  %  
1 3 ,  
5 9 . 0 9  %  
2 2 . 0 3  %  
2 2 ,  
1 0 0  %  
2 2 . 0 0  %  
7 7 ,  
-  
2 3 . 1 9  %  
1 1  4 6  2 3 . 9 1  %  
 
 
H e r b - d r u g   
c o m b i n a t i o n s  
 
5 ,  
3 9 . 4 6  %  
5 0 . 0 0  %  
1 ,  
7 . 6 9  %  
2 0 . 0 0  %  
7 ,  
5 3 . 8 5  %  
1 1 . 8 6  %  
1 3 ,  
1 0 0  %  
1 3 . 0 0  %  
1 1 5 ,  
-  
3 4 . 6 4  %  
8  5 9  1 3 . 5 6  %  
 
 
H o m e o p a t h i c   
r e m e d i e s  
2 ,  
1 1 . 7 6  %  
8 . 7 0  %  
5 ,  
2 9 . 4 1  %  
5 0 . 0 0  %  
 1 0 ,  
5 8 . 8 2  %  
1 6 . 9 4  %  
1 7 ,  
1 0 0  %  
1 7 . 0 0  %  
4 6 ,  
-  
1 3 . 9 6  %  
8  2 3  3 4 . 7 8  %  
 
 
T C M / P o l y - h e r b a l  
f o r m u l a t i o n s  
  
1 1 ,  
1 0 0  %  
1 8 . 6 4  %  
1 1 ,  
1 0 0  %  
1 1 . 0 0  %  
1 4 ,  
-  
4 . 2 2  %  
1  4  2 5 . 0 0  %  
 
 
G r a n d  t o t a l  
%  
2 3 ,  
1 0 0  %  
1 0 ,  
1 0 0  %  
5 ,  
1 0 0  %  
3 ,  
1 0 0  %  
5 9 ,  
1 0 0  %  
1 0 0 ,  
1 0 0  %  
3 3 2 ,  
1 0 0  %  
5 2  1 8 6  2 7 . 9 6  %  
 
Χ 2  t e s t  f o r  i n d e p e n d e n c e  o f  s e r i o u s  A D R s  o n  C A M  p r o d u c t  t y p e :  P  v a l u e  = 0 . 0 3  
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Figure 3.13: Comparison of outcomes associated with single and 
combination CAM product use 
 
 
 
 
 
Figure 3.14: Comparison of outcomes of adverse drug reactions 
associated various modes of use of herbal medicinal products  
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Figure 3.13: Comparison of outcomes associated with single and combination CAM product
use
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resolving or fully resolved than herbal remedies did, although the difference was 
not significant (92; 80.0 % vs. 55; 71.4%; p=0.178). Additionally, reports for 
herbal remedies were associated with a much higher proportion of unresolved 
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Figure 3.14: Comparison of outcomes of adverse drug reactions associated various modes of
us f herbal medicinal products
Chapter 3. Yellow Card Scheme Data Analysis 134
resolving or fully resolved (92; 80.0%). This was much higher than the proportion of resolving or
resolved ADRs associated with single CAM product use (45; 63.4%; P(Combination)-P(Single): p
=0.015). Combination product use was also associated with much fewer unresolved ADR reports
(3; 2.6% vs. 14; 31.1%; P(Combination)-P(Single): p < 0.001), and less fatality (2; 1.7% vs. 4;
5.6%; p =0.204).
This general pattern was also seen in figure 3.14 in which the outcomes of the specific ADRs
resulting from herbal medicinal product use alone or in combination with various types of prod-
ucts were compared. For this analysis, the herbal medicinal products suspected in the ADR
reports were compared in two ways: firstly, according to whether they were used as simple herbal
preparations containing 1-3 herbs alone (herbal remedies), or as combinations of herbs with con-
ventional drugs (herb-drug combinations); and secondly, according to whether they were used as
preparations combining more than 3 herbs without any chemicals or conventional drugs (poly-
herbal formulations) or as medicinal products combining herbs with chemical products besides
conventional drugs (herbal products). In the first case, although herb-drug combinations were
associated with significantly more ADRs than herbal remedies (34.6% vs. 23.2%; p=0.001), they
also had a higher proportion of ADRs that were either resolving or fully resolved than herbal
remedies did, although the difference was not significant (92; 80.0% vs. 55; 71.4%; p=0.178).
Additionally, reports for herbal remedies were associated with a much higher proportion of unre-
solved ADRs than those for herb-drug combinations (12; 15.6% vs. 1; 0.9%; p < 0.001). In the
second case, although poly-herbal preparations were associated with slightly more ADRs than
herbal products, they also had a slightly higher proportion of ADRs that were either resolving
or fully resolved (92.6% vs. 90.9%; p=0.860). However, none of the ADRs associated with either
of these was unresolved at the time of report. Notably, fatal outcomes were not associated with
any of the ADRs associated with herbal medicines irrespective of the mode of use.
In confirmation of the above pattern at the product level, figure 3.15 illustrates that, although
Pripsen R©, a combination product of senna and piperazine, was significantly associated with
more ADRs than the single herbal medicine, senna, (26.8% vs. 6.6%; p=0.001), it also had a
marginally higher proportion of ADRs that were either resolving or fully resolved at the time of
report (73; 82.0% vs. 15; 68.2%; p=0.197). Additionally, reports for senna were associated with
a much higher proportion of unresolved ADRs than those for Pripsen R© (7; 31.8% vs. 1; 1.1%;
p < 0.001). Finally, while there was no difference between the two products in terms of ADR
severity (0; 0% vs. 1; 1.1%; p=1.000), senna was associated with a much higher proportion of
serious ADRs when it was used alone (4; 18.2% vs. 0; 0%; p=0.001) than when it was used in
combination with piperazine.
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Figure 3.15: A holistic comparison of the ADR profiles of PRIPSEN® 
(Senna + Piperazine) and Senna herbal product 
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Figure 3.15: A holistic comparison of the ADR profiles of PRIPSEN R© (Senna + Piperazine)
and Senna herbal product
3.4 Discussion
3.4.1 Summary of findings
Generally, CAM products contributed a very insignificant proportion (< 1%) of ADR reports in
the YCS database within the (nearly) 50-year period studied, with an extremely low population-
based reporting ratio for the UK population relative to conventional medicines. This was in spite
of the various public health policy initiatives introduced within the period aimed at improving
ADR reporting. Most of the policies were specifically targeted at improving ADR report for
conventional medicines, and resulted in sustained increases in reports for conventional medicines
from the mid-1980s to the early 1990s, as well as following the year 2004. However, hardly any
of these policy changes yielded any sustained positive effect on the number of CAM-related YCS
reports received, including the three that were targeted at promoting ADR reports for CAMs.
As such, the sustained increases in YCS reports seen for conventional medicines could not be
replicated for CAMs, resulting in much lower CAM-related reports. This tendency towards non-
sustained increases in annual reports for CAMs was also found to be more greatly associated with
paediatric reports than with adult reports; with paediatric subjects contributing less than 10%
of the reports received. A major contributory factor is the high proportion (20.4%) of CAM-
related ADR reports for which no age-related information was provided; which would have most
likely included those for paediatric subjects. Also, at the reporter profile level, the much lower
paediatric ADR reports can be explained by the fact that, while the extension of ADR reporting
to community pharmacists in 1999 yielded the highest immediate improvement in CAM ADR
reports in general, pharmacist reporters accounted for much fewer reports (p=0.003) among
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paediatric subjects than they did among adults. This same argument can also be extended to
the introduction of self-reporting of ADRs by patients; which, while contributing significantly
to annual increases in CAM-related ADR reports generally, actually contributed much less (p <
0.001) to paediatric ADR reports.
On the whole, a combination of these factors resulted in paediatric subjects accounting for only
192 (8.6%) of the 2167 ADR reports received for CAM products in the period from the inception
of the YCS until July, 2012. Upon data filtering based on specified criteria, the 192 reports
yielded 186 valid paediatric ADR reports that profiled 332 specific paediatric ADRs, 30% of
which were described as serious by the reporter based on the CIOMS markers of seriousness.
Further analyses indicated rash and other skin and subcutaneous disorders as the most common
ADRs. Also, because over 75% of the ADRs reported were either resolving or fully resolved at the
time of report, and 6% were described as severe, about 70% of the reactions were brief, lasting 0-3
days, and 2% of them were fatal. Among the 100 serious ADRs, 23 resulted in hospitalisation, 10
were life-threatening, 5 were disabling or incapacitating, and 3 were fatal; while 59 were described
as serious for other medically significant reasons.
Age and sex were also found to play significant roles in the distribution of CAM-related ADR
reports. Although female subjects contributed a larger proportion of CAM-related ADR reports
than males in both adults and children, the difference was significant only for adult subjects
(P < 0.001). At the age group level, with the exception of the proportion of ADR reports for
the paediatric age group which was much lower than the proportional representation of that
demographic in the population (p=0.043), the proportions of ADR reports for the various age
groups generally aligned with the corresponding proportions of the respective sectors in the UK
population. However, while ADR reports were uniformly distributed among the four paediatric
age categories (p=0.122), they varied widely among the age groups for the adult population
(p < 0.001), with a significantly greater proportion of adult reports being received from middle-
aged adults. Despite the uniform distribution of ADR reports among paediatric age categories,
male subjects were found to have contributed a significantly higher proportion of ADR reports
received for subjects in the first year of life (p=0.007); while the converse was the case for
subjects aged 3 years (p=0.001). At the specific ADR level, female paediatric subjects contributed
marginally more ADRs than males (51.5%). This is related to the fact that, while ADRs belonging
to two of the four highly represented SOCs in the database, the SSD and GDASI classes, had
higher odds of being reported for female subjects, those for the other two highly represented
SOCs, the NSD and GID classes, had higher odds of report among male subjects. Also, among
the two most highly represented SOCs, the much higher female proportion of the SSD class
ADRs (p < 0.001) was almost totally offset by the much higher proportion of male NSD ADRs
(p=0.010). While rash was found to be the predominant ADR in the SSD class, as well as
across all SOCs represented, no specific ADR was seen to predominate among the ADRs in
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the NSD. However, ADRs associated with cognitive impairment, hyperkinesia and abnormal
sensation were found to be most reported. Although rash was reported in about two thirds of
female subjects and almost half the male subjects, it was only significantly associated with male
infants (p=0.018), However, while hyperkinesia-related ADRs, especially convulsions, were found
to be very high reported for male subjects (p=0.001), it was not associated with any specific
age category. While male subjects also accounted for a significantly greater proportion of serious
ADRs for paediatric subjects (p=0.001), these ADRs were particularly associated with younger
adolescents (P < 0.001).
Among the suspect CAM products reported in the database, products combining herbal medicines
with conventional medicines (herb-drug combinations) were found to generate the most ADRs.
Further analyses revealed these product types to be mainly associated with the alimentary sys-
tem & metabolism anatomical main group, with Pripsen R© being the product most frequently
associated with ADRs (89 ADRs). This proprietary combination product of senna and piper-
azine is applied in the treatment of enterobiasis, which indication was found to be predominant
among those reported for the CAM products in the database. Pripsen R© was distantly followed
by senna, a herbal laxative, (22 reports) and Karvol R©, an aromatherapy combination product (of
chlorbutol, levomenthol, pinus, terpineol and thymol) used for nasal decongestion (21 reports).
Although herb-drug combinations were associated with the highest number of ADRs, they were
least associated with serious ADRs. This was because most of the ADRs associated with them
were found to be resolving or fully resolved at the point of report, with no serious ADRs and
no fatalities. While no fatalities were also seen with all other modes of herbal medicinal product
use reported, these other product types were all associated with lower degrees of ADR resolution
and higher degrees of ADR non-resolution and seriousness. The same pattern was also seen with
serious ADRs associated with CAM product types generally, an analysis of which showed dietary
supplements and homeopathic remedies to have the highest serious ADR potentials, and herb-
drug combinations to have the least. These findings suggest that the nature of the CAM product
used is a far more critical factor with respect to its safety profile than its mode of use. The CAM
product most associated with fatalities was soyabean oil (71%), and predominantly in infants.
On the whole, CAM-related ADRs reported for paediatric subjects in the YCS were relatively few,
and of low severity (6%) and fatality (2%), with over 75% resolution rate, and mostly within the
first 3 days of the report (68%). These generally positive outcomes were, however, complicated by
their association with a high degree of incomplete or missing data. Although the case narratives
provided in the reports added extra information to the basic ADR report data in 61% of the
cases, there was still a high degree of non-report of key ADR criteria. For instance, there was
92% of missing data on ADR severity, about 60% of missing data on ADR duration, and 45% of
missing data on indications or purpose of use.
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3.4.2 Comparative analysis of results
This study found that less than 1% of all ADR reports in the YCS belonged to paediatric subjects
< 18 years. A recent similar study based on the Uppsala Monitoring Centre database over a
comparable period reported an incidence of 7.7% for children 0-17 years [589] for all medicines;
while a slightly older study reported 9.8% paediatric reports for Spain [598]. A UK study of
YCS reports from 2000 to 2009 reported 14.2% paediatric reports [590], about 70% of which was
vaccine-related. A more recent MHRA analysis of the trends in ADR reports from 2008-2012
shows that 11% of the reports for the period related to paediatric subjects [582]. The much lower
finding in the current study is attributable to the focus on CAMs. The low contribution of CAMs
to paediatric ADRs in pharmacovigilance databases has been well noted. Zuzak et al reported a
low frequency of 8.6% of toxic reactions for herbal and homeopathic remedies in a poison centre
database in Switzerland, a country for which they described the use of CAM as “rather high”
[369]. The much lower level found in the current study is attributable both to the country of
study as well as the type of database used (poison centre). CAM use in the UK has been found
to be generally low relative to other European countries [599]. A 17-year analysis of Yellow Card
reports made to the NIMH database found only 60 reports for herbal remedies [586]. The findings
also align with those of database studies in other parts of the world. An analysis of reports made
to the Singapore pharmacovigilance database in the period 1998-2012 [600] reported an incidence
of 3.8% for all CAM products, and 0.2% for CAMs among subjects aged 0-20 years. The very low
population-based reporting ratio (PBRR) of 1.193 reports per year per million UK inhabitants
(rym) found for all CAM-related ADRs in this study is supported by the finding of a high degree
of non-report of ADRs among British CAM users [559]. The non-sustained improvement in ADR
reports for CAM products noted in this analysis has also been reported for other PV efforts
for such products [601]; and emphasizes the need for active PV initiatives for these products
[602]. Recent SRs have highlighted the importance of using combined or multiple strategies to
achieve this end [603, 604]. As international long-term data and experience have shown PBRR
values greater than 300 rym to be reliable for signal detection [597], the much lower PBRR found
for CAMs in this study indicates the difficulty of relying on the YCS data for signal detection
for CAMs, as has been used in other national databases [605]. It has, however, been suggested
that the few number of CAM-related ADRs in the YCS could make it relatively easy to identify
adverse effects of concern by examining individual reports without waiting for statistical signal
detection [602].
ADR reports from female subjects and middle-aged adults were found to make up the largest
proportions of the CAM-related reports. This demographic pattern differs slightly from that
seen for conventional medicines. While a higher association of the female sex with ADRs has
been generally noted [584, 606, 607], a higher proportion of older adult-associated ADRs has
been seen for conventional medicines [582, 606]. The over-representation of CAM-related ADR
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reports for middle-aged adults and women found in the current study is, however, in line with
the demographic pattern reported for CAM use [608]. This suggests that the incidence of CAM-
related ADRs generally follows observed usage patterns for CAM. The over-representation of
infant males in the ADR reports aligns with most ADR report studies for that age group [609–
611]. Possible reasons for this finding could be related to those for the generally higher mortality
seen for male infants [612].
The finding of skin rash (and other SSD ADRs) as the most common ADRs found for paediatric
subjects, while already reported for CAMs [586, 613], is not in any way limited to them [403, 589,
614, 615]. This has been suggested to be due to higher skin sensitivity in children [589]. Nervous
system-related ADRs have also been reported as very common [610]. The proportion of serious
ADRs found in this study is similar to or less than the finding in many other paediatric studies
[610, 611, 616, 617].
Because a high safety profile is usually attributed to homeopathic products due to their long-
standing use and their use of ultra-dilutions of the “active” substances in the preparations [618–
620], the finding of a relatively high serious ADR potential for homeopathic medicinal products
in this study seems surprising. However, a recent SR of case reports and series has highlighted
the potential of these products for sometimes serious ADRs [621]. Also, suggestions have been
made as to the possible scientific bases for such untoward effects [622]. But objections have been
raised as to the true homeopathic nature of some of the products implicated in such reports
[623]. Also, some of the ADRs reported have been termed “homeopathic aggravations” that are
ultimately helpful to the patient, rather than adverse effects [624, 625]. From a patient safety
perspective, however, the findings of this study emphasize the need for more sensitive methods of
detecting harmful substances where they exist in such products [626, 627]. They also stress the
need for stricter regulation of the products, as well as more public education and reorientation as
to the safety concerns associated with them [628, 629]. These policies are particularly important
for Scotland in view of the high level of prescription of such products in Scottish GP practices,
particularly for children [630].
The high association of herb-drug combinations with ADRs seen in this study emphasizes the
importance of the contribution of herb-drug interactions to PV, as has been well noted in literature
[574, 631]. The value of including detailed case narratives in ADR reports in improving the
detection of such drug interactions has also been noted [632]. However, the finding in this study
of higher incidences of non-resolved and serious ADRs associated with single CAM products,
as well as herbal remedies, herbal products and poly-herbal formulations, suggests the greater
relevance of CAM product regulation with respect to enhancing CAM safety [15, 573, 633]. Apart
from ensuring proper and safe marketing strategies, consumer access and mode of use of these
products [634], such oversight would also ensure the use of proper methods of preparation for
specific product types, which has been recognised as another key safety concern [635].
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Soybean oil, which has been in medical use since 1962 as a source of omega-3 and -6 fatty acids
in parenteral nutrition [636], was the product most associated with fatal ADR reports in this
analysis. Despite its many nutritional benefits and medicinal uses, it has been implicated in
various adverse effects. While its topical use as an insect-repellent has been associated with aspi-
ration pneumonia [637], its parenteral use, either as a nutritional supplement or as a component
of the anaesthetic, propofol, has been associated with allergic reactions [638, 639], particularly
in young children [640]. Its allergenic potential has also been emphasized in a Spanish enquiry
into potential hypersensitivity due to food or food additive content of medicinal products [641].
Although the updated guidelines on reducing the risk of anaphylaxis during anesthesia published
by the European Network for Drug Allergy (ENDA) in 2011 does not preclude its use in food
allergy to egg or even soy products [642], there have been a number of reported cases of soybean
oil-associated hypersensitivity reactions in children [643–645].
3.4.3 Limitations of the study
The chief limitation of high degree of under-reporting that is associated with spontaneous report-
ing schemes also applies to this study. Moreover, as the problem of high non-report of ADRs has
been especially noted for CAMs [206, 559], it is likely that the ADR report pool used for this
analysis is not representative of CAM-related ADRs in the UK population. More importantly,
such under-reporting could have accounted for the relatively low proportion of ADR reports from
such practice-based CAM products as homeopathic remedies and the essential oils used in aro-
matherapy. This is particularly relevant for homeopathic remedies, as some of the associated
adverse outcomes might not have been reported due to their perception as “homeopathic aggra-
vations”. These points emphasize the need not only for active pharmacovigilance initiatives, but
also for proper public enlightenment as to the importance of reporting every adverse outcome ex-
perienced irrespective of how it may be perceived. Also, the high degree of missing data found in
the database, while not particularly specific for CAMs [589], none-the-less reduces the reliability
of the findings of this study. Finally, just as some of the natural health products included in this
analysis may not ultimately qualify to be classified as CAM, having now become fully integrated
into conventional medicine, so also the framework used in classifying products into respective
CAM types is far from fool-proof; as certain products may fall into more than one specific CAM
type depending on the formulation.
3.5 Conclusion
3.5 Conclusion There is a very low frequency of ADR reports in the YCS for CAM products
in general, and particularly in children aged < 18 years. This low frequency of reports is a
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huge challenge for effective database-oriented pharmacovigilance of complementary medicines
in the UK, particularly for paediatric subjects. It points to the need to apply more active
pharmacovigilance approaches for CAM products, thus justifying the inclusion of a primary study
of the outcomes of paediatric CAM use as the third aspect of this doctoral research, as will be
reported in the next chapter of the thesis. Because of the limitation of high degree of under-
reporting that is common with national PV databases, which was further complicated in the
current study by the high non-report of adverse outcomes associated with CAMs, the findings
of the next phase of the research are expected to help put into proper context the findings of
the exploratory analysis of YCS data reported in this chapter. Based on the present findings,
however, it can be surmised that CAM-related paediatric ADRs are few and short-lasting, and
of low severity and fatality. Although the combined used of herbs with conventional medicines
has been seen to be associated with high ADR reports, herbal remedies containing 1-3 herbs,
homeopathic remedies and dietary supplements have been found to be much more associated
with serious ADRs, with the dietary supplement, soybean oil, being most associated with fatal
outcomes. This suggests that the type of CAM product used should be a far more important
safety concern than the number or nature of the products used along with them. Thus, while
the need to minimise herb-drug and herb-herb interactions cannot be ruled out, these findings
emphasize the greater relevance of the proper regulation of CAM products, and justifies the
stricter guidelines for CAM product registration introduced by the European Medicines Agency.

Chapter 4
The Use of Complementary &
Alternative Medicine Among
Children in Aberdeen -A
Cross-Sectional Survey
4.1 Introduction
4.1.1 Background to the study
The findings of the systematic review reported in Chapter 2 highlight the paucity of paediatric
CAM use research in the UK, and particularly in Scotland. This is probably related to the
relatively lower prevalence of CAM use in the country relative to other economically advanced
countries in Europe and North America [555]. Global prevalence has been reported to be about
20-40% among healthy children seen in outpatient paediatric clinics, and over 50% in children
with chronic, recurrent and incurable conditions [482]. However, a recent SR of surveys (published
between 2000 and September 2011) that estimated the prevalence of CAM use among UK paedi-
atric patients reported an average one-year prevalence of 34% and an average lifetime prevalence
of 42% [395]. These low prevalence values contrast markedly with data reported for other Eu-
ropean countries (Germany, Switzerland, Denmark and Ireland) in another recent SR of studies
published from 1945 to July, 2013 [646]. Strikingly, however, these UK data were drawn largely
[395] or wholly [646] from England, with Scotland contributing only two studies in all, published
in 2007 [351] and 2008 [352], respectively. Although another Scottish paediatric CAM use study
was published recently that reported the use of CAM among cancer patients in Edinburgh [647],
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the need for more paediatric CAM use studies in Scotland, especially in the general population,
is clear. The importance of filling this gap is thus the main inspiration for the work reported in
this chapter. However, as in previous chapters, the main objective of this facet of the research
transcends merely obtaining an estimate of the prevalence of paediatric CAM use in Scotland.
It extends to ascertaining the outcomes associated with such paediatric CAM use in terms of
user-perceived effectiveness and safety; as well as investigating the attitudinal inclinations of the
Scottish population towards such therapies and research on them.
As another finding of the SR reported in chapter 2 is the observed tendency for non-rigorous
research, resulting in low methodological quality, this chapter will describe the special efforts
taken in the design of this aspect of the research to overcome this limitation. While, due to
the preliminary nature of paediatric CAM research in Scotland, and in view of the limitations
of doctoral research, a cross-sectional design was chosen for the research, care was taken to
ensure that it was analytical, and not merely descriptive. In addition to ensuring greater external
validity and generalisability by employing multi-centre participant recruitment, the data collection
instrument was validated (face and content validity) by pre-testing and cognitive interviewing
of purposive samples of the target population in order to ensure the validity of the resulting
findings. Also, inferential statistical analyses were conducted on the findings, including not only
point and interval estimates for the population, but also bivariate logistic regression to identify
potential predictors of CAM use and associated outcomes. Finally, effort was made to emphasize
certain aspects of paediatric CAM use and its research that were considered particularly relevant
to the main objectives of the current research, but had been overlooked or de-emphasized in
previous studies. Chief among these aspects is the prevalence and nature of reported adverse
effects associated with paediatric CAM use, which had been found (in the SR in chapter 2)
to have been over-looked by more than 60% of included studies. The exploratory analysis of
the MHRA YCS database presented in chapter 3 also pointed to a very low frequency of ADR
reports for natural health products in general, and particularly in children aged < 18 years,
suggesting that CAM-associated paediatric ADRs are few, and of low severity and fatality. The
findings of these secondary studies emphasize the need for their verification in a suitable primary
study, making this matter an important objective of the research reported in this chapter. Also,
the SR in chapter 2 highlighted a tendency towards confirmation bias due to a low incidence
(46%) of valid conclusions congruent with the outcomes reported by study participants, and its
ethical implications, particularly in the current patient-centred healthcare dispensation. Effort
was therefore made in the study herein reported to accord the opinions of the participants their
due consideration so as to ensure a valid summary of the findings that would lead to equally valid
conclusions and POEM-based recommendations. Another source of weakness observed among
included studies in the SR is the high use of proxy report of outcomes. While, as a result
of ethical factors, it was not possible to avoid this source of weakness by surveying paediatric
subjects directly, the participants were encouraged to complete the relevant sections of the survey
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in consultation with the children affected. Although it was hoped to result in a joint report of
the outcomes of the CAM modalities used, it is not clear if this was actually achieved in all cases.
In all, this chapter reports the detailed procedures, findings, discussion and conclusions of a
novel and up-to-date analytical cross-sectional survey of paediatric CAM use in the Aberdeen
metropolitan area of North-east Scotland.
4.1.2 Survey setting
The survey was carried out within Aberdeen metropolitan area. This refers to Aberdeen city
and the surrounding suburbs within its commuter belt to which it is related socio-economically.
Although no clear-cut boundaries were set for the locus of the study, as Aberdeen is the main
urban centre for NE Scotland geo-political region, the study participants were broadly drawn
from across this region in the degree to which they relate with Aberdeen city. Geographically,
the NE Scotland region ranges from Aberdeenshire East and Banffshire & Buchan coast on the
north through Aberdeen metropolis and West Aberdeenshire to Angus and Dundee city on the
south. The region accounts for 32 postcodes in the Scottish postcode division. Understandably,
as the study was not intended as a survey of the entire North-east Scotland region, a greater part
of participant recruitment was conducted within Aberdeen metropolis.
4.1.3 Specific aims and objectives
As detailed in chapter 1, the specific aims of this aspect of this research are summarised in the
following research questions:
1. What is the nature and demography of the use and user-reported outcomes of paediatric
CAM products and practices in the Aberdeen area with respect to user-perceived effective-
ness and safety?
2. What implications do the findings have for research and/or health policy and planning in
Scotland?
In order to properly answer these questions, the following specific objectives were identified:
1. to develop a suitable and validated user-reported outcomes measures instrument for the
study;
2. to carry out a survey on paediatric CAM use in Aberdeen metropolitan area using the
pre-tested instruments;
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3. to carry out descriptive and inferential statistical, as well as regression, analyses of the data
obtained in order to:
(a.) determine the extent and nature of paediatric CAM use/non-use in the Aberdeen
metropolitan area;
(b.) determine the dependent and independent factors associated with paediatric CAM
use/non-use in the target population;
(c.) determine user-perceived effectiveness and safety outcomes of paediatric CAM use in
the target groups, and their associated dependent and independent factors;
(d.) identify the attitudes of the parents within the target area towards paediatric CAM
use, and future research on it;
(e.) generate data on paediatric CAM use in the target area that can be compared with
that reported for similar population groups in other aspects of this research;
4. to draw out conclusions and recommendations from the findings of the study.
4.2 Methods
4.2.1 Research governance
To ensure that the study would be carried out to the highest ethical standards and in conformity
with Robert Gordon University’s research ethics committee, approval for the study was sought
from the Robert Gordon University School of Pharmacy & Life Sciences Ethics committee. As the
study was to be conducted in the general population, and would not involve any NHS patients,
it was not considered necessary to seek approval from the North of Scotland Research Ethics
Committee. As public schools/cre`ches and other establishments were to be used for participant
recruitment, permission was also sought from the relevant officers in the Aberdeen City Council
Education Board, as well as from the chief administrators of all establishments used for (partic-
ipant recruitment for) the survey. Additionally, various specific measures were instituted in the
course of questionnaire design and administration, as well as data entry and analysis, to respect
the freewill and social desirability of the participants, and to protect, safeguard and preserve their
respective identities.
4.2.2 Development and validation of survey instrument
From an overview of some of the paediatric CAM use studies identified in the course of the SR,
a list of items was gathered to develop a questionnaire for the study. Additional items were
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also included to the pool of items based on the peculiarities of the study setting, and the list
was re-organised into a 10 paged, 46-item draft questionnaire divided into 3 sections (Appendix
4.1). Following internal review by members of the research team, the draft questionnaire was
revised to yield an 8 paged, 32-item version. This was then used to develop a user-adaptive
online questionnaire using the SNAP R© survey software (Version 10). In order to make it user-
adaptive, in addition to a survey feedback section, a number of mandatory routing questions were
incorporated into the original list of questions, resulting in a total of 61 questions in all. The
developed questionnaire was thereafter uploaded to the RGU web server, and a unique clickable
link (http://www2.rgu.ac.uk/Pharmacy/survey/cam/pilot) was generated for it to facilitate
online access by participants. The first version comprised five sections organised as follows:
(i) A cover page introducing the study to the potential participant, and defining CAM, with
clickable links to lists of common CAM products and practices as a memory aid; and finally
requesting the potential participant to opt (via their response to a screening question)
whether or not to participate in the study (1 question);
(ii) Section 1 requesting information about the participant (9-11 demographic questions, de-
pending on adaptation);
(iii) Section 2 requesting information on CAM use in own children, with clickable links to lists
of common CAM products and practices as a memory aid (4-20 questions, depending on
adaptation);
(iv) Section 3 requesting information on the participant’s own use of CAM, and his/her general
views on CAM use and research (9-13 questions depending on adaptation); and
(v) A Survey Feedback Questionnaire requesting specific feedback on the questionnaire as a
whole, as well as the preferred mode of access to it (i. e. online vs. paper), and suggestions
on specific sections of the questionnaire (8-16 questions depending on adaptation).
The uploaded questionnaire was thereafter validated by two sequential phases of focus group
pre-tests, which were held in May and October 2013. After each phase, the questionnaire was
revised in line with the feedback received, so as to improve the eventual outcome of the survey.
The focus groups involved purposive samples of parents drawn from two separate settings within
Aberdeen city centre; and were aimed at verifying the comprehensibility and acceptability of the
questionnaire in a bid to ascertain its face and content validity. As explained in chapter 1, because
the objective of the study was not to measure specific health status in patients with particular
health conditions, detailed psychometric analysis was not required.
Although both focus groups sought to verify the quality of the questionnaire in the two aspects
described above, the first was more elaborate, and focused much more on the comprehensibility
Chapter 4. Cross-Sectional Survey 148
of the survey, while the second laid greater emphasis on its general acceptability by participants.
Each focus group was preceded by online completion of the questionnaire by participants, after
receiving the link to the survey from the student in an invitation mail. In the first case, although
ten parents were mailed the online link to the survey and invited to take part in the focus
group after completing the survey, two opted out of the survey through the screening question
on the cover page. While the remaining eight went on to complete the survey, two of them
finally opted out of participating in the focus group for reasons of convenience, leaving only
six parents –two fathers and four mothers- to participate in the session. The questions asked
during the focus group discussion sought to determine the initial impressions and opinions of the
participants on each section of the questionnaire, as well as how each participant understood and
then responded to the questions. In this sense, the focus group discussion was akin to a group
cognitive interview aimed at identifying possible socio-cultural, linguistic or other related barriers
to proper comprehension and completion of the survey by parents. Then suggestions were sought
on how such could be overcome. The hour-long, audio-recorded session was facilitated by the
student using a topic guide he developed specifically for the study (see Appendix viii). A member
of the supervisory team was also in attendance, and acted as time keeper/recorder. Afterwards
all factors highlighted were summarised by the student for discussion by the research team. The
survey feedback questionnaire data generated by the eight pre-test survey participants were also
summarised for consideration by the team. After due consideration, the points on which there
was significant agreement were taken on board in the revision of the questionnaire ahead of the
next phases of the research. The revised version was eleven questions shorter than the previous
one. While it had a much briefer cover page that still contained the links to the list of examples
of CAM types as well as the preliminary screening question giving participants an option on
taking the survey, it had no survey feedback questionnaire at the end. Also while the previous
questionnaire focused on school-aged children schooling solely within Aberdeen city, the revised
version contained additional questions that would be relevant to parents with children of all age
groups in Aberdeen and Aberdeenshire.
4.2.3 Pilot and secondary validation of survey instrument
A pilot study of the revised survey instrument was conducted in two schools (one primary and
one secondary) located in one of the Aberdeen Northern suburbs between the months of June
and September, 2013. Firstly, early in the month of June, a brief mail to parents containing
the unique link to the revised survey (http://www2.rgu.ac.uk/Pharmacy/survey/cam/pilot2/
index.htm) was sent to each school administrator for circulation to parents. Each was requested
to inform the parents of the coming survey before circulation so as to avoid a perception of
cold-calling; and also to utilise the very same mediums of communication they normally used.
A reminder mail was also sent to each administrator for circulation a fortnight later. Following
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a zero response from the parents in the schools by the end of the school session in the first
week of July, further interactions were made with the school administrations with a view to
understanding the possible causes. Although the feedback received indicated that a technical
failure had complicated survey administration in one of the schools, the general suggestion was
that the nonresponse was not unrelated to the general apathy to school-related activities among
schoolchildren and their parents towards the end of a school year and the approaching summer
vacation. The administrators, therefore, suggested that the pilot be repeated in August 2013,
early in the coming school year.
The pilot survey was re-launched in the schools on August 22 (primary school) and 27 (secondary
school) for a 4-week period, with reminder mails recirculated at fortnightly intervals. In the
first case, the school administrator had the student’s invitation mail containing the survey link
posted on their school blog, preceded by a brief introduction from him. In the second case, the
survey invitation mail was circulated to all parents through the contact e-mail addresses they
provided the school. At the end of the survey period, only seven responses had been received
–solely from the first school, and all within the first two days of the blog being initially uploaded.
After a consideration of the very poor response by the research team, it was considered necessary
to convene another focus group of parents of schoolchildren to re-evaluate the instrument with
the specific objective of determining whether the presence or absence of any particular features
in the instrument could have contributed to the poor showing observed. This led to the second
validation phase of the instrument in October, 2013.
All the seven parents/guardians invited to participate in this second pre-test and focus group fully
participated. Unlike the first focus group session, this session focused much more on validating
the general acceptability and user-friendliness of the survey, especially in terms of identifying
possible barriers to participant engagement. Moreover, since, unlike in the first session, all but
one of the participants had used CAM for their children, the session was further used to explore
whether any key issues generally considered important by CAM users had been overlooked in the
instrument. Also revisited was the question of whether the online method of parental access to
the survey was considered sufficient to achieve a sufficient reach of participants within the target
area. Suggestions were also received on possible ways of improving the appeal of the questionnaire
to participants as well as its reach. As in the first case, the focus group discussion was facilitated
by the student using a topic guide also developed specifically for the study (Appendix ix); a
member of the supervisory team was also in attendance. The session lasted 30 minutes.
Based on the inputs received, additional revisions were made to the questionnaire, and final
preparations were made for launching the main survey. The major revisions effected on the
previous version were the removal of the screening question at the bottom of the cover page, the
inclusion of colourful pictures of people using various CAM products and practices at strategic
parts of the survey, and ten additional questions. The new questions aimed to gather information
Chapter 4. Cross-Sectional Survey 150
on the specific medium of online access to the survey and also relevant details of previous CAM use
by parents of adult children. However, to cover all the possible hindrances to survey engagement,
it was also agreed that a paper version of the questionnaire should be developed as an alternative
access mode. While the two versions were essentially similar in content and general outlook, the
paper version was significantly shorter than the online one (39 questions instead of 60 questions).
However, this was mainly due to the absence of the mandatory routing or linked questions that
were necessary in the online survey to make it user-adaptable to a more diverse parent group.
Also, while both versions contained similar free-text tabular sections for entry of the specific
CAM types used, the paper version also contained a much less detailed list of CAM types in a
tick box format, rather than the links to the detailed list of common CAM types included in
the online version. In addition, the paper version also contained a question aimed at finding out
participant preference on mode of survey access (online vs. paper). A copy of the paper-based
version is provided in Appendix x.
4.2.4 Main Survey
The main survey was conducted in two sequential phases over five months, between November
2013 and March 2014. A number of points were taken into consideration to determine the mini-
mum sample size required for the study to be statistically representative of the child population in
Aberdeen. According to the 2011 population census, the number of primary and secondary school
children in Aberdeen City was 21, 204 (11, 955 primary and 9, 249 secondary). Also, according
to the Infact R© database of the Scottish Funding Council and the Higher Education Statistics
Agency, the numbers of undergraduate students aged up to 18 years enrolled in the 2009/10 ses-
sion in the three HEIs in Aberdeen were 11,420 (7,690 for Aberdeen College, 2,185 for Aberdeen
University, and 1,545 for Robert Gordon University). These data were used to determine the
minimum sample size required using the formula: n= [Z2 ∗ P (1 − P )]/D2 (21). For this study,
the z statistic of the 95% confidence level chosen was 1.96; the prevalence level of CAM use, P,
(or response distribution between paediatric CAM users and non-users) was assumed as 50% (or
0.5); and a ±5% (or 0.05) degree of precision (or margin of error), D, was allowed. Based on these
assumptions, the minimum sample of children required for a statistically representative study of
the Aberdeen area was calculated to be 378. Assuming one child per parent and a 30% response
rate for the study, it was determined that at least 1,260 parents would need to be surveyed in
order to be certain of recruiting the required minimum sample. As a dual approach was used
for recruitment, this figure was shared equally between the two survey modes; leading to 600
copies of the paper-based questionnaire being produced for distribution. However, considering
the low response rates often associated with web surveys (22-24), no restriction in the number of
potential participants approached was set for the online survey.
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The online survey was launched on November 1, 2013 and was live for the next two months. It
was hosted on the RGU web server; and, in view of the poor response experienced following a
localised distribution during the pilot phase, the web link generated for it (http://www.rgu.
ac.uk/cam/parent) was distributed to the public through a variety of media outlets. These in-
cluded: the RGU home page; mails to institutional e-mails of staff in Aberdeen College, Aberdeen
University and RGU; a radio interview of the student about the study on the Aberdeen Radio
Station Original 106 on November 12, 2013; NetMums NE Scotland (http://www.netmums.com/
ne-scotland); its own Facebook page (https://www.facebook.com/groups/CAM.RGU/?fref=
ts); twitter messages; the Aberdeen Facebook page with 21, 830 members as at November 13,
2013 (https://www.facebook.com/pages/Aberdeen/47236254126); a press release by the RGU
Communications Unit resulting in news articles on local dailies across NE Scotland (the Ab-
erdeen Evening Express of November 14, 2013; the Fraserburgh Herald and Inverurie Herald of
November 16, 2013; and the Peterhead Buchan Observer of November 20, 2013); and finally a
friends-of-friends mail approach through a network of friends of the student and members of the
research team residing in different parts of Aberdeen. In each case, periodic reminders were pro-
vided where appropriate up until the end of December, 2013. All completed online surveys were
transmitted via the internet to the student’s e-mail box upon submission, enabling the tracking
of submissions received over the survey period.
The paper-based survey was conducted between January 20, 2014 and March 28, 2014. A variety
of locations within Aberdeen were used for recruitment. However, although participant recruit-
ment was largely based in Aberdeen city, because participants were recruited from their places of
work without prejudice to their area of residence, in addition to their children’s schools/cre`ches,
it was possible to reach a wider population residing beyond the city. For participant recruitment
at work places, the student obtained permission to stand at specific locations within the premises,
especially close to the entrances, and handed out questionnaires to consenting parents as they
passed by. Participants had the option of completing and returning the questionnaire immedi-
ately on the spot, or doing so privately and returning it later completion via collection boxes left
at designated points for that purpose. For participant recruitment through schools, the student
provided the school administrators with as many copies of the questionnaire as they requested
for, which they then handed out to their wards or their parents; and also collected them back
after completion. In all eight different centres -three schools, three work places and two social
centres- located in different parts of Aberdeen metropolis were surveyed.
4.2.5 Data entry, validation and analysis
At the end of the survey, data resulting from responses to the online survey were automatically im-
ported via SNAP R© into SPSS worksheets. After formatting the database to ensure compatibility
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with the paper version, the student manually entered the responses from the paper-based survey
in line with the pattern pre-set by SNAP R©, resulting in a comprehensive database for the study.
After data cleaning, the quality of data entry was validated by one of the supervisors through
a quality control check on a sample of manually entered paper-based surveys. Afterwards, addi-
tional columns were inserted into the database to generate derived data from the dataset. These
resulted in the generation of additional data such as geographical area, urban-rural classification,
parental CAM use profile, parent-child CAM use similarity, and survey completion status among
others. CAM use in children was measured in terms of lifetime (or ever) use and chronological
use (Always/Current/Previous/Never); while personal CAM use by parents was measured solely
as lifetime CAM use. Based on the outputs of frequency analyses and other descriptive statistical
analyses of key variables in the data, further columns were inserted to further group key vari-
ables into dichotomous categories so as to enable bivariate correlation as well as binary logistic
regression as appropriate. Although children of all ages were included in the study, the bulk of
statistical analysis was focused on paediatric subjects. All analyses were carried out in IBM R©
SPSS Statistical package Version 21 or Minitab R© 16, as appropriate. Inference was made at 95%
confidence intervals, with significance level of P ≤ 0.05.
4.3 Results
The results of the various steps taken in the instrument development and validation, main survey
and survey data entry and analyses are presented in figures 4.1 to 4.13 and tables 4.1 to 4.19.
While a general summary of the findings will be presented in section 4 as part of the discussion
of results, a brief running textual summary of the data presented in each table or figure will be
provided along with their respective tables or figures all through the results section.
4.3.1 Ethical Requirements
Approval for the study was obtained from the Robert Gordon University School of Pharmacy
& Life Sciences Ethics committee (Appendix xi). Permission for the study was also obtained
from the Head of Schools and Education Establishments at Aberdeen City Council, as well as
from the chief administrator of each of the establishments in which (participant recruitment
for) the survey was conducted. These included the administrative heads of Treehouse early
care centre; Rocking horse nursery; the Public Relations, IT, and Communications departments
for RGU, University of Aberdeen and North East Scotland College; Forehill school; Oldmachar
Academy; the Junction church; and NetMums NE Scotland. In order to preserve and protect
freewill in line with ethical requirements, each participant was provided with detailed information
about the study before being invited to take part, such that participation implied informed
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consent. Out of respect for the privacy of participants, not only was the survey administered
anonymously, but also questions targeting specific personal information relating to social lifestyle
and health condition were avoided. The standard operating procedures of the School of Pharmacy
& Life Sciences for data collection were followed. Completed questionnaires were stored in locked
cabinets upon return. The responses obtained were stored in SPSS file format in the student’s
password-protected university computer; and were processed and used only for the purposes of
the study.
4.3.2 Development and validation of survey instrument
An overview of the outcomes of the questionnaire development and validation process is outlined
in figure 4.1. The main areas of feedback received and taken on after the first and second
pre-test focus group discussions are outlined in tables 4.1, 4.2 and 4.3, respectively; while a
comparative summary of the online and paper versions of the questionnaire used for the main
survey is presented in table 4.4.
Of the 23 comments/observations made during the first pre-test focus group discussion, only 5
(21.7%) were outrightly rejected, while the rest were accepted wholly or in part. The partici-
pants had the most agreement on the facts that the survey took an acceptable time to complete
(100%); as well as in their preference for online mode (87.5%; 100%). While various aspects of
the questionnaire had to be revised based on inputs from participants, the questions that gener-
ated the most comments, and thus required the most revision, were the compound grid format
questions on specific CAM use and its associated outcomes. While the compound grid format was
retained, both the introductory instructions and the layout were significantly reviewed resulting
in no further complaints on it in the second focus group discussion. While the second focus group
discussion re-emphasized the high acceptability of the online mode, it also highlighted the poten-
tial advantages of the traditional paper-based approach in certain settings, as well as the value
of a multi-pronged, “all of the above” approach to participant recruitment in the online mode,
with a view to including as many parents as possible who eventually came across it. Although
the resulting paper version of the survey was considerably shorter than the online version, it
covered an essentially similar ambit as its parent version. The sole differences between the two
final versions used in the main survey were the absence in the paper version of the question on
willingness of CAM users to participate in further CAM research, and the absence in the online
version of the question on survey mode preference among participants in general.
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Figure 4.1: Survey development & validation process 
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Table 4.1: Summary of comments, proposals and decisions from first pre-test survey focus group discussion
 
 
Table 4.1: Summary of comments, proposals and decisions from first pre-test survey focus group discussion 
 Comment/Observation (Number of commentators; n/6) Proposed solution Decision taken 
A. General impressions/Introductory (cover) letter 
1. A number of strange and difficult to pronounce terms –like “Anthroposorphic”, “user-driven”, 
“homeopathic medicines” (3/6) 
Use words generally easy to understand; avoid jargon 
on cover page 
Accepted 
2. Pictures on the cover page –attractive (4/6) Should be retained Accepted 
3.  Too much text included; “too wordy” (3/6) Reduce text; avoid using bold characters Accepted: revised from a 356-
word letter format to a 156-
word free format 
4. Links to the list of common CAM products and practices –helpful and informative (3/6) Retain; but make headings more colourful Accepted 
5. 2 separate links to the lists for CAM types; also list for CAM products more detailed than that for 
CAM practices –a bit confusing (1/6) 
Harmonize and merge into a single list Rejected: list would be too 
long 
6. Not be keen on completing it if seen for the first time among mails from child’s school (2/6) Avoid “cold-calling”: send an introductory mail first Accepted 
7. Not be inclined to complete it if paper-based; prefer mail survey if introductory mail is short (1/6) None made Retain online mode 
8. Online format preferred –much shorter, as user-adaptive (1/6) Retain current mode Accepted 
9. Not interested in surveys generally (nor at all in CAM); so prefer online ones: easier to delete (1/6) None made Still retain online mode 
10. General public apathy towards surveys (2/6) Conduct survey in settings like CAM shops/centres, 
etc. 
Rejected: would skew the 
findings 
11. Using target survey area as just Aberdeen city is a bit too restrictive: 5/6 participants live in 
Aberdeenshire! (3/6) 
None given Broaden survey area to 
Aberdeen metropolitan area 
B. SECTION ONE: Parent demographics 
1. Why ask about Marital status? (1/6) Provide an opt out option –like: Prefer not to answer Rejected; but make question 
non-mandatory 
2. Confusion about some ethnic origin categories –like: White Scottish vs. Other White British vs. 
Other White –a bit confusing (2/6) 
Use the standard categories used for ethnicity Accepted; categories modified 
3. Insufficient free text space provided to further describe “other White British” ethnic category (1/6) Use “White British” only Rejected: the “White Scottish” 
are chief target population 
C. SECTION TWO: CAM use in children 
1. How “helpful and discomforting” CAM was? –a bit confusing; and question couldn’t be skipped 
either –temptation to discontinue at that point (3/6) 
Break into 2 separate questions to separate the 
“positive” effects of CAM from the  “negative” ones 
Instruction modified for clarity; 
but question format retained 
2. Used “ifurther down in the past” –confusing; also that aspect was not rated (2/6) Correct typo; modify expression and formatting Accepted 
3. Age by next birthday? –confusing (2/6) “Age in years” or just “Age” Accepted 
4. Use of grid table format a bit confusing: did not know there were more than one questions to be 
answered (2/6) 
None given Instruction modified for clarity 
5. Wrong sentence structure: “no more necessary to use CAM” (1/6) Use correct structure Accepted 
D. SECTION THREE: Personal CAM use & attitudes towards CAM 
1. “CAM should be used in adults, but not in children”? –confusing, presumptuous, misleading (1/6) Reword or ask as separate questions Reworded to focus on children 
2. “CAM should not be used together with conventional medicines” –confusing, as some could, while 
others wouldn’t  (1/6) 
None given All attitudinal questions to be 
prefaced by: “I think/believe” 
3. “CAM can cause harmful side effects in children" –One’s answer to that would depend on his 
background or knowledge level, wouldn’t it? (1/6) 
Include an “Don’t know” or “Can’t answer” option “Don’t know” option added 
4. Personal lifetime use of CAM for parents versus only last 12 months as for children Also request only 12-month CAM use for parents as 
well so as to generate comparable submissions 
Rejected: the format is needed 
to answer research question 
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Table 4.2: Summary of responses from pre-test survey feedback questionnaire
 
 
T a b l e  4 . 2 :  S u m m a r y  o f  r e s p o n s e s  f r o m  p r e - t e s t  s u r v e y  f e e d b a c k  q u e s t i o n n a i r e  
 Q u e s t i o n  R e s p o n s e s  
( F r e q u e n c y ,  % )  
D e t a i l s  F u r t h e r  e x p l a n a t i o n s  
1 .  W o u l d  y o u  s a y  t h e  s u r v e y  t o o k  y o u  a n  
a c c e p t a b l e  t i m e  t o  c o m p l e t e  
Y e s  ( 8 ,  1 0 0  % )   
2 .  A b o u t  h o w  l o n g  d i d  i t  t a k e  y o u  t o  c o m p l e t e  
t h e  s u r v e y ?  
<  5  m i n u t e s  ( 4 ,  5 0  % )  
5 - 1 0  m i n u t e s  ( 4 ,  5 0  % )  
3 .  W e r e  t h e r e  a n y  q u e s t i o n s  y o u  f o u n d  i n  a n y  
w a y  d i f f i c u l t  t o  a n s w e r ?  
Y e s  ( 4 ,  5 0  % )  
 
( i )  Q u e s t i o n  o n  e t h n i c i t y  •  E x p l a n a t i o n  r e q u i r e d  t o  p r o c e e d  b u t  c o u l d  n o t  
e x p l a i n  a s  t h e r e  w a s  a  t e x t  l i m i t  o n  t h e  b o x  
p r o v i d e d  
( i i )  Q u e s t i o n s  o n  C A M  u s e  a n d  a s s o c i a t e d  o u t c o m e s  •  K n o w i n g  h o w  m a n y  b o x e s  n e e d e d  t o  b e  t i c k e d ,  
a n d  t h e  l i n e  " h o w  h e l p f u l  a n d  d i s c o m f o r t i n g "  
c o n f u s e d  m e  
•  N o t  s u r e  i f  p a r t  o f  t h e  q u e s t i o n  r e l a t e d  t o  
p r e v i o u s  u s e  o f  C A M  
•  Q  a s k s  s h o u l d  C A M  b e  u s e d  i n  c h i l d r e n ,  b u t  
d o e s n ' t  a l l o w  y o u  t o  r e s p o n d  t h a t  C A M  s h o u l d n ' t  
b e  u s e d  
( i i i )  Q u e s t i o n s  o n  s h a r i n g  d i s c o m f o r t i n g  e x p e r i e n c e s  
r e l a t e d  t o  C A M  w i t h  o t h e r s  
•  N o t  s u r e  w h a t  t h i s  q u e s t i o n  w a s  l o o k i n g  f o r  
( i v )  Q u e s t i o n s  o n  p e r s o n a l  v i e w s  a n d  o p i n i o n s  o n  
C A M  u s e  i n  g e n e r a l  
•  S o m e  e r r o r s  i n  t h e  t e x t  - s t i l l  u n d e r s t a n d a b l e  -
s o m e  a m b i g u o u s  
N o  ( 4 ,  5 0  % )  -  -  
4 .  W e r e  t h e r e  a n y  q u e s t i o n s  y o u  f o u n d  
i n a p p r o p r i a t e  o r  t h i n k  t o  b e  u n n e c e s s a r y ?  
Y e s  ( 2 ,  2 5  % )  ( i )  Q u e s t i o n  o n  m a r i t a l  s t a t u s  •  I  d o  n o t  s e e  h o w  m a r i t a l  s t a t u s  i s  r e l e v a n t  t o  t h e  
s t u d y  b e i n g  u n d e r t a k e n  
 ( i i )  Q u e s t i o n s  o n  C A M  u s e  a n d  a s s o c i a t e d  o u t c o m e s  •  D o n ' t  t h i n k  y o u  n e e d  t o  a s k  i s  C A M  m o r e  
e f f e c t i v e  t h a n  c o n v e n t i o n a l  m e d s  
N o  ( 6 ,  7 5  % )  -  
5 .  I s  t h e r e  a n y  o t h e r  q u e s t i o n  o r  a d d i t i o n a l  
i n f o r m a t i o n  y o u  t h i n k  s h o u l d  b e  a d d e d  t o  t h e  
s u r v e y ?  
Y e s  ( 2 ,  2 5  % )  ( i )  P r e v i o u s  C A M  u s e  e x a m p l e s ?  O r  d o  y o u  j u s t  w a n t  t o  r e s e a r c h  t h e  l a s t  1 2  m o n t h s ?  
( i i )  W h a t  a r e  t h e  f a c t o r s  t h a t  i n f l u e n c e d  c h o i c e  o f  C A M s  i n  c h i l d r e n ?  i . e .  r e c o m m e n d a t i o n / e f f e c t i v e n e s s /  
N o  ( 2 ,  2 5  % )  -  
-  
-  
-  
D o n ’ t  k n o w  ( 4 ,  5 0  % )  
6 .  H o w  u s e r - f r i e n d l y  d i d  y o u  f i n d  t h e  s u r v e y ?  V e r y  u s e r  f r i e n d l y  ( 7 ,  
8 7 . 5  % )  
  J u s t  O K  ( 1 .  1 2 . 5  % )  
7 .  D o e s  i t  m a k e  a  d i f f e r e n c e  t o  y o u  b y  w h i c h  
m o d e  ( e i t h e r  p a p e r  o r  o n - l i n e )  t h i s  s u r v e y  i s  
p r e s e n t e d  t o  y o u  f o r  c o m p l e t i o n ?  
Y e s ,  i t  d o e s  ( 7 ,  8 7 . 5  % )  
 
P r e f e r e n c e :  O n l i n e  m o d e  ( 7 ,  1 0 0  % )  
N o t  s u r e  i t  d o e s  ( 1 ,  
1 2 . 5  % )  
-  
8 .  D o  y o u  h a v e  a n y  c o m m e n t s  t o  m a k e  o n  t h e  
q u e s t i o n n a i r e  l a y o u t  o r  s t r u c t u r e  - o r  a n y  
o t h e r  a s p e c t ?  
Y e s  ( 4 ,  5 0  % )  ( i )  2  q u e s t i o n s  a s k e d  o n  t h e  s a m e  l i n e  - s h a d e d  a n d  u n s h a d e d  b o x e s –  t h i n k  t h i s  c o u l d  b e  b e t t e r  p r e s e n t e d  
( i i )  G e n e r a l l y  t i d y  u p  s o m e  m i n o r  t e x t  e r r o r s  a n d  r e v i e w  q u e s t i o n s  t o  r e m o v e  a m b i g u i t y  
( i i i )  M y  c h i l d r e n  d o n ' t  a t t e n d  s c h o o l  i n  A b e r d e e n  
( i v )  T h e  q u e s t i o n  r e l a t i n g  t o  c h i l d r e n  a g e s  e t c .  i s  l a i d  o u t  p o o r l y  ( i n s u f f i c i e n t  s p a c e  f o r  f u l l  c o m m e n t )  
N o  ( 4 ,  5 0  % )  -  
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Table 4.3: Summary of comments, proposals and decisions from second pre-test survey focus group discussion
 
 
Table 4.3: Summary of comments, proposal  and decisions fr m second pre-test s vey focus group discussion 
 
 Comment/Observation (Number of commentators; n/7) Proposed solution Decision taken 
1. Official/institutional e-mails may not be a convenient medium of access to survey (3/7) Consider using more direct routes like personal e-
mails or institutional Blackboards (for students)  
Accepted: an “all of the above” 
approach to be used; participant 
preference to be tested in main 
survey 
2. Online mode preferred over paper (7/7); but “paper version easier to distribute within 
enclosed settings like schools” (1/7) 
Retain online mode; but don’t rule out paper mode 
for enclosed settings 
Paper mode to be considered for 
main survey 
3.  Invitational e-mail title not really inviting enough, even for CAM enthusiasts (4/7); so high 
likelihood of immediately deleting mail without opening unless expecting it (1/7) 
None made Revise e-mail title; also, paper 
mode to be considered 
4. Local newspapers could be a good means of spreading survey information to older 
population (1/7) 
None made To be considered; survey to be 
broadened to cover older parents: 
enquire after previous use in adult 
children 
5. Survey posting on Facebook could help spread it quickly through “liking” (5/7) None made An “all of the above” approach to be 
used; participant preference to be 
tested in main survey 
6. Did not read the cover page –a bit bland, not really attention-grabbing (5/7) Put in more pictures –especially of people using 
various CAM therapies 
Accepted 
7. Links to list of CAM types not clicked (5/7) Better to make the lists page compulsory Accepted; but for the Paper-based 
version only 
8. Survey did not provide fresh information on CAM therapies (5/7) –except through lists of 
therapies (1/7) 
None made To be tested in main survey after 
inclusion of pictures of CAM types 
9. Lists contained too many therapies, so didn’t really read through them all (2/7) None made A revised and much shorter list to 
be used in paper-based version 
10. Screening question on cover page requesting potential participants to opt to take survey 
would make it a lot easier to avoid taking survey –leading to further loss of potential 
participants (1/7) 
Remove it; depend rather on the invite in the 
introductory mail containing link to survey 
Accepted 
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Table 4.4: Comparative overview of the structural properties of the online and paper-based versions of the parent CAM questionnaires used for
main survey
 
 
T a b l e  4 . 4 :  C o m p a r a t i v e  o v e r v i e w  o f  t h e  s t r u c t u r a l  p r o p e r t i e s  o f  t h e  o n l i n e  a n d  p a p e r - b a s e d  v e r s i o n s  o f  t h e  p a r e n t  C A M  
q u e s t i o n n a i r e s  u s e d  f o r  m a i n  s u r v e y  
 
S e c t i o n  O n l i n e  v e r s i o n  P a p e r - b a s e d  v e r s i o n  
C o v e r  p a g e  B r i e f  g e n e r a l  d e f i n i t i o n  o f  C A M  f o l l o w e d  b y  a n  i n v i t a t i o n  t o  “ P L E A S E  C L I C K  H E R E  a n d  
H E R E ”  f o r  e x a m p l e s  o f  C A M  p r o d u c t s  a n d  p r a c t i c e s .  T h i s  w a s  p r e f a c e d  b y  t h e  
i n f o r m a t i o n  t h a t  C A M  u s e  i n  c h i l d r e n  i s  n o t  r e q u i r e d  f o r  p a r t i c i p a t i o n  i n  t h e  s t u d y ;  
a n d  f o l l o w e d  b y  a  p r o m i s e  o f  a  s u r v e y  c o m p l e t i o n  t i m e  o f  “ a b o u t  5 - 1 0  m i n u t e s ”  
S a m e  a s  f o r  o n l i n e  v e r s i o n  e x c e p t  i n  t h e  a b s e n c e  o f  t h e  i n v i t a t i o n  t o  
“ P L E A S E  C L I C K  H E R E  a n d  H E R E ”  f o r  e x a m p l e s  o f  C A M  p r o d u c t s  a n d  
p r a c t i c e s .  
  
S e c t i o n  O n e  1 3  q u e s t i o n s  i n  a l l :  
A  m a x i m u m  o f  1 2  q u e s t i o n s  o n  p a r e n t  d e m o g r a p h i c s ,  f o l l o w e d  b y  o n e  q u e s t i o n  o n  
m e d i u m  o f  o n l i n e  a c c e s s  t o  t h e  s u r v e y   
1 6  q u e s t i o n s  i n  a l l :  
7  q u e s t i o n s  e n c o m p a s s i n g  t h e  1 2  o n l i n e  q u e s t i o n s  o n  p a r e n t  
d e m o g r a p h i c s ,  i n  a d d i t i o n  t o  o n e  q u e s t i o n  o n  g e o g r a p h i c a l  a r e a  o f  
r e s i d e n c e ,  a n o t h e r  o n  s u r v e y  m o d e  p r e f e r e n c e ,  t h r e e  o n  t y p e s  o f  C A M  
m o d a l i t i e s  u s e d  i n  c h i l d r e n ,  a n d  f o u r  o n  c h i l d  a g e ,  s e x  a n d  l i f e t i m e  o r  1 2 -
m o n t h  C A M  u s e  s t a t u s .  
S e c t i o n  t w o  3 2  q u e s t i o n s :  C A M  u s e  i n  c h i l d r e n  
F o u r  q u e s t i o n s  o n  c h i l d  a g e ,  s e x  a n d  l i f e t i m e  o r  1 2 - m o n t h  C A M  u s e  s t a t u s ;  e i g h t  o n  
t h e  n u m b e r ,  s p e c i f i c s  a n d  o u t c o m e s  r a t i n g  o f  c h i l d  C A M  u s e ;  s i x  o n  k n o w l e d g e  o f   
a n d  c o n t i n u e d / d i s c o n t i n u e d  c h i l d  C A M  u s e ;  f o u r  o n  s p e c i f i c  o u t c o m e s  o f  c h i l d  C A M  
u s e ;  t h r e e  o n  h e l p f u l  C A M  r e c o m m e n d a t i o n s  a n d  h a r m f u l  C A M  r e p o r t i n g ;  a n d  s e v e n  
o n  p r e v i o u s  a d u l t  c h i l d  C A M  u s e  a n d  o u t c o m e s   
1 1  q u e s t i o n s :  D e t a i l e d  i n f o r m a t i o n  o n  C A M  u s e  i n  c h i l d r e n .  
F i v e  q u e s t i o n s  o n  t h e  s p e c i f i c s  o f  C A M  u s e  i n  c h i l d r e n  ( i r r e s p e c t i v e  o f  
a g e ) ,  a s  w e l l  a s  t h e  t i m i n g  ( d u r i n g  o r  b e y o n d  t h e  l a s t  1 2  m o n t h s )  a n d  
o u t c o m e s  r a t i n g  f o r  e a c h  t h e r a p y ;  t w o  q u e s t i o n s  o n  k n o w l e d g e  o f  a n d  
c o n t i n u e / d i s c o n t i n u e d  c h i l d  C A M  u s e ;  a n d  f o u r  q u e s t i o n s  o n  h e l p f u l  C A M  
r e c o m m e n d a t i o n s  a n d  h a r m f u l  C A M  r e p o r t i n g  
S e c t i o n  t h r e e  1 5  q u e s t i o n s :  
F o u r  q u e s t i o n s  o n  p e r s o n a l  C A M  u s e  s p e c i f i c s  a n d  p o s i t i v e  o u t c o m e s  r a t i n g ;  1 0  
a t t i t u d i n a l  q u e s t i o n s  o n  C A M  u s e ;  a n d  o n e  f i n a l  q u e s t i o n  o n  p a r t i c i p a t i o n  i n  f u r t h e r  
C A M  s t u d y  
1 2  q u e s t i o n s .  
T w o  q u e s t i o n s  o n  p e r s o n a l  C A M  u s e  s p e c i f i c s  a n d  p o s i t i v e  o u t c o m e s  
r a t i n g ;  f o l l o w e d  b y  1 0  a t t i t u d i n a l  q u e s t i o n s  o n  C A M  u s e .  
T o t a l  n u m b e r  
o f  q u e s t i o n s  
A  m a x i m u m  o f  6 0  q u e s t i o n s  – i n c l u d i n g  1 6  r o u t i n g  q u e s t i o n s  3 9  q u e s t i o n s  
T o t a l  n u m b e r  
o f  q u e s t i o n s  
f o r  c h i l d  C A M  
u s e r s  
A  m a x i m u m  o f  6 0  q u e s t i o n s  i n  a l l  ( a s  a b o v e ) ,  d e p e n d i n g  o n  s p e c i f i c  u s e r  f e a t u r e s  3 9  q u e s t i o n s  
T o t a l  n u m b e r  
o f  q u e s t i o n s  
f o r  c h i l d  C A M  
n o n - u s e r s  
A  m a x i m u m  o f  2 9  q u e s t i o n s  2 7  q u e s t i o n s  
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4.3.3 Participant recruitment
The results of participant recruitment for the study across the survey area via the online and
paper-based approaches are outlined in tables 4.5 and 4.6. 550 of the 600 paper-based ques-
tionnaires produced were distributed to parents in different settings within Aberdeen city; and
152 completed questionnaires were returned. Eight of these were invalidated for not providing
information on CAM use in children. While it was not possible to determine the exact number
of parents reached through the online route, only 68 responses were received, all of which were
usable. The combined 212 valid responses were widely distributed across the study area. 29 of
the 32 postcode areas within the survey area were represented in the study, participants were
understandably not uniformly distributed across the area either by postcode (X2 = 572.825;
df=28; p=0.000) or geographical area (X2 = 108.095; df=8; p=0.000). In all 212 parents of 391
children were recruited, 149 (70.3%) of which were drawn from Aberdeen city and its northern
and western suburbs; with participant recruitment decreasing as the distance from Aberdeen city
increased.
The paper-based mode accounted for the bulk of recruitment, as only about one third of the
participants (68 parents; 32.1%) were recruited by the online approach. However, while the
proportions of participants recruited via the paper-based approach were significantly greater
than those recruited via the online mode in many parts of Aberdeen city, the converse was the
case as the distance from Aberdeen increased, albeit non-significantly.
 
 
Figure 4.2: Distribution of study participants based on their residence in 
urban or rural areas 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Distribution of study participants based on their residence in urban or rural areas
Figure 4.2 and table 4.6 show that, while almost 70% of the participants resided in urban areas or
accessible small towns, this was significantly accounted for by the use of the paper-based approach
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Table 4.5: Results of participant recruitment via online and paper-based surveys
 
 
T a b l e  4 . 5 :  R e s u l t s  o f  p a r t i c i p a n t  r e c r u i t m e n t  v i a  o n l i n e  a n d  p a p e r - b a s e d  s u r v e y s  
G e o g r a p h i c a l  
A r e a  
S p e c i f i c  t o w n s / c o m m u n i t i e s  P O S T  
C O D E  
%  P a -  
r e n t s  
C h i l -
d r e n  
M e a n  S E M  O N L I N E  M O D E  P A P E R - B A S E D  M O D E  Χ 2   
P  v a l u e  
 
P a -
r e n t s  
C h i l d -
r e n  
M e a n  S E M  P a -
r e n t s  
C h i l d -
r e n  
M e a n  S E M  
 
A B E R D E E N  C I T Y  
C E N T R E  
B r i d g e  o f  D e e  a r e a  A B 1 0  6 . 1  1 3  2 4  1 . 8 5  . 1 9 1  6  1 0  1 . 6 7  . 2 1 1  7  1 4  2 . 0 0  . 3 0 9   
B o n  a c c o r d  c r e s c e n t / C r o w n  s t r e e t ;  T o r r y  A B 1 1  3 . 3  7  1 4  2 . 0 0  . 3 0 9  4  8  2 . 0 0  . 4 0 8  3  6  2 . 0 0  . 5 7 7   
G e o r g e  s t r e e t ,  F o r e s t e r h i l l ,  R o s e m o u n t ,  
K i t t y b r e w s t e r  a r e a s  
A B 2 5  7 . 1  1 5  2 5  1 . 6 7  . 2 1 1  1  1  1 . 0 0  -  1 4  2 4  1 . 7 1  . 2 2 1   
 1 6 . 5  3 5  6 3  1 . 8 0  . 1 2 8  1 1  1 9  1 . 7 3  . 1 9 5  2 4  4 4  1 . 8 3  . 1 6 7  . 0 2 8  
N O R T H  A B E R D E E N  O l d  A b e r d e e n ,  W o o d s i d e ,  T i l l y d r o n e ,  e t c .  A B 2 4  6 . 6  1 4  2 8  2 . 0 0  . 3 1 4  3  5  1 . 6 7  . 3 3 3  1 1  2 3  2 . 0 9  . 3 9 2  . 0 3 3  
W E S T  A B E R D E E N  M a s t r i c k ,  C o r n h i l l ,  S h e d d o c k s l e y .  e t c .   A B 1 6  4 . 7  1 0  1 5  1 . 5 0  . 1 6 7  4  5  1 . 2 5  . 2 5 0  6  1 0  1 . 6 7  . 2 1 1  . 5 2 7  
A B E R D E E N  
N O R T H E R N  S U B U R B S   
B r i d g e  o f  D o n ,  D a n e s t o n e ,  G r a n d h o l m ,  
P e r s l e y ,  e t c .   
A B 2 2  3 0 . 7  6 5  1 0 7  1 . 6 5  . 0 7 7  8  1 4  1 . 7 5  . 3 6 6  5 7  9 3  1 . 6 3  . 0 7 4  . 0 0 0  
 
A B E R D E E N  
W E S T E R N  S U B U R B S  
M i l l i t i m b e r   A B 1 3  1 . 9  4  1 0  2 . 5 0  . 6 4 5  1  3  3 . 0 0  -  3  7  2 . 3 3  . 8 8 2   
P e t e r c u l t e r  A B 1 4  0 . 9  2  3  1 . 5 0  . 5 0 0  1  2  2 . 0 0  -  1  1  1 . 0 0  -   
B i e l d s i d e ,  C u l t s ,  C r a i g i e b u c k l e r ,  
K i n g s w e l l s ,  S u m m e r h i l l ,  e t c .   
A B 1 5  9 . 0  1 9  3 1  1 . 6 3  . 1 3 7  7  8  1 . 1 4  . 1 4 3  1 2  2 3  1 . 9 2  . 1 4 9   
 1 1 . 8  2 5  4 4  1 . 7 6  . 1 5 6  9  1 3  1 . 4 4  . 2 4 2  1 6  3 1  1 . 9 4  . 1 9 3  . 1 6 2  
 
A B E R D E E N -
A B E R D E E N S H I R E  
A l t e n s / C o v e  a r e a ,  N i g g ,  P o r t l e t h e n ,  e t c .  A B 1 2  4 . 2  9  2 6  2 . 8 9  . 5 8 8  3  9  3 . 0 0  1 . 0 0  6  1 7  2 . 8 3  . 7 9 2   
B l a c k b u r n ,  B u c k s b u r n ,  D y c e ,  e t c .  A B 2 1  1 . 4  3  8  2 . 6 7  . 3 3 3  2  5  2 . 5 0  . 5 0 0  1  3  3 . 0 0  -   
B a l m e d i e ,  P o t t e r t o n ,  W h i t e c a i r n s ,  e t c .  A B 2 3  0 . 9  2  4  2 . 0 0  . 0 0 0  -  -  -  -  2  4  2 . 0 0  . 0 0 0   
  6 . 6  1 4  3 8  2 . 7 1  . 3 8 4  5  1 4  2 . 8 0  . 5 8 3  9  2 4  2 . 6 7  . 5 2 7  . 2 8 5  
 
 
A B E R D E E N S H I R E  
E A S T  A N D   
B A N F F S H I R E  &  
B U C H A N  C O A S T  
 
E l l o n  A B 4 1  1 . 4  3  5  1 . 6 7  . 6 6 7  -  -  -  -  3  5  1 . 6 7  . 6 6 7   
P e t e r h e a d  A B 4 2  0 . 9  2  4  2 . 0 0  . 0 0 0  1  2  2 . 0 0  -  1  2  2 . 0 0  -   
F r a s e r b u r g h  A B 4 3  0 . 5  1  5  5 . 0 0  .  1  5  5 . 0 0  -  -  -  -  -   
B a n f f  A B 4 5  0 . 5  1  2  2 . 0 0  .  -  -  -  -  1  2  2 . 0 0  -   
I n v e r u r i e  A B 5 1  4 . 2  9  1 2  1 . 3 3  . 1 6 7  6  8  1 . 3 3  . 2 1 1  3  4  1 . 3 3  . 3 3 3   
T u r r i f f  A B 5 3  0 . 5  1  1  1 . 0 0  .  1  1  1 . 0 0  -  -  -  -  -   
  8 . 0  1 7  2 9  1 . 7 1  . 2 5 4  9  1 6  1 . 7 8  . 4 3 4  8  1 3  1 . 6 3  . 2 6 3  . 8 0 8  
 
 
 
A B E R D E E N S H I R E  
W E S T  
 
B a n c h o r y  A B 3 1  1 . 4  3  7  2 . 3 3  . 3 3 3  3  7  2 . 3 3  . 3 3 3  -  -  -  -   
W e s t h i l l  A B 3 2  1 . 4  3  8  2 . 6 7  . 6 6 7  1  4  4 . 0 0  -  2  4  2 . 0 0  . 0 0   
A l f o r d  A B 3 3  0 . 9  2  6  3 . 0 0  . 0 0 0  1  5  5 . 0 0  -  1  1  1 . 0 0  -   
A b o y n e  A B 3 4  0 . 9  2  2  1 . 0 0  . 0 0 0  2  2  1 . 0 0  -  -  -  -  -   
S t o n e h a v e n  A B 3 9  5 . 2  1 1  1 9  1 . 7 3  . 1 9 5  7  1 1  1 . 5 7  . 2 0 2  4  8  2 . 0 0  . 4 0 8   
I n s c h  A B 5 2  0 . 5  1  2  2 . 0 0  .  -  -  -  -  1  2  2 . 0 0  -   
H u n t l y  A B 5 4  0 . 9  2  6  3 . 0 0  . 0 0 0  1  3  3 . 0 0  -  1  3  3 . 0 0  -   
  1 1 . 3  2 4  5 0  2 . 0 8  . 2 0 8  1 5  3 2  2 . 1 3  . 3 0 7  9  1 8  2 . 0 0  . 2 3 6  . 2 2 1  
 
 
A N G U S  A N D  D U N D E E  
C I T Y  
L a u r e n c e k i r k  A B 3 0  0 . 9  2  6  3 . 0 0  . 0 0 0  1  3  3 . 0 0  -  1  3  3 . 0 0    
D u n d e e ,  P e r t h  &  K i n r o s s  D D 2  0 . 5  1  2  2 . 0 0  .  -  -  -  -  1  2  2 . 0 0  -   
M o n t r o s e  D D 1 0  1 . 4  3  6  2 . 0 0  . 0 0 0  3  6  2 . 0 0  . 0 0 0  -  -  -  -   
A r b r o a t h  D D 1 1  0 . 5  1  2  2 . 0 0  .  -  -  -  -  1  2  2 . 0 0  -   
  3 . 3  7  1 6  2 . 2 9  . 1 8 4  4  9  2 . 2 5  . 2 5 0  3  7  2 . 3 3  . 3 3 3  . 7 0 5  
M I S S I N G  ( P o s t c o d e  d a t a  n o t  p r o v i d e d )  0 . 5  1  1  1 . 0 0  . 0 0 0  -  -  -  -  1  1  1 . 0 0  -  -  
A B E R D E E N  M E T R O P O L I T A N  A R E A  x   2 1 2  3 9 1  1 . 8 4  . 0 6 1  6 8  1 2 7  1 . 8 7  . 1 2 2  1 4 4  2 6 4  1 . 8 3  . 0 7 0   
%  1 0 0      3 2 . 1  3 2 . 5    6 7 . 9  6 7 . 5     
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Table 4.6: Participant distribution based on the Scottish 6 fold Urban-Rural classification profile
 
 
T ble .6: Partic pant distribution based on the Scottish 6 fold Urban-
Rural classification profile 
 
Scottish 6 fold 
Urban-Rural 
Classification 
ONLINE PAPER-BASED Χ2 test 
(Survey 
mode) 
Number 
of parents 
Number of 
children 
Mean SEM Number of 
parents 
Number of 
children 
Mean SEM 
Large urban areas 31 57 1.84 .168 108 196 1.81 .083 Χ2=42.655 
df=1 
P=0.000 
Other urban areas 3 6 2.00 .000 1 2 2.00 - - 
- Accessible small 
towns 
1 3 3.00 - 3 7 2.33 .992 
ALL URBAN AREAS 
(x; %a,b) 
35; 
23.8 %a 
51.5 %b 
66 1.89 .152 112; 
76.2 %a 
78.3 %b 
205 1.83 .083 Χ2= 40.33 
df=1 
p=0.000 
Accessible rural 
area 
29 51 1.67 .183 29 53 1.88 .122 Χ2=0.000 
df=1 
P=1.000 
Remote small towns - - - - - - - - - 
- Remote rural area 4 10 2.50 .957 2 5 2.50 .500 
ALL RURAL AREAS 
(x; %a,b) 
33; 
51.6 %a 
48.5 %b 
61 1.85 .195 31; 
48.4 %a 
21.7 %b 
58 1.87 .120 Χ2= 0.063 
df=1 
P=0.803 
Χ2 test (Urban-
Rural) 
Χ2=0.059 
df=1 
P=0.808 
Χ2=45.881 
df=1 
P=0.000 
 
a = Percentage of recruitment by survey mode 
b= Percentage of recruitment by Urban-Rural setting 
(X2 = 45.881; df=1; P=0.000 ), rather than the online one (X2 = 0.059; df=1; P=0.808).
Participant recruitment by the online mode was independent on the urban/rural setting of the
survey area (X2 = 0.059; df=1; p=0.808); just as the mode of survey used had no significant
effect on participant recruitment in rural areas (X2 = 0.063; df=1; P=0.803).
4.3.4 Participant demographics
The chief demographic features of the 212 parents who participated in the study are outlined
in table 4.7. High proportions of them were Caucasian (84.4%), mothers or female guardians
(73.6%), educated beyond secondary school level (85.3%), living largely in urban areas (69.7%),
and currently married, cohabiting or in a civil partnership (87.2%), with mostly one to two
children (86.3%). About 70% of the Caucasian population (corresponding to about 60% of the
entire population) was White Scottish. More than half of the parents were aged 30-44 years
(59.9%), and had children that were all aged less than 12 years (64.1%). However, they were
uniformly distributed with respect to religious inclination (X2 = 0.005; df=1; p=0.945). The
parents provided information on 391 own children, 82.4% of which (322) were paediatric subjects
aged up to 17 years. Only 23 parents (10.8%) had only adult children. Although there were
virtually equal numbers of male and female paediatric subjects (X2 = 0.304; df=1; P=0.435),
the females were slight more numerous (52.2%) than males.
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Table 4.7: Participant demographics
 
198 
 
Table 4.7: Participant demographics 
Demographic Categories Frequency % Χ2 test 
Parents 212 100  
Parental status Father/Male guardian 56 26.4 Χ2=47.170; df=1; 
P=0.000 Mother/Female guardian 156 73.6 
Parent age 
(1 Missing) 
16-29 years 23 10.9  
Χ2=151.597; df=4; 
P=0.000 
30-44 years  126 59.7 
45-59 years 51 24.2 
>60 years  11 5.2 
Marital status 
(1 Missing) 
Married/Living with partner 184 87.2 Χ2=116.920; df=1; 
P=0.000 Single/Separated/Divorced/Widowed 27 12.8 
Ethnicity 
(1 Missing) 
White Scottish 127 59.9  
Χ2=247.270; df=4; 
P=0.000 
Other White British or Other White 52 24.5 
Black or Black British 21 9.9 
Asian or Asian British 7 3.3 
Mixed racial background/Other 4 1.9 
Level of  educational 
(1 Missing) 
Further or higher education 180 85.3 Χ2=105.218; df=1; 
P=0.000 Secondary education or below 31 14.7 
Locality of residence 
(1 Missing) 
Urban areas 147 69.7 Χ2=32.649; df=1; 
P=0.000 Rural areas 64 38.3 
Religious inclination 
(1 Missing) 
Religious 105 49.8 Χ2=0.005; df=1; 
P=0.945 No religious 106 50.2 
 Self CAM use profile 
(2 Missing) 
Ever used 141 67.5 Χ2=135.3976; df=1;  
P=0.000 Never used/Not sure 68 32.5 
 Number of CAM 
 modalities self-used 
Sum 
Mean (SD) 
437 
3.10 (2.33) 
  
 Number of children 
 per parent 
1 or 2 children 183 86.3 Χ2=111.868; df=1; 
P=0.000 More than 2 children 29 13.7 
 Child age categories Aged <5 years  38 17.9  
 
Χ2=57.566; df=6; 
P=0.000 
Aged 5-11 years  63 29.7 
Aged <12 years  35 16.5 
Aged 12-17 years  14 6.6 
Aged <17 years  24 11.3 
Aged >17 years  23 10.8 
Aged up to and above 17 years  15 7.1 
Children 391 100  
 Number of 
 children 
Mean 
(SD) 
1.84  
(0.89) 
 
 Age range 0-17 years 322 82.4 Χ2=163.706; df=1; 
P=0.000 >17 years 69 17.6 
Paediatric subject details     
 Sex distribution Females 168 52.2 Χ2=0.304; df=1; 
P=0.435 Males 154 47.8 
 Age Descriptives  
 (year) 
Range 0.30-17.00  
Mean (SD) 7.25 (4.47) 
Median (IQR) 6.00 (4.00-11.00) 
Mode 5.00 
 Age group 
 distribution 
Infants (<2 years) 31 9.60  
Χ2=62.149; df=3; 
P=0.000 
Pre-schoolers (2-5 years) 103 32.00 
School-age (6-11 years) 123 38.20 
Adolescents (12-17 years) 65 20.20 
4.3.6 The dependent and independent factors associated with 
paediatric CAM use 
The parent-related factors found to determine CAM use are outlined in table 4.9. 
Although significant differences were found between parent who had ever used 
CAM in their children (paediatric CAM users) and those who had never done so 
(paediatric CAM non-users) based on several categorical parental factors, only 
five of them were found to be significantly correlated with paediatric CAM use. 
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4.3.5 Extent and nature of paediatric CAM use
The extent and nature of paediatric CAM use in the survey setting is summarised in table
4.8. Two thirds of parents reported having ever used CAM in their children. 59.4% of these
(corresponding to 40.1% of the whole sample) had always used CAM both in the past as well
as within the last 12 months; 23.1% reported having used CAM only within the last 12 months;
while only 17.5% (corresponding to just over 10% of the whole sample) reported having used it
only in the past. Parents reported significant lifetime CAM use in all own children and across the
main child age groups, as well as among paediatric subjects aged up to 17 years; but there was no
significant difference (X2 = 0.014; df=1; P=0.904) between the numbers of adult children who
have ever or never used CAM. Although about two-thirds of both male and female paediatric
subjects had ever used CAM, there was no difference in lifetime CAM use across the sexes. CAM
was, however, reported to have used more in females than males. With respect to the chronology
of CAM use, significantly more paediatric subjects were reported to have always used CAM, both
in the past as well as within the last 12 months (X2 = 93.408; df=1; p=0.000). While a similar
pattern was observed among males and females separately, it was found to be independent on
gender.
4.3.6 The dependent and independent factors associated with paediatric CAM
use
The parent-related factors found to determine CAM use are outlined in table 4.9. Although
significant differences were found between parent who had ever used CAM in their children
(paediatric CAM users) and those who had never done so (paediatric CAM non-users) based on
several categorical parental factors, only five of them were found to be significantly correlated with
paediatric CAM use. These major determinants of paediatric CAM use included a parental age
of 30-44 years (X2 = 0.231; p=0.001); having a child aged either less than 12 years (X2 = 0.153;
p=0.026) or aged up to 17 years (X2 = 0.211; p=0.002); having completed the paper-based survey
(X2 = 0.321; p=0.000); and having used CAM personally (X2 = 0.324; p=0.000). Distinctively,
the only parental factor for which there was a negative correlation with paediatric CAM use was
religious inclination, although this was not significantly so (X2 = −0.094; p=0.173).
Among the five factors found to determine paediatric CAM use, personal CAM use by parents
was found to have the greatest likelihood of doing so [OR =4.235; 95% C I (2.274-7.887)], closely
followed by completion of the paper-based survey rather than the online one [OR =4.177; 95% C
I (2.251-7.751)]; while having a young child aged less than 12 years was found to have the lowest
significant likelihood of doing so [OR =2.106; 95% C I (1.088-4.080)]. When these five major
determinants were entered into a binary logistic regression model to determine the significance of
their predictive abilities, the child age-related factors were found to be non-significant. When all
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Table 4.8: Extent and nature of paediatric CAM use
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Table 4.8: Extent and nature of paediatric CAM use 
CAM use status Categories Frequency % Χ2 test Mean (SD) 
Parent level data on CAM use in children  212 100   
Lifetime CAM use in 
own children 
Ever used 143 67.5 Χ2=25.830; df=1; 
P=0.000 
 
Never used/Uncertain 69 32.5 
Chronological CAM 
use in own children 
Always used 85 59.4  
Χ2=44.531; df=3;  
P=0.000 
 
Currently use 33 23.1 
Previously used 25 17.5 
Number of different modalities used  401 - - 2.80 (2.04) 
Child level data on CAM use -     
Number of Children (All parents)  391 100  1.84 (0.89) 
(189 parents) Paediatric subjects 322 82.4 Χ2=163.71; df=1;  
P=0.000 
1.70 (0.80) 
(38 parents) Adult children 69 17.6 1.82 (0.90) 
Life-time CAM use      
 In general Ever used 247 63.2 Χ2=27.133; df=1;  
P=0.000 
 
Never used 144 36.8 
 By current child age      
Across age groups Ever used     
0-17 years 213 86.2 Χ2=129.72; df=1;  
P=0.000 >17 years 34 13.8 
Never used 144   
0-17 years 109 75.7 Χ2=38.028; df=1;  
P=0.000 >17 years 35 24.3 
Within age groups 0-17 years 322    
Ever used 213 66.1 Χ2=33.590; df=1;  
P=0.000 Never used 109 33.9 
>17 years 69   
Ever used 34 49.3 Χ2=0.014; df=1;  
P=0.904 Never used 35 50.7 
Parent-reported CAM use in paediatric subjects     
Life-time CAM use      
In general Ever used 213 66.1 Χ2=33.590; df=1;  
P=0.000 
 
Never used/Uncertain 109 33.9 
By sex      
Across sexes Ever used 213 66.1   
Females 113 53.1 Χ2=0.793; df=1; 
P=0.373 Males 100 46.9 
Never used/Uncertain 109 33.9  
Females 55 50.5 Χ2=0.0092; df=1; 
P=0.924 Males 54 49.5 
Within sexes Females 168 52.2   
Ever used 113 67.3 Χ2=20.024; df=1;  
P=0.000 Never used/Uncertain 55 32.7 
Males 154 47.8  
Ever used 100 64.9 Χ2=13.740; df=1;  
P=0.000 Never used/Uncertain 54 35.1 
Chronology of paediatric CAM use      
In general Always used 137 64.3 Χ2=93.408; df=1;  
P=0.000 
 
Currently use 45 21.1 
Previously used 31 14.6 
By sex      
Across sexes Always used 137 42.5   
Females 75 54.7 Χ2=1.234; df=1; 
P=0.267 Males 62 45.3 
Currently use 45 14.0  
Females 21 46.7 Χ2=0.2000; df=1; 
P=0.655 Males 24 53.3 
Previously used 31 9.6  
Females 17 54.8 Χ2=0.290; df=1; 
P=0.590 Males 14 45.2 
Within sexes Females 113 53.1   
Always used 75 66.4  
Χ2=55.712; df=1;  
P=0.000 
Currently use 21 18.6 
Previously used 17 15.0 
Males 100 46.9  
Always used 62 62.0  
Χ2=38.484; df=1;  
P=0.000 
Currently use 24 24.0 
Previously used 14 14.0 
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Table 4.9: Dependent and independent factors of parental CAM use in own children (categorical variables)
 
 
Table 4.9: Dependent and independent factors of parental CAM use in own children (categorical variables) 
Factor Demographic categories 
(Possible factors) 
Total Ever  
used 
Never 
used 
Χ2 test of 
independence 
Correlation with 
paediatric CAM use 
Odds of using CAM 
in children 
Binary logistic 
regression 
n % n % Χ2 P value r P value OR 95 % CI Exp(B) 95 % CI 
Parental status Father/Male guardian 56 32 57.1 24 42.9 1.143 0.258       
Mother/Female guardian 156 111 71.2 45 28.8 27.923 0.000* 0.132 0.055 
Parental age Being aged 30-44 years 126 96 76.2 30 23.8 34.571 0.000* 0.231 0.001* 2.713 [1.501-4.902] 2.362* [1.064-5.254] 
Any other age group 85 46 54.1 39 45.9 0.578 0.444       
Urbanity of 
residential area 
Living in an urban/accessible small areas 147 104 70.7 43 29.3 25.313 0.000* 0.111 0.106 
Living in a rural/remote areas 64 38 59.4 26 40.6 2.258 0.134    
Marital status Married/Cohabiting/In civil Partnership 184 127 69.0 57 31.0 26.630 0.000* 0.096 0.165  
Single/Separated/Divorced/Widowed 27 15 55.6 12 44.4 0.333 0.564   
Number of children 1 or 2 children 183 125 68.3 58 31.7 24.530 0.000* 0.046 0.508  
3 or more children 29 18 62.1 11 37.9 1.690 0.194   
Child age category Aged <5 years  38 25 65.8 13 34.2 3.789 0.052    
Aged <12 years  35 25 71.4 10 28.6 6.249 0.011* 0.111 0.107 
Aged <18 years  24 16 66.7 8 33.3 2.667 0.102   
Aged >=18 years  15 11 73.3 4 26.7 1.087 0.109  
Having a child aged <5 years old 80 57 71.3 23 28.7 14.450 0.000* 0.063 0.301 
Having a child aged <12 years old 164 117 71.3 47 28.7 29.878 0.000* 0.153 0.026* 2.106 [1.088-4.080] 0.792 [0.357-2.439] 
Having a child aged <18 years old 189 134 70.9 55 29.1 33.021 0.000* 0.211 0.002* 3.790 [1.550-9.268] 2.298 [0.596-8.855] 
Having an adult child 38 20 52.6 18 47.4 0.105 0.746       
Child sex category Only male children 65 45 69.2 20 30.8 9.615 0.002*  
Only female children 73 51 69.9 22 30.1 11.521 0.001* 
Both male and female children 51 38 74.5 13 25.5 12.255 0.000*   
Having a male child 116 83 71.6 33 28.4 21.552 0.000* 0.018 0.805 
Having a female child 124 89 71.8 35 28.2 23.518 0.000* 0.027 0.716 
Ethnicity White Scottish 127 86 67.7 41 33.3 15.945 0.000*   
White or Other White British 52 37 71.2 15 28.8 9.308 0.002*  
Black or Black British 21 13 61.9 8 38.1 1.190 0.275 
Asian or Asian British 7 3 42.9 4 57.1 0.143 1.000   
Mixed racial background or Others 4 3 75.0 1 25.0 1.000 0.625 
Being Caucasian 179 123 68.7 56 31.3 25.078 0.000* 0.071 0.302 
Highest educational 
qualification 
Educated just to secondary level or less 31 19 61.3 12 38.7 1.581 0.209 - - 
Educated beyond secondary level 180 123 68.3 57 31.7 24.200 0.000* 0.053 0.442 
Religious inclination Religious 105 66 62.9 39 37.1 6.943 0.008* -0.094 0.173 
Not religious/Uncertain 106 76 71.7 30 28.3 19.962 0.000*   
Survey mode Online mode 68 31 45.6 37 54.4 0.529 0.467  
Paper mode 144 112 77.8 32 22.2 44.444 0.000* 0.321 0.000* 4.177 [2.251-7.751] 4.682* [2.237-9.802] 
Personal CAM use Ever used 141 110 78.0 31 22.0 44.262 0.000* 0.324 0.000* 4.235 [2.274-7.887] 6.680* [3.172-14.067] 
Never used/Uncertain 68 31 45.6 37 54.4 0.529 0.467       
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other factors are controlled for, parental self CAM use was found to be the strongest predictor of
paediatric CAM use [OR =6.680; 95% CI (3.172-14.067)]. It was closely followed by completion
of a paper-based survey [OR =4.682; 95% CI (2.237-9.802)]; while a parental age group of 30-44
years was found to be the least significant predictor [OR =2.362; 95% CI (1.064-5.254)]. The
logistic regression model used was found to increase the ability of the null model to accurately
predict paediatric CAM use from 67.3% to 78.4%, with a Hosmer-Lemeshow test indicating no
significant differences between actual and predicted values (X2 = 3.883; df=6; p=0.692).
More detailed analyses (table 4.10) revealed that level of personal CAM use by parents, as
described by the mean number of CAM modalities they had used, was significantly (t=2.124;
p=0.035) higher for the parents who also reported using CAM in own children (3.32 modalities/-
parent) than in those who had not (2.32 modalities/parent). However, this significant difference
was found to be only among the cohort of parents who have always used CAM in their children
(3.61 modalities/parent); and not among those who either used CAM previously in their children,
or have only just begun to do so within the last 12 months. When the relationship between the
numbers of CAM modalities that had been used personally by parents and several continuous
variables describing child CAM use by parents was determined (table 4.11), all the child CAM
use variables were found to be significantly positively correlated with it except the mean numbers
of adult children who had ever or never used CAM and that of the young children (paediatric
subjects) who had never used CAM.
Linear regression models of the four significant correlates of level of personal parental CAM use
showed that, while all four were significantly predicted, the number of different CAM modalities in
children was the most significantly predicted (R2 =0.4111; F=75.246; p=0.000); while the number
of children aged up to 17 years who used CAM was the least (R2=0.059; F=6.349; p=0.013).
Specifically, the regression models imply that when all other factors are constant, we can be 95%
confident that for every additional CAM used personally by parents, the number of their own
young children aged up to 17 years that would use CAM would increase by 0.07 times; while the
number of different modalities used in their children would increase by 0.56 times. Alternatively,
while there is a 95% chance of 1.372 children in Aberdeen metropolitan area using CAM even
when their parents have not done so, this number would increase by 0.05 times for every CAM
modality used by their parents provided all other factors are unchanged. Similarly, while there
is a 95% chance of 1.083 different CAM modalities to be used by young children in Aberdeen
metropolitan area even when their parents had not used any, this number would increase by 0.56
times for every CAM modality their parents used, if all other factors are constant. This same
analogy would apply for predicting the number of CAM modalities used by children either within
the last 12 months or beyond that.
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Table 4.10: Comparison of level of parental self CAM use with parental paediatric CAM use status
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Table 4.10: Comparison of level of parental self CAM use with parental paediatric CAM use status 
Level of 
parental 
Self CAM use 
Paediatric 
CAM use 
status 
(2-way) 
Number 
of 
parents 
Number 
of CAM 
modalities 
Mean SD t test for equality of means (Independent samples test) 
Equal variances assumed (Levene’s test F=2.515; p=0.115) 
t df Sig. 
(2-tailed) 
Mean 
difference 
SEM 
(difference) 
95 % CI of difference 
Lower Upper 
Number of CAM 
modalities used 
personally 
Ever used 110 365 3.32 2.46 2.124* 139 0.035 0.996 0.469 0.089 1.922 
Never used 31 72 2.32 1.60 
Total 141 437   
Level of 
parental 
Self CAM use 
Paediatric 
CAM use 
status 
(4-way) 
Number 
of 
parents 
Number 
of CAM 
modalities 
Mean SD Post Hoc multiple comparisons for One-way ANOVA test 
ANOVA test (2.660; p=0.051) 
I J Mean diff. 
(I-J) 
SEM 
(difference) 
Sig. 
(2-tailed) 
95 % CI of difference 
Lower Upper 
Number of CAM 
modalities used 
personally 
Always used 66 238 3.61 2.65 Always - - - - - - 
Currently used 25 79 3.16 2.50 - Currently 0.446 0.539 0.409 -0.62 1.51 
Previously used 19 48 2.53 1.43 - Previously 1.080 0.597 0.073 -0.10 2.26 
Never used 31 72 2.32 1.60 - Never 1.283* 0.499 0.011 0.30 2.27 
Total  141 437          
 
 
Table 4.11: Relationship between degree of parental self CAM use and degree of paediatric CAM use by parents 
Continuous CAM use variables Number  
of parents 
Sum Mean SD Correlation Linear regression 
Model 
summary 
ANOVA Unstandardized coefficients 
r P value Gradient Constant 
R square F Sig. B Std. Error B Std. Error 
Number of CAM modalities used personally by parents 141 437 3.10 2.33 1.000 - - - - - - - - 
Number of children <=17 years who ever used CAM 134 213 1.59 0.70 0.243* 0.013 0.059 6.349* 0.013 0.070 0.028 1.372 0.114 
Number of children <=17 years who never used CAM 68 109 1.60 0.92 -0.144 0.425 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- - 
- 
- 
Number of children >18 years who ever used CAM 19 34 1.79 0.92 -0.006 0.982 - 
- Number of children >18 years who never used CAM 19 35 1.84 0.90 -0.383 0.275 
Number of paediatric CAM modalities used within last 12 months 104 237 2.28 1.50 0.435* 0.000 0.189 20.102* 0.000 0.254 0.057 1.407 0.249 
Number of paediatric CAM modalities used previously 88 188 2.14 1.37 0.412* 0.000 0.158 14.926* 0.000 0.234 0.060 1.365 0.264 
Number of different CAM modalities ever used 143 401 2.80 2.04 0.641* 0.000 0.411 75.246* 0.000 0.560 0.065 1.083 0.267 
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Table 4.11: Relationship between degree of parental self CAM use and degree of paediatric CAM use by parents
 
2 0 3  
 
T a b l e  4 . 1 0 :  C o m p a r i s o n  o f  l e v e l  o f  p a r e n t a l  s e l f  C A M  u s e  w i t h  p a r e n t a l  p a e d i a t r i c  C A M  u s e  s t a t u s  
L e v e l  o f  
p a r e n t a l  
S e l f  C A M  u s e  
P a e d i a t r i c  
C A M  u s e  
s t a t u s  
( 2 - w a y )  
N u m b e r  
o f  
p a r e n t s  
N u m b e r  
o f  C A M  
m o d a l i t i e s  
M e a n  S D  t  t e s t  f o r  e q u a l i t y  o f  m e a n s  ( I n d e p e n d e n t  s a m p l e s  t e s t )  
E q u a l  v a r i a n c e s  a s s u m e d  ( L e v e n e ’ s  t e s t  F = 2 . 5 1 5 ;  p = 0 . 1 1 5 )  
t  d f  S i g .  
( 2 - t a i l e d )  
M e a n  
d i f f e r e n c e  
S E M  
( d i f f e r e n c e )  
9 5  %  C I  o f  d i f f e r e n c e  
L o w e r  U p p e r  
N u m b e r  o f  C A M  
m o d a l i t i e s  u s e d  
p e r s o n a l l y  
E v e r  u s e d  1 1 0  3 6 5  3 . 3 2  2 . 4 6  2 . 1 2 4 *  1 3 9  0 . 0 3 5  0 . 9 9 6  0 . 4 6 9  0 . 0 8 9  1 . 9 2 2  
N e v e r  u s e d  3 1  7 2  2 . 3 2  1 . 6 0  
T o t a l  1 4 1  4 3 7    
L e v e l  o f  
p a r e n t a l  
S e l f  C A M  u s e  
P a e d i a t r i c  
C A M  u s e  
s t a t u s  
( 4 - w a y )  
N u m b e r  
o f  
p a r e n t s  
N u m b e r  
o f  C A M  
m o d a l i t i e s  
M e a n  S D  P o s t  H o c  m u l t i p l e  c o m p a r i s o n s  f o r  O n e - w a y  A N O V A  t e s t  
A N O V A  t e s t  ( 2 . 6 6 0 ;  p = 0 . 0 5 1 )  
I  J  M e a n  d i f f .  
( I - J )  
S E M  
( d i f f e r e n c e )  
S i g .  
( 2 - t a i l e d )  
9 5  %  C I  o f  d i f f e r e n c e  
L o w e r  U p p e r  
N u m b e r  o f  C A M  
m o d a l i t i e s  u s e d  
p e r s o n a l l y  
A l w a y s  u s e d  6 6  2 3 8  3 . 6 1  2 . 6 5  A l w a y s  -  -  -  -  -  -  
C u r r e n t l y  u s e d  2 5  7 9  3 . 1 6  2 . 5 0  -  C u r r e n t l y  0 . 4 4 6  0 . 5 3 9  0 . 4 0 9  - 0 . 6 2  1 . 5 1  
P r e v i o u s l y  u s e d  1 9  4 8  2 . 5 3  1 . 4 3  -  P r e v i o u s l y  1 . 0 8 0  0 . 5 9 7  0 . 0 7 3  - 0 . 1 0  2 . 2 6  
N e v e r  u s e d  3 1  7 2  2 . 3 2  1 . 6 0  -  N e v e r  1 . 2 8 3 *  0 . 4 9 9  0 . 0 1 1  0 . 3 0  2 . 2 7  
T o t a l   1 4 1  4 3 7           
 
 
T a b l e  4 . 1 1 :  R e l a t i o n s h i p  b e t w e e n  d e g r e e  o f  p a r e n t a l  s e l f  C A M  u s e  a n d  d e g r e e  o f  p a e d i a t r i c  C A M  u s e  b y  p a r e n t s  
C o n t i n u o u s  C A M  u s e  v a r i a b l e s  N u m b e r   
o f  p a r e n t s  
S u m  M e a n  S D  C o r r e l a t i o n  L i n e a r  r e g r e s s i o n  
M o d e l  
s u m m a r y  
A N O V A  U n s t a n d a r d i z e d  c o e f f i c i e n t s  
r  P  v a l u e  G r a d i e n t  C o n s t a n t  
R  s q u a r e  F  S i g .  B  S t d .  E r r o r  B  S t d .  E r r o r  
N u m b e r  o f  C A M  m o d a l i t i e s  u s e d  p e r s o n a l l y  b y  p a r e n t s  1 4 1  4 3 7  3 . 1 0  2 . 3 3  1 . 0 0 0  -  -  -  -  -  -  -  -  
N u m b e r  o f  c h i l d r e n  < = 1 7  y e a r s  w h o  e v e r  u s e d  C A M  1 3 4  2 1 3  1 . 5 9  0 . 7 0  0 . 2 4 3 *  0 . 0 1 3  0 . 0 5 9  6 . 3 4 9 *  0 . 0 1 3  0 . 0 7 0  0 . 0 2 8  1 . 3 7 2  0 . 1 1 4  
N u m b e r  o f  c h i l d r e n  < = 1 7  y e a r s  w h o  n e v e r  u s e d  C A M  6 8  1 0 9  1 . 6 0  0 . 9 2  - 0 . 1 4 4  0 . 4 2 5  -  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  
-  -  
-  
-  
N u m b e r  o f  c h i l d r e n  > 1 8  y e a r s  w h o  e v e r  u s e d  C A M  1 9  3 4  1 . 7 9  0 . 9 2  - 0 . 0 0 6  0 . 9 8 2  -  
-  N u m b e r  o f  c h i l d r e n  > 1 8  y e a r s  w h o  n e v e r  u s e d  C A M  1 9  3 5  1 . 8 4  0 . 9 0  - 0 . 3 8 3  0 . 2 7 5  
N u m b e r  o f  p a e d i a t r i c  C A M  m o d a l i t i e s  u s e d  w i t h i n  l a s t  1 2  m o n t h s  1 0 4  2 3 7  2 . 2 8  1 . 5 0  0 . 4 3 5 *  0 . 0 0 0  0 . 1 8 9  2 0 . 1 0 2 *  0 . 0 0 0  0 . 2 5 4  0 . 0 5 7  1 . 4 0 7  0 . 2 4 9  
N u m b e r  o f  p a e d i a t r i c  C A M  m o d a l i t i e s  u s e d  p r e v i o u s l y  8 8  1 8 8  2 . 1 4  1 . 3 7  0 . 4 1 2 *  0 . 0 0 0  0 . 1 5 8  1 4 . 9 2 6 *  0 . 0 0 0  0 . 2 3 4  0 . 0 6 0  1 . 3 6 5  0 . 2 6 4  
N u m b e r  o f  d i f f e r e n t  C A M  m o d a l i t i e s  e v e r  u s e d  1 4 3  4 0 1  2 . 8 0  2 . 0 4  0 . 6 4 1 *  0 . 0 0 0  0 . 4 1 1  7 5 . 2 4 6 *  0 . 0 0 0  0 . 5 6 0  0 . 0 6 5  1 . 0 8 3  0 . 2 6 7  
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4.3.7 The user-perceived effectiveness and safety outcomes of paediatric CAM
use in the target groups, and their associated dependent and indepen-
dent factors
The survey findings on the perceived effectiveness and safety outcomes of paediatric CAM use
among parent users in the Aberdeen metropolitan area, as well as their determinants, are outlined
in tables 4.12 to 4.19. While tables 4.12 and 4.13 provide an insight into the parental rating pref-
erences observed during the study; tables 4.14 to 4.18 summarize the specific outcomes associated
with the CAM products and practices at parent- and modality-levels; and table 4.19 outlines the
factors that determine and/or predict user-perceived effectiveness.
Table 4.12 gives an overview of the use of CAM modalities in children as reported and assessed
by their parents. Although the total number of CAM modalities self-used by parents was not
significantly higher than that used for their children (t= -1.816; p=0.071), many more CAM
practices were self-used by parents than for their children (t=-6.290; p=0.000). This was further
emphasized by the fact that while there was no significant difference between the number of
CAM products and practices self-used by parents (t=1.836; p=0.069), many more CAM products
than CAM practices were used in children (t=6.496; p=0.000). With respect to child CAM
use, although there was no significant difference between the number of CAM modalities that
were used within or beyond the last 12 months (t=0.889; p=0.376), significantly more (t=4.780;
p=0.000) novel CAM modalities were used (401 different modalities) than were reused by 52
parent cohorts (103 similar modalities; 25.7%). Similarly, while fewer CAM product and practice
types were rated by participants in the paper-based than they had selected from the lists provided,
the difference was significant only for CAM product types (t=2.224; p=0.028).
Table 4.13 gives a breakdown of the rating preferences of parents between CAM product and
practice types, and further indicates that, although many more CAM products than CAM prac-
tices were used in children as compared to their parents, the proportion of products rated was
similar for both parties (P(1) - P(2) =0.0922482; p=0.117). This was probably because the 20
parents (14.0%) who did not rate the CAM used by their children used many more product types
than practice types (31 product types vs. 7 practice types).
The parent-level summary of the reported outcomes associated with CAM use outlined in table
4.14 indicates that of the 123 parents that rated the CAM they had ever used in their children,
102 (82.9%) perceived at least one of the modalities they had used helpful in their children,
74.5% of which number (76 parents) reported that at least one of such modalities had helped
their children “a lot”.
Although the proportions of parents who perceived CAM use as “a lot helpful” were similar among
child CAM users and self CAM users (74.5% vs. 73.1%; P(1) - P(2)= 0.0143288; p=0.805); the
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Table 4.12: Number and rating of CAM modalities used
 
2 0 5  
 
T a b l e  4 . 1 2 :  N u m b e r  a n d  r a t i n g  o f  C A M  m o d a l i t i e s  u s e d   
 C A T E G O R Y  O N E  C A T E G O R Y  T W O  C o m p a r i s o n  
 N u m b e r  o f  
p a r e n t s  
S u m  M e a n  S D  N u m b e r  
o f  p a r e n t s  
S u m  M e a n  S E M  t  S t a t i s t i c  P  v a l u e  
P A R E N T A L  P A E D I A T R I C  C A M  U S E  R A T I N G  v s .  P A R E N T A L  S E L F  C A M  U S E  R A T I N G  
 D i f f e r e n t  m o d a l i t i e s  e v e r  u s e d  
i n  c h i l d r e n  
C A M  m o d a l i t i e s  u s e d  
p e r s o n a l l y  b y  p a r e n t s  
 
N u m b e r  o f  d i f f e r e n t  C A M  m o d a l i t i e s  u s e d  1 4 3  4 0 1  2 . 8 0  2 . 0 4  1 4 1  4 3 7  3 . 1 0  2 . 3 3  - 1 . 8 1 6  0 . 0 7 1  
 P a e d i a t r i c  C A M  u s e  S e l f  C A M  u s e   
N u m b e r  o f  s p e c i f i c  C A M  p r o d u c t s  r a t e d  1 0 7  2 4 1  2 . 2 5  1 . 3 3  1 0 6  2 5 6  2 . 4 2  1 . 8 1  - 1 . 3 0 9  0 . 1 9 3  
N u m b e r  o f  s p e c i f i c  C A M  p r a c t i c e s  r a t e d  5 2  7 4  1 . 4 2  0 . 7 8  8 4  1 7 6  2 . 1 0  1 . 3 4  - 6 . 2 9 0 *  0 . 0 0 0  
 S p e c i f i c  C A M  p r o d u c t s  r a t e d  S p e c i f i c  C A M  p r a c t i c e s  r a t e d   
P a e d i a t r i c  C A M  p r o d u c t s  v s .  p r a c t i c e s  r a t e d   1 0 7  2 4 1  2 . 2 5  1 . 3 3  5 2  7 4  1 . 4 2  0 . 7 8  6 . 4 9 6 *  0 . 0 0 0  
S e l f - u s e d  C A M  p r o d u c t s  v s .  p r a c t i c e s  r a t e d  1 0 6  2 5 6  2 . 4 2  1 . 8 1  8 4  1 7 6  2 . 1 0  1 . 3 4  1 . 7 9 3  0 . 0 7 6  
D E T A I L S  O F  P A E D I A T R I C  C A M  U S E  &  R A T I N G S  
 W i t h i n  t h e  l a s t  1 2  m o n t h s  B e y o n d  t h e  l a s t  1 2  m o n t h s   
N u m b e r  o f  p a e d i a t r i c  C A M  m o d a l i t i e s  u s e d  1 0 4  2 3 7  2 . 2 8  1 . 5 0  8 8  1 8 8  2 . 1 4  1 . 3 7  0 . 8 8 9  0 . 3 7 6  
 D i s t i n c t  m o d a l i t i e s  e v e r  u s e d  
c u r r e n t l y  o r  p r e v i o u s l y  
M o d a l i t i e s  u s e d  p r e v i o u s l y  a s  
w e l l  a s  c u r r e n t l y  
 
P a e d i a t r i c  C A M  m o d a l i t i e s  u s e d  d i s t i n c t l y  o r  r e p e a t e d l y  1 4 3  4 0 1  2 . 8 0  2 . 0 4  5 2  1 0 3  1 . 9 8  1 . 2 0  4 . 7 8 0 *  0 . 0 0 0  
 C A M  p r o d u c t  t y p e s  s e l e c t e d  C A M  p r o d u c t  t y p e s  r a t e d   
N u m b e r  o f  C A M  p r o d u c t  t y p e s  s e l e c t e d / r a t e d  1 0 4  2 5 0  2 . 4 0  1 . 3 5  8 2  1 7 3  2 . 1 1  1 . 0 8  2 . 2 2 4 *  0 . 0 2 8  
 C A M  p r a c t i c e  t y p e s  s e l e c t e d  C A M  p r a c t i c e  t y p e s  r a t e d   
N u m b e r  o f  C A M  p r a c t i c e  t y p e s  s e l e c t e d / r a t e d  6 3  9 1  1 . 4 4  0 . 8 4  4 0  5 7  0 . 7 5  0 . 1 1 8  0 . 1 3 7  0 . 8 9 2  
 
 
 
T a b l e  4 . 1 3 :  P a r e n t a l  C A M  r a t i n g  p r o f i l e s  f o r  p a e d i a t r i c  a n d  s e l f - u s e d  C A M  
 
 
 
 
P r o d u c t  a n d  p r a c t i c e  t y p e s  s e l e c t e d  
a n d  r a t e d  f o r  c h i l d r e n  
C A M  r a t i n g  p r o f i l e  P a e d i a t r i c  
C A M  
S e l f - u s e d  
C A M  
B i n o m i a l  t e s t  
( 2 - P  t e s t )  
P r o d u c t  t y p e s  P r a c t i c e  t y p e s  N u m b e r  o f  
p a r e n t s  
%  N u m b e r  o f  
p a r e n t s  
%  P  ( 1 )  -  P  ( 2 )  z  s c o r e  P  v a l u e  
S e l e c t e d  R a t e d  S e l e c t e d  R a t e d  
1 2 0  1 0 4  2 0  0  R a t e d  o n l y  p r o d u c t s  7 1  4 9 . 7  5 7  4 0 . 4  0 . 0 9 2 2 4 8 2  1 . 5 7  0 . 1 1 7  
8 7  6 9  5 3  4 6  R a t e d  b o t h  p r o d u c t s  a n d  p r a c t i c e s  3 6  2 5 . 2  5 0  3 5 . 5  - 0 . 1 0 2 8 6 2  - 1 . 9 0  0 . 0 5 8  
1 2  0  1 1  1 1  R a t e d  o n l y  p r a c t i c e s  1 6  1 1 . 2  3 4  2 4 . 1  - 0 . 1 2 9 2 4 7 *  - 2 . 9 0  0 . 0 0 4  
3 1  0  7  0  D i d  n o t  r a t e  a n y  C A M  u s e d  2 0  1 4 . 0  -      
2 5 0  1 7 3  9 1  5 7  T o t a l   1 4 3   1 4 1  
   Χ 2  t e s t  S t a t i s t i c  5 2 . 6 0 8 *   5 . 9 1 5  
D e g r e e  o f  f r e e d o m  3   2  
P  v a l u e  0 . 0 0 0   0 . 0 5 2  
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Table 4.13: Parental CAM rating profiles for paediatric and self-used CAM
 
 
Table 4.12: Number and rating of CAM modalities used  
 CATEGORY ONE CATEGORY TWO Comparison 
 Number of 
parents 
Sum Mean SEM Number 
of parents 
Sum Mean SEM t Statistic P value 
PARENTAL PAEDIATRIC CAM USE RATING vs. PARENTAL SELF CAM USE RATING 
 Different modalities ever used 
in children 
CAM modalities used 
personally by parents 
 
Number of different CAM modalities used 143 401 2.80 0.171 141 437 3.10 0.197 -1.816 0.071 
 Paediatric CAM use Self CAM use  
Number of specific CAM products rated 107 241 2.25 0.128 106 256 2.42 0.176 -1.309 0.193 
Number of specific CAM practices rated 52 74 1.42 0.108 84 176 2.10 0.146 -6.290* 0.000 
 Specific CAM products rated Specific CAM practices rated  
Paediatric CAM products vs. practices rated  107 241 2.25 0.128 52 74 1.42 0.108 6.496* 0.000 
Self-used CAM products vs. practices rated 106 256 2.42 0.176 84 176 2.10 0.146 1.793 0.076 
DETAILS OF PAEDIATRIC CAM USE & RATINGS 
 Within the last 12 months Beyond the last 12 months  
Number of paediatric CAM modalities used 104 237 2.28 0.147 88 188 2.14 0.147 0.889 0.376 
 Distinct modalities ever used 
currently or previously 
Modalities used previously as 
well as currently 
 
Paediatric CAM modalities used distinctly or repeatedly 143 401 2.80 0.171 52 103 1.98 0.166 4.780* 0.000 
 CAM product types selected CAM product types rated  
Number of CAM product types selected/rated 104 250 2.40 0.132 82 173 2.11 0.119 2.224* 0.028 
 CAM practice types selected CAM practice types rated  
Number of CAM practice types selected/rated 63 91 1.44 0.106 40 57 1.43 0.118 0.137 0.892 
 
 
 
Table 4.13: Parental CAM rating profiles for paediatric and self-used CAM 
 
 
 
 
Product and practice types selected 
and rated for children 
CAM rating profile Paediatric 
CAM 
Self-used 
CAM 
Binomial test 
(2-P test) 
Product types Practice types Number of 
parents 
% Number of 
parents 
% P (1) - P (2) z score P value 
Selected Rated Selected Rated 
120 104 20 0 Rated only products 71 49.7 57 40.4 0.0922482 1.57 0.117 
87 69 53 46 Rated both products and practices 36 25.2 50 35.5 -0.102862 -1.90 0.058 
12 0 11 11 Rated only practices 16 11.2 34 24.1 -0.129247* -2.90 0.004 
31 0 7 0 Did not rate any CAM used 20 14.0 -     
250 173 91 57 Total  143  141 
   Χ2 test Statistic 52.608*  5.915 
Degree of freedom 3  2 
P value 0.000  0.052 
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Table 4.14: Summary of user-perceived effectiveness and safety outcomes rating of parental paediatric and self CAM use
 
 
 
T a b l e  4 . 1 4 :  S u m m a r y  o f  u s e r - p e r c e i v e d  e f f e c t i v e n e s s  a n d  s a f e t y  o u t c o m e s  r a t i n g  o f  p a r e n t a l  p a e d i a t r i c  a n d  s e l f  C A M  u s e  
A s p e c t  o f  C A M  u s e  a s s e s s e d  O u t c o m e s  r a t i n g  q u e s t i o n  N u m b e r  o f  
r e s p o n d e n t s  
( p a r e n t s )  
R e s p o n s e  d i s t r i b u t i o n  Χ 2  t e s t  
Y e s  N o   
n  %  n  %  S t a t i s t i c  P  v a l u e  
F o r  C A M  m o d a l i t i e s  e v e r  u s e d  i n  o w n  c h i l d r e n  D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u  u s e d  f o r  y o u r  c h i l d ( r e n )  h e l p f u l  1 2 3  1 0 2  8 2 . 9  2 1  1 7 . 1  5 3 . 3 4 1 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  A  L O T  h e l p f u l ?  1 0 2  7 6  7 4 . 5  2 6  2 5 . 5  2 4 . 5 1 0 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  n o t  m u c h  o r  n o t  a t  
a l l  h e l p f u l ?  
1 2 3  6  4 . 9  1 1 7  9 5 . 1  1 0 0 . 1 7 1 *  0 . 0 0 0  
W e r e  y o u  u n s u r e  a b o u t  t h e  h e l p f u l n e s s  o f  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
1 2 3  6 0  4 8 . 8  6 3  5 1 . 2  0 . 0 7 3  0 . 7 8 7  
D i d  y o u  e x p e r i e n c e  a n y  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
1 2 3  9  7 . 3  1 1 4  9 2 . 7  8 9 . 6 3 4 *  0 . 0 0 0  
D i d  y o u  e x p e r i e n c e  a  l o t  o f  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
9  2  2 2 . 2  7  7 7 . 8  2 . 7 7 8  0 . 0 9 6  
F o r  C A M  m o d a l i t i e s  u s e d  i n  o w n  c h i l d r e n  i n  t h e  
l a s t  1 2  m o n t h s  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u  u s e d  f o r  y o u r  c h i l d ( r e n )  h e l p f u l  1 0 4  8 4  8 0 . 8  2 0  1 9 . 2  3 9 . 3 8 5 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  A  L O T  h e l p f u l ?  8 4  6 5  7 7 . 4  1 9  2 2 . 6  2 5 . 1 9 0 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  n o t  m u c h  o r  n o t  a t  
a l l  h e l p f u l ?  
1 0 4  3  2 . 9  1 0 1  9 7 . 1  9 2 . 3 4 6 *  0 . 0 0 0  
W e r e  y o u  u n s u r e  a b o u t  t h e  h e l p f u l n e s s  o f  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
1 0 4  4 6  4 4 . 2  5 8  5 5 . 8  1 . 3 8 5  0 . 2 3 9  
D i d  y o u  e x p e r i e n c e  a n y  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
1 0 4  5  4 . 8  9 9  9 5 . 2  8 4 . 9 6 2 *  0 . 0 0 0  
D i d  y o u  e x p e r i e n c e  a  l o t  o f  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
5  1  2 0 . 0  4  8 0 . 0  1 . 8 0 0  0 . 3 7 5  
F o r  C A M  m o d a l i t i e s  u s e d  i n  o w n  c h i l d r e n  
b e y o n d  t h e  l l a s t  1 2  m o n t h s  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u  u s e d  f o r  y o u r  c h i l d ( r e n )  h e l p f u l  8 8  7 0  7 9 . 5  1 8  2 0 . 5  3 0 . 7 2 7 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  A  L O T  h e l p f u l ?  7 0  5 2  7 4 . 3  1 8  2 5 . 7  1 6 . 5 1 4 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  n o t  m u c h  o r  n o t  a t  
a l l  h e l p f u l ?  
8 8  4  4 . 5  8 4  9 5 . 5  7 2 . 7 2 7 *  0 . 0 0 0  
W e r e  y o u  u n s u r e  a b o u t  t h e  h e l p f u l n e s s  o f  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
8 8  4 1  4 6 . 6  4 7  5 3 . 4  0 . 4 0 9  0 . 5 2 2  
D i d  y o u  e x p e r i e n c e  a n y  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
8 8  5  5 . 7  8 3  9 4 . 3  6 9 . 1 3 6 *  0 . 0 0 0  
D i d  y o u  e x p e r i e n c e  a  l o t  o f  d i s c o m f o r t  w i t h  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
5  1  2 0 . 0  4  8 0 . 0  1 . 8 0 0  0 . 3 7 5  
F o r  C A M  m o d a l i t i e s  e v e r  u s e d  p e r s o n a l l y  b y  
p a r e n t s  t h e m s e l v e s  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u  u s e d  f o r  y o u r  c h i l d ( r e n )  h e l p f u l  1 4 1  1 3 0  9 2 . 2  1 1  7 . 8  1 0 0 . 4 3 3 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  A  L O T  h e l p f u l ?  1 3 0  9 5  7 3 . 1  3 5  2 6 . 9  2 7 . 6 9 2 *  0 . 0 0 0  
D i d  y o u  f i n d  a n y  o f  t h e  C A M  y o u r  c h i l d ( r e n )  u s e d  n o t  m u c h  o r  n o t  a t  
a l l  h e l p f u l ?  
1 4 1  1 0  7 . 1  1 3 1  9 2 . 9  1 0 3 . 8 3 7 *  0 . 0 0 0  
W e r e  y o u  u n s u r e  a b o u t  t h e  h e l p f u l n e s s  o f  a n y  o f  t h e  C A M  y o u r  
c h i l d ( r e n )  u s e d ?  
1 4 1  3 7  2 6 . 2  1 0 4  7 3 . 8  3 1 . 8 3 7 *  0 . 0 0 0  
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proportion who found at least one of the CAM modalities used to be helpful was significantly
less for child CAM users than for self CAM users (82.9 vs. 92.2%; P(1) - P(2)= -0.0927175;
p=0.023). Similarly, while equally small proportions of parents perceived their use of CAM for
their children or for themselves as “not much” or “not at all” helpful (4.9% vs. 7.1%; P(1) – P(2)
= -0.0221415; p=0.446); many more parents (P(1) - P(2) =0.225394; p=0.000) were unsure of
the outcomes of the CAM they used for their children (60; 48.8%) than the CAM they self-used
(37; 26.2%). Although adverse outcomes of CAM use (perceived discomfort) was not studied for
self-used CAM modalities, only nine different parents (7.3%) reported any form of discomfort in
their children following CAM use; two of whom (22.2%) described the adverse effect as extreme.
These adverse outcomes were found to be uniformly distributed between parents who reported
using CAM in their children within the last 12 months and those who had used it further down
in the past.
With respect to the modality level outcomes of CAM use, the specific CAM modalities reported
as having been used continuously (or re-used) over the years by the same parents, along with
their user-perceived effectiveness (UPE) ratings, are listed in table 4.15; while the UPE ratings
for the distinct modalities used in children are compared with self-used modalities in tables 4.16
and 4.17. The CAM modalities reported by parents as having caused “a little” or “a lot” of
discomfort to their children, along with the specific discomforts reported, are outlined in table
4.18.
Among the modalities used consistently by parents listed in table 4.15, although parents rated
75% of product modalities and 95.66% of all practice modalities at least “a little” helpful to
their children, they were unsure of the helpfulness of up to one third (33.75%) of the products.
Although parents rated the helpfulness of both products and practices used in their children very
highly, the parental UPE rating for the practices rated at least “a little” helpful was significantly
higher than for products (95.7% vs. 65.0%; p=0.003)
Tables 4.16 and 4.17 show that parents perceive the CAM modalities they have used much more
effective in themselves than in their children. However, in both child and adult CAM use, whether
for all CAM modalities rated or only for the commonly used ones, CAM practices were associated
with significantly higher UPE ratings than CAM products. There were only two instances where
non-significant differences were observed: the mean % UPE ratings for commonly used CAM
practices used in children relative to those used in their parents (-14.09%; t = -1.45; p = 0.167);
and the % mean UPE ratings for the products used in children relative to the practices used in
them (-10.3%; t = -0.92; p = 0.378). Generally, while the ratings for self-used modalities ranged
from 79.3% in products to 93.2% for practices; they ranged from 67.3% to 82.5%, respectively,
for paediatric CAM modalities. Also, while parents were uncertain about the effectiveness of a
substantial number of modalities, only in relatively few instances was CAM rated as either “not
much” or “not at all” helpful. There were only 6 such instances in child CAM use, 5 of which
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Table 4.15: List and user-perceived effectiveness ratings for CAM modalities used both within
the last 12 months as well as previously
 
 
Table 4.15: t and us -p rceived ffectiveness ratings for CAM 
modalities used both within the last 12 months as well as previously  
CAM modality 
 
 
 
Number 
of 
reports 
UPE Ratings Preva-
lence 
(n=52) 
% 
PE 
Odds of 
a high PE 
rating 
A lot  A 
little 
Not 
sure 
Not 
much 
Not at 
all 
CAM Products 
Anthroposorphic medicine 1 1     1.9   
Arnica 4 2 1 1   7.7 75.0 1.00 
Aromatherapy 3 2 1    5.8 100.0 2.00 
Aveeno 1 1     1.9   
Bach flower remedy 1    1  1.9   
Balm 1 1     1.9   
Camomile 1  1    1.9   
Cod liver oil 2   2   3.9   
Echinacea 4 2  2   7.7 50.0 1.00 
Garlic 1 1     1.9   
Ginger 1 1     1.9   
Herbal teas 1  1    1.9   
Herbal remedies 1 1     1.9   
Homeopathy 1  1    1.9   
Honey 2  1 1   3.9   
Lavendar oil 1 1     1.9   
Melatonin 1 1     1.9   
Multivitamins 16 6 1 9   30.8 43.8 0.60 
Nettle soap 1   1   1.9   
Olbas oil 12 5 5 2   23.1 83.3 0.71 
Omega 3 4 3  1   7.7 75.0 3.00 
Organic foods 1 1     1.9   
Oscilococcinum 1 1     1.9   
Rescue® remedy 2 1 1    3.9   
Tea tree oil 2 1  1   3.9   
Teething remedy 1 1     1.9   
Thuja 1 1     1.9   
Traditional Chinese Medicine (TCM) 1 1     1.9   
Vitamin C 1   1   1.9   
Vitamin D 1   1   1.9   
Yogurt 9 2 2 5   17.3 44.4 0.29 
Total ratings 80 37 15 27 1 0    
% of total product ratings 100.0 46.25 18.75 33.75 1.25 0.00    
Mean % PE for the products rated (with a prevalence of at least 5 %; x≥3 reports) =67.36 % 
CAM Practices 
Breathing exercises 3 3     5.8 100.0 ∞ 
Chiropractic 1 1     1.9   
Cranio-sacral therapy 1 1     1.9   
Healing 5 5     9.6 100.0 ∞ 
Massage 9 7 1 1   17.3 88.9 0.78 
Reflexology 2 2     3.9   
Yoga 2 1 1    3.9   
Total ratings 23 20 2 1 0 0    
% of total practice ratings 100.0 86.96 8.70 4.34 0.00 0.00    
Mean % PE for the practices rated (with a prevalence of at least 5 %; x≥3 reports) =96.3 % 
Binomial test P(UPE Products)-P(UPE Practices): difference =-0.306522; p= 0.003 
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Table 4.16: User-perceived effectiveness (UPE) ratings of CAM products in children and their parents
 
 
Table 4.16: User-perceived effectiveness (UPE) ratings of CAM products in children and their parents 
CAM Products UPE rating (Child use) Total  Preva-
lence 
% 
PE 
(%) 
Odds of 
rating 
“A lot” 
UPE rating (Self use) Total Preva-
lence 
%  
PE 
(%) 
Odds of 
rating  
“A lot” 
Odds of 
CAM use in 
children  
A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
African traditional medicines          1 1    2 1.89    
Agnus castus   1  1 2 1.89    
Aloe vera 2 1 3 2.80   4  4 3.77    
Anthroposorphic medicine 1  1 0.93   1     1 0.94    
Aptamil 1 1 0.93             
Arnica 3 3 2 8 7.48 75.0 0.6 1 5 1   7 6.60 85.7 0.17 1.14 
Aromatherapy –non specific 3 2  5 4.67   4 3  1  8 7.55 87.5 1.00 0.625 
Atkin’s diet -       2    2 1.89    
Aveeno 1 1 0.93             
Bach flower remedy 1 1 2 1.87   5 3 1   9 8.49 88.9 1.25 0.22 
Balm 3  3 2.80   1     1 0.94    
Bilberry 1 1 0.93             
Bio propilis       1     1 0.94    
Calcium     1     1 0.94    
Camomile 1 1 1 3 2.80    1    1 0.94    
Chondroitin          1   1 0.94    
Cinnamon      1    1 0.94    
Clove oil     1     1 0.94    
Cod liver oil 2 2 1.87   1  4   5 4.67    
Colloidal silver       1    1 0.94    
Colocynthis 1 1 0.93             
Cranberry      1 1    2 1.89    
Dairy-free products 1 1 0.93             
Detox diet       1    1 0.94    
Dietary supplement  1 1 2 1.87   4 2    6 5.66 100.0 2.00 0.33 
Echinacea 6 1 4  11 10.28 63.6 1.2 6 5 2   13 12.26 84.6 0.86 0.85 
Essential oils        1     1 0.94    
Eucalyptus 1 1 0.93   1     1 0.94    
Evening primrose 1  1 2 1.87   4  2   6 5.66 66.7 2.00 0.33 
Floradix® herbal remedy          1   1 0.94    
Folic acid     1  1   2 1.89    
Garlic 1 1 0.93   1     1 0.94    
Ginger 2 2 1.87   3     3 2.83    
Gingko biloba      1     1 0.94    
Ginseng     1  1   2 1.89    
Gluten-free diet     2 1    3 2.83    
Green tea 1 1 0.93             
Herbal tea 1 2 1  4 3.74   3 6 1  1 11 10.38 81.8 0.375 0.36 
Herbal medicines 2   2 1.87   8 6 3 1 1 19 17.92 73.7 0.42 0.11 
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H o m e - m a d e  r e m e d i e s   1     1  0 . 9 3    1      1  0 . 9 4     
H o m e o p a t h i c  r e m e d y  1  2  2    5  4 . 6 7    5  2  1  1   9  8 . 4 9  7 7 . 8  1 . 2 5  0 . 5 6  
H o n e y  5  2  3    1 0  9 . 3 5  7 0 . 0  1 . 0 0  2  1  1    4  3 . 7 7    2 . 5  
H o r s e t a i l           1      1  0 . 9 4     
I r o n  s u p p l e m e n t s            1  1    2  1 . 8 9     
J a n  d e  V r i e s  s u p p l e m e n t s           1      1  1 . 9 4     
L a c t o s e - f r e e  m i l k   1     1  0 . 9 3              
L a v e n d a r  o i l  2  2     4  3 . 7 4    3  2  1    6  5 . 6 6  8 3 . 3  1 . 0 0  0 . 6 7  
L e m o n / l i m e  o i l            4     4  3 . 7 7     
M a c r o b i o t i c  d i e t           1      1  0 . 9 4     
M e l a t o n i n  1      1  0 . 9 3              
M i l k  t h i s t l e           1      1  0 . 9 4     
M u l t i v i t a m i n s  1 7  5  2 8  1   5 1  4 7 . 6 6  4 3 . 1  0 . 5  8  6  8  1  1  2 4  2 2 . 6 4  5 8 . 3  0 . 5 0  2 . 1 2 5  
N e t t l e    1    1  0 . 9 3      1    1  0 . 9 4     
O l b a s  o i l  1 5  1 4  4    3 3  3 0 . 8 4  8 7 . 9  0 . 8 3  1 1  5  1    1 7  1 6 . 0 4  9 4 . 1  1 . 8 3  1 . 9 4  
O m e g a  3  3  1  2    6  5 . 6 1  6 6 . 7  0 . 5  1  1  1    3  2 . 8 3    2 . 0 0  
O r g a n i c  f o o d s  1      1  0 . 9 3    1      1  0 . 9 4     
O s c i l o c o c c i n u m  1      1  0 . 9 3              
P a i n  r e l i e f           1      1  0 . 9 4     
P e p p e r m i n t  o i l           1  1     2  1 . 8 9     
R a s p b e r r y           1      1  0 . 9 4     
R e s c u e  r e m e d y  1  1     2  1 . 8 7    1   1  1   3  2 . 8 3     
R o s e m a r y   1     1  0 . 9 3     1     1  0 . 9 4     
S l e e p  r e m e d y             1    1  0 . 9 4     
S p e c i a l  d i e t  – n o n - s p e c i f i c           2      2  1 . 8 9     
S t .  J o h n ’ s  w o r t            1    1  2  1 . 8 9     
S t a r f l o w e r  o i l           1  -     1  0 . 9 4     
T e a  t r e e  o i l  2  2  1  1   6  5 . 6 1  6 6 . 7  0 . 5 0  2  5  1    8  7 . 5 5  8 7 . 5  0 . 3 3  0 . 7 5  
T e e t h i n g  r e m e d y  3  2  1    6  5 . 6 1  8 3 . 3  0 . 5 0  -          ∞  
T h u j a  4   1    5  4 . 6 7    1      1  0 . 9 3     
T h y m e  o i l  1      1  0 . 9 3    1      1  0 . 9 3     
T r a d i t i o n a l  C h i n e s e  m e d i c i n e s  3      3  2 . 8 0    4  1     5  4 . 6 7     
V i t a m i n  C  1   3    4  3 . 7 4    2  2     4  3 . 7 7     
V i t a m i n  D   2  2    4  3 . 7 4     1     1  0 . 9 4     
V i c k s  v a p o u r  r u b  1  1     2  1 . 8 7     1     1  0 . 9 4     
W h i t e  t e a             1    1  0 . 9 4     
Y o g u r t  1 1  9  1 4    3 4  3 1 . 7 8  5 8 . 8  0 . 4 8  7  8  6    2 1  1 9 . 8 1  7 1 . 4  0 . 5 0  1 . 6 2  
Z i n c            2  -    2  1 . 8 9  -  -  -  
S u m  o f  U P E  r a t i n g s   1 0 5  5 7  7 4  5  -  2 4 1    0 . 7 7  1 1 9  8 4  4 4  5  4  2 5 6    0 . 8 7  0 . 9 4  
%  o f  t o t a l  r a t i n g s  4 3 . 6  2 3 . 7  3 0 . 7  2 . 0  0 . 0 0  1 0 0     4 6 . 5  3 2 . 8  1 7 . 2  2 . 0  1 . 5  1 0 0      
T o t a l  n u m b e r  o f  u s e r s  1 0 7  p a r e n t  u s e r s  i n  o w n  c h i l d r e n  1 0 6  p a r e n t  s e l f - u s e r s   
M e a n  ( S E M )  %  U P E  R A T I N G  f o r  p r o d u c t s  r a t e d  6 8 . 1  ( 5 . 0 )  %  8 1 . 7  ( 2 . 9 )  %   
S t a t i s t i c a l  d i f f e r e n c e  i n  U P E  b a s e d  o n  p r o p o r t i o n  o f  t o t a l  r a t i n g s  r e p o r t e d  ( c h i l d  v s .  p a r e n t )  - 0 . 1 2 0 7 7 0 *  ( - 0 . 1 9 8 0 7 2 ,  - 0 . 0 4 3 4 6 6 7 ) ;  z  =  - 3 . 0 6   P  =  0 . 0 0 2  
S t a t i s t i c a l  d i f f e r e n c e  i n  M e a n  %  U P E  R A T I N G  f o r  c o m m o n l y  u s e d  p r o d u c t s  ( c h i l d  v s .  p a r e n t )  - 1 3 . 5 8 % *  ( - 2 4 . 8 1 ,  - 2 . 3 5 ) ;  t =  - 2 . 5 2 ;   p  =  0 . 0 2 0  
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Table 4.17: User-perceived effectiveness (UPE) ratings of CAM practices in children and their parents
 
 
Table 4.17: User-perceived effectiveness (UPE) ratings of CAM practices in children and their parents 
CAM Practices UPE rating (Child use) Total Preva-
lence 
% 
PE 
(%) 
Odds of 
rating 
“A lot” 
UPE rating (Self use) Total Preva-
lence 
% 
PE 
(%) 
Odds of 
rating  
“A lot” 
Odds of 
CAM use in 
children 
A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
Acupuncture          13 7 4   24 28.57 83.3 1.18 0 
Aerobics           1    1 0.12    
Alexander technique          1     1 0.12    
Breathing exercises 6 1    7 13.46 100.0 6.00 7 1    8 9.52 100.0 7.00 0.875 
Chiropractic  1  2   3 5.77 33.3 0.50 8 4    12 14.29 100.0 2.00 0.25 
Cranio-sacral therapy 1     1 1.92   1     1 0.12    
Cupping therapy          1     1 0.12    
Ear candling          1     1 0.12    
Guided imagery 1     1 1.92             
Healing 12     12 23.08 100.0 ∞ 10 1    11 13.10 100.0 10.00 1.09 
Hypnotherapy   1   1 1.92 - - 2    1 3 3.57    
Massage  20 7 7  1 35 67.31 77.14 1.33 25 11    36 42.86 100.0 2.27 0.97 
Meditation          4 1    5 5.95 100.0 4.00 0 
Mindfulness          1     1 0.12    
Music/dance therapy 1     1 1.92   3     3 3.57    
Naturopathy 1     1 1.92   2     2 2.38    
Osteopathy          10     10 11.90 100.0 ∞ 0 
Pilates          4 1    5 5.95 100.0 4.00 0.00 
Reflexology 3  2   5 9.62 60.0 1.50 12 4 4   20 23.81 80.0 1.50 0.25 
Reiki 1     1 1.92   3 - 2   5 5.95 60.0 1.50 0.20 
Relaxation therapy          1 1    2 2.38    
Shiatsu          1 1    2 2.38    
Special exercises          2     2 2.38    
Tai chi          1     1 0.12    
Thermotherapy          1     1 0.12    
Visualisation          1     1 0.12    
Yoga 5 1   6 11.54 100.0 5.00 12 4 1   17 20.24 94.12 2.40 0.35 
Sum of UPE ratings  52 9 12 - 1 74   2.36 127 37 11 - 1 176   2.59  
% of total ratings 70.3 12.2 16.2 - 1.3 100    72.2 21.0 6.25  0.56 100     
Number of users 52 parent users in own children 84 parent self-users  
Mean % UPE RATING for practices rated  78.4 (11.0) % 92.5 (3.9) %  
Statistical difference in UPE based on proportion of total ratings reported (child vs. parent) -0.107494* (-0.201856, -0.0131317); z = -2.23  p= 0.026 
Statistical difference in Mean % UPE rating for commonly used practices (child vs. parent) -14.09 % (-34.74, 6.57); t = -1.45;  p = 0.167 
COMPARISONS FOR RATINGS IN CHILD CAM USE 
Statistical difference in UPE based on total ratings reported (products vs. practices) -0.152125* (-0.257148, -0.0471024); z=-2.84; p= 0.005 
Statistical difference in Mean % UPE rating for commonly used CAM (products vs. practices) -10.3 % (-34.7, 14.2); t = -0.92; p = 0.378  
COMPARISONS FOR RATINGS IN PARENT SELF CAM USE 
Statistical difference in UPE based on total ratings reported (products vs. practices) -0.138849* (-0.200899, -0.0767996); z=-4.39; p= 0.000 
Statistical difference in Mean % UPE rating for commonly used CAM (products vs. practices) -10.79 %* (-20.67, -0.89); t = -2.25; p = 0.034 
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were rated as “not much”; with the only one rated as “not at all” helpful being a CAM practice,
massage, the most commonly used practice. Of the 10 modalities that parents rated poorly in
terms of effectiveness, 4 were products (an unspecified herbal tea; an unspecified herbal medicine,
multivitamins –the most commonly used product modality, and St. John’s Wort, a medically
recognised herb); and 1 practice modality, hypnotherapy. When the UPE ratings for the CAM
modalities that were re-used or used consistently within and beyond the last 12 months (table
4.15) were compared with those of modalities that were used only at one point in time only, they
were not found to be markedly higher, except for CAM practices.
Finally, table 4.18 shows the very low incidences of reported adverse events for CAM use in
children. An adverse event incidence of just 3.81% was associated with overall CAM use in
children, amounting to a 96.19% safety level for paediatric CAM use. Of the total of 12 adverse
events reported, only 2 reports (0.63%) were described as causing a lot of discomfort. CAM safety
was, however, not studied for self CAM use by parents.
Table 4.19 outlines the dependent and independent factors associated with parents finding pae-
diatric CAM use helpful. Among the five parental factors upon which a positive perception of
paediatric CAM use effectiveness was dependent, only two were associated with significant odds
ratios –finding personal CAM use effective [OR (95% CI) =17.292 (3.011-99.305)] and the use of
similar CAM type(s) in children [OR (95% CI) =3.327 (1.004-11.031). And of these two depen-
dent factors, only finding personal CAM use effective was found to significantly predict perceived
effectiveness outcomes for paediatric CAM use [Exp(B) (95% C) =9.301 (1.454-59.505)]. The
results of the logistic regression indicate that a finding of a positive outcome for CAM use in
parents would be associated with a 9-fold increased likelihood of a positive outcome report for
CAM use in children when other factors are controlled for. The regression model used had a
Hosmer and Lemeshow Chi square test of 0.863 (p=0.863), with a Cox and Snell R2 value of
0.102; and improved the predictive power of the null from 81.8% to 84.1%.
4.3.8 Attitudes of the parents in Aberdeen metropolitan area towards paedi-
atric CAM use and future research on it
The attitudes of parents within the Aberdeen metropolitan area towards paediatric CAM use and
research are summarised in figures 4.3 to 4.13. The effect of CAM use status on parental attitudes
was investigated by comparing the views of the 143 parents (67.5%) who had used CAM in their
children to those of the 69 parents (32.5%) who had never done so on a set of ten questions. The
investigation comprised six questions on the use of CAM in children generally; and two questions
each on the effectiveness and safety outcomes of CAM use. As the questions were phrased in the
first person singular, responding parents were able to own the responses they provided, rather
than give general ones. The question that investigated participant disposition towards further
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Table 4.18: CAM products and practices rated as having caused some degree of discomfort to children
 
 
Table 4.18: CAM products and practices rated as having caused some degree of discomfort to children 
Caused “a little” discomfort Caused “a lot of”  discomfort 
Modality (Discomfort reported) Number and 
frequency of report 
Incidence CAM Modality  
(with associated UPE level) 
Frequency of report Incidence 
CAM Practices 
Massage (Abdominal discomfort; 
Soreness) 
2 reports (out of 
35 episodes of use) 
5.71 %    
Hot water massage (Scalding) 1 report (out of 1 
episode of use) 
Not 
determined 
   
Number of practices reported to have 
caused “a little discomfort” 
3 reports (out of 74 
rated episodes of use) 
4.05 % Number of practices reported to have 
caused “a lot of discomfort” 
0  
CAM Products 
“Doctor’s choice” (Allergy) 1 report (out of 1 
episode of use) 
Not 
determined 
Homeopathic remedy (Skin reaction) 2 reports (out of 
5 episodes of use) 
40.0 % 
Yogurt (Not stated/Unpleasant taste) 2 reports (out of 
34 episodes of use) 
5.88 %    
Thuja (Unpleasant taste) 1 report (out of 
5 episodes of use) 
20.0 %    
Homeopathic remedy (Unpleasant taste) 1 report (out of 
5 episodes of use) 
20.0 %    
Green tea (Unpleasant taste) 1 report (out of 1 
episode of use) 
Not 
determined 
   
Traditional Chinese medicine (Allergy) 1 report (out of 3 
episodes of use) 
33.3 %    
Number of products reported to have 
caused “a little discomfort” 
7 reports (out of 241 
rated episodes of use) 
2.90 % Number of products reported to have 
caused “a lot of discomfort” 
2 reports (out of 241 
rated episodes of use) 
0.83 % 
Total number of modalities associated 
with “a little discomfort” 
10 reports (out of 315 
episodes of use) 
3.17 % Total number of modalities 
associated with “a lot of discomfort” 
2 reports (out of 315 
episodes of use) 
0.63 % 
Percentage of adverse events reported among all rated episodes of CAM use 12 adverse event reports out of 315 rated episodes of use (3.81 %) 
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Table 4.19: Dependent and independent factors of user-perceived effectiveness rating of paediatric CAM use
 
 
T a b l e  4 . 1 9 :  D e p e n d e n t  a n d  i n d e p e n d e n t  f a c t o r s  o f  u s e r - p e r c e i v e d  e f f e c t i v e n e s s  r a t i n g  o f  p a e d i a t r i c  C A M  u s e  
 
F a c t o r  T o t a l   
c a s e s  
F o u n d  C A M  u s e d   
i n  c h i l d r e n  h e l p f u l  
C o r r e l a t i o n  w i t h  
 f i n d i n g  c h i l d  
C A M  u s e  h e l p f u l  
O d d s  o f  f i n d i n g  
c h i l d  C A M  u s e  
h e l p f u l  
B i n a r y   
l o g i s t i c  
r e g r e s s i o n  Y e s  N o /  
N o t  s u r e  
M i s s i n g  
d a t a  
n  %  n  %  n  %  r  P  v a l u e  O R  ( 9 5  %  C I )  E x p ( B )  ( 9 5  %  C I )  
P e r s o n a l  C A M  u s e  1 4 1  8 5  6 0 . 3  1 7  1 2 . 1  3 9  2 7 . 7  0 . 0 4 2  0 . 6 4 6      
F i n d i n g  p e r s o n a l  C A M  u s e  h e l p f u l  1 3 0  8 3  6 3 . 8  1 2  8 . 2  3 5  2 6 . 9  0 . 3 9 9 *  0 . 0 0 0  1 7 . 2 9 2 *  ( 3 . 0 1 1 - 9 9 . 3 0 5 )  9 . 3 0 1 *  ( 1 . 4 5 4 - 5 9 . 5 0 5 )  
U s e  o f  s i m i l a r  C A M  t y p e  i n  c h i l d  7 1  6 1  8 5 . 9  1 0  1 4 . 1  -  -  0 . 2 1 7 *  0 . 0 4 2  3 . 3 2 7 *  ( 1 . 0 0 4 - 1 1 . 0 3 1 )  2 . 5 7 4  ( 0 . 7 0 5 - 9 . 4 0 1 )  
H a v i n g  a l w a y s  u s e d  C A M  i n  c h i l d r e n  8 5  6 4  7 5 . 3  8  9 . 4  1 3  1 5 . 3  0 . 0 6 7  0 . 5 0 3      
R a t i n g  o n l y  C A M  p r o d u c t  u s e  i n  c h i l d r e n  7 1  5 4  7 6 . 1  1 7  2 3 . 9  -  -  0 . 0 4 6  0 . 6 4 3      
C o n t i n u e d  u s e  o f  a  s p e c i f i c  C A M  i n  c h i l d r e n  5 2  4 6  8 8 . 5  6  1 1 . 5  -  -  0 . 0 3 8  0 . 7 5 1      
B e i n g  a  m o t h e r / f e m a l e  g u a r d i a n  1 5 6  8 2  5 2 . 6  1 5  9 . 6  5 9  3 7 . 8  0 . 0 8 3  0 . 3 6 4      
B e i n g  a g e d  3 0 - 4 4  y e a r s  1 2 6  6 6  5 2 . 4  1 6  1 2 . 7  4 4  3 4 . 9  - 0 . 0 8 7  0 . 3 4 0      
L i v i n g  i n  a n  u r b a n  a r e a / a c c e s s i b l e  s m a l l  t o w n  1 4 7  7 5  5 1 . 0  1 3  8 . 8  5 9  4 0 . 1  0 . 1 0 4  0 . 2 5 4      
B e i n g  i n  a n  o n - g o i n g  c o u p l e d  r e l a t i o n s h i p  1 8 4  8 9  4 8 . 4  1 9  1 0 . 3  7 6  4 1 . 3  - 0 . 0 2 8  0 . 7 6 0      
H a v i n g  a  c h i l d  a g e d  < 5  y e a r s  8 0  3 7  4 6 . 3  9  1 1 . 3  3 4  4 2 . 5  - 0 . 0 5 1  0 . 5 7 4      
H a v i n g  o n l y  c h i l d r e n  a g e d  < 5  y e a r s  4 0  1 8  4 5 . 0  5  1 2 . 5  1 7  4 2 . 5  - 0 . 4 3 7 *  0 . 0 0 0  0 . 6 8 6  ( 0 . 2 2 2 - 2 . 1 1 4 )  -  -  
H a v i n g  a  c h i l d  a g e d  < 1 2  y e a r s  1 6 4  8 4  5 1 . 2  1 6  9 . 8  6 4  3 9 . 0  0 . 0 5 9  0 . 5 1 3      
H a v i n g  o n l y  c h i l d r e n  a g e d  < 1 2  y e a r s  1 3 9  7 0  5 0 . 4  1 4  1 0 . 1  5 5  3 9 . 6  - 0 . 2 0 2 *  0 . 0 4 2  1 . 0 9 4  ( 0 . 4 0 3 - 2 . 9 7 0 )  -  -  
H a v i n g  a  c h i l d  a g e d  < 1 8  y e a r s  1 8 9  8 5  5 0 . 3  2 0  1 0 . 6  7 4  3 9 . 2  - 0 . 0 3 2  0 . 7 2 5      
H a v i n g  o n l y  c h i l d r e n  a g e d  < 1 8  y e a r s  1 7 4  8 8  5 0 . 6  1 8  1 0 . 3  6 8  3 9 . 1  0 . 0 0 6  0 . 9 4 7      
B e i n g  C a u c a s i a n  1 7 9  8 3  4 6 . 4  2 1  1 1 . 7  7 5  4 1 . 9  - 0 . 1 9 4 *  0 . 0 3 2  0 . 0 0 0  -  -  -  
B e i n g  e d u c a t e d  b e y o n d  s e c o n d a r y  l e v e l  1 8 0  9 2  5 1 . 1  2 8  1 0 . 0  7 0  3 8 . 9  0 . 0 5 5  0 . 5 4 7      
B e i n g  r e l i g i o u s  1 0 5  6 1  4 8 . 6  8  7 . 6  4 6  4 3 . 8  0 . 0 9 0  0 . 3 2 4      
C o m p l e t i n g  a  p a p e r - b a s e d  s u r v e y  1 4 4  7 7  5 3 . 5  1 6  1 1 . 1  5 1  3 5 . 4  - 0 . 0 0 6  0 . 9 4 6      
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paediatric CAM research was asked only to parents who had indicated in the online survey that
they had ever used CAM for their children.
 
 
 
Figure 4.3: Parental attitudes towards CAM use in children 
 
Figure 4.4: Parental attitudes on the idea that people should be allowed 
to make up their own minds about the choice to use CAM  
 
 
 
Figure 4.3: Parental attitudes towards CAM use in children
Figure 4.3 illustrates the attitudes of participants on the idea that CAM use should be avoided
in children. The responses indicate that 140 parents (68.3 % of the 205 respondents), including
29 (42.03 %) of those who had never used CAM in their children, disagreed with the idea. About
a quarter of the respondents, including statistically equal numbers of users and non-users, were
however uncertain about it. Strangely, of the 11 parents (5.37%) who agreed with CAM use being
avoided in children, 3 (1.47%) had used CAM in their children; with 2 of them having always used
it for them. Closer investigation revealed that, while one of these three users had not rated the
CAM their children had used, the other two had rated the CAM used as “a little helpful” with
“no discomfort whatsoever” in three of the four reported instances of use (75%). The remaining
case, the CAM practice massage, was rated “not sure” with “a little discomfort”.
In line with this general trend in support of CAM use in children, the findings indicate that, while
parents in the study area overwhelmingly (87.0%; 120 of 138 respondents) prefer to be allowed
to make up their own minds on whether and what CAM they would use in their children (figure
4.4), four fifths of them (79.8%; 147 of 184 respondents) required more information on CAM to be
able to do so (figure 4.5). In each of these instances, both users and non-users of CAM modalities
in children supported the views.
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In spite of the apparent preference among parents for CAM use in children to be a private affair,
74.2% of parents (156 of 206 respondents) agreed that parents should inform doctors of the use
of CAM in their children (figure 4.6); and 63.1% (130 of 206 respondents) supported CAM being
made readily available on the NHS (figure 4.7). However, while 47.1% (97 of 206 respondents)
disagreed with the idea of avoiding the use of CAM along with prescribed conventional medicines,
31.1% (64 respondents, including 34 users) were uncertain about this.
Parental views on the outcomes associated with CAM use in children, illustrated in figures 4.9 to
4.12, indicate that, although nearly half of the respondents (46.4%; 95 of 205 respondents) believed
certain health conditions in children were better managed with CAM than with conventional
prescribed medicines (figure 4.9); 52.2% (107 of 205 respondents) were uncertain about CAM
being more effective generally. Also, and notably, more parents disagreed (35.6%) than agreed
(12.2%) with this idea; and most of those in opposition were CAM users (54 respondents; 74%).
The same trend was seen among the majority who were uncertain on this matter, as about 60% (64
respondents; 59.8%) were CAM users. In all, 118 of the 137 CAM users (86.1%) who responded
were either unsure about or totally against the idea that CAM is generally more effective than
prescribed complementary medicines.
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available
A similar trend was observed with respect to the safety outcomes associated with CAM use in
children. While almost half of the parents (45.5%; 93 of 204 respondents) disagreed with the
idea that CAM causes harmful side effects in children (figure 4.11); 44.4% of them (19 of 295 re-
spondents) were not sure about CAM modalities being generally safer in children than prescribed
conventional medicines (figure 4.12). However, unlike observed for perceived effectiveness, more
people agreed (66; 32.2%) than disagreed (48; 23.4%) with the idea of CAM being safer than
prescribed conventional medicines. But as seen earlier, a greater proportion of those who either
totally disagreed with the idea (70.8%; 34 of 48 opposers) or were uncertain (59.3%; 54 of 91
respondents) were CAM users. In all, 64.2% of the CAM users that answered this question (88
of 137 CAM users) were either unsure of the idea of CAM being generally safer than prescribed
conventional medicines or totally against it.
Finally, figure 4.13 illustrates the spread of opinions among the cohort of parents who were asked
about their disposition towards participating in a further telephone interview study on CAM
use in their children. Of the 16 participants of the online survey who had used CAM in their
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Figure 4.8: Parental attitudes on the idea that CAM should not be used along with conventional
medicines in children
children, and thus qualified to be asked this question, close to two thirds (10; 62.5%) were willing
to participate, while 3 participants (18.75%) each were either unwilling or yet to decide.
4.4 Discussion
4.4.1 Development and validation of survey instrument
The extensive process followed in the development and validation of the survey ensured that
its content could not only be understood by the intended participants, but also was inclusive
enough for a wide range of parents. Instrument validation is an important marker of study quality
achieved by only 9 (20%) of the studies included in the SR reported in chapter 2. Although a non-
statistical method was used to validate the questionnaire used in this study, qualitative methods
like focus groups and cognitive interviews are recognised methods of questionnaire validation
[80], even for health-related outcomes [648, 649]. Moreover, as the study was not designed to be
longitudinal, and as such did not intend to measure change in health status, it was not specifically
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children with CAM
necessary to further subject the instrument to detailed psychometric analyses to determine its
reliability and sensitivity to change [79].
4.4.2 Participant recruitment
Although, no response rate (RR) could be calculated for the online aspect of the study, the 27.64%
RR obtained for the paper-based version was much lower than the 60% generally accepted as the
standard for paper-based surveys [329, 330]. However, this was similar to the RRs obtained in
some of the papers included in the SR reported in chapter 2 [358, 373, 374, 492]. The most
recent Scottish study on CAM use in children [647] had a RR of 44%, despite being specifically
targeted at known children with cancer. In the light of these, the low RR obtained in this study is
understandable. While the impact of response bias on the results of patient satisfaction surveys
has been noted [650], it has also been established that low RRs do not automatically invalidate the
findings of the survey studies with which they are associated [651]. Moreover, the poor showing
in this singular respect was overcome in the study by achievement all the other indices of quality
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Figure 4.12: Parental attitudes on the greater safety of CAM use in children relative to con-
ventional medicines
recruitment. Not only did the study achieve a sample size of > 300 children, it also surpassed the
378 children determined as the minimum sample required for statistical representativeness. In
fact, this survey studied CAM use in the largest number of children amongst all the CAM surveys
previously conducted in Scotland. The Scottish study with a sample size nearest to the one in
the current study studied 327 children recruited from a hospital setting in Aberdeen [351]. Also,
only one of the British paediatric CAM studies was able to recruit a larger number of children
[348]. However, a similar study conducted in Finland in 2007 recruited 4,032 school children aged
less than 12 years [652]. Also, of the eight studies in the SR reported in chapter 2 that obtained
sample sizes of more than 600 children, only one was conducted in the UK. While the difficulty
of recruiting paediatric subjects for research studies is generally acknowledged, the higher sample
sizes recruited in studies conducted in other parts of the world suggest the relatively greater
difficulty of conducting paediatric research in the UK.
Although, a large proportion of the respondents were eventually drawn from Aberdeen city’s
northern suburbs, this was not because efforts were not made to ensure uniform distribution
of the study. The requirements of the use of multiple centres [331, 332]; a population-based
approach [333, 334]; and a broad-based online sampling frame [653] were all met; which efforts
were manifest in the spread of participants across 29 of the 32 postcode areas in the survey
Chapter 4. Cross-Sectional Survey 189
 
 
Figure 4.13: Disposition of parent CAM users towards participation in a 
further study n paediat ic CAM use 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Disposition of parent CAM users towards participation in a further study on
paediatric CAM use
area, and five of the six areas in the Scottish 6-fold urban-rural classification profile. Moreover,
the key demographic features of the participants match those outlined for Aberdeen city and
its shire in many respects [654]. These include features such as female young children being
marginally more in number than males; a high proportion of “small family” households; a very low
proportion of single parent households; a high population of people with post-secondary education
qualification; and a relatively low proportion of those without formal qualifications, among others.
The distribution of young children in different parts of the study area is also generally similar to
available demographic data. Thus, while there is significant room for improvement in the area
of participant recruitment, these facts indicate that the study and its findings can be considered
generally representative of the target population.
4.4.3 Nature of paediatric CAM use and its correlates
67.5% of parents were found to have used CAM in their children at one point or the other; with
the prevalence being 63.2% among children generally, and 66.1% for those aged up to 17 years.
These prevalence values are much higher than the values indicated for UK children in general
[395]; or even for children in Aberdeen [351]. One reason for this could be because the Aberdeen
study focused only on product-based CAM modalities. Another Scottish study based in Glasgow
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that included CAM practices along with products [352] found a prevalence level of 61% among
children with inflammatory bowel disease. The most recent Scottish study based in Edinburgh
[647] also studied both products and practices, and found a prevalence level of 55%. In the light
of these data, the findings of this study indicate that paediatric CAM use is higher in Aberdeen
area than other parts of Scotland, and the UK. This may not be unrelated to the relatively higher
income status of Aberdeen city [655], a factor that has been associated with paediatric CAM use
in other studies [220, 656].
Of the 213 children aged up to 17 years (66.1%) who had ever used CAM, 137 (64.3%) had always
used it; while 45 (21.1%) and 31 (14.6%) either started using it within the last 12 months, or
used it previously. The fact that much more of the children have always used CAM than have
used it either in the past or only within the last 12 months indicates that paediatric CAM use
is growing in Aberdeen metropolitan area as it is in other parts of the world, and particularly in
Europe [599]. The last paediatric CAM use study conducted in Aberdeen 7 years ago [351] not
only reported a much lower prevalence of 29% for CAM products, but also a 12-month prevalence
of 20%, suggesting a declining level of use. While a longitudinal study is required to verify this
finding, the findings of this study have high significance for healthcare policy and planning.
Paediatric CAM use was found in this study to be highly correlated with an age group of 30-44
years, Caucasian race, post-secondary education and parental self CAM use. These are all in
line with the main demographic features associated with CAM use both in literature and also in
the UK [608, 657]. Religiosity was however found not to be an important factor for CAM use in
the study area, unlike reported for some other parts of the world [658, 659]. In line with other
studies [370, 383], personal CAM use by parents was also found to be the strongest predictor
of paediatric CAM use. This factor was also seen to be a predictor of consistent CAM use in
children. This finding is significant given that, due to ethical reasons, many more CAM studies
have been conducted in adults than in children. If these findings are verified in regression analyses
in future paediatric CAM studies, it could reduce the necessity of conducting extensive paediatric
CAM studies, given the huge challenges associated with them.
4.4.4 User-perceived effectiveness and safety outcomes of paediatric CAM use
in the target groups
This study found a UPE of 68.1% and 78.4% for CAM products and practices, respectively.
While these values are lower than the equivalent values for self-used CAM among parents, they
are generally higher than the findings for most UK studies. Apart from Simpson and Roman
[348] that reported a perceived effectiveness of 85% among therapies used, no other UK study
reported a PE level as high as the current study. As the other Scottish study with a UPE level
(61%) that is closest to this study was also carried out in Aberdeen [351], this finding may be
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more indicative of parents in within the Aberdeen area. The finding is however lower than the
79% mean UPE rating reported by the studies in the SR of chapter 2. One reason for this could
be the variety of measurement levels and format used for UPE measurement, varying from a
simple “Yes/No” nominal rating scale to vastly varying levels of ordinal rating scales. The need
for a more standardised method of rating UPE cannot therefore be over-emphasized.
This study also found a very low report of adverse events associated with CAM modalities (12
reports; 3.81%). This finding is very much in line with the finding among similar studies included
in the SR; as well as the main outcome of the exploratory analysis of the YCS database reported
in chapter 3. Of the 12 reports flagged up by respondents, only 2 were classified as having caused
the users “a lot of discomfort”. While these findings are further proof of the high degree of safety
associated with CAM use, it is striking that homeopathic remedies are the most associated with
the adverse events reported; and particularly with causing “a lot of discomfort”. This finding,
however, agrees with those of the exploratory analysis of the YCS data reported in chapter 3
of this thesis, which also highlighted the relatively high serious ADR potential of homeopathic
medicinal products. Homeopathic products have severally been reported in literature as among
the safest form of CAM [50, 157]; and have been promoted with the aim of avoiding the risk
of drug interactions associated with herbal medicines [660]. Moreover, a study prescribing data
in 323 medical practices in Scotland [630] found that “a substantial number of Scottish general
practitioners prescribe homoeopathic and herbal remedies, with an approximate doubling in the
number of children prescribed homoeopathic remedies”. In the light of the findings from this
study, there is great need for closer monitoring of homeopathic medicine use, particularly in
children.
4.4.5 Limitations of the study
There are a number of limitations with this study. For one, there is still a lot of misunderstanding
as to what really constitutes CAM. Many of the modalities listed as CAM are normally used by
the participants without any intended health benefit. As such, although care was taken to define
CAM to study participants, because the specific purposes for which the modalities they reported
were used were not obtained, it is a bit difficult to verify that they were really used as CAM,
and not just a food. A further qualitative study is needed to clarify this. Also, although a lot of
effort was put into obtaining a truly representative sample, this could not really be achieved in
the very sense of the word. A study with a stricter recruitment process is therefore needed. The
many ethical challenges that hamper direct survey of children also came to play in this study.
The need for direct reporting by the child users cannot be overstressed. As the current study was
cross-sectional, it is limited in its deductive ability. A longitudinal study is therefore needed to
verify most of the findings reported in this study, particular the high outcomes associated with
the various CAM modalities.
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4.5 Conclusion
The findings of this primary study provide clear evidence of a high prevalence of and significant
satisfaction with CAM use by parents in their children within the Aberdeen metropolitan area.
Also parental attitudes on CAM use in children have been shown to be generally positive; as they
are most often shared by both those who have used CAM in their children and those who have
not. This is an indication that paediatric CAM use is likely to increase with the passing years.
This calls for significant attention from the government and other stake-holders in healthcare
to ensure that this development is harnessed to the greatest advantage of the ordinary patient.
One area of such emphasis would be to consider how best to meet the need expressed by a
large proportion of our parent sample for more information on these therapies. Another is the
consideration of recognising more of these modalities, especially the ones most highly perceived
as effective by users, by bringing them into the NHS. Apart from meeting the needs of about
two thirds of parents, it would also ensure that they are used more safely; and that any adverse
events that arise are better managed.
Chapter 5
Comparative Summary of Research
Findings
5.1 Triangulation of findings on UPES outcomes
The last three chapters reported the three broad research aspects of this doctoral research on
the outcomes associated with paediatric CAM use. The current chapter aims to discuss the
various strands of evidence obtained, to achieve a valid and concise summary of findings through
triangulation.
Triangulation has been described as the use of more than one approach in the investigation of a
research question in order to enhance confidence in the ensuing findings [661]. This may range
from gathering data through the use of more than one method or sampling strategy; to the use
of more than one researcher in gathering or interpreting data; to the application of more than
one theoretical position in data interpretation [662]. However, while the term can be used to
refer to all instances of multi-method research, it is more suited for those specific instances in
which researchers seek to validate their findings by cross-checking them through another method
[663, 664]. It is in this sense that triangulation is used in this chapter.
As stated in chapter one of this thesis, the aim of this doctoral research is to systematically
determine the outcomes of CAM use in the general paediatric population of Aberdeen in north-
east Scotland in terms of its user-perceived effectiveness and safety (UPES). As reported in the
intervening chapters, this research has studied the UPES outcomes in the target population from
various perspectives. Scope-wise, while the SR of relevant literature in the research area reported
in chapter two served to set the broader context by identifying the global trends in that field of
research; the database analysis reported in chapter three and the analytic cross-sectional study
reported in chapter four served to verify those trends within the more specific contexts of the
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UK (in general) and Aberdeen (in particular). With respect to methods, while the SR in chapter
two and the database analysis in chapter three approached the study of the UPES outcomes
from a secondary data perspective, the cross-sectional study reported in chapter four followed a
primary study perspective. And finally, from a temporal perspective, while the research reported
in chapters two and three approached the study retrospectively, that in chapter four focused on
providing a snapshot of the current realities on the subject within the specific study area.
In terms of the paradigms that guided the various aspects of this research, while mainly posi-
tivist paradigms guided the research reported in chapters two and three; critical and subtle realist
paradigms predominated in that reported in chapter four. Although the use of a mixture of re-
search paradigms and methods can engender some tensions, because of the sequential application
of the different paradigms in the course of this research, it was hoped that the resulting combi-
nation will be complementary rather than contradictory. Whether this was really achieved will
be verified in the current chapter by seeking possible coherence in the various findings obtained
from the preceding three strands of research. However, while a variety of issues were raised in
the last three chapters of this thesis, the current chapter will focus on those relating to the UPES
outcomes of paediatric CAM use.
5.2 Comparative summary of findings
5.2.1 High perceived effectiveness
A major finding of the SR reported in chapter two is the high report of positive outcomes by
majorities of CAM users in primary research studies globally, with the notable exception of
the UK studies. In that study, a positive outcome was described specifically as the report of
perceived effectiveness (helpfulness, benefit, improvement, etc.) by more than 55% of CAM
users surveyed or reported episodes of CAM use. While this finding was reported by 34 of the
46 studies included in the SR (74%), including 25 studies (54.3%) where it was so reported in
> 70% of the subjects/episodes of use; the proportions of users reporting perceived effectiveness
outcomes among the five UK studies included in the SR were not only relatively low, but also
vastly different. Three of the five UK studies reported a UPE less than 50% [349, 350, 352]; and
were among the five studies with the lowest UPE outcomes report of those included in the SR. Of
the remaining two, while one of them, a hospital-based study conducted in Aberdeen, reported a
UPE of 61% [351], the other, the oldest UK study, and the only population-based one, reported
a UPE of 85% [348]. This observed marked departure of UK studies from the globally reported
high positive outcomes of paediatric CAM use is confirmed by the findings of a recent SR of the
prevalence of CAM use among paediatric patients in the UK, which reported an average PE of
48.3% (range 14-61%) for included studies [395].
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At first glance, the findings of a UPE of 82.9% among users; and 74.9% among reported episodes
of use of specific CAM therapies in the cross-sectional study reported in chapter four of this thesis
seems to disagree with this trend. A second look, however, highlights a number of similarities,
as well as suggests possible explanatory factors. Each of the two UK studies with high UPE
reports was similar to the study reported in this thesis in either of two aspects –either in being
conducted in the Aberdeen area or being population-based rather than hospital-based. While
further research is required to verify this hypothesis, since these two factors are the most obvious
features that distinguish these three studies from the other UK studies, there seems to be good
justification to consider them relevant to the trends observed.
The effects of conducting CAM research in clinic-based settings, especially when they are con-
ducted by medical professionals, are well noted in literature; and their possible contributions to
the findings observed in the SR have already been discussed in section 2.4.5 (pp 49-50; para-
graph 3). Primarily, they stem from social desirability bias; and may result in non-disclosure or
over-enthusiasm by the patient participants, depending on their perception of the researcher’s po-
sition on CAM use [356, 414, 665]. As such, they would be expected to limit the report of positive
outcomes associated with CAM in research carried out in conventional medical centres; while over-
estimating those associated with research conducted in complementary health facilities. These
trends have been discerned in the findings of the studies included in the SR, as earlier discussed
(section 2.4.5). Also observed are the effects of use of non-clinic-based, population-based or postal
research designs on the UPE reported. 10 of the studies included in the SR fell into this category;
one of which [374] did not report a summary UPE rating for the therapies reported by partici-
pants. However, of the nine studies that did report summary data on UPE of the CAM modalities
used, two thirds (7 studies; 78%) reported a UPE > 60% [348, 353, 354, 372, 375, 377, 504]; while
only two studies reported a UPE < 60% [361, 666]. Similar trends have also been observed in
adult population-based CAM studies [667–669]. These data highlight the intricate association
between the setting and method of participant recruitment and the UPE outcomes reported;
which explains the apparent disparity between the findings of the cross-sectional study reported
in chapter four and those of the SR reported in chapter two.
Additionally, higher CAM use and UPE have been associated with aﬄuent and educated commu-
nities [555, 670]. The status of Aberdeen as a relatively aﬄuent city is well known in literature
[671]. It has been recognised as fast out-pacing London’s property boom, as average house prices
are 120% higher than 10 years ago, representing the biggest regional percentage rise in the UK
[672]. This relative aﬄuence has been harnessed in comparative research designs that seek to in-
vestigate the role of aﬄuence or urbanity in the research question [673, 674]. The high proportion
of Aberdeen city residents in the cross-sectional study could therefore explain the much higher
UPE outcomes found. Moreover, as the last study carried out in Aberdeen was conducted about
10 years ago, during the period of the economic recession; the vastly improved economic landscape
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in Aberdeen within the period [672] can further explain the increased UPE outcomes reported in
the present study. Thus, in view of these considerations, the findings of the cross-sectional survey
arguably validate, rather than confound, those of the SR.
To further validate this opinion, the survey findings were mined for further evidence in this regard.
Three specific aspects of the findings of the survey were considered. These included:
(i) the reasons for discontinuation of CAM use in children;
(ii) whether the main purposes for CAM use in children had actually been achieved; and,
(iii) the willingness of users to recommend CAM use to other parents
Of the 67 responses received from the 62 parents who provided insight as to why they had stopped
using a CAM modality in their children, 40 (59.7%) stated that they had done so because their
child’s condition had improved; while only one parent (1.5%) stated that they had done so because
their child’s condition had not, leading them to try some other therapy. Of the 108 parents who
responded to the question on whether they had achieved their main purposes for using CAM in
the children, 99 (91.7%) stated that they had done so; 6 parents (5.6%) stated that they had not;
while 3 parents (2.9%) were unsure. Finally, of the 114 parent users who responded to the question
on recommending CAM to other parents, 107 (93.9%) stated that they would do so; while four
(3.5%) responded negatively, and three (2.6%) were unsure. Taken together, these additional
findings from the survey clearly highlight the high association of positive outcomes with CAM
use in children, thus further strengthening the earlier findings on high perceived effectiveness.
These findings would, however, be strengthened by further studies on outcomes associated with
the supervised use of CAM in clinic or hospital settings. While two of the studies included in
the SR studied such outcomes, due to the fewness and non-conventional health care setting of
such studies, the significant improvement in eczema [357] and respiratory diseases [358] reported
by patients needs validation by studies carried out in conventional health care settings. As the
survey findings also indicate that, of the 179 responses as to the source of recommendation of
the CAM used in their children, 54 (30%) had specified various conventional health care practi-
tioners, it implies that CAM is still very much used in conventional healthcare settings within
Scotland, as Ross et al [630] reported a decade ago. The conventional health care profession-
als listed as sources of CAM recommendations included doctors (21 parents); pharmacists and
nurses (17 parents); health visitors (15 parents); and psychologists (1 parent). It would be very
helpful to determine through further research the outcomes of such instances of CAM use within
conventional healthcare settings. In the absence of such further studies, however, it is safe to
state that the findings of the cross-sectional study highly validate the high report of UPE found
in the SR. This also implies that the perceptions of parents in the Aberdeen metropolitan area
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on the effectiveness of paediatric CAM use are very much like those of parents in other parts of
the world.
5.2.2 Low report of adverse outcomes
Another key finding of the SR is the low report of adverse outcomes by CAM users surveyed.
While nine of the fourteen papers that provided clear numerical data on the adverse outcomes
studied adverse outcomes (64%) reported them in 0−5% of CAM users, and four of the remaining
five studies reported them in < 10% of users, the majority of the studies included in the SR (27
of the 46 studies; 59%) showed no evidence of having investigated negative outcomes of CAM
use in children. This observation questioned the validity of the low adverse outcomes found in
the SR, as it made them no more representative of the studies included in the review. It was not
obvious whether the non-mention of adverse outcomes in the majority of included studies was as
a result of an omission or lack of research emphasis on the part of the researchers, or due to the
actual absence of their report by users. It therefore became necessary to confirm the findings of
the SR in this respect through other data sources.
The exploratory database analysis reported in chapter three provided a good opportunity to
achieve this; even though, due to a couple of limitations, it was still not fool-proof. These
limitations included the general non-representativeness that hampers pharmacovigilance efforts
through national databases like the YCS due to under-reporting of ADRs. There was also the
additional challenge of the relative difficulty in defining CAM, which made it difficult to clearly
distinguish which particular products in the database were actually used as CAM. To avoid
missing out on any reported incident of CAM use, a broad definition of “CAM product” was,
therefore, adopted for the study; resulting in the analysis of ADR reports made for all natural
health products on the YCS database. However, as the data analysed compassed a period of
almost 50 years, from the inception of the database in 1963 to July, 2012, the analysis was
expected to nonetheless provide a broad picture of the safety profile of the products in the UK
population.
The findings of the analysis were found to align with the low level of ADR report suggested by
the findings of the SR, as CAM-related ADRs reported for paediatric subjects in the YCS were
relatively few; and predominantly skin rash. Of the 698, 638 ADRs reported on the database
for the period, only 2,167 (0.3%) concerned a natural health product; with only 192 (0.03%)
being reported for children aged up to 17 years. Although these 192 paediatric reports yielded a
total of 332 specific ADRs, detailed analysis showed them to be of low severity (6%) and fatality
(2%), with over 75% resolution rate, and mostly within the first 3 days of the report (68%). The
significance of these findings was, however, questioned by their association with a high degree of
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incomplete or missing data on both the severity of ADRs (92%) and their duration (60%). As a
result, another source of validation was further necessitated.
In view of the above, the analytical cross-sectional study reported in chapter four was designed
to focus, among other things, on elucidating the adverse outcomes associated with CAM use in
children. This information was thus required of all who acknowledged any form of CAM use in
their children. To improve the possibility of detecting such adverse outcomes with minimal guilt
feelings on the part of users, adverse outcomes were described simply as “any discomfort”; and
users were required to both rate the degree of such discomforts as well as specify what exactly they
were. The findings indicated that only 9 of 123 parent users that answered that question (7.3%)
reported either “a little” or “a lot” of discomfort following their children’s use of CAM; with 97
parents (79%) stating that they had experienced “no discomfort whatsoever”; and 17 parents
who had selected either “not sure” or “not much discomfort” (14%) not stating any specific
adverse outcome upon further questioning. Of the 9 parents who indicated a positive degree of
discomfort, only 2 parents (1.6%) described the discomfort as “a lot”. Upon further enquiry,
these nine parent users listed 11 specific discomforts, 8 (73%) of which were either allergy/skin
reaction or unpleasant taste (4 reports each; 36%). Of the 14 responses received as to who they
had informed of the discomforts they had experienced, 9 (64.3%) stated either nobody or other
family members; and 3 (21.4%) mentioned a CAM therapist; while only 2 (14.3%) mentioned a
doctor. Significantly, no parent mentioned having reported any of the discomforts experienced to
the MHRA; thus validating the low proportion of report of patient-reported NHP-related ADRs
observed in the exploratory analysis of the YCS data (7 reports; 3.7%).
These findings align with those of the YCS database analysis both in terms of the low frequency
of adverse outcomes as well as their nature. They also indicate that the finding of low adverse
outcomes reports seen in the SR was very much in order. Therefore, it is valid to state that CAM
use in children within the Aberdeen metropolitan area is widely perceived as safe, just as it is in
other parts of the world.
5.2.3 Safety concerns over homeopathic medicinal products
Homeopathic medicinal products have generally been accepted as safe [50, 157] -and essentially so
for the very same reasons for which their effectiveness has long been contested –their relative lack
of “biologically active substances” due to the use of ultra-high dilutions [619, 675]. Even when
adverse outcomes have been associated with these products, such ADRs have been described as
both rare and non-severe [624]. In the light of these opinions, the findings of different aspects of
the current research on this subject are interesting.
The findings of the SR agree with the idea that homeopathic medicinal products are not really
associated with adverse outcomes. While the two studies that focused solely on homeopathic
Chapter 5. Triangulation of Major Findings 199
product use in children [357, 358] did not report any ADRs among users; the other study that
focused on herbal and homeopathic medicinal product use [382] did not study adverse outcomes.
The findings of the exploratory analysis of YCS database, however, seemed to differ markedly
in this regard. While the 23 reported episodes of homeopathic product use in children in the
database were associated with 46 ADRs, 13.9% of the 332 ADRs listed; they were also associated
with 17 serious ADRs from 8 episodes of use. This resulted in a serious ADR potential of
34.8%. Also, although 10 of the 17 serious ADRs (59%) reported for such products were deemed
serious for reasons other than for the main CIOMS markers of seriousness, and none of the ADRs
was fatal; 5 of them (29.4%) were described as life-threatening, while the remaining 2 resulted
in hospitalisation. Although homeopathic products were found to be very far behind dietary
supplements in their serious ADR potential, in view of the general public opinion on the safety
of these products, as well as the findings of the SR, these findings were still considered strange.
It, therefore, became necessary to consider the findings of the cross-sectional survey in order to
verify the validity of these findings.
The findings of the survey indicate that, not only was homeopathic product use among children
in the Aberdeen area associated with adverse outcomes generally; it was also highly associated
with “serious” ones. Based on the reports of parent users, homeopathic products accounted for
four (44.4%) of the nine ADRs reported for CAM products. Also, these products alone accounted
for the two “serious” ADRs reported, which had been described by users as having caused their
children “a lot of discomfort”. These findings therefore indicate that the implication of home-
opathic products in serious ADRs in the exploratory analysis of the YCS is valid. They also
suggest that the non-report of ADRs in the two studied that focused on such products in the SR
could be another evidence in support of the tendency towards confirmation bias observed among
authors in that review. On the other hand, it could also be that the ADRs reported were actually
“homeopathic aggravations”, rather than ADRs, as has been suggested by homeopaths [50, 676].
Stub et al [677] have proposed an adverse event duration of 14 days, as well as the absence of
a feeling of well-being, as key criteria that distinguish ADRs from homeopathic aggravations.
While information on the duration of the adverse outcomes reported was not obtained during the
survey, the data available does indicate that the parents concerned did not find the implicated
homeopathic products “a lot helpful”. In addition, data from the YCS database analysis indicates
that homeopathic products were generally associated with the longest ADR durations. Of the 15
ADRs for homeopathic products that had valid details on ADR duration, five (33%) were found
to have lasted 14-72 days. Also, not only were three of the five ADRs considered serious by their
reporters, but also they were not among the serious ADRs described as life-threatening or causing
hospitalisation. While more specific data is needed for greater certainty, going by the criteria pro-
posed by Stub et al, the additional details provided for the ADRs concerned do not really support
their categorization as homeopathic aggravations. Whatever the case, however, as the consensus
on reporting standards proposed as a supplement to the Consolidated Standards of Reporting
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Trials (CONSORT) statement specifically for Reporting data on Homeopathic treatments (Red-
Hot) requires that aggravations be included under adverse effects [678], such a distinction may
not ultimately be particularly helpful.
Another caveat usually placed on adverse outcome reports associated with homeopathic products
is the source of the product implicated; particularly in terms of whether or not it had been
prescribed by a homeopath, and also the level of training and qualification of the homeopath
prescriber [679, 680]. Such indirect, practitioner-associated factors, rather than those related to
the medicine itself, have been proposed as the major source of risk associated with homeopathy
[620, 681]. Although an enquiry was made as to the source of knowledge about the CAM used,
the information provided was not product-specific. The parents concerned, however, did not
include a homeopath, or any other CAM provider, among the sources they listed for the products
implicated in the survey. Similarly, the source of the product used was generally not mentioned
in the YCS database, except for a single case report in which the associated product was a pollen
solution obtained from a homeopath. This product caused angioedema in a 5-year old male child;
which resulted in emergency hospitalisation, but resolved fully within three days. In the absence
of further details in this regard, however, nothing much can be made of this single isolated event.
Thus, it is safe to conclude that there is insufficient evidence from the research reported in this
thesis to rule out indirect or practitioner-related factors as causes of the ADRs observed.
The above mentioned limitations notwithstanding, an amalgamation of the findings of the YCS
database analysis and the survey clearly raises serious concern about the safety of homeopathic
products, as has also been emphasized in a recent SRs on the subject [621, 677]. This obviously
calls for further investigation in view of the relatively high use of homeopathic products in the
UK, not only within the four homeopathic hospitals, but also in different conventional health
care settings [682]. This recommendation is particularly relevant for Scotland in view of the high
level of prescription of such products in Scottish GP practices, particularly for children [630].
5.3 Conclusion
A triangulation of the findings of the three major aspects of this doctoral research indicates that
the outcomes associated with CAM use among children in Aberdeen metropolitan area are similar
to those reported for other parts of the world. There is a high perception of positive outcomes
among parents for these therapies; and a low perception of negative outcomes. Specifically,
paediatric CAM use in the area is associated with high user-perceived effectiveness and safety
outcomes.
Chapter 6
Conclusions and Recommendations
6.1 Research overview
As outlined in chapter one of this report, this doctoral research aimed to answer the following
research questions:
1. What is the strength and quality of published literature relating to user-reported effec-
tiveness and safety outcomes of paediatric CAM product use in terms of methodologies,
methods and models?
2. What are the key findings of published literature on impact of paediatric CAM product use
in terms of user-reported effectiveness and safety outcomes?
3. What is the extent and nature of the pharmacovigilance data on paediatric CAM product
use in the UK?
4. What is the nature and demography of the use and user-reported outcomes of paediatric
CAM products and practices in the Aberdeen area of NE Scotland with respect to perceived
effectiveness and safety?
5. What implications do the findings have for research and/or health policy and planning in
Scotland?
This concluding chapter provides a summary of the answers obtained for these questions based
on the findings of the research reported in the intervening chapters. The answers to the questions
1-4 are summarised in the next section; while their implications for health policy and planning
in Scotland are outlined in the last section.
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6.2 General conclusions
6.2.1 Conclusions from the systematic review
The SR of literature on user-perceived effectiveness and safety outcomes of paediatric CAM in
the period between January 2000 and July 2011 identified 46 relevant studies, half of which were
conducted in North America; five within the UK; and two in Scotland. These studies generally
reported high degrees of positive outcomes, as well as a low degree of negative outcomes, by
the majority of CAM users in the populations surveyed. Adverse outcomes were studied in less
than half of included studies, indicating a lack of emphasis on such outcomes among paediatric
subjects. These findings were, however, complicated by the generally low methodological quality
of included studies; as only nine of the studies met 8 of the 12 standard quality indices by which
the studies were assessed. This was mainly due to an observed tendency to non-rigorous research
and confirmation bias among authors that manifested in various ways.
6.2.2 Conclusions from the Yellow Cards database analysis
Despite several public health policy initiatives to encourage ADR reporting, CAM product use
in paediatric populations was found to contribute an insignificant proportion of ADR reports
in the YCS database within the (nearly) 50-year period studied. The few CAM-related ADRs
reported were of low severity and fatality; and with a high resolution rate. The reports, however,
contained a high degree of incomplete or missing data. Among the CAM product types, although
herb-drug combination products and herbal remedies accounted for the highest proportions of
ADRs, and herbal products the least, nutritional supplement and homeopathic products were
most associated with fatal and relatively high serious ADR potentials, respectively.
6.2.3 Conclusions from the cross-sectional survey of parents in the Aberdeen
area
Paediatric CAM use was found to be both high and growing in the Aberdeen metropolitan area,
as it is in other parts of the world; with a much higher use of product-based CAM than practice
therapies among children. Trends in CAM use in the area were also found to generally align
with those observed for CAM use in literature. Parents reported a much higher perception of
the effectiveness of the therapies they used for their children than in most previous UK studies,
with significantly better outcomes reported for practice therapies than products, except for the
commonly used ones. Self CAM use among parents, as well as parental perception of helpfulness
of the therapies self-used, were found to be the greatest determinants of paediatric CAM use and
perceived effectiveness outcomes, respectively. Irrespective of their use of CAM for their children,
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parents in the Aberdeen area indicated a general preference for a more informed choice of CAM
therapies for use in their children along with conventional care; and all this within the supervised
framework of doctors and the NHS. They also demonstrated high willingness to participate in
future CAM research.
6.3 Implications of findings for health policy and planning
The findings of this study point to a number of recommendations for research as well as health
policy and planning. A POEM-based, bottom-line summary will be provided at the end.
6.3.1 Recommendations for further work
(i.) The SR reported in this thesis covered the period between January 2000 and July 2011. It
was also limited by language restriction to the English language. There is, therefore, need
for an updated and more rigorous SR of the study area. Such further review should aim
at verifying the findings of the review currently reported; especially with respect to the
tendency to confirmation bias noted among authors.
(ii.) Future paediatric CAM studies need to ensure stricter adherence to procedural ethics,
especially as stipulated in such standard reporting criteria as STROBE; so as to improve
their overall methodological quality.
(iii.) The database analysis reported in chapter three covered a period up until July 2012. As the
YCS officially marked its fiftieth year of formal establishment in 2014, a more up-to-date
analysis is called for. Apart from ensuring that the analysis would contain annual data for
full year periods, it would also provide a complete summary of the activities of the MHRA
within its first 50 years.
(iv.) The survey reported in chapter four, although analytical, was nonetheless cross-sectional.
The SR highlighted the paucity of longitudinal studies of CAM interventions, particularly
in children. Such studies are particularly relevant for investigating effectiveness of inter-
ventions. Further studies should focus on such study designs. They would more clearly
demonstrate whether the effectiveness outcomes reported by parents are sustained over a
period.
(v.) In view of the few and non-specific responses to the enquiry about the details of the benefits
reportedly associated with paediatric CAM use, there is need for in-depth qualitative studies
to determine exactly what parents mean by stating that they perceive CAM to be helpful.
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(vi.) The high degree of uncertainty among parents as to the outcomes associated with CAM
product use in their children suggests that proxy report may not be as effective as one would
desire. This is particularly emphasized by the significantly lower degree of uncertainty
among parents of their own self-used CAM. Further studies on UPE should, therefore,
emphasize direct reporting by the children in whom the CAM is used wherever possible.
(vii.) Considering the apparent non-emphasis on CAM safety investigation in previous paediatric
CAM use studies, future studies need to strongly emphasize them. Also, in view of the
extreme importance of patient safety, the outcomes found (or lack thereof) should also be
reported, no matter how doubtful they may appear to the researchers.
(viii.) In view of the highlighted tendency towards confirmation bias among research authors on
UPE of CAM interventions, authors of future studies on CAM use should ensure that the
result summaries and conclusions they generate are strictly in line with the data their
participants provided, irrespective of how implausible they may seem to the researchers
themselves. This would ensure that the voices of participants are given their due place in
research findings, particularly in the current patient-centred care era.
6.3.2 Recommendations for health policy and planning
(i.) In response to parental expression of their need for more information concerning CAM
modalities, there is need for more open communication about CAM use in children. While
the NHS website currently has a number of pages dedicated to CAM therapies, these appear
to be mostly unknown to parents; and/or are probably not rich enough to properly inform
them. Also, because the CAM-related information provided is usually science-based, rather
than based on user outcomes, it tends to be generally more critical of CAM use; which
could ultimately discourage parents. Therefore, in recognition of the broad acceptance of
CAM among parents, the future CAM content of such websites need to be more inclusive
of user outcomes; as well as more targeted to the needs of parents.
(ii.) The restrictions that currently hinder direct access to paediatric subjects for research in
the UK should be reviewed in order to enable the voice of children to be heard in future
research on paediatric health interventions. This is especially so for studies dealing with
perceived outcomes.
(iii.) In view of the highlighted inefficiency of the various public health initiatives instituted over
the years in improving ADR reporting for CAM products, there is need for more effective
initiatives that are specifically targeted towards CAM products. One such policy that could
prove helpful in this regard is the requirement of the placement of yellow cards as part of
package inserts for such products. As parents indicated in the survey that they obtained
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information about CAM mainly from the internet, and then the television, similar policy
could target advertisements of CAM products in both print and electronic media, including
parenting websites, requiring them to notify users of the possibility of adverse effects, and
the need to report them where they occur.
(iv.) In view of the highlighted implication of homeopathic products in serious ADRs, as well
as their reported high use in Scottish GP practices, there is great need for a Scottish
agency specifically devoted to monitoring for NHP-related ADRs, especially for homeopathic
products. While the function of gathering ADR-related data in the Scottish NHS is currently
under the ambit of the ISD Scotland, the failure of several efforts by the supervisory team
to obtain usable data on homeopathic products from this agency for analysis by the student
suggests that more needs to be done to ensure that that aspect of ISD mission statement is
fully realised for NHPs. Had such data been readily available, it would have helped bring
the database analysis nearer home; as well as helped to further validate the findings of the
UK-wide YCS analysis in this regard.
(v.) With high proportions of both parent-users and non-users of CAM calling for its integration
in the NHS, stake-holders in the health industry need to commission more studies on CAM;
so as to actively consider the modalities that qualify for such integration, and to encourage
such. The establishment of a body similar to the US NCCIH that is specifically focused on
CAM research with the goal of integration is highly recommended in this vein.
(vi.) Considering the desire of parents for more informed choice on their children’s use of CAM
within the context of a supervised health system, health professionals should realise that
parents want to be more involved in their children’s healthcare choices; and should collab-
orate with them to achieve the best outcomes.
6.3.3 Summative conclusion
This doctoral research deduced international perspectives on the UPES outcomes of paediatric
CAMs from the findings of the maiden SR reported in chapter two. It highlighted that the high
report of positive health outcomes and low report of adverse outcomes reported by CAM users
in published studies were complicated by the generally low methodological quality of the studies.
The premier analysis of the NHP-associated ADR reports made to the YCS that was reported in
chapter three served to provide a British perspective of safety outcomes of CAM use in children;
highlighting the fewness and low severity and fatality of the NHP-related ADRs reported. Finally,
the local Scottish perspective provided by the first population-based Scottish study of paediatric
CAM use reported in chapter four evidenced the high prevalence of and significant satisfaction
with paediatric CAM use by parents in the Aberdeen area. The triangulation of the results from
these three strands conducted in chapter five validated the common theme that CAM is used
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widely among children, with high perceived effectiveness and safety outcomes. While various
recommendations have been made in the preceding two sections of this chapter, this final section
proposes to provide a POEM-based summary of the findings of this research on the outcomes of
paediatric CAM use as reported by parents in the Aberdeen area of NE Scotland.
The findings reported in this thesis highlight that parents in Aberdeen are very much like their
counterparts in other parts of the world as far as the use of CAM in their children and the
associated outcomes are concerned. Not only do many more parents now use CAM in their
children, but also many users and non-users acknowledge the importance of such use; implying a
general trend towards increased paediatric CAM use in the future. Key evidence in this regard
include not only the generally high perceived effectiveness of paediatric CAM use among parent
users; but also the higher prevalence of self CAM use and its perceived effectiveness among
parents generally. Also, as in other parts of the world, a high majority of parents in Aberdeen
prefer to make up their own minds about CAM use in their children; but also express a need
of suitable information to enable them do so effectively. As such, they do not mind discussing
such CAM use with appropriately trained health care professionals; and would largely prefer the
free availability of CAM on the NHS, so they can effectively use CAM along with prescribed
conventional medicines. The bottom line therefore is that parents in Aberdeen, as with parents
world-wide, highly desire to be involved in the health care decisions concerning their children; and
consider the informed use of CAM in children a good opportunity to do so. The proper recognition
and acceptance of this finding in future health care policy and planning will significantly improve
child health and development in not only Aberdeen, but also the rest of Scotland.
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CHAPTER ONE: BACKGROUND TO THE REVIEW 
 
1.1 CAM: Definition and Classification 
The World Health Organisation (WHO) views Complementary and Alternative 
Medicine (CAM) somewhat as a new improved version of Traditional Medicine 
(TM), in that it originated from it and shares many of its features, differing only 
in the context within which it is used. Therefore, while it defines TM as ‘the sum 
total of knowledge, skills and practices based on the theories, beliefs and 
experiences indigenous to different cultures, whether explicable or not, used in 
the maintenance of health, as well as in prevention, diagnosis, improvement or 
treatment of physical and mental illnesses’ (1), it defines CAM in the same 
document as ‘a broad set of health care practices that are not part of a country’s 
own tradition and are not integrated into the dominant health care system’. 
Because of the close association between the two terms, in its publications, the 
WHO prefers to use the term TM/CAM to either separate term. It, therefore, 
broadly categorizes TM/CAM into Medication Therapies (MT)— if they involve 
use of herbal medicines, animal parts and/or minerals — or Non-Medication 
therapies (NMT)— if they are carried out primarily without the use of 
medication, as in the case of acupuncture, manual therapies and spiritual 
therapies (2). Although not specifically so indicated by the WHO, MT can be 
extrapolated to include homeopathic medicines and essential oils. Although 
these products are utilized as part of some NMT, they still are essentially 
medication therapies in their own right. Described in this way, MT can be more 
correctly termed Pharmaceutical-type CAM, or simply Complementary and 
Alternative Medicines (CAMs) (3,4,5). As it would be practically impossible to 
systematically review all CAM types together -and considering the 
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pharmaceutical background of this research- the current review will be restricted 
to the CAMs. 
 
The WHO’s current goal is the integration of as many TM/CAM therapies as 
possible into national healthcare systems, in the bid to improve global health 
status and quality of life (2). While this has been greatly lauded by developing 
countries, in many developed countries –especially the UK and the USA – it has 
met with much conflict and opposition (6,6,7). In spite of this mixture of 
opinions, however, trends in CAM use have continued to rise world-wide 
(8,9,10,11,12,13,14,15). Similar trends have also been reported in paediatric 
populations (16,17,18,19,20,21,22,23,24,25,26,27,28). 
 
1.2 CAMs: Popularity, Efficacy, and Safety 
In virtually all surveys of CAM use world-wide, CAMs have consistently been 
found to be the most popular CAM type used –even among paediatric 
populations (18, 29, 30, 31, 32, 33, 34, 35, 36, 14, 37, 38, 39, 26, 40, 41, 42, 
43). Apart from being the most popular form of CAM used world-wide, CAMs –
with the notable exception of homeopathic products- also escape what can be 
rightly termed the bane of all CAM: the ‘hocus pocus’ label. Unlike most of the 
other CAM types, herbal products, dietary supplements and probiotics are largely 
evidence-based (44, 45, 46), with so many literature reports of experimental 
and quasi-experimental pre-clinical and clinical studies –including randomized 
controlled trials- validating their claims and affirming their efficacy (47, 48, 49, 
50, 51, 52, 53, 54, 55). In spite of these advantages, however, CAMs –
especially herbals- are plagued with the problems of large-scale adulteration 
(56, 57, 58, 59, 60, 61, 62, 63, 64), and a high tendency of often unfavourable 
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interactions with conventional drugs (65, 66, 67, 68, 69, 70, 71, 72, 73, 74). 
Homeopathic products, on the hand, in spite of numerous clinical trials in various 
health conditions, are still plagued with the problem of controversial efficacy (75, 
76, 77, 6, 78, 79, 80). Given the popularity of these products, these drawbacks 
have grave implications for patient safety, and have raised concerns as to the 
over-all safety and effectiveness of these medicines. These concerns have been 
the subject of various studies (81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 72), and 
have also been raised with respect to their use in paediatric subjects (91, 92, 
93,  94, 95, 96, 97, 98,99). 
 
1.3 Effectiveness of Health Interventions: Definition and Assessment 
Historically, efficacy studies were the backbone of clinical research, being 
accepted as the gold standard for determining whether or not a treatment 
worked (100). From the turn of the century, however, there has been a shift of 
emphasis towards effectiveness studies. Effectiveness studies differ from efficacy 
studies in that they focus on real-world use of interventions as against an ideal-
setting perspective.(101, 102, 103,   104, 105). In other words, efficacy studies 
are explanatory, whereas effectiveness studies are pragmatic (106, 107). 
Despite these distinctions, there is still sufficient confusion among researchers 
over the right terminology to warrant mislabelling of some ‘effectiveness’ studies 
as ‘efficacy’ studies, and vice versa. As a result, many systematic reviews of 
‘effectiveness’ studies often mistakenly include studies that are actually ‘efficacy’ 
studies. To guard against this common error, Gartlehner and his colleagues at 
the RTI-International–University of North Carolina Evidence-based Practice 
Center, in a research carried out for the Agency of Healthcare Research and 
Quality of the United States’ Department of Health and Human Services, have 
Appendix I. Systematic Review Protocol 7 
6 
 
identified six criteria by which effectiveness studies can be distinguished with 
high specificity and sensitivity from efficacy studies during systematic reviews 
(108). 
 
The effectiveness of a health intervention can be assessed from two major 
perspectives –objectively: from the clinician’s/experimenter’s perspective 
(clinical effectiveness, CE), or subjectively: from a patient’s/consumer’s 
perspective (perceived effectiveness, PE) (109, 110, 111). The cost-
effectiveness/cost-benefit of the intervention can then be obtained by 
deducing the economic implications of achieving or improving the effectiveness 
data realized from these two perspectives relative to those for another 
intervention (112, 113, 114, 115).  While CE focuses on the attainment of 
clinical/therapeutic outcomes/goals/end-points –and is best judged by carefully 
designed and well conducted pragmatic 'real world' randomized (controlled) 
trials. (116,  117, 118, 119, 120, 121), PE focuses on the attainment of 
humanistic outcomes through assessing the health-related quality of life 
(HRQoL) of the receiver, and is best assessed using observational studies –
essentially cross-sectional surveys, cohort or case-control studies, and 
qualitative research (109, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 
132, 133, 134, 135, 136, 137, 138). With many CAMs having been reported to 
be efficacious in specific disease conditions, and the complications arising from 
their popularity, the importance of effectiveness studies in assessing their over-
all usefulness cannot be overemphasized. This fact is even much more valid for 
homeopathic products, since effectiveness studies can help to settle the 
controversies generated by efficacy studies. 
 
Appendix I. Systematic Review Protocol 8 
7 
 
Although evidence obtained from well-conducted randomized controlled trials 
(RCTs) is generally accorded greater recognition and placed on a higher level in 
the popular hierarchies of evidence in the evaluation of healthcare interventions 
(139, 140, 141), studies have shown that observational studies are not 
particularly inferior to randomized trials (142, 143, 144), and are actually 
superior to them in studies where opinions, attitudes and perceptions about 
interventions are being investigated (145, 146, 111). As a result, these have 
increasingly been used in the study of the PE of CAM (147, 148, 149, 150, 151, 
152, 153, 154, 155, 156, 157). Such studies have also been carried out in 
paediatric subjects (31, 158, 159, 160, 161, 162, 137), and these will be the 
focus of the present review. 
 
1.4 Medication Safety –the CAMs Perspective 
Despite the great advances in the field of surgery, and the persistent debates, 
the use of medications remains the most common intervention in allopathic 
medicine, being the preferred initial intervention in most health conditions, as 
well as an essential component of post-surgical management (163, 164, 165, 
166, 167, 168). However, this popularity does not come without a price, as 
adverse drug events (ADEs) account for the greatest proportion of medical 
errors in both adults and children (169, 170, 171, 172, 173, 174, 175, 176, 177, 
178, 179, 180). Consequently, medication safety has become a very important 
goal as far as patient safety is concerned (181, 182, 183, 184, 185, 186, 187). 
This is particularly so in unlicensed or  ‘off-label’ medicine use –as is widespread 
in the treatment of paediatric subjects (188, 189, 190, 191, 192, 172, 193, 194, 
195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205). As CAMs are the most 
popular CAM therapies used in both  adults and children (see above), and are to 
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a large extent unlicensed as drugs by statutory regulatory agencies (206, 207, 
208, 209, 3, 210), it is understandable that they will share the same safety 
concerns as orthodox medicines –if not (and very likely) much more. 
 
Although the importance of reducing medication errors has been noted (171, 
211, 212, 213, 214), the key factor in the achievement of medication safety is 
the early detection and subsequent prevention of ADEs (215, 216, 217, 218, 
219, 220, 221, 222). In appraising the various methods that have been utilized 
in the detection of ADEs and measurement of medication safety in adults and 
children (173, 183, 223, 224, 225, 226),several studies have highlighted  the 
importance of surveillance methods involving interaction with in patients and 
outpatients (227, 228, 229, 218, 230, 231, 232, 233). Apart from cases where 
diagnosis was required or where patient consciousness, judgement or 
communication was impaired (234, 235, 233), the ADE information realised from 
such interaction –essentially through patient interviews and surveys- was found 
to be not only in concord with that reported by clinicians, but also 
complementary to it (236, 237, 230, 231, 238). In addition to the improved 
generation of information about the experiences of past patients for the benefit 
of future patients in both hospital and community settings, potential advantages 
of such methods include earlier detection of ADEs, and  additional toxicity data 
to compare with efficacy during regulatory review (239, 240, 241, 233).  
 
Thus, in spite of initial criticism and scepticism (242, 243, 244, 245, 246, 247, 
248, 249, 250, 251), the active role of ‘users’ or ‘consumers’ in the assessment 
of healthcare quality has become firmly established as a sine qua non in the 
achievement of not only individual patient medication safety, but also the HRQoL 
Appendix I. Systematic Review Protocol 10 
9 
 
of the entire populace (252-262). However, the general reluctance of patients 
and drug users to voluntarily report adverse drug events (247,249,263-267), 
greatly emphasizes the need for frequent, well-designed and innovative 
pharmacoepidemiological studies with a view to eliciting ADE reports (240,268-
273). Such studies are particularly important in the area of CAMs if a significant 
degree of safety is to be achieved therein. Here, because their use is 
characterized by a high degree of self-medication as a result of strong cultural 
and familial sentiments (274-279), there is understandably a higher degree of 
under-reporting of adverse events (3,81,87,280-285).  
 
 
1.5 Perceived Risk/Safety: Understanding the underlying motivations 
With the trend towards ‘switching’ more and more prescription-only medications 
(POMs) to over-the-counter (OTC) medications (286-289), and the associated 
increase in self-medication with its many hazards (89,290-299), another 
important issue in the achievement of medication safety and the over-all HRQoL 
of the populace has become the perceived risk (or, conversely, perceived safety) 
of medication use among (especially) the lay public (300-312). Perceived risk 
(or, conversely, perceived safety) differs from actual risk (or, safety -as 
discussed in the previous section) in that it focuses, not particularly on specific 
adverse events experienced by patients/consumers, but rather on their feelings, 
attitudes, opinions, perceptions, and beliefs –even if not concrete- about  the 
intervention (143,300,313-327). As such, psychological and sociological 
methodologies, rather than scientific methods, are employed in studying it (328-
334), and these have been utilized in determining and understanding the 
motivations underlying the health and medication choices made by both 
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healthcare providers and the lay public, particularly in novel or fringe areas like 
CAM use (149,335-345). 
 
Perceived safety/risk has been associated with various factors, including 
communication, age, gender, culture, experience and trust (346-351). Although 
it is understandably a greater underlying motivation for the use of self-
prescribed medications, like OTC and complementary medicines 
(292,302,334,352-368), it has also been identified as an important factor in 
patient medication adherence (369-376).An understanding of the underlying 
motivations for unhealthy self-made choices offers the possibility of avenues 
through which the people concerned could be better informed as to the ways to 
better achieve their personal goals with better choices. This has been illustrated 
in several reports of –and arguments for-  improvement of risk awareness of 
various interventions (and, thus, healthier choices) following suitably tailored 
patient-education and public health enlightenment initiatives (256,346,377-
387). With the continued popularity of CAMs in spite of the reports of their 
safety risks (93,281,388-391), these efforts have also been directed at the 
improvement of CAM consumer risk awareness as a means of improving 
medication safety (150,392-399,399-408). Some of theses efforts have been 
targeted at paediatric subjects, and will be the subject of the current review.    
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CHAPTER TWO: REVIEW PROTOCOL 
2.1 Systematic Reviews of Perceived Paediatric CAM Effectiveness and 
Safety: An Overview 
Although there are quite a number of systematic reviews of the effectiveness 
and/or of safety paediatric CAM interventions in recent times 
(17,79,93,205,409-427), a scoping search with Google Scholar identified none 
that focused on user perceptions on paediatric CAM. The two closest hits –the 
reviews by Jackson et al (428) and Lorenc et al (429)- focused rather on the 
psychological models associated with the decision-making process used by 
parents in the choice of paediatric CAM, as have been highly researched recently 
in literature (353,430-437). In other words, they looked more at the ‘hows’ of 
the choice of paediatric CAM use than on the ‘whys’. The other and more 
relevant study that focused on perceptions –that by Cuzzollin et al (438)- apart 
from focusing more on the relationship between the patients’ mothers and 
paediatricians, rather than on the CAM interventions themselves, was just an 
overview of the literature, and not actually a systematic review. Moreover, 
considering the numerous recent articles on the subject discovered during the 
scoping search (439-446), it is obvious that it is quite dated. The need for a 
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fresh and systematic review of the subject cannot, therefore, be 
overemphasized. This current study aims at meeting that need. 
 
2.2 Review Objectives 
• To determine, outline and compare the strengths and weaknesses of all 
identified studies in peer-reviewed journals on paediatric CAM use in 
terms of methodological quality and consistency of findings (447).  
• To summarize and discuss key findings of the studies identified; 
• To identify gaps in the literature to inform further phases of the doctoral 
research; 
• To inform the most appropriate methodological approaches in further 
research; 
• To obtain standard reference data on the subject with which to compare 
the findings of the proposed research. 
 
 
2.3 Inclusion criteria 
 
• Populations:  
- Specific CAM studies on subjects aged up to 21 years; 
 
• Intervention: 
Pharmaceutical-type CAM, i.e. CAMs, as earlier defined –specifically: 
herbal medicines, animal parts and/or minerals; homeopathic medicines, 
essential oils and dietary supplements/megavitamins - used alone or in 
combination with other forms of CAM/conventional medicine. Also Bach 
flower remedies and other such similar product-based CAM will also be 
included. 
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• Outcomes: 
User views, opinions, attitudes and perceptions on effectiveness outcomes 
of CAM use; as well as any toxicity and adverse effects encountered 
during the intervention. 
 
• Study design: Surveys, and other observational studies –prospective or 
retrospective, quantitative or qualitative.    
 
• Language: Although the importance of language non-restriction in 
systematic reviews of CAM use has been reported  (448, 449), due to 
various limitations and logistic considerations, only articles published in 
English –or which include an abstract in English- will be selected for this 
study. 
 
• Date limit: Although focus on safety/risk perception of health 
interventions commenced in the early 1990s, and there has been no 
previous systematic review of the perceived outcomes of paediatric CAM 
use, since the systematic review of the prevalence of CAM use in children 
by Ernst in 1999 reported the perceived effectiveness outcomes of 
included papers, I propose that this current review covers articles 
published as from 2000 until July 2011. 
 
2.4 Exclusion criteria 
 
• Perception studies that do not include research on paediatric subjects or 
their parents/guardians/carers, but are rather targeted only at health 
professionals or other non-user/consumers; 
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• Perception studies that do not focus on user perspectives on CAM use, but 
rather on the decision-making process involved. 
• Studies on CAM use in general that do not focus on the specific, named 
CAMs that are the focus of the review. 
 
2.5 Database Selection 
A perusal of some of the systematic reviews of paediatric CAM use identified 
through the scoping search yielded a total of about 35 main databases utilized in 
the literature searches. Following a detailed descriptive analysis of the list, 13 
databases were selected for the current review. These were selected not only on 
the basis of their specificity to CAM and their relevance to the major focus of the 
current review, but also on their general importance and acceptability among 
health researchers. The 13 databases thus selected are as follows: 
 1. Paediatric Complementary and Alternative Medicine (PedCAM)  
 2. NHS Evidence –Complementary and Alternative Medicine  
 3. PubMed  
 4. MEDLINE 
 5. Royal Council for Complementary Medicine )RCCM) Databases  
 6. Allied and Complementary Medicine Database (AMED)  
 7. EMBASE 
 8. CAB Global Health Dialog   
 9. Alt-Health Watch  
 10. Natural Medicines Comprehensive Database  
 11. Complementary and Alternative Library and Information   
 Service (CAMLIS) 
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 12. The Cumulative Index to Nursing and Allied Health Literature  
 (CINAHL) 
 13. The International Pharmaceutical Abstracts (IPA) 
 
Although no particular journals will be manually searched, all articles referred to 
in systematic review articles identified will be specifically looked up –if not 
already identified from the search of the databases already selected- and will be 
assessed for conformity with the stated inclusion and exclusion criteria. In 
addition, any outstanding paper/study noted/suspected by any member of the 
Team to have been missed out will be specifically searched for and tested for 
suitability using the inclusion and exclusion criteria. In either case, where any 
such study qualifies for inclusion following this specific search, the treason for its 
initial exclusion will be determined and reported appropriately. The references 
will be managed with the RefWorks software through the Robert Gordon 
University Library. 
 
 
 
2.6 Search terms and search term combinations 
The following words and phrases will be utilized in the search with appropriate 
truncation or wild cards. As such, although only singular forms of nouns are 
given, the search will be such as to also identify all the plural forms. Also, 
alternative spellings (for instance, paediatric vs. pediatric) will be accepted. 
These words/phrases are among those identified as relevant/key to the subject 
in the background to the review. The words/phrases are as follows:  
• Adolescent 
• Adverse/side effect 
• Alternative Medicine 
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• Child(ren) 
• Complementary Medicine 
• Father 
• Guardian 
• Health-related Quality of Life (HRQOL) 
• Holistic Health/Medicine 
• Integrative Medicine 
• Mother 
• Nonconventional Medicine 
• Opinion 
• Outcomes 
• P(a)ediatric 
• Parent 
• Patient-oriented 
• Patient-led 
• Perception 
• Perspectives 
• Perceived benefit 
• Perceived effectiveness 
• Perceived efficacy 
• Perceived Safety  
• Prevalence 
• Traditional Medicine  
• Unconventional Medicine 
• Use 
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These words and phrases will be used in the following combinations in the 
ensuing search of the databases:  
Combination 1 
(Alternative Medicine or Complementary Medicines or Holistic Health or Holistic 
Medicine or Integrative Medicine or Nonconventional Medicine or Traditional 
Medicine or Unconventional Medicine) 
AND 
(Adolescent or Child(ren) or Father or Guardian or Mother or P(a)ediatric or 
P(a)ediatrics) or Patient-led or Patient-oriented or Parent) 
AND 
(Adverse effects or side effects or Perceived Benefit or Perceived Effectiveness 
or Perceived Efficacy or Perceived Safety or Opinions or Perspectives or 
Prevalence or Use) 
 
Combination 2 
(Bach flower remedies or Complementary medicines or Dietary supplements or 
Herbals or non-vitamin, non-mineral natural products or Homeopathy or 
Megavitamin therapy or Pharmaceutical-type CAMs or Traditional Chinese 
Medicine) 
AND 
(Adolescent or Child(ren) or Father or Guardian or Mother or P(a)ediatric or 
P(a)ediatrics) or Patient-led or Patient-oriented or Parent) 
AND 
(Adverse effects or side effects or Effectiveness or Opinions or Perceptions or 
Prevalence or Safety or Use) 
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2.7 Study selection and Data extraction 
In all about 3-4 persons will be involved in the review, viz: 
• ON will screen and select studies for relevance based on their titles. 
•  As a quality control measure, a random sample of 50 titles will be 
reviewed independently by DS/YK, according to stated criteria, and the 
two results will compared (with those obtained by ON) to ensure inter-
rater reliability 
• The very same process will be followed in order to identify relevant 
studies based on their abstracts. 
• After removal of duplicates, ON will critically appraise the remaining 
papers, and systematically extract, and comparatively record in a clear 
tabular format, the basic characteristic features of the methodologies and 
findings/results of the studies.  
• Similar quality control checks will be carried out separately by DS and YK 
for the whole papers, like those done for the titles and abstracts. 
• DS and YK will cross-check the tabulated extracted information for 
reliability 
• Any conflicts at each stage will be resolved in consultation with JM. Where 
there are unresolved conflicts, both views will be reported. 
 
2.8 Assessment of Methodological Quality of Studies Identified  
The studies selected for critical appraisal will be assessed for conformity with the 
standard guideline for each particular study -PRISMA and STROBE statements 
(452, 453) for systematic reviews/meta-analyses and observational studies 
respectively, and the CASP guidelines (454), for qualitative research reports. 
Reference will be made to other standard guidelines (455) whenever necessary. 
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2.9 Data synthesis and Strategy for dissemination of results 
A combination of formats –narrative, quantitative and pictorial, as appropriate- 
will be used to present the data realized. As the intended audience includes 
other researchers, policy makers, and clinicians/healthcare providers, apart from 
the PhD thesis that is the ultimate purpose of this review, the results will also be 
disseminated through relevant peer-reviewed journals and conference 
papers/abstracts. Specific databases focused on either CAM –like the Paediatric 
Complementary and Alternative Medicine (PedCAM) and NHS–Complementary 
and Alternative Medicine databases, for instance- or systematic reviews –like the 
Centre for Reviews and Dissemination (CRD)- will be specially targeted. 
 
2.10 Amendments to the protocol in the course of the review 
As a quality check, before the commencement of the review, this protocol will 
undergo peer-review both internally among the Review Team, and externally by 
some key stake-holders from the intended audience. However, should the need 
arise, in the course of the review, to deviate from any of the strategies set out in 
this protocol, such amendment(s) will be discussed internally among the Review 
Team, and, where a consensus is reached, recorded as a separate document, 
with clear explanations as to the necessity that warranted it/them. 
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Appendix II
Database Search Output
The following Appendix contains the database search output
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Access to Yellow Card and ADROIT Data 
Guidance Notes 
 
 
1. INTRODUCTION 
 
The Medicines and Healthcare products Regulatory Agency (MHRA), an executive 
agency of the Department of Health, protects and promotes public health and patient 
safety by ensuring that medicines, healthcare products and medical equipment meet 
appropriate standards of safety, quality, performance and effectiveness, and are used 
safely. The Agency operates post-marketing surveillance systems for reporting, 
investigating and monitoring adverse reactions to medicines and adverse incidents 
involving medical devices to safeguard public health. 
 
The safety of medicines is monitored using the Yellow Card Scheme1 which has been 
in existence since 1964. The Yellow Card database (Adverse Drug Reactions On line 
Information Tracking (ADROIT) database) contains over half a million reports of 
adverse drug reactions (ADRs) experienced by patients. Each report details an ADR 
or ADRs that the reporter suspects may be associated with the patient’s use of a 
medicine or drug and the data are coded according to the internationally accepted 
Medical Dictionary for Regulatory Activities (MedDRA)2. The Yellow Card Scheme 
is voluntary for healthcare professionals and there are specific reporting requirements 
for the pharmaceutical industry. Patient reporting is being incorporated within the 
Scheme through ongoing initiatives but these data are currently held separately on the 
MHRA’s database.  
 
The 2004 Independent Review of Access to the Yellow Card Scheme3 recognised the 
research potential of the Yellow Card/ADROIT database, as one of the largest single 
compendiums of suspected adverse drug reactions in Europe. Following the Review 
the systems described in this guidance document have been developed to ensure that 
(any) information included in the database that is subject to release on request under 
the Freedom of Information Act4 (FOIA) will be readily available while at the same 
time protecting the confidentiality of individuals and their personal data as the Data 
Protection Act5 (DPA) requires. 
 
 
2. GENERAL PRINCIPLES  
 
The MHRA welcomes the interest that other organisations and individuals have 
expressed in researching the Yellow Card database in the interests of patients and for 
public health benefit. The Agency is conscious of the duty of confidentiality to 
patients and reporters that is required by the DPA. Research on confidential data is 
                                               
1
 Further information about the Yellow Card Scheme can be found on the MHRA website at 
www.yellowcard.gov.uk 
2
 http://www.meddramsso.com/ 
3
 Report of an Independent Review of Access to the Yellow Card Scheme, TSO, London 2004 
4
 http://www.hmso.gov.uk/acts/acts2000/20000036.htm 
5
 http://www.hmso.gov.uk/acts/acts1998/19980029.htm 
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nevertheless lawful when it is undertaken with the consent of the subjects involved 
and in accordance with ethical and scientific principles.  
 
The MHRA’s purpose in opening the database is to maximise the accumulated value 
of the database for the benefit of patients and public health. This guidance summarises 
the arrangements the Agency has set up to enable any organisation or 
individual/applicant to access the Yellow Card database in order to carry out 
independent research or investigations. Any UK or non-UK resident, may apply for 
access to Yellow Card and ADROIT data and there are no restrictions in respect of 
the scientific experience or qualifications of any applicant.  If you require any 
assistance completing this form or are unsure which parts to fill in, please contact the 
MHRA.  Contact details are provided on page 6.  
 
However, in providing access the MHRA needs to be assured of the appropriateness 
and quality of the research and the scientific integrity of proposals. Applicants are 
therefore required to accept the following principles: 
 
1. The proposal must be of potential scientific value and/or have significant public 
health implications. The research methods must be described in the proposal so 
that their scientific merit and feasibility can be independently reviewed and 
evaluated.  
 
2. Any potential benefits and risks for patients during the course of the research 
process and/or anticipated as a consequence of the research should be set out in 
the proposal. 
 
3. Data from the Yellow Card Scheme that is subject to the Data Protection Act, 
such as individual personal data, must not be provided to third parties without the 
approval of the Independent Scientific Advisory Committee for MHRA database 
research (ISAC) and the consent of the reporter and patient.  
 
4. The research must be conducted only by the principal applicant and co-applicants 
named in the application.  
 
5. Any change or amendment to the research plan or methodology must be notified 
in writing to the MHRA for approval and should the principal applicant and/or co-
applicants change during the course of the study the MHRA must be notified. 
 
6. Any information which identifies a patient and/or reporter that is made available 
to a principal applicant will be released on a confidential basis. The applicant must 
ensure appropriate safeguards are in place to restrict further access only to those 
named in the research application. 
 
7. Applicants are obliged to follow the general principles of the Human Rights Act 
19986, the Data Protection Act 19987 and the principles set out for research by the 
Department of Health8. 
 
                                               
6
 http://www.hmso.gov.uk/acts/acts1998/19980042.htm 
7
 http://www.hmso.gov.uk/acts/acts1998/19980029.htm 
8http://www.dh.gov.uk/PolicyAndGuidance/ResearchAndDevelopment/ResearchAndDevelopmentAZ/
ResearchGovernance/ResearchGovernanceArticle/fs/en?CONTENT_ID=4002130&chk=pebh9u 
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2.1 Confidentiality of Yellow Cards 
 
Since September 2000 all patient identifiers have been removed from the Yellow Card 
in line with the Data Protection Act (DPA) 1998 and the General Medical Council 
(GMC) guidelines on confidentiality (General Medical Council, 2000)9. Prior to this 
date, to identify duplicate reports reporters were asked to enter the patient’s name and 
date of birth on the Yellow Card. The inclusion of identifying details also facilitated 
the follow-up of reports when additional data were requested. 
 
In accordance with the legal requirements of the DPA, the MHRA has subsequently 
updated the Yellow Card and ADROIT database to remove all patient identifiers; and 
the MHRA will not release any information that could identify the person who 
submitted a Yellow Card, (the reporter), or the patient without the consent of the 
person(s) concerned. 
 
2.2 Responsibilities of applicants provided with Yellow Card data  
 
The principal applicant has responsibility for ensuring that any research using Yellow 
Card data has been clearly defined within their application and that these comply with 
the general principles as defined in this guidance document (listed above) and the 
undertakings provided on the application form (Annex A). The principal applicant 
must ensure that the data are held securely and used solely for the defined intended 
purpose.  
 
 
 
3. APPLICATION FORM COMPLETION NOTES 
 
When applying for access to Yellow Card and ADROIT data (Category II10) all 
applicants must complete the application form at Annex A and confirm that they have 
read and accept the undertakings on the application form and these guidance notes. 
The undertakings require that applicants do not disclose the data to persons not named 
on the application form or use the data for purposes not described in the research 
proposal. All data released by the MHRA for research is subject to the condition that 
the principal applicant must inform the MHRA of any issues effecting the safety of a 
medicine, whether licensed or unlicensed, that are identified during the research and 
submit all resulting publications to the Agency four calendar weeks prior to 
publication (see Section I). 
 
Details of the proposed use of the data and statistical analyses should be provided. If 
approval has been given by a NHS research ethics committee prior to the application 
this should be mentioned and the ethics committee and its reference number 
specified11. Applicants should be aware that prior approval by an ethics committee 
does not predetermine approval by the ISAC. All relevant agreements with other 
academic, commercial or other organisations should be disclosed. If it is anticipated 
                                               
9
 The GMC Guidelines were updated in April 2004 ‘Confidentiality: Protecting and Providing 
Information’. http//www.gmc-uk.org/standards/secret.htm 
10
 Definitions of data categories are provided in section 3.1 
11
 In most cases it is unlikely that ethical approval will have been obtained prior to scientific scrutiny 
by the ISAC. 
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that the research may have a patentable or commercially exploitable outcome this 
should also be recorded as the MHRA reserves the right to a share in any 
commercially exploitable outcome. 
 
The application form at Annex A may be used for requests for Category Ib data 
releasable under FOIA. For such applications completion of only the first third of the 
application form is requested (as detailed on the form).  
 
All applications should be submitted to the MHRA at the following address: 
 
The Pharmacovigilance Group 
Post Licensing Division 
MHRA 
Market Towers 
1 Nine Elms Lane 
London 
SW8 5NQ 
 
E-mail:   
pharmacovigilance@mhra.gsi.gov.uk 
 
 
3.1 Guidance for completing the application form12 
 
 
Section A - REFERENCE NUMBER 
 
Please leave this section blank. The reference number will be supplied by the MHRA. 
 
 
Section B - PERSONAL DETAILS 
 
The principal applicant and all co-applicants should provide their contact details 
within this section.  
 
 
Section C - TITLE AND SUMMARY OF THE PROPOSAL 
 
The applicant should set out the title of the proposal, the name and address of the 
Department / Institution / place at which the research will be conducted and the 
proposed start date.  
 
In addition applicants should provide a short summary of their proposal including the 
key goals and set out the relevance of the research to future patient care and/or public 
health.  
Section D – USE OF OTHER DATABASES   
 
                                               
12
 Further information can be obtained from MHRA, contact details provided in Section 5. 
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The combination of Yellow Card data with other databases may have the potential to 
identify patients and/or reporters. All applicants must state whether they intend to use 
the Yellow Card and ADROIT data in combination with another database or any other 
data sources. 
 
Section E - CATEGORY Ib YELLOW CARD DATA FIELDS &  
Section F - DETAILS OF PROPOSAL 
 
As with all other information held by the MHRA, release of Yellow Card data is 
subject to the Data Protection Act (DPA) 1998 and the Freedom of Information Act 
(FOIA) 2000. Some information is already routinely published or provided on 
request. Applicants should therefore consult the MHRA website13 before developing 
details of the proposal and deciding on the range of data to be requested. See also 
Section J regarding the charges payable to the MHRA for release of certain data.  
 
Data Protection Act (DPA) 
 
The DPA14 is primarily concerned with requests from individuals to know what 
personal information about them is held by, in this case, the MHRA (this is known as 
a subject access request). The DPA applies to data from which it is possible to 
identify a living individual. Subject to certain exemptions, it prohibits disclosure, 
without consent, of any personal information that identifies a living person. In certain 
cases this may apply to release of specific non-personal ADR data from a Yellow 
Card that may indirectly identify a reporter or a patient or in cases where only a 
limited number of cases exist.  
 
Requests from individuals to find out whether the Agency holds information on them 
(subject access requests) will continue to be considered under the terms of the DPA 
and will not be subject to consideration by the ISAC. 
 
The DPA principles are set out at Annex B. 
 
Freedom of Information Act (FOIA) 
 
The purpose of the FOIA15 is to “make provision for the disclosure of information 
held by public authorities”. The FOIA creates a statutory right of access to recorded 
information held by public authorities but the Act also provides exemptions from the 
duty to disclose the information, and imposes a requirement on public authorities to 
adopt and maintain a publication scheme. Certain FOIA exemptions are “absolute” 
while others are “qualified”. A full list of the FOIA exemptions is provided at Annex 
C. If a researcher seeks information about patients, he is seeking third party 
information and such requests will be considered under the FOIA but are also subject 
to DPA principles. Exemptions that may preclude the disclosure of certain types of 
Yellow Card data include Personal Information (absolute exemption 40), Information 
Intended For Future Publication (qualified exemption 22) and Investigations And 
Proceedings Conducted by Public Authorities (qualified exemption 30).  
                                               
13
 Go to www.yellowcard.gov.uk and select “download ADR listings” 
14
 http://www.hmso.gov.uk/acts/acts1998/19980029.htm 
15
 http://www.hmso.gov.uk/acts/acts2000/20000036.htm 
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The FOIA relates only to information that a public body, in this context the MHRA, 
holds at the time the request is made. The following paragraphs outline what 
information is already held by the Agency and is therefore subject to the FOIA. They 
also outline circumstances where the Agency will seek to obtain information that it 
does not hold in order to enable proposals recommended by the ISAC. 
 
Categories of Yellow Card Data 
 
In considering requests for Yellow Card and ADROIT data these can be divided into 
Category I requests that are releasable under the FOIA and not prohibited from 
release by DPA and Category II requests that are subject to FOIA exemptions and the 
restrictions of the DPA. In the latter case these data could not be released without 
scientific and ethical consideration of whether it would be appropriate for the reporter 
and patient to be approached to provide consent for use of their data. 
 
 
Category Ia Data 
 
Anonymised aggregated adverse drug reaction (ADR) data that do not identify the 
patient or reporter are known as Category Ia data, and are proactively provided on the 
MHRA website in the format of Drug Analysis Prints (DAPs) which are regularly 
updated16. Guidance on their interpretation is also available on the same website. 
Requests for these data are freely available under FOIA and are included in the 
Agency’s FOIA Publication Scheme. Therefore, all anonymised Category Ia data will 
be available from the MHRA upon request on the same basis as other FOI requests 
that the Agency receives17.  
 
Category Ib Data 
 
There are further data that can be provided from individual Yellow Cards that exclude 
any information that identifies a reporter and/or patient or provides any opportunity 
for the recipient to contact or identify the reporter and/or patient. Release of these 
data, known as Category Ib data, may include the age categories of the patients; the  
proportion of males and/or females who experienced the reaction; the drug or drugs 
involved; the dose and duration of drug therapy; the route of drug administration and 
the suspected adverse drug reaction(s) that the patient experienced (a full list of these 
Category Ib fields is provided at Annex D). These data are generally releasable under 
the FOIA, without consideration by the ISAC, although provision of these data will 
depend on the number of cases held by the Agency. In this context, among other 
Government departments, the Office of National Statistics (ONS) will only release 
information when at least five cases are included in any data subsets18. The ISAC has 
adopted the same policy to prevent identification of patients and/or reporters. 
Requests for data that have less than five cases in any one cell will be aggregated with 
adjacent cells prior to release. Any aggregation will be clearly marked when the data 
are provided.  
 
                                               
16
 Go to www.yellowcard.gov.uk and select “download ADR listings” 
17
 Go to  http://www.mhra.gov.uk and select “About us”, then “FOI” 
18
 The ONS is in the process of a disclosure review of health statistics. When this is finalised the ISAC 
may follow a similar approach to release of subsets of data. 
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The MHRA will not charge for release of Category Ib data unless the time taken to 
edit or redact the data requested exceeds 24 working hours in which case the Agency 
will levy a fee in line with the Agency’s charging policy for FOIA requests19, (Section 
J).  
 
 
Category II Data 
 
Certain data contained on the ADROIT database may indirectly identify either the 
reporter or the patient. These data fields may, for example, include patient unique 
details in the narrative text provided by the reporter, the patient’s medical history, 
dates of drug administration and reaction and specific test results relevant to the 
suspected adverse reaction, that might enable the patient to be identified. Requests for 
reporter and patient details or for data that may identify the reporter or patient are 
considered as Category II data. Release of these data is subject to the terms of the 
FOIA and the DPA.  Exemption 40: Personal Information of the FOIA and the DPA 
invoke certain restrictions on disclosure for these data that the Agency already holds 
that would identify individuals.  
 
All Category II data requests will be reviewed by the ISAC. In certain cases ethical 
approval may also be required. Requests for data that relate to a small number of 
ADR cases may also identify the reporter or patient and these requests will have to be 
considered by the Committee. In addition, any requests for actual images of Yellow 
Cards or for large subsets of these data would be referred to the Committee.  
 
The Independent Review proposed arrangements that would satisfy legal and ethical 
requirements for studies that might be undertaken that would involve direct access to 
confidential personal data on patients and/or might also involve direct access by the 
researcher to patients. A number of safeguards have been established to ensure that 
release of these data would follow scientific and ethical approval and that reporter and 
patient consent would be obtained prior to release of any of their identifiable data. 
These include requests in which the reporter would need to be approached in the first 
instance so that the reporter could decide whether the patient should be asked for 
his/her consent. This would be necessary for a genetic research study to investigate 
whether certain patients are predisposed to specific ADR(s) or when a researcher 
requested access to the entire database to develop signal detection methodologies. 
Under such circumstances, these applications will require ethical approval from a 
Research Ethics Committee (REC) through the Central Office for Research Ethics 
Committees (COREC20) system.  
 
Following both scientific and ethical approval the MHRA will be responsible for 
contacting the reporter to ask if he/she is prepared to assist the applicant with the 
study.  That responsibility will not be delegated outside the Agency under any 
circumstances.  If appropriate, the reporter should also be told to ask the patient if 
they are willing to be contacted by a researcher in the context of a particular study. 
Consent from both the reporter and the patient must be obtained before their contact 
details are disclosed to the researcher. The MHRA will require a short summary of the 
                                               
19Go to  http://www.mhra.gov.uk and select “About us”, then “FOI” 
20
 http://www.corec.org.uk/ 
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research proposal in layman’s terms for the reporters to give to patients when 
informing them of the proposed research and possible implications. 
 
It will be the responsibility of the reporter to decide in each case whether a patient 
should be asked to participate. The MHRA will allow a time period of two months for 
the reporter to respond before sending a reminder letter to the reporter. If no response 
is received within a month of sending the reminder the Agency will not pursue the 
request further. In writing to the reporter the MHRA will endorse participation for 
those studies approved by the Committee and REC but will not further influence their 
decisions. Once responses are available from reporters the MHRA will inform the 
researcher of the proportion of patients who have agreed to assist.   
 
Data of deceased patients and reporters 
 
As a general policy21 the ONS treats the deceased the same as the living as they 
consider that there remains a duty of confidence owed to the deceased, even though 
the DPA refers to living individuals and does not extend to the deceased. The 
Committee supports this view and for this reason, all requests for release of data from 
deceased patients will be considered under the same conditions as the living. If a 
patient has deceased the reporter as a matter of courtesy should consider whether to 
contact the next of kin if he intends to disclose details of the patient for research. 
 
When a reporter who has submitted a Yellow Card has died the decision on whether 
to contact the patient for consent would be referred by the MHRA to the reporter’s 
NHS (or private) successor in-post.  
 
 
Section G - RELEVANT APPLICATIONS AND PUBLICATIONS  
 
Applicants should include details of all their previous or ongoing research that utilised 
Yellow Card and/or ADROIT data.  
 
 
Section H - SECURITY & CONFIDENTIALITY  
 
The ISAC and the MHRA consider that confidentiality of Yellow Card data is 
paramount. For this reason any release of data that is subject to the DPA must be 
subject to stringent conditions.  
 
Applicants must confirm that they will guarantee the ongoing confidentiality of the 
data by abiding by the principles in the DPA (Annex B) and specify where any data 
released to them for research will be held and what security measures will be in place 
to prevent disclosure to third parties. 
 
Section I - PUBLICATION  
 
                                               
21
 The ONS is also reviewing its policy in relation to the deceased. 
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The MHRA encourages publication of research using the Yellow Card database. 
However, applicants must state on the application if they intend to publish or place 
the results of the research in the public domain.  
 
The Agency requires that all publications or other data based on research using 
Yellow Card and ADROIT data are submitted at least four calendar weeks in advance 
of any public release of research findings. This requirement is not to impose a delay 
on publication but is necessary to enable the MHRA to fulfil its statutory 
responsibilities and arrange any necessary regulatory action required in the light of the 
research findings. Any regulatory action would be timed to coincide with publication. 
The Agency may also offer comments on the proposed publication but the principal 
applicant will not be obliged to accept these.  However, in situations in which the 
MHRA has concerns about the implications of the research and the applicant does not 
acknowledge these the Agency reserves the right to comment independently. 
 
A separate pre-publication notification must be submitted to the ISAC for every 
publication based on released Yellow Card / ADROIT data. 
 
 
Section J - FINANCE  
 
Category Ia Data  
 
The MHRA as a Trading Fund, is required, under the terms of its Trading Fund Order, 
to cover its costs. No charge will be made for Category Ia anonymised aggregated 
ADR data, in the format of DAPs, as these are already provided free of charge on 
request as part of the MHRA’s publication scheme.  
 
Category Ib Data 
 
The Agency will not normally charge for release of specific case details known as 
Category Ib data (Annex D) unless the time taken to edit or redact the data requested 
exceeds 24 working hours in which case the Agency will levy a fee in line with 
Agency’s charges for FOIA requests22. 
 
Category II Data  
 
In the long term a scale of three levels of fees proportionate to work incurred may be 
applied for release of Category II data in order to be cost-neutral to the Agency. The 
intended fee structures will reflect those situations where the Agency holds the 
requested data (but needs to remove personal identifiers) and those where the Agency 
will need to obtain the necessary information that it does not already hold. In the 
interim when information is already held by the Agency, the MHRA will levy an 
initial fee of £50 per application before the ISAC reviews an application for Category 
II data. This fee should be submitted at the time of application.  
 
The Agency will then charge a fee based on £25 per Agency personnel per hour of 
work. This will enable requests for case details over and above those listed in Annex 
D to be provided the most economical to the applicant while the costs for research 
                                               
22
 Go to  http://www.mhra.gov.uk and select “About us”, then “FOI” 
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which requires the Agency to contact the reporter and through them the patient will be 
proportionate to the amount of work required. In the latter case, additional costs 
including payment of reporters and patients for their time and inconvenience will have 
to be borne by the applicant. All fees are non-refundable to applicants even if the 
response from reporters (and patients) is poor. 
 
Additional fees for pre-1991 data 
 
Prior to introduction of the ADROIT database in 1991 the MHRA held Yellow Card 
data on the Norsk database, the original computer system on which the Product 
Licence Database was stored. When Norsk data were transposed onto the ADROIT 
database only basic details from each ADR report were added to the new database, 
such as the name of the drug, the reaction and the outcome of the reaction. For 
applicants who request pre-1991 Yellow Card data an additional charge may be 
incurred for the time required for Agency staff to retrieve additional data from old 
ADR case reports not currently held on ADROIT if more than the basic details are 
required the level of which will be discussed with the Agency.  
 
 
Section K - CURRICULUM VITAE OF APPLICANT(S) 
 
All applicants (the principal and all co-applicants) should enclose an abridged 
curriculum vitae with each application. A summary of relevant qualifications and 
career(s) to date and if applicable a list of not more than ten relevant publications 
should be provided. 
 
Section L - SUPPLEMENTARY INFORMATION  
 
For audit purposes, applicants are requested to provide details of the source from 
which they learnt about this application process for access to the Yellow Card 
database.  
 
 
4. REVIEW PROCESS 
 
4.1 Review process of applications 
 
Upon receipt of an application a validation check will be made. If further information 
is required before the application can be processed, the principle applicant will be 
contacted before the application is accepted. Once an application has been logged the 
principal applicant will receive an acknowledgement for the application in the form of 
a letter or e-mail depending on the mode of submission. A reference number for the 
application will then be provided along with the intended date of review by the ISAC.  
 
4.2 Outcome of the review process 
 
The principal applicant will be informed of the outcome of their application following 
review by the ISAC. Where the application has been approved by the Committee the 
principle applicant will receive the requested data from MHRA staff within a defined 
timeframe. If an application is refused the applicant will be informed of the reasons 
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and have an opportunity to appeal (section 4.3) or re-submit an amended application 
to the Committee. 
 
 
4.3 Appeal mechanism 
 
If the MHRA accepts the advice of ISAC to turn down an application for data, the 
unsuccessful applicant will be sent a letter setting out the reasons why.  The applicant 
will be told that he/she has 28 days from the date of the letter to make representations, 
and that these should be made in writing to the YellowCard ISAC Secretary as 
appropriate.  The applicant will be informed that once this 28 day period has expired, 
he/she will have to make a fresh application.  If an appeal is to be carried out then the 
Licensing Authority will appoint a person or persons to undertake a review of the 
documentation.  A letter will be sent to the applicant with the outcome of the appeal.  
The decision of the Licensing Authority will be final. 
 
5. CONTACT FOR FURTHER INFORMATION  
 
Write to:  
 
The Pharmacovigilance Group 
Post Licensing Division 
MHRA 
Market Towers 
1 Nine Elms Lane 
London 
SW8 5NQ 
 
E-mail:   
pharmacovigilance@mhra.gsi.gov.uk 
 
Tel: 020 7084 2788  
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Glossary 
 
Adverse Drug Reaction (ADR) 
A reaction which is harmful and unintended and which occurs at a dose normally used 
for the prophylaxis, diagnosis or treatment of disease or the modification of 
physiological function.  
 
Adverse Drug Reactions On line Information Tracking (ADROIT) 
The MHRA’s computer system for storage and analysis of UK and foreign adverse 
drug reaction (ADR) data.  
 
Co-applicant 
A co-applicant is a researcher who will have significant intellectual input into, and 
part responsibility for, the research if the application is successful. 
 
Committee on Safety of Medicines (CSM) 
The CSM was one of the independent advisory committees established under the 
Medicines Act (Section 4) which advises the UK Licensing Authority on the quality, 
efficacy and safety of medicines in order to ensure that appropriate public health 
standards are met and maintained.  In November 2005 the CSM was replaced by the 
new Commission on Human Medicines (CHM). 
 
Medical Dictionary for Regulatory Activities (MedDRA) 
The internationally accepted medical terminology for use in drug regulation. 
Developed under the auspices of the ICH and based on MEDDRA (Medical 
Dictionary for Drug Regulatory Affairs) which was in turn based on the MHRA’s 
medical dictionary.  
 
Medicines Act 
The Medicines Act was given Royal Assent in October 1968. It provided for a 
comprehensive system of licensing affecting manufacture, sale, supply and 
importation of medicinal products into the UK. Medicines regulation in the UK is 
now governed by a combination of powers under the Act on EU law. 
 
Medicines and Healthcare products Regulatory Agency (MHRA) 
On 1 April 2003, the Medicines and Healthcare products Regulatory Agency 
(MHRA) replaced the Medical Devices Agency (MDA) and the Medicines Control 
Agency (MCA). The MHRA is an Executive Agency of the Department of Health 
with Trading Fund status. The MHRA is committed to safeguarding public health by 
ensuring that medicines, healthcare products and medical equipment meet appropriate 
standards of safety, quality, performance and effectiveness, and are used safely.  
 
Norsk Database 
The original computer system on which the Product Licence Database was stored.  
 
Pharmacovigilance 
Pharmacovigilance is the process of (a) monitoring medicines as used in everyday 
practice to identify previously unrecognised or changes in the patterns of their adverse 
effects; (b) assessing the risks and benefits of medicines in order to determine what 
action, if any, is necessary to improve their safe use; (c) providing information to 
users to optimise safe and effective use of medicines; (d) monitoring the impact of 
any action taken.  
 
Principal applicant 
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A principal applicant is the lead researcher who has the main intellectual input into, 
and responsibility for the research if the application is successful. This is the 
individual with whom the MHRA will correspond about the application.   
 
Public domain 
Information that is openly available to everyone and not subject to copyright 
protection. 
 
Redaction  
The careful editing of a document to remove confidential information. 
 
Reporter 
Reporters of adverse drug reactions via the Yellow Card Scheme are health care 
professionals (e.g. doctors, dentists, coroners, pharmacists, nurses, radiographers and 
optometrists). The Yellow Card Scheme is voluntary for health care professionals and 
they also report indirectly to us via the pharmaceutical industry. Patient reporting is 
being incorporated within the Scheme through ongoing initiatives but these data are 
currently held separately on the MHRA’s database. 
 
Side effect 
A consequence other than the one for which an agent or measure is used.  
 
Signal detection 
A signal can be defined as reported information on a possible causal relation between 
an adverse event and a medicine, the relation being previously unknown or poorly 
documented. The Yellow Card Scheme can be used to detect signals that require 
further pharmacovigilance investigation.  
 
Trading Fund 
A Trading Fund is a financing framework for Government operations, covering 
operating costs and receipts, capital expenditure, borrowing and net cash flow, which 
gives an agency greater freedom to manage its financial affairs than if its costs are 
met by its parent Department. 
 
UK Licensing Authority 
UK Government Ministers of Health and Agriculture. 
 
 
List of abbreviations 
 
ADROIT  Adverse Drug Reactions On-line Information Tracking 
ADR   Adverse drug reaction       
COREC   Central Office for Research Ethics Committees   
CSM   Committee on Safety of Medicines 
DAP   Drug Analysis Print  
DPA   Data Protection Act 1998     
FOIA   Freedom of Information Act 2000 
GMC   General Medical Council  
REC   Research Ethics Committee  
MCA   Medicines Control Agency      
MDA   Medical Devices Agency     
MedDRA  Medical Dictionary for Regulatory Activities   
MHRA  Medicines and Healthcare products Regulatory Agency  
ONS   Office of National Statistics  
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Annex A 
 
ACCESS TO YELLOW CARD & ADROIT DATA  
APPLICATION FORM 
 
Applicants requesting Category Ib Yellow Card data (Annex D) should only complete 
sections A, B, C, D and E of this form. Those requesting Category II data must complete all 
sections of the application form (except section E) and provide the undertakings below. 
 
Undertakings by the MHRA in relation to information provided by applicants 
 
The information submitted on this form will be considered by the ISAC established 
by the Medicines and Healthcare products Regulatory Agency (MHRA) to advise on 
applications for access to Yellow Card data. Any personal data provided in an 
application will be used only for statistical analysis, management, planning and in the 
provision of services by the MHRA. In accordance with the Data Protection Act 1998, 
the ISAC and the MHRA will respect the confidentiality of all personal information, 
but reserve the right to publish in an anonymous and unidentifiable form summary 
data about applications received (via the Internet or in its annual report) for reference 
and audit purposes. 
 
Undertakings by the applicant(s) in relation to information provided by the MHRA 
 
1. I confirm that I have read and understood the Data Protection Statement and the 
Access to Yellow Card Data Guidance Notes. 
 
2. I agree to use the data only for the intended purpose for which access was granted.  
 
3. I will submit in writing any change to the research plan or any amendment to the 
principal applicant and/or co-applicants to the ISAC for approval. 
 
4. I will ensure that the data are stored in a confidential manner and that the data or 
analyses of the data are not released to third parties without consent from the   
ISAC.  
 
5. I will inform the MHRA of any new drug safety issues identified at the time of 
recognition.  
 
6. I agree to submit any draft publications from use of these data to the MHRA for 
comments four calendar weeks prior to publication.  
 
7. To the best of my knowledge the information provided in this application is 
accurate and comprehensive.  
 
Signature of principal applicant: _________________________ Date:  _________ 
 
Signature of co-applicant:   __________________________ Date:  _________ 
 
Signature of co-applicant:  ______________________________ Date:  _________ 
 
Signature of co-applicant:  ______________________________ Date:  _________ 
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Section A - REFERENCE NUMBER23 ___________________________ 
 
Section B - PERSONAL DETAILS 
 
B.1 Principal applicant 
Title (Prof/Dr/Mr/Mrs/Miss/Ms/other please detail): Professor    
 
Full name: Derek Stewart 
 
Place of work: Robert Gordon University 
 
Job title and organisation: Professor of Pharmacy Practice 
 
Address: School of Pharmacy & Life Sciences, Robert Gordon University 
 
City: Aberdeen 
 
Zip / Postcode: AB10 1FR 
 
Country: UK 
 
Telephone: 01224 262432 
 
Fax: 01224 262555 
 
E-mail: d.stewart@rgu.ac.uk 
 
B.2 Co-applicant 
Title (Prof/Dr/Mr/Mrs/Miss/Ms/other please detail): Dr 
 
Full name: James McLay 
 
Place of work: University of Aberdeen 
 
Job title and organisation: Senior Lecturer 
 
Address: Institute of Medical Sciences 
 
City: Aberdeen 
 
Zip / Postcode: AB25 2ZD 
 
Country: UK 
 
Telephone: 01224 552463 
 
Fax: 01224  
 
E-mail: j.mclay@rgu.ac.uk 
                                               
23
 The reference number will be provided by the Committee on Yellow Card Data secretariat on receipt 
of a valid application. The applicant is not required to complete this section.  
Appendix III. YCS Application Form 121
18 
 
B.3 Co-applicant 
Title (Prof/Dr/Mr/Mrs/Miss/Ms/other please detail): Dr 
 
Full name: Yash Kumarasamy 
 
Place of work: Robert Gordon University 
 
Job Title and organisation: Lecturer in Clinical Pharmacy 
 
Address: School of Pharmacy & Life Sciences, Robert Gordon University 
 
City: Aberdeen 
 
Zip / Postcode: AB10 1FR 
 
Country: UK 
 
Telephone: 01224 262595 
 
Fax: 01224 262555 
 
E-mail: y.kumarasamy@rgu.ac.uk 
 
B.4 Co-applicant 
Title (Prof/Dr/Mr/Mrs/Miss/Ms/other please detail): Mr 
 
Full name: Okechukwu Obisike Ndu 
 
Place of work: Robert Gordon University 
 
Job title and organisation: PhD student 
 
Address: School of Pharmacy & Life Sciences, Robert Gordon University 
 
City: Aberdeen 
 
Zip / Postcode: AB10 1FR 
 
Country: UK 
 
Telephone: 01224 262432 
 
Fax: 01224 262555 
 
E-mail: o.o.ndu@rgu.ac.uk 
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Section C - TITLE AND SUMMARY OF THE PROPOSAL  
 
C.1 Title of proposal for use of Yellow Card data 
A review of Yellow Card reports on complementary and alternative medicines 
(CAMs) 
 
C.2 Summary of proposal including key goals  
(not more than 500 words) 
The World Health Organisation (WHO) defines complementary and alternative 
medicines (CAMs) as ‘a broad set of health care practices that are not part of a 
country’s own tradition and are not integrated into the dominant health care system’, 
categorising these as ‘medication therapies’ and ‘non-medication therapies’. While 
the use of ‘medication therapies’ (e.g. herbal products, homeopathic products, 
vitamins and minerals, essential oils) is increasing globally, there are few reports 
which focus on safety.  
 
The aim of this research is to analyse reports of suspected ADRs from the UK Yellow 
Card Scheme (YCS) related to ‘medication therapies’ classified as CAMs. Data will 
be analysed in terms of  
 
- the number of reports for individual products 
- completeness of the reports 
- patient characteristics (sex and age) 
- reporter status (patient reports v healthcare professional reports) 
- date of report 
- the opinion of the reporter to the seriousness of the reaction 
- free text description of the reaction, richness of descriptions  
- MedDRA coded reaction terms 
- reaction start and end date 
- onset of reaction time  
- reaction duration 
- reaction outcome 
- recovery time 
- any specific treatment given 
- reaction severity 
- any sequelae 
- name of product as reported 
- prescribing indications 
- dose 
- dosage form and strength 
- route 
- patient medical and drug history 
- information on the parent where relevant 
- details of any death reported. 
 
Please note that there is no intention to contact the patient/reporter/healthcare 
professional.  
 
Analysis will be descriptive in terms of  
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- characteristics of those experiencing ADRs 
- reactions 
- products 
- outcomes. 
 
C.3 Name and address of Department / Institution / place at which the research /  
analysis will be conducted 
School of Pharmacy & Life Sciences, Robert Gordon University 
 
C.4 Proposed start date   1 December 2011  
  
Duration if known   9 months 
 
 
Section D – USE OF OTHER DATABASES   
 
D.1 Are you  intending to use the  Yellow Card data  in  combination  
with  another  database  or other  data sources24   (local, national,  
international or personal data archive)?       No 
If yes, please specify 
 
Section E – CATEGORY Ib YELLOW CARD DATA FIELDS 
 
This section is not required for applications for Category II data. 
 
E.1 Please tick the following data fields that you require and provide details: 
 
 
 
 
Yes 
 
No 
 
Details 
Patient age categories     
Patient gender    
Suspect drug(s)    
Dose of suspect drug    
Route of administration    
Duration of treatment    
Suspected adverse drug reaction(s)     
*Category I data case details listed above are releasable under the Freedom of Information Act (FOIA) 
without consideration by the ISAC.  These are known as Category Ib data. Provision of these data will 
depend on the number of cases held by the Agency. The MHRA will not release any data subset in 
which there are five or fewer cases per cell. This is necessary to prevent identification of patients 
and/or reporters. Where there are less than five cases per cell the data will be aggregated with adjacent 
cells. Any aggregation will be clearly marked on the dataset. 
 
 
                                               
24
 For example GP, hospital, Health board, death, employee records 
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APPLICANTS FOR CATEGORY II DATA MUST COMPLETE ALL THE 
SECTIONS THAT FOLLOW  
 
Please remember your obligations under the DPA once you begin to process personal 
data.  These are set out at Annex B. 
 
Section F - DETAILS OF PROPOSAL  
 
F.1 What category of data request are you requesting? 
(refer to guidance notes for definitions of data categories) 
Category II 
 
F.2 Would your research involve contacting the     
 reporter and/or patient via the MHRA?        No 
If yes, please justify why you are requesting data that include 
 information related to individuals.  
 
F.3 Do you consider that the exemptions under FOIA are 
 applicable to the release of the data you are requesting?   Yes   
 
F.4 Please provide a short description of the proposed research methodology 
including design of the study, data management and data analyses. This 
section must be in language that is comprehensible to a non-specialist reader.    
(not more than 500 words) 
Analysis of data will be undertaken by a PhD student at the School of Pharmacy & 
Life Sciences under the supervision of Professor Derek Stewart (principal supervisor), 
Dr James McLay and Dr Yash Kumarasamy. DS, JM and YK have expertise in 
pharmacovigilance research. 
 
Prior to undertaking analysis, logical checks on the data (outliers, missing data etc) 
will be performed and any anomalies clarified by contacting MHRA.  
 
Data will be imported into a bespoke SPSS database (SPSS Cary, NC, USA, version 
17). Analysis will largely be descriptive (frequencies, means, medians etc) and 
univariate to explore any associations between independent variables (age etc) and 
outcomes (ADRs). 
 
A report of findings will be submitted to MHRA and for publication.  
 
F.5 Please describe the statistical methods you plan to use in the analysis of the 
data. 
Analysis will largely be descriptive (frequencies, means, medians etc) and univariate 
to explore any associations between independent variables (age etc) and outcomes 
(ADRs). 
 
F.6 Have you received ethical approval for your request?               No 
If yes, please provide a copy of the ethics committee’s  
approval and its reference number.  
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F.7 Is the proposal subject to any agreements with any       
academic, commercial or other organisations?       No 
If yes, give details 
 
F.8 Is the proposal likely to lead to any patentable       
or commercially exploitable results?       No 
If yes, give details 
 
F.9 Do you consider that the consequences of your research may  
have implications for public health?          No 
If yes, give details 
 
 
Section G - RELEVANT APPLICATIONS AND PUBLICATIONS  
 
G.1 Have you used Yellow Card data previously?      No 
If yes, give details (include relevant publications)  
 
G.2 Is this application a resubmission of a previous application?       No  
If yes, give details of how this application differs from the original application 
 
G.3 Have you previously submitted other applications  
 to the ISAC or its predecessor, the Interim   
Committee on Yellow Card Data?           No 
If yes, give details  
 
Section H – SECURITY & CONFIDENTIALITY  
 
H.1 Please confirm that you will abide by the principles of the  
DPA 1998 as detailed in the guidance notes        Yes  
 
H.2 Where will the Yellow Card hard copy and consequential working papers and 
manuscripts be held? Where computer or electronic data systems will be used 
please give details. 
Hard copies and working papers will be held in locked cupboards within the School of 
Pharmacy & Life Sciences at Robert Gordon University. Only the PhD student and 
supervisors will have access. Electronic data will be stored on one password protected 
PC within the university.  
 
H.3 What security arrangements will be made to prevent unauthorised access to 
the Yellow Card data when held on a university or research network and/or a 
personal laptop or other computer?  
All documents (SPSS database, SPSS outputs, draft and final reports will be stored on 
password protected computers). Only the PhD student and supervisors will have 
access. 
 
H.4 Please provide details of data security policies that will apply to all individuals 
and organisations named in this application who will have access to the data.   
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We will strictly adhere to the data protection policies of Robert Gordon University, 
available at http://www4.rgu.ac.uk/dp/general/page.cfm?pge=45483 
 
At Robert Gordon University we abide by the eight principles put in place by the Data 
Protection Act 1998. Data must be:  
1. fairly and lawfully processed;  
2. processed for limited purposes;  
3. adequate, relevant and not excessive;  
4. accurate;  
5. not kept for longer than is necessary;  
6. processed in line with your rights;  
7. secure; and,  
8. not transferred to countries without adequate protection.  
By law, Robert Gordon University (a "Data Controller") must keep to these principles 
in its processing of personal data. 
 
We will also adhere to all RGU research governance policies, available at 
http://www4.rgu.ac.uk/files/Research%20Governance%20Policy%20%2814%20Oct
%202010%291.pdf 
 
I have also attached a copy of the School of Pharmacy & Life Sciences Research 
Governance Standard Operating Procedure. 
 
H.5 What measures will be put in place to ensure that the data are not disclosed to 
third parties not named in the research application? 
Third parties will have no access to the data (all password protected). 
 
 
 
H.6 How long do you intend to retain the Yellow Card Data?  
 If longer than 12 months please provide justification 
Until five years following completion and award of the PhD. 
 
H.7 What method of data destruction will be employed when the research use of 
the Yellow Card data has been completed? 
Professor Stewart will ensure that all data will be deleted from password protected 
computers.  
 
 
Section I - PUBLICATION  
 
I.1 Are you intending to publish or place the results of     
your proposal in the public domain?            Yes  
 If yes, please specify 
Results will be presented in a PhD thesis at Robert Gordon University. In addition, we 
intend to submit findings to appropriate peer reviewed journals such as ‘Drug Safety’. 
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I.2 Please confirm that you will submit any draft publications to  
the MHRA for any necessary  regulatory action at least four  
calendar weeks prior to publication        Yes  
 
 
 
Section J - FINANCE  
 
Fees are detailed in the guidance notes. 
 
Please indicate to whom the MHRA should send invoices   
 
Professor Derek Stewart 
Professor of Pharmacy Practice 
School of Pharmacy & Life Sciences 
Robert Gordon University 
Aberdeen 
Scotland 
AB10 1FR 
 
Section K - CURRICULUM VITAE OF APPLICANT(S) 
 
K.1 All applicants (including principal and co-applicants) who will have access to 
any Yellow Card data must provide up-to-date curriculum vitae with each 
application. 
 
K.2 Summary of relevant qualifications and career(s) to date, if applicable 
(not more than 200 words) 
Professor Derek Stewart 
Professor of Pharmacy Practice 
School of Pharmacy & Life Sciences 
Robert Gordon University 
Aberdeen 
Scotland 
AB10 1FR 
 
PgCert (Tertiary Learning Teaching Methods), BSc (Pharmacy, 1st), MSc (Clinical 
Pharmacology), PhD.  
Member of the Royal Pharmaceutical Society, Scottish Pharmacy Board and British 
Pharmacological Society prescribing sub-committee. Executive editor of the British 
Journal of Clinical Pharmacology and the editorial panel of International Journal of 
Clinical Pharmacy.  
 
Dr James McLay 
Senior Lecturer Medicine and Therapeutics 
Aberdeen Medical and Dental School 
University of Aberdeen  
BPharm, MBChB, PhD, FRCP 
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Executive member of the British Pharmacological Society. Executive Editor of the 
British Journal of Clinical Pharmacology. Chair of the British Hypertension Society 
Educational Committee. Chair of the Specialist Advisory Committee for Clinical 
Pharmacology and Therapeutics. 
  
Dr Yash Kumarasamy 
Lecturer in Clinical Pharmacy 
School of Pharmacy & Life Sciences 
Robert Gordon University 
Aberdeen 
Scotland 
AB10 1FR 
 
PgCert (Higher Education Learning and Teaching), MBBS, MSc (Clinical 
Pharmacology), PhD. FHEA, MRSC 
A clinical pharmacologist with an interest in public health and epidemiology. 
 
Okechuukwn Obisike Ndu 
PhD student  
School of Pharmacy & Life Sciences 
Robert Gordon University 
Aberdeen 
Scotland 
AB10 1FR 
 
 
K.3 List up to ten relevant publications  
Tobaiqy M, Stewart D, Helms P, Williams J, Crum J, Steer C, McLay J. Parental 
reporting of adverse drug reactions associated with attention-deficit hyperactivity 
disorder (ADHD) medications in children attending specialist paediatric clinics in the 
UK. Drug Safety 2011;34(3):211-219. 0114-5916/11/0003-0211/$49.95/0 
 
Tobaiqy M, Stewart D, Helms PJ, Bond C, Lee AJ, Bateman N, McCaig D, McLay 
JS. A pilot study to evaluate a community pharmacy-based monitoring system to 
identify adverse drug reactions associated with paediatric medicines use. European 
Journal of Clinical Pharmacology 2010;66:627-632. 10.1007/s00228-101-0790-9 
 
Tobaiqy M, Stewart D, Helms PJ, Bond CM, Lee AJ, McLay JS. Views of parents 
and pharmacists following participation in a paediatric pharmacovigilance study. 
Pharmacy World & Science 2010;32:334-338. 10.1007/s11096-010-9374-0 
 
Stewart D, Helms P, McCaig D, Bond C, McLay J. Monitoring adverse drug 
reactions in children using community pharmacies: a pilot study. British Journal of 
Clinical Pharmacology 2005; 59: 677-683. 
 
Elkout H, McLay JS, Simpson CR, Helms, PJ. Use and safety of long-acting 2-
agonists for pediatric asthma. Pediatric Health. 2010; 4, Issue 3:295-310. 
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Elkout H, McLay J.S, Simpson C.R, Helms, P.J A retrospective observational study 
comparing rescue medication use in children on combined versus separate long-acting 
β-agonists and corticosteroids. Archive Dis Childhood. 2010; 95, Issue 10: 2010, 817-
821. 
 
Naina Mohamed, I., Helms, P.J., Simpson, C.R., Milne, R.M., McLay, J.S. Using 
primary care prescribing databases for pharmacovigilance. BJCP. 2011; 71, Issue 2; 
244-249   
 
Naina Mohamed, I., Helms, P.J., Simpson, C.R., Milne, R.M., McLay, J.S. Using 
routinely collected prescribing data to determine drug persistence for the purposes of 
pharmacovigilance. J Clin Pharmacol. 2011; 51:279-284 
 
Elkout H, Simpson CR, Helms PJ, McLay JS.  Changes in primary care prescribing 
patterns for paediatric asthma: A prescribing database analysis. Archives Dis 
Childhood. 2011. Accepted for publication. 
 
Karzouini A Mohammed, B.S, Cameron, GA.,  Helms, PJ, McLay JS Paracetamol 
prescribing in primary care: Too little and too much? BJCP. 2011. Accepted for 
publication.  
 
 
 
 
Section L - SUPPLEMENTARY INFORMATION  
 
L.1 Where did you learn about this application process? 
 
Internet ______________________________________________ 
 
L.2 If you have any comments on this application form, please provide feedback 
below: 
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Annex B 
 
The Data Protection Act 1998 Principles (Schedule 1)25 
 
1. Personal data shall be processed fairly and lawfully and, in particular, shall not be 
processed unless (a) at least one of the conditions in Schedule 2 is met, and (b) in 
the case of sensitive personal data, at least one of the conditions in Schedule 3 is 
also met. 
 
2. Personal data shall be obtained only for one or more specified and lawful 
purposes, and shall not be further processed in any manner incompatible with that 
purpose or those purposes. 
 
3. Personal data shall be adequate, relevant and not excessive in relation to the 
purpose or purposes for which they are processed. 
 
4. Personal data shall be accurate and, where necessary, kept up to date. 
 
5. Personal data processed for any purpose or purposes shall not be kept for longer 
than is necessary for that purpose or those purposes. 
 
6. Personal data shall be processed in accordance with the rights of data subjects 
under this Act. 
 
7. Appropriate technical and organisational measures shall be taken against 
unauthorised or unlawful processing of personal data and against accidental loss 
or destruction of, or damage to, personal data. 
 
8. Personal data shall not be transferred to a country or territory outside the 
European Economic Area unless that country or territory ensures an adequate 
level of protection for the rights and freedoms of data subjects in relation to the 
processing of personal data. 
 
 
                                               
25
 http://www.hmso.gov.uk/acts/acts1998/80029--l.htm#sch1 
Appendix III. YCS Application Form 131
28 
Annex C 
 
The Freedom of Information Act 2000 (FOIA) Exemptions 
 
Absolute exemptions 
 
Section 21 - Information accessible to applicant by other means. 
 
Section 23 - Information supplied by, or relating to, bodies dealing with security matters. 
 
Section 32 - Court records, etc. 
 
Section 34 - Parliamentary privilege. 
 
Section 40 - Personal information. 
 
Section 41 - Information provided in confidence. 
 
Section 44 - Prohibitions on disclosure. 
 
 
Qualified exemptions 
 
Section 22 - Information intended for future publication. 
 
Section 24 - National security. 
 
Section 26 – Defence 
 
Section 27 - International relations. 
 
Section 28 - Relations within the United Kingdom. 
 
Section 29 - The economy. 
 
Section 30 - Investigations and proceedings conducted by public authorities. 
 
Section 31 - Law enforcement. 
 
Section 33 - Audit functions. 
 
Section 35 - Formulation of government policy, etc. 
 
Section 36 - Prejudice to effective conduct of public affairs. 
 
Section 37 - Communications with Her Majesty, etc. and Honours. 
 
Section 38 - Health and safety. 
 
Section 39 - Environmental information. 
 
Section 42 - Legal professional privilege. 
 
Section 43 - Commercial interests. 
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Annex D 
 
Category I releasable data fields (Category Ib data) 
 
Category I data case details listed below are releasable under the Freedom of 
Information Act (FOIA) without consideration by the ISAC. These are known as 
Category Ib data. Provision of these data will depend on the number of cases held by 
the Agency. The MHRA will not release any data subset in which there are five or 
fewer cases per cell. This is necessary to prevent identification of patients and/or 
reporters. Where there are less than five cases per cell the data will be aggregated with 
adjacent cells. Any aggregation will be clearly marked on the dataset. 
 
Patient age categories (<18, 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, >85 
years) 
Patient gender (number of female and male patients) 
Suspect drug(s) 
Dose of suspect drug 
Route of administration 
Duration of treatment 
Suspected adverse drug reaction(s)  
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Prof Derek Stewart 
School of Pharmacy & Life Sciences, 
Robert Gordon University 
Aberdeen 
AB10 1FR 
     
19/10/2011 
 
Our Ref: AYCD030 
 
Dear Prof Stewart 
 
Application: A review of Yellow Card reports on Complementary and 
Alternative Medicines (CAM). 
 
The Independent Scientific Advisory Committee (ISAC) for MHRA database research 
considered the above application on 7th October 2011. The Committee considered 
that your application was an appropriate use of Yellow Card data and that the 
proposed methodology is appropriate for the objectives of the study. The Committee 
advised that the application should be granted provided you comply with the following 
conditions: 
 The applicants should be asked to update their proposal for computer 
security, rather than password protected these should be encrypted.   
 In addition, as your proposal will involve the release of Category II data, I 
should remind you of the undertakings you agreed to when you completed the 
application form. These are included at Annex A. 
 You must abide by the Guidelines for Safe Disposal of Electronic Yellow Card 
Data for External Users included at Annex B. 
 Please note the enclosed information at Annex C on the National Research 
Register (NRR). We strongly recommend that you register with the NRR. 
 
The MHRA has accepted the advice of the ISAC. If you are willing to accept the 
above conditions, please let me know as soon as possible and no later than 28 days 
after the date of service of this letter. 
 
Yours sincerely, 
 
 
 
Ms Sharon Suri  
 
Yellow card Secretary to the ISAC 
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Annex A  
 
Undertakings by the applicant(s) in relation to information provided by the 
MHRA 
 
1. I confirm that I have read and understood the Data Protection Statement and the 
Access to Yellow Card Data Guidance Notes. 
 
2. I agree to use the data only for the intended purpose for which access was 
granted. 
 
3. I will submit in writing any change to the research plan or any amendment to the 
principal applicant and/or co-applicants to the ISAC for approval. 
 
4. I will ensure that the data are stored in a confidential manner and that the data or 
analyses of the data are not released to third parties without consent from the ISAC. 
 
5. I will inform the MHRA of any new drug safety issues identified at the time of 
recognition. 
 
6. I agree to submit any draft publications from use of these data to the MHRA for 
comments four calendar weeks prior to publication. 
 
7. To the best of my knowledge the information provided in this application is 
accurate and comprehensive.
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Annex B 
 
Guidelines for Safe Disposal of Electronic Yellow Card 
Data for External Users 
 
1. Scope 
 
This guideline provides a brief on general procedures for the safe disposal of 
externally held paper and electronic1 Yellow Card data for applicants requesting 
access to Yellow Card data for scientific research. 
 
2. Introduction 
 
The MHRA and most other modern organisations are increasingly dependent on 
computer systems. Substantial costs may be incurred if a system, or the information 
it contains, is lost, damaged, destroyed or if information is obtained by those not 
entitled to it. Large amounts of valuable information can be easily stored on external 
computers and portable computing devices, such as laptops, notebooks, smart 
phones and Personal Digital Assistants (PDA). It is therefore paramount to ensure 
data is protected by both minimising the amount of information stored and adequately 
safeguarding it. 
The Data Protection Act 1998 (DPA) applies to personal data. Its purpose is to 
ensure that such data are processed fairly and lawfully and in particular that personal 
data is not disclosed to third parties unlawfully. The DPA covers computer records, 
discs, CDs, USB memory sticks and information held in paper files (e.g. index cards, 
filing systems etc). 
 
The seventh data protection principle requires data controllers to ensure that 
appropriate security measures are in place to prevent the unauthorised or unlawful 
processing of personal data and against accidental loss or destruction of, or damage 
to, personal data. When the processing of personal data is carried out by a data 
processor on behalf of the data controller, the contract for that processing must 
require the data processor to comply with obligations equivalent to those imposed on 
the data controller by the seventh principle. Whether the measures in place are 
appropriate will depend upon whether they provide a level of security appropriate to 
the harm which might result from a breach of security and the nature of the data to be 
protected, as well as taking into account the state of technological development and 
the cost of implementing the measures. 
 
3. Background 
 
The MHRA operates post-marketing surveillance systems for reporting, investigating 
and monitoring adverse reactions to medicines and adverse incidents involving 
medical devices to safeguard public health. The safety of medicines is monitored 
using the Yellow Card Scheme which has been in existence since 1964. 
 
The Independent Scientific Advisory Committee for MHRA database research (ISAC) 
and the MHRA consider that confidentiality of Yellow Card data is paramount. For 
this reason such data is provided to third parties on the following stringent conditions. 
 
 
1 Data/Bits & bytes, stored on a digital storage device, e.g. hard disk, flash memory key, CD-ROM etc 
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4. Data Use 
 
4.1 Desktop Computers 
 
If you use a desktop Personal Computer (PC) you must: 
 
• Have adequate security in place at all times when you are not using it, i.e. lock the 
office when no one is there; 
• Ensure that your computer receives regular Operating System security patches, 
firewall and anti-virus updates; 
• Be familiar with your computer’s connection capabilities. If it has network/telephone 
access, be sure to know how you can securely connect to an authorised network or 
the Internet. Be sure to disconnect any network/telephone connections and to turn it 
off when not in use; 
• You must understand the level of data you are using. Never store or process 
information with protective markings unless authorised to do so and in a secure 
environment; 
• Be aware of your surroundings and of the opportunity for un-authorised people 
looking ‘over your shoulder.’  
 
The items above are not exhaustive and provide general pointers to make you aware 
of the types of issues involved. It is always important to ‘err, on the side of caution’. 
 
4.2 Portable computers 
 
Due to risk of theft, portable computers (including PDAs, laptops etc) must not be 
used to store identifiable Yellow Card data. Data must be stored at all times in the 
location you have told the MHRA. 
 
4.3 Encrypting data for transmission 
 
Recipients of Yellow Card data can only send data to third parties with permission of 
the MHRA, for example if an applicant has obtained data through an ISAC 
application and these data need to be shared electronically with a co-applicant. 
 
Many software applications2 are available that can encrypt files (of any size) to 
increase protection against unauthorised disclosure. These files can then be copied 
onto removable storage media (such as CD) for safer transportation and can also be 
sent as attachments via standard email. The current (2006) 
US government approved encryption standard (and adopted in the UK) is the 
‘Rijndael - Advanced Encryption Standard’ (AES). 
 
AES is currently the most secure encryption standard available and is recommended 
for the encryption of identifiable Yellow Card data, if for any reason a researcher 
needs to send identifiable Yellow Card data by email to another colleague. 
 
 
 
2 Dedicated 3rd party specialist applications are available. Also many leading compression applications have the 
facility to encrypt (& compress) data e.g. WinZip (v9 & above) or WinRar.(v3.6 & above) 
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4.4 How to comply with the Advanced Encryption Standard when encrypting 
Yellow Card data for transportation 
 
If sending data as outlined in 4.3, a few options are available: 
 
4.4.1 Winzip 
WinZip(v10) can encrypt data using the approved AES encryption algorithm. The 
European Medicines Agency (EMEA) has selected this method for the safe dispatch 
of information to its delegates and other Agencies. 
 
4.4.2 Secure Email delivery Service 
Another method is the use of a secure email delivery service. Encrypting an entire 
email message (including attachments) prevents ‘outsiders’ from reading it when it is 
in transit. There are two options: 
 
1. Configure an email client (e.g. Outlook) to digitally encrypt and sign documents 
prior to transmission. This method requires the recipient’s email application to be 
configured to successfully accept and decode the encrypted email. 
 
2. The use of a secure web-based email delivery service, such as the popular 
Hushmail (hushmail.com) or Voltage mail (vsn.voltage.com/index.htm). The 
registered user would build the message on-line via the web interface and add any 
attachments before sending the email to the recipient. The recipient would not have 
to be a registered user to receive the email. However, he/she would have to register 
to send encrypted email via the service. 
 
5. Data Removal Guidelines 
 
You must be cautious of the fact that in the event your computer is sold or stolen, the  
data can potentially be accessed by unscrupulous people. 
 
It is a professional and moral obligation to protect (in accordance with the DPA) 
sensitive Yellow Card data which is no longer required, from unnecessary disclosure. 
When required, data stored on a computer must be carefully disposed of in an 
efficient and cost-effective manner. The data owner must be certain that Yellow Card 
data which is no longer required is obliterated. 
 
Proper organisation of research data on large storage devices is important as this will 
allow you to safely locate and clear the data, minimising the risk of accidental 
erasure. Ideally, Yellow Card data should be stored under a main folder. In order to 
manage large amounts of data, other folders should be created, these folders should 
be created in a hierarchy structure. This will make the task of shredding individual or 
even large chunks of data files easier and safer. 
 
6. Hard Disk File Shredding 
Proper organisation of research data on large storage devices is important as this will  
allow you to safely locate and clear the data, minimising the risk of accidental 
erasure. Ideally, research data should be stored under a main folder. In order to 
manage large amounts of data, other folders should be created, these folders should 
be created in a hierarchy structure. This will make the task of shredding individual or 
even large chunks of data files easier and safer. 
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6.1 Removal Methods for NHS/DH 
 
The NHS/DH computer system is part of a secure ‘restricted’ network (this is the 
minimum classification level for the NHS), so Yellow Card data stored on 
NHS computers can be deleted in the normal way, in accordance with the 
organisation’s IT policies. The NHS routinely adopts special procedures when 
computers needs to be removed for disposal or a hard disk upgrade is required. If 
machines are reused internally they are simply rebuilt/re-imaged, if they are leaving 
the NHS then they are completely wiped clean using an accredited software 
application or degaussed for extra security. This echoes the Department of Health’s 
(DH’s) policy for erasing/discarding computers. 
 
6.2 Removal Methods for non-NHS/DH organisations 
6.2.1 Best Practice 
When handling sensitive data, the following recommended options provide a 
safer and more secure data disposal environment. 
The ‘best practice’ method would be a combination approach which includes: 
• The creation of a formal computer data disposal document (like this one) explaining 
the process. 
 
• The use of data wiping software or ‘File Shredding’ software 
¾Where the user does not have a separate drive solely for working with 
Yellow Card data, File Shredding is the recommended option. File shredding 
is a technique used to wipe individual folders or files residing on hard disks 
but can also be used on other removable read/write media. The software will 
typically run a routine that deletes the chosen files/folders and then overwrites 
the areas of the hard drive with repeated patterns of random characters. The 
more “passes” made by the overwriting routine, the harder it becomes to 
recover the original information. 
Recommended File Shredding software is Blancco’s File 
Shredder3 
 
¾Where the user has a separate drive letter (i.e. another partition) allocated  
for working with Yellow Card data, an option is to ‘wipe’ that drive partition 
using the recommended software. The partition will be completely wiped, 
overwritten many times (US Dept of Defence (DoD) standard) and may 
require the standard re-formatting. This method is 
ideal and will satisfy all critical concerns about possible recovery of sensitive 
data. However, this option requires additional technical knowledge. 
Recommended software - the Government’s, Communications 
Electronic Security Group(CESG) approved: OnTrack’s ‘Data 
Erasure v2’ Pro OR the Blancco Pro application.4 
 
• Use of data encryption software to maintain good security in the event the 
PC equipment is stolen and/or any unauthorised recovery of deleted data 
is performed 
 ¾The whole system can be easily and transparently encrypted. Usually 
one additional password is required at boot up (to allow access) and the 
system can be used normally 
Recommended Encryption software - Becrypt Disk Protect5 
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6.2.2. Hard Disk Disposal/Re-use 
When disposing hard disks containing Yellow Card data the MHRA 
recommends 
• The government (CESG) approved OnTrack’s ‘Data Erasure v2’ 
Pro OR the Blancco PRO application6 
 
Please note that when wiping Yellow Card data from your storage media, the 
software must comply with the ‘Gutmann’ and US DoD. Of these, the Gutmann 
standard is most secure – use for personalised/identifiable medical data or 
documents classified as ‘Confidential’ or above, for other cases the US 
DoD standard is suitable. If you wish to use a different software package please 
contact the MHRA to see if it is suitable. 
Be sure to understand all the places where data duplication may be located. 
Data residing on removable storage media (including for backup purposes) such as, 
CD/DVD’s, USB Flash memory devices, floppy disks etc. need to be completely 
erased using the appropriate disk wiping software. If appropriate, the medium should 
be destroyed by physically breaking or shredding, this procedure is also known as 
purging. 
 
6.2.3. Physical destruction/purging  
 
Shredding 
This is the most popular method of destroying paper or even CDs and floppy disks, 
etc. Shredders preferably the ‘cross-cut’ variety, come in a variety of sizes and 
capacities for office environments. For larger volumes, hiring the services of 
specialist vendors for disposal of information may be required. 
Some vendors will bring equipment to your facility and shred documents on site. If 
records are to be shredded on the vendor's premises, certified shredding is required. 
 
Purging 
Whilst shredding works for paper and CDs, disposal of stronger rigid materials such 
as hard disks, digital tapes or optical disks require degaussing, pulverisation, drilling, 
melting/incineration (tasks usually outsourced). Sanding off the physical recording 
surface is another option. 
 
MHRA/IMD 
 
November 2006 
 
 
 
 
3 Blancco - http://www.blancco.com/main.site?action=siteupdate/view&id=21 
4 OnTrack - http://www.ontrack.co.uk/dataeraser/ 
5Becrypt Disk Protect - http://www.becrypt.com/our_products/disk_protect.php 
6 Data Eraser - http://www.ontrack.co.uk/dataeraser/  
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Annex C 
 
National Research Register 
 
The National Research Register (NRR) is a register of ongoing and recently 
completed projects funded by, or of interest to, the UK National Health Service. 
 
ISAC strongly recommends that UK researchers using Yellow Card data consider 
registering as NRR data providers, in order that others engaged in research within 
the UK can be made aware of current works. 
 
Registration with the NRR is entirely voluntary and will not replace information on 
ISAC approved protocols published in summary minutes or in the ISAC Annual 
Report 
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MHRA 
151 Buckingham Palace Road 
Victoria 
London SW1W 9SZ 
United Kingdom 
www.mhra.gov.uk 
 
 
Professor Alison Strath 
School of Pharmacy and Liife Sciences 
Robert Gordon University 
Schoolhill, Aberdeen 
AB10 1FR 
 
a.strath@rgu.ac.uk 
 
11/07/2013 
                                                                                                           
Dear Prof. Strath 
 
Thank you for your correspondence regarding request for Yellow Card data. 
 
Firstly, to provide some background the MHRA is a government agency which is responsible for the regulation of 
medicines and medical devices in the UK. The Yellow Card Scheme was established in 1964 and collates 
spontaneous ‘suspected’ Adverse Drug Reactions (ADR) reports associated with drug substances from 
healthcare professionals, companies and members of the public. These reports are held on a database and are 
available in the form of Drug Analysis Prints which can be downloaded from our website www.mhra.gov.uk/daps.  
 
I am pleased to provide you with the total number & breakdown of suspected Adverse Drug Reports (ADRs) 
received per year for the period 01/01/1996 – 31/12/2013 in UK. Please see table 1. 
 
Table 1: 
 
 
Year Total number of 
reports 
1996 17107
1997 16623
1998 18042
1999 18482
2000 33145
2001 21444
2002 17590
2003 19190
2004 19933
2005 21834
2006 21424
2007 21190
2008 25029
2009 25462
2010 23305
Total 319800
 
When interpreting this data it is important to take the following points into consideration: 
 
The number of reports received via the Yellow Card Scheme does not directly equate to the number of people 
who suffer adverse reactions to drugs for a number of reasons, as this scheme is associated with an unknown 
and variable level of under-reporting - i.e. not all reports of suspected ADRs are reported as it is not mandatory for 
healthcare professionals to report suspected ADRs to the MHRA.  
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Please be aware that ADR reporting rates are influenced by the seriousness of reactions, their ease of 
recognition, the extent of use of a particular drug, and may be stimulated by promotion and publicity about a drug. 
In addition the number of reports received should not be used as a basis for determining incidence of a reaction 
as neither the total number of reactions occurring, nor the number of patients using the drug is known. 
 
Further more we currently provide two categories of data requests i.e category I(a/b) and II. Category I a/b data 
are releasable under the provisions of the Freedom of Information Act (FOIA) 2000. Category 1a comprises 
anonymised aggregated data e.g. Drug Analysis Prints (DAPs) which I’ve mentioned above. Category 1b data 
requests comprises a pre-defined basic set of case details such as patient age categories; the proportion of males 
and/or females who experienced the reaction; the suspected drug or drugs; the dose and duration of the 
suspected drug(s) and the suspected adverse drug reaction(s) (see the Yellow Card application form Annex D for 
further details)  
http://www.mhra.gov.uk/Committees/IndependentScientificAdvisoryCommitteeforMHRAdatabaseresearch/index.h
tm. 
Please note if you request large quantities of data there may be a charge.  
 
I hope this has been helpful, if you still require additional information, do not hesitate to contact me. 
 
Yours Sincerely, 
 
 
Olutoyin Agbaje 
Signal Assessor 
Vigilance Intelligence and Research Group 
MHRA - Floor 3.O BPR 
 
Cc: Rauf Pathan - Therapeutic Team Co-ordinator. 
 
COPYRIGHT NOTICE: 
 
The information supplied in response to your request is the copyright of MHRA and/or a third party or 
parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any 
information provided without prior agreement from the copyright holder. For full details on our copyright 
policy please visit the below link or e-mail the MHRA 
Information Centre: http://www.mhra.gov.uk/home/Idcplg?IdcService=SS_GET_PAGE&nodeId=412 
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MHRA 
151 Buckingham Palace Road 
Victoria 
London SW1W 9SZ 
United Kingdom 
www.mhra.gov.uk 
 
 
Professor Alison Strath 
School of Pharmacy and Life Sciences 
Robert Gordon University 
Schoolhill, Aberdeen 
AB10 1FR 
a.strath@rgu.ac.uk
 
18/09/2013 
                                                                                                           
Dear Prof. Strath 
 
Thank you for your recent correspondence requesting a break down of the number of Yellow Card reports 
received per year. 
 
Firstly, to provide some background the MHRA is a government agency which is responsible for the regulation of 
medicines and medical devices in the UK. The Yellow Card Scheme was established in 1964 and collates 
spontaneous ‘suspected’ Adverse Drug Reactions (ADR) reports associated with drug substances from 
healthcare professionals, companies and members of the public. These reports are held on a database and are 
available in the form of Drug Analysis Prints (DAPs) which can be downloaded from our website 
www.mhra.gov.uk/daps.  
 
I am pleased to provide you with the total number of suspected spontaneous UK Adverse Drug Reaction (ADRs) 
reports received per year between the time periods of 01/01/1963 – 31/12/1995 & 01/01/2011 – 31/12/2012 . 
Please see annex 1. 
 
When interpreting this data it is important to take the following points into consideration: 
• The number of reports received via the Yellow Card Scheme does not directly equate to the number of 
people who suffer adverse reactions to drugs for a number of reasons, as this scheme is associated with 
an unknown and variable level of under-reporting - i.e. not all reports of suspected ADRs are reported as 
it is not mandatory for healthcare professionals to report suspected ADRs to the MHRA.  
• Please be aware that ADR reporting rates are influenced by the seriousness of reactions, their ease of 
recognition, the extent of use of a particular drug, and may be stimulated by promotion and publicity about 
a drug. In addition the number of reports received should not be used as a basis for determining 
incidence of a reaction as neither the total number of reactions occurring, nor the number of patients 
using the drug is known. 
• Further more we currently provide two categories of data requests i.e category I(a/b) and II. Category I 
a/b data are releasable under the provisions of the Freedom of Information Act (FOIA) 2000. Category 1a 
comprises anonymised aggregated data e.g. DAPs which I’ve mentioned above. Category 1b data 
requests comprises a pre-defined basic set of case details such as patient age categories; the proportion 
of males and/or females who experienced the reaction; the suspected drug or drugs; the dose and 
duration of the suspected drug(s) and the suspected adverse drug reaction(s). 
http://www.mhra.gov.uk/Committees/IndependentScientificAdvisoryCommitteeforMHRAdatabaseresearch
/index.htm. 
 
Please note if you request large quantities of data there may be a charge. I hope this has been helpful, if you still 
require additional information, do not hesitate to contact me. 
 
Yours Sincerely 
 
Olutoyin Agbaje 
Signal Assessor - VRMM 
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MHRA 
Cc: –Sharon Jethwa- Signal Management Team Co-ordinator. 
 
COPYRIGHT NOTICE:
The information supplied in response to your request is the copyright of MHRA and/or a third party or 
parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any 
information provided without prior agreement from the copyright holder. For full details on our copyright 
policy please visit the below link or e-mail the MHRA 
Information Centre: http://www.mhra.gov.uk/home/Idcplg?IdcService=SS_GET_PAGE&nodeId=412
 
Annex 1.
Year 
Total number 
of UK ADR 
reports 
1963 21 
1964 1296 
1965 3737 
1966 2228 
1967 3234 
1968 3193 
1969 3911 
1970 3317 
1971 2711 
1972 3554 
1973 3308 
1974 4470 
1975 4505 
1976 6071 
1977 10894 
1978 11412 
1979 10516 
1980 9680 
1981 11172 
1982 11118 
1983 12127 
1984 12998 
1985 12601 
1986 15270 
1987 16305 
1988 18378 
1989 18561 
1990 17869 
1991 19930 
1992 20118 
1993 18030 
1994 17514 
1995 17618 
2011 25133 
2012 26038 
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RESEARCH PROTOCOL (Version 3 –February 25, 2013)  
PROJECT TITLE: A descriptive analysis of yellow card reports on paediatric 
Natural Product  Complementary & Alternative Medicines 
RESEARCH TEAM: Okechukwu Ndu, James McLay, Lorna McHattie, Alison Strath, 
Lesley Diack     
1.0 BACKGROUND TO THE STUDY: The World Health Organisation defines 
Complementary and Alternative Medicine (CAM) as ‘a broad set of health care 
practices that are not part of a country’s own tradition, and are not integrated 
into the dominant health care system’ (1). The Cochrane Collaboration defines 
CAM in a similar way (2), and classifies it (3) based essentially on the model put 
forth by the National Center for Complementary and Alternative Medicine (4) into 
five major categories: natural product-based therapies (like herbal and 
homeopathic medicines, dietary supplements, and probiotics), mind-body 
medicine therapies (like meditation, yoga, and guided imagery), manipulative and 
body-based practices (like spinal manipulation, massage, and acupuncture), 
alternative (or whole) medical systems (like Anthroposophic medicine, 
homeopathy, and traditional Chinese medicine), and other therapies (such as 
energy medicine and various forms of healings). While CAM use has been found to 
be increasing across the world in both adults and children (5-11), most surveys 
have found the natural product CAM therapies (NP-CAM) to be the most popular 
of all therapies used (12-15). With their popularity has, however, come a growing 
emphasis on safety issues surrounding their regulation and use (16-22). In the 
UK, the main system for drug safety monitoring is the Medicines and Healthcare 
Okechukwu Obisike Ndu                                                                                       
PhD student (1010078)                                                         
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Products regulatory Agency (MHRA) through its Yellow Card Scheme (17,23,24). 
But despite various initiatives aimed at stimulating the reporting of NP-CAM-
associated suspected adverse drug reactions (such as including CAM providers, 
community pharmacists, nurses and even patients themselves as accredited 
reporters in the scheme), the number of reports related to NP-CAM has been 
reported to be low (17,25). While studies have summarized the adverse drug 
reports to the MHRA with respect to various drug classes (26-29) and children 
(30-35), none has thus far focused on NP-CAM. The current study proposes to fill 
this gap. Pharmacovigilance data on NP-CAM reported to the MHRA from its 
inception in July, 1964 until July, 2012 has been obtained, and will form the basis 
of the study.    
2.0 PROPOSED METHOD: The study is proposed to follow a descriptive 
retrospective method  of database analysis. 
2.1 AIM: To analyse reports of suspected adverse drug reactions (ADRs) related 
to NP-CAM in  subjects aged up to 18 years in the UK Yellow Card Scheme 
(YCS).  
2.2 SPECIFIC OBJECTIVES: 
(i) To characterize NP-CAM-related YCS reports in terms of patient demography, 
dates of  reports, type, presentation, and mode of administration of the 
products concerned,  variety and (perceived) seriousness of ADRs, nature, 
clinical classification, duration and  outcome of the reported events, and 
reporter status; 
(ii) To investigate the relationship between patient and reporter-related factors 
and ADR nature  and outcome. 
(ii) To identify and highlight areas of potential concern for further investigation. 
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2.3 STUDY SETTING: The database of reports on subjects aged up to 18 years 
submitted to the MHRA through its YCS from July, 1964 to July, 2012 will be the 
focus of the study. All such reports made within the period shall be considered 
irrespective of the specific geographical location of origin within the UK.   
2.4 ANALYSIS OF RESULTS:  The results of the study will be analysed 
statistically in line with the study objectives. Descriptive statistics (means, 
medians, proportions, etc.) will be used to characterise the subjects of the ADRs, 
the type of reporter involved, the ADRs reported and their outcomes, as well as 
the NP-CAM associated. Inferential statistics will be used to investigate the 
relationships between patient and reporter-related factors and the number quality 
and outcome of ADRs reported at 95 % level of significance. All analyses will be 
carried out using SPSS 17.0. 
2.5 RESEARCH GOVERNANCE: To ensure that the study is carried out to the 
highest ethical standards and in conformity with Robert Gordon University’s 
research ethics committee guidelines, as well as the requirements of the MHRA 
Independent Scientific Advisory Committee (ISAC), approval for the study will be 
obtained from the Robert Gordon University School of Pharmacy & Life Sciences 
Ethics committee. As there is no intention to contact the patients, reporters or 
healthcare professionals involved, there will be no need for approval by the North 
of Scotland Research Ethics Committee. All procedures will conform to the School 
of Pharmacy & Life Sciences standard operating procedures for data collection. All 
data obtained will be stored in SPSS format in a password-protected university 
computer under the oversight of the principal researcher (ON), and will be 
processed, used and stored in line with the Data Protection Act of 1998. No third 
parties will have access to the data. At the end of the study, all related data will 
be deleted from the password-protected computer used. Apart from the PhD 
thesis resulting from the study, any research outputs accruing from the results of 
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this study will be submitted to the MHRA at least four calendar weeks prior to 
publication for any necessary regulatory actions.   
3.0 WORK PLAN TIME-LINES: The study is proposed to commence by April 1, 
2013, and end by the end of June, 2013, over a period of three months. 
NOTE: Application has been made for the release of non-identifiable NP-
CAM-related patient dispensing data from the Information Services 
Division (ISD) of the Scottish NHS. If the application is successful, the 
data will be studied and analysed in line with the above-stated 
provisions. 
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A QUESTIONNAIRE PRE-TEST FOCUS GROUP  
FOR A SURVEY OF PARENTS ON 
THE USER-PERCEIVED EFFECTIVENESS AND SAFETY OUTCOMES OF 
COMPLEMENTARY & ALTERNATIVE MEDICINE IN SCHOOL-AGED CHILDREN 
GUIDELINE FOR FOCUS GROUP DISCUSSION 
 
***SWITCH ON THE AUDIO RECORDER*** 
***CHECK FOR THE “ON” LIGHT ON THE AUDIO RECORDER*** 
 
Date  
 
Time  
00:00 
 
A: INTRODUCTORY REMARKS  (Time allotted: 5 minutes) 
 Hi, everybody. My name is Okeh NDU, and I am currently in my third year of doctoral 
research in the School of Pharmacy & Life Sciences under the supervision of Drs. Lesley 
Diack and Lorna McHattie, and Prof. Alison Strath. I am privileged to have Lorna here 
with me today to co-facilitate today’s focus group. I thank you all very much for 
coming to attend this focus group pre-test.  
 
We are here to discuss issues around a questionnaire on Complementary & Alternative 
Medicine (CAM) use in children that I have designed for on-line completion by parents 
of schoolchildren. The aim of this discussion is to find out whether, from your 
perspective as parents, this CAM questionnaire actually elicits the type of information it 
is intended to draw out from study participants; and where it does not, why that is so; 
and finally, how it could be better presented in order to achieve its objectives. Your 
input will be taken on board in further development of the questionnaire. Please note 
that, because we are having this discussion as a focus group of parents, we would like 
to hear your views and opinions as it pertains to you as a parent. As such, there are no 
right or wrong answers. The overall aim of this process is not to reach a consensus on 
Okechukwu Obisike NDU (1010078) 
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any matter, but to get all shades of opinions on every aspect of the questionnaire that 
can help us ensure a more robust research process. Generally, I will try to provide a bit 
of structure to the discussion, more-or-less in line with the topic guide I have 
distributed; but, please, feel free to contribute your ideas whenever an issue you 
consider important is raised. We will be keeping an audio record of this discussion so 
that I don’t have to take notes; and so I encourage us all to try our very best to speak 
out loud, so that the Marantz® will be able to catch what we say clearly irrespective of 
where we are seated. In the end, I will summarize all that has been said into a report. 
In doing so, I want to assure us all of these two facts: 
(i)  I will not refer to any participant by name; and 
(ii) The information generated from this discussion will be kept confidential, 
and used only for research purposes. And I plead with everyone present 
to do likewise as well. 
Before we go into the discussion phase, please, can I confirm that we have all 
completed and returned the consent form for participating in this focus 
group?  
DOES ANYONE HAVE ANY QUESTIONS ABOUT ALL I HAVE SAID SO FAR? 
 
B: THE DISCUSSION                                          (Time allotted: 45 minutes) 
QUESTION ONE: As a parent, what was your first impression of the questionnaire?   
 As a parent –if you received this link in the mail from your  child’s  
 school- what would you think of the idea of a CAM  survey?  
          (3 MINUTES)  
 
QUESTION TWO: What did you think of the quantity and quality of the 
 information provided in the ntroductory/invitation page?    
               (5 MINUTES) 
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 -Is the information there sufficient?  
 -Is the definition of CAM given sufficient/effective? Did you understand  
 it?  
 -What about the lists of CAM practices and products provided? Did  
 you go through them? Were they helpful?  
 -Do you think there is any hint of coercion involved in the invitation  
 page? 
 
QUESTION THREE: What was your general impression of the section on 
 parent demographics?  -Was there any item there you felt was out of 
 place?          (10 MINUTES) 
 If so, which? Why so? How would it be phrased to be more acceptable to  
 you?   
 
QUESTION FOUR: How did you understand the questions on CAM use in 
 schoolchildren? 
  -Was there any confusion?       (10 MINUTES) 
 -What do you think you were supposed to do there? 
 -Would you have felt uncomfortable if you had been asked the   
 purpose for which the CAM was used? 
 -What about the questions on outcomes associated with CAM use? How  
 did you understand them? 
 
QUESTION FIVE: What do you think of the general statements on opinions 
 surrounding CAM use?  
  -What did you understand them to mean?    (10 MINUTES) 
  -Was there any you felt uncomfortable with?  
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  -Did you think any of them was leading? 
  -Do you think any needs re-wording? 
 
QUESTION SIX: What potential problems do you think parents could 
 encounter in completing the questionnaire in its current form? 
 
QUESTION SEVEN: In what way did your completing the questionnaire affect 
 your general impression on CAM use –especially with respect to 
 children?          (2 MINUTES) 
 
WRAP-UP QUESTION: Does ANYBODY have ANY OTHER COMMENTS on 
 any part of the questionnaire, or on the survey as a whole?  
       
C: CONCLUSION           (5 MINUTES) 
Once more, let me express my deep gratitude to you for honouring this invitation, and 
for your great co-operation in this entire exercise. Please, take the next few 
minutes to complete a brief EVALUATION QUESTIONNAIRE to let us know your 
views of this focus group discussion. FINALLY, SHOULD YOU BE INVITED TO TAKE 
THIS SURVEY AGAIN THROUGH YOUR CHILD’S SCHOOL, PLEASE, DO NOT 
BOTHER TO DO SO. 
THANK YOU FOR YOUR TIME! 
***SWITCH OFF THE AUDIO RECORDER*** 
***CHECK FOR THE RED LIGHT ON THE AUDIO RECORDER*** 
 
Discussion 
concluded at: 
00:00 
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TITLE OF STUDY:  
PERCEIVED EFFECTIVENESS & SAFETY OF COMPLEMENTARY & ALTERNATIVE 
MEDICINE USE BY STUDENTS IN ABERDEEN                                                                   
-A FOCUS GROUP STUDY 
 
OCTOBER 18, 2013 
@ABERDEEN COLLEGE, GALLOWGATE, ABERDEEN 
 
TOPIC GUIDE 
1. What were your first impressions of this survey?   
 
2. In what ways could we stimulate public interest in the survey?  
     
3. How could the survey be distributed so as to reach you or potential participants 
more easily?  
 
4. What could be done to make completing the questionnaire more acceptable to 
fresh participants? 
 
5. Is there any aspect of CAM use that you think has been overlooked in this 
questionnaire? 
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Complementary & Alternative Medicine (CAM) Use among 
Children in North-East Scotland 
- A Parent Survey 
 
 
 
 
 
 
Thank you for your interest in this survey. Please note that your views and opinions are 
welcome whether or not you have used CAM for your child/children. 
 
 
 
 
 
 
 
WHAT IS CAM? 
CAM refers to practices and products that people use along with or in place of conventional medicine to maintain 
general health & well-being, or to prevent, treat or manage specific health conditions. There are various types of CAM 
products and practices, including various supplements, special diets and herbal and homeopathic remedies, as well as 
various exercises and other self-help practices that are used to promote health. Some of these are so familiar, 
commonplace or ordinary that most people do not even realise they are CAM. 
 
This CAM use survey will take you about 5-10 minutes to complete. 
 
Thank you for your time. 
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SECTION ONE: GENERAL INFORMATION ABOUT YOU 
This section asks general information about you and your children. 
 
Q1. Your parental status is:  
 Father or male guardian……………………….. 
 Mother or female guardian…………………….. 
 
Q2. Your age falls within:  
 16-29 years……………………………………… 
 30-44 years………………………………………. 
 45-59 years……………………………………… 
 60 years and above ……………………………. 
 
Q3. Your marital status is:  
 Single……………………………………………. 
 Cohabiting……………………………………….. 
 Civil union/Partnership…………………………. 
 Married…………………………………………… 
 Separated……………………………………….. 
 Divorced…………………………………………. 
 Widowed………………………………………… 
 
Q4. Where do you live? 
 Aberdeen………………………………………… 
 Aberdeenshire…………………………………… 
 Dundee…………………………………………… 
 Rest of Angus…………………………………… 
 Moray…………………………………….………. 
 Perth & Kinross…………………………………. 
 Fife……………………………………………….. 
 
Q5. The first part of your postcode is: 
 Postcode (e. g. AB 10)……….…  
 
Q6. Your ethnic origin is:  
 White Scottish…………………………………. 
 Other White British 
  English………………………………… 
  Irish……………………………………. 
  Welsh………………………………….. 
  Other White British…………………… 
 Other White ……………………………………. 
 Black British…………………………………… 
 Other Black 
  African…………………………………. 
  Caribbean……………………………… 
  Other………………………………….. 
 Chinese British………………………………… 
 Other Chinese…………………………………. 
 Other Asian British 
  Bangladeshi…………………………… 
  Indian………………………………….. 
  Pakistani………………………………. 
  Other………………………………….. 
 Other Asian…………………………………….. 
 Mixed racial background 
  White & Black African……………….. 
  White & Black Caribbean………….… 
  White & Asian………………………… 
  White & other mixed background…… 
  Other mixed background……………. 
 Any other ethnic origin………………………. 
 
Q7. Would you be inclined to describe yourself 
as a person of faith?  
 Yes……………………………………………….. 
 No………………………………………………… 
 I don’t know……………………………………… 
 
Q8. Your highest educational qualification is: 
 No formal qualifications…………………………………. 
 Secondary/High school………………………………….. 
 College…………………………………………………….. 
 University………………………………………………….. 
 
Q9. Would you have preferred to take this survey online (e-
mail/Facebook) instead of on paper? 
 Yes, I prefer the online mode…………………………… 
 No, I prefer the paper mode…………………………….. 
 Well, I don’t really mind…………………………………. 
I don’t know………………………………………………. 
 
Q10. Which of the following types of CAM products have 
you ever used for your child/children?  
  Herbal medicinal products (including herbal teas)……. 
 Dietary supplements (e.g. Omega 3, multivitamins)….. 
 Probiotics (e. g. Yogurts)………………………………… 
 Special diets (e. g. Gluten-free, Ketogenic, Atkins)…… 
 Aromatherapy (e. g. Olbas oil, Calrub, Tea tree oil)….. 
 Homeopathic products…………………………………… 
 Bach flower remedies……………………………………. 
 Traditional Chinese Medicines………………………….. 
 Ayurveda/Kampo/Other traditional medicines………… 
 They have used others not listed above……………….. 
 They have NOT used any CAM products……………… 
 
Q11. Which of the following types of non-product CAM 
therapies have you ever used for your child/children?  
 Acupuncture/Acupressure..………………………………. 
 Biofeedback………………………………………………. 
 Breathing exercises……………………………………… 
 Chiropractic/ Osteopathy………………………………… 
 Guided imagery…………………………………………… 
 Hypnosis…………………………………………………… 
 Healing (e. g. Reiki, Spiritual, Faith/Prayer……………. 
 Massage…………………………………………………… 
 Mickel therapy……………………………………………. 
Music therapy…………………………………………….. 
 Reflexology……………………………………………….. 
 Shiatsu…………………………………………………….. 
 Sunflower Method……………………………………….. 
 Yoga……………………………………………………….. 
 They have used others not listed above………………. 
 They have NOT used any CAM practices…………….. 
 
Q12. If your children have used any other CAM types than 
those listed above, please enter them here:  
 
 
 
 
 
Q13. Please provide the following general information on 
your children:  
Child Age in 
years                           
(e. g. 10) 
Sex                  
(√) 
Ever used 
CAM                    
(√) 
Used CAM in 
last 12 
months (√) 
M F Yes No Yes No 
1 
       
2 
       
3 
       
4 
       
5 
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S E C T I O N  T W O :  D E T A I L E D  I N F O R M A T I O N  O N  C A M  U S E  I N  C H I L D R E N  
T h i s  s e c t i o n  s e e k s  d e t a i l e d  i n f o r m a t i o n  a b o u t  y o u r  c h i l d / c h i l d r e n ’ s  u s e  o f  C A M .  I f  y o u  h a v e  n o t  u s e d  a n y  C A M  t y p e s  f o r  t h e m ,  t h e n  p r o c e e d  t o  S e c t i o n  t h r e e .  
 
Q 1 4 .  F o r  e a c h  o f  t h e  C A M  p r o d u c t s  a n d / o r  p r a c t i c e s  y o u r  c h i l d / c h i l d r e n  h a v e  u s e d  p l e a s e  i n d i c a t e  h o w  r e c e n t l y  t h e y  ( h a v e )  u s e d  i t ,  h o w  y o u  f o u n d  o u t  a b o u t  i t ,  y o u r  
p e r c e p t i o n  o f  t h e  d e g r e e  o f  h e l p f u l n e s s  a n d  d i s c o m f o r t  ( i f  a n y )  t h a t  r e s u l t e d ,  a s  w e l l  a s  t h e  s p e c i f i c  t y p e  o f  d i s c o m f o r t  ( i f  a n y )  e x p e r i e n c e d .   
 
F o r  c l a r i t y ,  p l e a s e  e n t e r  t h e  s p e c i f i c  n a m e s  o f  C A M  p r o d u c t s  u s e d  – e .  g .  E c h i n a c e a ,  Y o g u r t ,  E v e n i n g  P r i m r o s e ,  H o n e y ,  M e l a t o n i n ,  e t c . .  F o r  C A M  p r a c t i c e s ,  e n t e r  s u c h  
t e r m s  a s  A c u p u n c t u r e ,  A r t  t h e r a p y ,  K i n e s i o l o g y ,  P i l a t e s ,  Y o g a ,  e t c .  w i t h  n o  f u r t h e r  d e s c r i p t i o n .  
 
F e e l  f r e e  t o  u s e  m o r e  t h a n  o n e  l i n e  f o r  e a c h  e n t r y  w h e r e  n e c e s s a r y .  
 
S /  
N o  
S p e c i f i c  n a m e  o f  e a c h  C A M  
t y p e  u s e d  
( e . g .  E c h i n a c e a ,  R e s c u e  
r e m e d y ,  F a c i a l  m a s s a g e ,  e t c . )  
U s e d  i n  t h e  l a s t  
1 2  m o n t h s  
U s e d  m o r e  t h a n  
1 2  m o n t h s  a g o  
H o w  d i d  y o u  f i n d  o u t  
a b o u t  i t ?                                                                  
H o w  h e l p f u l  w a s  i t ?                          
( √ )
H o w m u c h  d i s c o m f o r t  d i d  i t  
c a u s e ?  ( √ )  
W h a t  d i s c o m f o r t  ( i f  a n y )  
d i d  i t  c a u s e ?  
Y e s  
( √ )  
N o  
( √ )  
Y e s  
( √ )  
N o  
( √ )  
( F a m i l y ,  f r i e n d ,  d o c t o r ,  
n u r s e ,  i n t e r n e t ,  e t c . )  
A   
l o t  
A   
l i t t l e  
N o t  
s u r e  
N o t  
m u c h  
N o t  a t  
a l l  
A   
l o t  
A   
l i t t l e  
N o t  
s u r e  
N o t  
m u c h  
N o t  
a n y  
1                   
2                   
3                   
4                   
5                   
6                   
7                   
8                   
9                   
1 0                   
1 1                   
1 2                   
1 3                   
1 4                   
1 5                   
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Q15. If (any of) your children has stopped using any of 
the CAM you have listed, please indicate why they did 
so? 
(Please tick all that apply.) 
 We haven’t stopped using any……………………. 
 They got better, so don’t need it any more………. 
 We decided to try something else………………… 
 The CAM caused too much discomfort………….. 
 The CAM was too expensive……………………… 
 The CAM was no longer available /accessible….. 
 We stopped for some other reasons………….….. 
 No special reason: we just stopped………………. 
 
Q16. Would you say that you achieved the main pur-
pose for which your child/children used the therapies 
you found helpful?  
 We didn’t find any helpful……………………….…. 
 Yes…………………………………………………… 
 No……………………………………………………. 
Q17. Would you recommend any of the CAM types to 
other parents?  
 Yes………………………………………………….. 
 No…………………………………………………… 
 
Q18. If (any of) your children experienced any form of 
discomfort with any of the CAM you used, who did you 
inform of the incident?  
(Please tick all that apply.) 
 They didn’t experience any discomfort………….. 
 Nobody……………………………………………… 
 Family members/Friends………………………….. 
 The pharmacist/health shop staff………………… 
 A CAM therapist……………………………………. 
 A doctor……………………………………………… 
 Any other health professional……………………… 
 The MHRA*/Yellow Card Scheme……………….. 
 Some other person………………………………… 
*MHRA –Medicines & Healthcare products Regulatory Agency 
 
SECTION THREE: YOUR PERSONAL USE AND OPINIONS ON CAM 
This section enquires of your personal use of, opinions on, and attitudes towards CAM. 
 
Q19. If you have ever used any CAM therapies for yourself, please let us know which ones (as much as you can 
remember), and how helpful you found them. If you have never used CAM for yourself, please proceed to Q20 
below to complete the survey.   
S/ 
No 
CAM type used 
 
How helpful was it?                         
(√) 
S/
No 
CAM type used 
 
How helpful was it?              
(√) 
A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
 A 
lot 
A 
little 
Not 
sure 
Not 
much 
Not at 
all 
1        11       
2        12       
3        13       
4        14       
5        15       
6        16       
7        17       
8        18       
9        19       
10        20       
 
Q20. For each statement below of some general attitudes towards CAM use, please tick the option that best 
describes how much you agree or disagree. Please note that there are no right or wrong answers.   
 
 
General statement about CAM use Strongly 
disagree 
Disagree Not 
sure 
Agree Strongly 
agree 
I don’t 
know 
1 I think CAM may be used in adults, but not in children. 
 
      
2 I believe certain health conditions are better managed with CAM than 
with conventional medicines prescribed by medical doctors. 
      
3 I think CAM should not be used together with conventional medicines 
prescribed by medical doctors. 
      
4 I believe CAM can cause harmful side effects 
 
      
5 I think CAM should be available on the NHS. 
 
      
6 I believe CAM is generally safer than conventional medicines prescribed 
by medical doctors. 
      
7 I think CAM users should inform their doctors that they use CAM. 
 
      
8 I believe CAM is generally more effective than conventional medicines 
prescribed by medical doctors. 
      
9 I think there is need for more information on CAM therapies. 
 
      
10 I believe people should be allowed to make up their own minds on using 
CAM. 
      
 
THANK YOU FOR PARTICIPATING IN THIS SURVEY. 
Please return the completed survey to us in the envelope provided. 

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ROBERT GORDON UNIVERSITY 
SCHOOL OF PHARMACY AND LIFE SCIENCES 
ETHICAL APPROVAL FORM FOR UNDERGRADUATE, TAUGHT MSc, PhD AND EXTERNAL PROJECTS 
 
SECTION 1 – to be completed  
Research Student Name OKECHUKWU NDU (1010078) 
Study Coordinator Lesley Diack 
Research Project Title Prevalence and user perceived effectiveness and safety of complementary and alternative medicine in young people in aberdeen 
 
SECTION 2 – to be completed by the School Research Ethics Committee                   Date submitted to panel: 25 February 2013 
Indicate Yes or No to 
each question and 
comment as appropriate. 
 Panel member 1 Panel member 2 Panel member 3 
 
Student Response 
Is the research question 
clear?  Yes Yes YES 
      
Is the project scientifically 
robust? 
Yes 
Yes, although maybe  
family structure such as 
single parent or 
divorced, number of 
siblings etc should be 
covered in the 
questionnaire as this 
might impact on the use 
of CAM. In the case of 
divorced parents, who 
do you ask if the 
responsibility of looking 
after the child is 
shared?  
YES 
      
Are the procedures for 
obtaining informed consent 
clear and appropriate? If an 
audit does the student have 
approved access to 
information? 
Yes Yes YES 
      
Is the extent of participant 
involvement clear? Yes Yes YES 
      
Are the recruitment 
procedures ethical and 
appropriate? 
Yes Yes YES 
 
Are the inclusion and 
exclusion criteria relevant Yes Yes 
YES, but could be 
clearer/more specific. 
 
and appropriate? 
Is the extent and type of 
participant involvement 
ethical? 
(consider issues of 
unnecessary invasiveness, 
exposure, undue stress, 
anxiety and concern, 
inappropriate time 
commitments) 
Yes Yes YES 
      
Are there clear procedures 
for ensuring compliance 
with the Data Protection 
Act? 
Yes 
Yes, although 
dissemination of 
findings is not 
mentioned 
YES 
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Please check the boxes 
below with your decision Panel member 1 Panel member 2 Panel member 3 
1.  Approved – submit to LREC / 
MREC as appropriate and provide 
copy of approval letter to 
supervisor OR provide supervisor 
with evidence that submission 
not necessary 
   
2.  NOT Approved – MINOR 
ISSUES approval subject to 
submitting a response, to ethics 
review panel via supervisor, 
addressing minor issues outlined 
above 
   
3.  NOT approved – MAJOR 
ISSUES serious issues of concern 
to be addressed and whole 
proposal to be resubmitted via 
supervisor for further ethical 
review. 
   
4.  NOT approved – UNETHICAL 
the study is unethical and a re-
submission will not be 
considered. 
   
Comments:    
 
SECTION 3  - OVERALL ETHICAL DECISION to be completed by Chair of School Research Ethics Committee 
1.  Approved – submit to LREC / MREC as appropriate and provide copy of approval letter to supervisor OR  
      provide supervisor with evidence that submission to LREC / MREC not necessary   
2.  NOT Approved – MINOR ISSUES: subject to submitting a response, to ethics review panel via supervisor, addressing minor issues outlined above  
3. NOT approved – MAJOR ISSUES: there are serious issues of concern to be addressed and whole proposal to be resubmitted via supervisor for further 
ethics panel review.  
4. NOT approved – UNETHICAL: the study is completely unethical and a re-submission will not be considered.   
 
Signed (on behalf of the School Research Ethics Committee)  Dr Morag McFadyen    Date: 22/03/2013   
   
Membership: Dr Stuart Cruickshank, Dr Lesley Diack (Chair), Dr Marie Goua, Dr Graeme Kay, Dr Morag McFadyen, Mrs Katie Maclure, Dr 
Stephen Macmanus, Dr Colin Thompson, Dr Anita Weidmann, Dr Wendy Wrieden. 
 
 
 
 
 
 
